	CHROM	POS	REF	ALT	Location	SYMBOL	Gene_full_name	VARIANT_CLASS	95-0290_GT	95-0290_VF	95-0290_AD	95-0290_DP	95-0290_GQ	Existing_variation	Genomic_region	CANONICAL	Feature	Feature_type	BIOTYPE	Consequence	INTRON	EXON	HGVSc	HGVSp	DISTANCE	STRAND	Interpro_domain	CLNSIG	CLNREVSTAT	CLNDN	OMIM_phenotype	Orphanet_disorder	Orphanet_association_type	HPO_name	PUBMED	gnomADg_AF	gnomADg_AC	gnomADg_AN	gnomADg_nhomalt	gnomADg_cov_median	gnomADg_cov_perc_20x	gnomADg_filter	gnomADg_popmax	gnomADg_AF_popmax	gnomADg_AC_popmax	gnomADg_AF_nfe	gnomADg_AC_nfe	gnomADe_AF	gnomADe_AC	gnomADe_AN	gnomADe_nhomalt	gnomADe_cov_median	gnomADe_cov_perc_20x	gnomADe_filter	gnomADe_popmax	gnomADe_AF_popmax	gnomADe_AC_popmax	gnomADe_AF_nfe	gnomADe_AC_nfe	kaviar_AF	kaviar_AC	CSVS_AF	CSVS_AC	FJD_MAF_AF	FJD_MAF_AC	denovoVariants_SAMPLE_CT	CADD_PHRED	CADD_RAW	MutScore	N_Pathogenic_pred	N_Benign_pred	N_predictions	Pathogenic_pred	Benign_pred	SpliceAI_SYMBOL	SpliceAI_DS_AG	SpliceAI_DS_AL	SpliceAI_DS_DG	SpliceAI_DS_DL	SpliceAI_DP_AG	SpliceAI_DP_AL	SpliceAI_DP_DG	SpliceAI_DP_DL	ada_score	rf_score	MaxEntScan_alt	MaxEntScan_diff	MaxEntScan_ref	LoFtool	ExACpLI	gnomAD_exomes_CCR	phastCons30way_mammalian	phyloP30way_mammalian	MGI_mouse_phenotype	GTEx_V8_gene	GTEx_V8_tissue	Expression_GNF-Atlas	Pathway_KEGG	GO_biological_process	GO_cellular_component	GO_molecular_function	Interactions_IntAct	Original_pos
43	chr1	6536011	CTC		chr1:6536011-6536013	PLEKHG5	pleckstrin homology and RhoGEF domain containing G5	deletion	0/1	0.16	21_4	25	72	rs760139855	EXONIC	YES	NM_001265593.1	Transcript	protein_coding	inframe_deletion		3/21	NM_001265593.1:c.334_336del	NP_001252522.1:p.Glu112del		-1.0					Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3), Autosomal recessive; Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3), Autosomal recessive	Autosomal recessive lower motor neuron disease with childhood onset;Autosomal recessive intermediate Charcot-Marie-Tooth disease type C	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Respiratory insufficiency due to muscle weakness;Talipes equinovarus;Joint contracture of the hand;Autosomal recessive inheritance;Areflexia;Scoliosis;Hyperlordosis;Spinal muscular atrophy;Distal muscle weakness;Proximal muscle weakness;Childhood onset;Difficulty climbing stairs;Waddling gait;Distal amyotrophy;EMG: neuropathic changes;Difficulty walking;Rapidly progressive;Abnormal lower motor neuron morphology;Scapuloperoneal amyotrophy;Distal muscle weakness;Hammertoe;Distal sensory impairment;Decreased motor nerve conduction velocity;Pes cavus;Areflexia;Mildly elevated creatine kinase;Autosomal recessive inheritance;Decreased number of large peripheral myelinated nerve fibers		0.0	0.0	151968.0	0.0	32	0.99	AC0_AS_VQSR				0.0	0.0	6.0099e-05	15.0	249588.0	0.0	100	1.0	PASS	amr	2.89586e-05	1.0	1.77085e-05	2.0	0.0000193,0.0004051	3,63			0.00193	22		14.6	1.190882		0	0	0			PLEKHG5	0.0	0.0	0.0	0.0	34.0	3.0	-23.0	-19.0						0.803	0.0	25.309348899			muscle phenotype; homeostasis/metabolism phenotype; integument phenotype ; renal/urinary system phenotype; cardiovascular system phenotype ; 			ciliary ganglion;pons;kidney;subthalamic nucleus;dorsal root ganglion;atrioventricular node;trigeminal ganglion;skin;superior cervical ganglion;skeletal muscle;globus pallidus;	.	G protein-coupled receptor signaling pathway;regulation of Rho protein signal transduction;endothelial cell chemotaxis;positive regulation of apoptotic process;positive regulation of I-kappaB kinase/NF-kappaB signaling;regulation of small GTPase mediated signal transduction;regulation of protein catabolic process at presynapse, modulating synaptic transmission	cytoplasm;cytosol;plasma membrane;cell-cell junction;lamellipodium;endocytic vesicle;perinuclear region of cytoplasm;presynapse	guanyl-nucleotide exchange factor activity;Rho guanyl-nucleotide exchange factor activity	AHCYL1[unassigned1304];	6536010
170	chr1	92946625	G	C	chr1:92946625	GFI1	growth factor independent 1 transcriptional repressor	SNV	0/1	0.31	54_24	78	99	rs149914857	EXONIC	YES	NM_005263.5	Transcript	protein_coding	missense_variant		4/7	NM_005263.5:c.319C>G	NP_005254.2:p.Pro107Ala		-1.0	.,.,.	Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Severe_congenital_neutropenia_2,_autosomal_dominant|not_specified|not_provided	?Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3), Autosomal dominant; Neutropenia, severe congenital 2, autosomal dominant, 613107 (3), Autosomal dominant	Autosomal dominant severe congenital neutropenia	Disease-causing germline mutation(s) in	Autosomal dominant inheritance;Neutropenia;Acute myeloid leukemia;Monocytosis;Neutropenia;B lymphocytopenia;Autosomal dominant inheritance;Lymphopenia;Osteopenia;Premature loss of teeth;Pyoderma gangrenosum;Cellulitis;Pharyngitis;Recurrent skin infections;Gingivitis;Recurrent aphthous stomatitis;Recurrent sinopulmonary infections;Fever;Rhinitis;Eosinophilia;Acute myeloid leukemia;Periodontitis;Abdominal pain;Oral ulcer;Recurrent infection of the gastrointestinal tract;Monocytosis;Recurrent ear infections;Myelodysplasia;Hemangioma;Pneumonia;Recurrent bacterial infections;Antineutrophil antibody positivity;Neutropenia;Acute lymphoblastic leukemia;Diarrhea;Recurrent viral infections;Aplastic anemia	25741868	0.00259513	395.0	152208.0	2.0	34	0.98	PASS	nfe	0.00454278	309.0	0.00454278	309.0	0.00221317	530.0	239476.0	2.0	54	0.89	PASS	nfe	0.00328063	344.0	0.00328063	344.0	0.0022379	348	0.002	6.0	0.00439	50		22.8	2.636671	0.28	7	12	19	SIFT,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,DEOGEN2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	GFI1	0.03	0.0	0.05	0.0	20.0	-16.0	5.0	20.0						0.557	0.03	0.000000000	0.782	1.101	behavior/neurological phenotype ; hematopoietic system phenotype; mortality/aging ; nervous system phenotype ; hearing/vestibular/ear phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; 			superior cervical ganglion;globus pallidus;bone marrow;	.	regulation of transcription involved in G1/S transition of mitotic cell cycle;negative regulation of transcription by RNA polymerase II;negative regulation of calcidiol 1-monooxygenase activity;negative regulation of vitamin D biosynthetic process;negative regulation of neuron projection development;viral process;hemopoiesis;negative regulation of NF-kappaB transcription factor activity;regulation of toll-like receptor signaling pathway;negative regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;regulation of histone H3-K4 methylation;positive regulation of interleukin-6-mediated signaling pathway;cellular response to lipopolysaccharide	nucleus;nucleoplasm;nuclear matrix;nuclear body;transcriptional repressor complex	DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;transcription regulatory region DNA binding;metal ion binding	PIAS4[17636019];PIAS3[11060035];ZBTB17[19164764];SPI1[17197705];UBE2I[17636019];HDAC1[16287849];EHMT2[16287849];PRDM5[17636019];RELA[20547752];U2AF1L4[16819553];CHAF1A[21570500];PICK1[16713569];TP53[23410974];	92946625
181	chr1	108023396	G	C	chr1:108023396	NTNG1	netrin G1	SNV	0/1	0.39	88_56	144	99		EXONIC	YES	NM_001372170.1	Transcript	protein_coding	synonymous_variant		8/8	NM_001372170.1:c.1554G>C	NP_001359099.1:p.Pro518%3D		1.0						Atypical Rett syndrome	Disease-causing germline mutation(s) in	Ventriculomegaly;Wide mouth;Abnormality of the antitragus;Fine hair;Thick vermilion border;Long philtrum;Underdeveloped nasal alae;Aplasia/Hypoplasia of the cerebellum;Hearing impairment;Developmental regression;Intellectual disability;EEG abnormality;Seizure;Camptodactyly of finger;Clinodactyly of the 5th finger;Abnormality of the metacarpal bones;Wide nose;Microcephaly;Gastroesophageal reflux;Abnormal fingernail morphology;Nephrolithiasis;Cerebral cortical atrophy;Spasticity;Abnormality of movement		6.57108e-06	1.0	152182.0	0.0	32	0.96	PASS				0.0	0.0					51	0.65											9e-05	1		1.148	-0.130307		0	0	0			NTNG1	0.0	0.0	0.0	0.0	14.0	-11.0	-17.0	-1.0						0.268	0.44	0.537538047			.			ciliary ganglion;trigeminal ganglion;superior cervical ganglion;atrioventricular node;	Axon guidance	axonogenesis;modulation of chemical synaptic transmission;synaptic membrane adhesion	extracellular region;plasma membrane;anchored component of plasma membrane;Schaffer collateral - CA1 synapse;glutamatergic synapse;anchored component of presynaptic active zone membrane	protein binding;cell adhesion molecule binding;cell-cell adhesion mediator activity	RPN1[30021884];LRRC4[21946559];LRRC4C[21946559];	108023396
194	chr1	109805791	A	T	chr1:109805791	CELSR2	cadherin EGF LAG seven-pass G-type receptor 2	SNV	0/1	0.39	58_37	95	99	rs139406620,COSV99605153	EXONIC	YES	NM_001408.3	Transcript	protein_coding	missense_variant		8/34	NM_001408.3:c.4736A>T	NP_001399.1:p.Asp1579Val		1.0	EGF-like domain&EGF-like domain&EGF-like calcium-binding domain&EGF-like domain					.	.	.		0.00114311	174.0	152216.0	0.0	34	0.99	PASS	nfe	0.00151404	103.0	0.00151404	103.0	0.00127914	321.0	250950.0	1.0	53	0.98	PASS	amr	0.00173903	60.0	0.00166558	189.0	0.0011447	178	0.006	20.0	0.00483	46		23.3	2.858639	0.243	10	8	18	M-CAP_pred,MetaLR_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,DEOGEN2_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,MetaSVM_pred,MutationAssessor_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,ClinPred_pred	CELSR2	0.0	0.0	0.01	0.0	-6.0	-27.0	-8.0	31.0						0.228	1.0	0.000000000	1.0	1.312	nervous system phenotype ; 			caudate nucleus;ciliary ganglion;amygdala;temporal lobe;prefrontal cortex;trigeminal ganglion;superior cervical ganglion;cingulate cortex;cerebellum;pons;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;thalamus;	.	regulation of transcription, DNA-templated;homophilic cell adhesion via plasma membrane adhesion molecules;G protein-coupled receptor signaling pathway;Wnt signaling pathway;neural plate anterior/posterior regionalization;regulation of cell-cell adhesion;dendrite morphogenesis;Wnt signaling pathway, planar cell polarity pathway	cytoplasm;plasma membrane;integral component of membrane	G protein-coupled receptor activity;calcium ion binding	KLF6[16169070];PHF10[16169070];SRC[17474147];LCA5[26638075];GARS[16169070];CRK[17474147];NCK1[17474147];	109805791
371	chr1	167825532	G	A	chr1:167825532	ADCY10	adenylate cyclase 10	SNV	0/1	0.71	7_17	24	99	rs75116612	EXONIC	YES	NM_018417.6	Transcript	protein_coding	missense_variant		17/33	NM_018417.6:c.2042C>T	NP_060887.2:p.Ala681Val		-1.0	.,.,.	Uncertain_significance	criteria_provided,_single_submitter	not_provided	{Hypercalciuria, absorptive, susceptibility to}, 143870 (3), Autosomal dominant	Idiopathic hypercalciuria	Disease-causing germline mutation(s) in	Hypercalciuria;Renal calcium wasting;Osteoporosis;Osteopenia;Calcium oxalate nephrolithiasis;Autosomal dominant inheritance;Heterogeneous;Hypercalciuria;Calcium oxalate nephrolithiasis		0.00157766	240.0	152124.0	1.0	32	0.95	PASS	nfe	0.00305765	208.0	0.00305765	208.0	0.00122178	307.0	251272.0	0.0	100	1.0	PASS	nfe	0.00243039	276.0	0.00243039	276.0	0.0012604	196	0.002	7.0	0.00167	19		10.47	0.618662	0.032	0	19	19		SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	ADCY10	0.0	0.03	0.0	0.0	-28.0	-3.0	27.0	-3.0						0.982	0.0	0.000000000	0.819	-0.166	homeostasis/metabolism phenotype; cellular phenotype; cardiovascular system phenotype ; reproductive system phenotype; 			ciliary ganglion;testis - interstitial;dorsal root ganglion;trigeminal ganglion;superior cervical ganglion;atrioventricular node;testis;skeletal muscle;globus pallidus;	Purine metabolism	epithelial cilium movement;cAMP biosynthetic process;spermatogenesis;intracellular signal transduction;positive regulation of apoptotic process;cellular response to inorganic substance	nucleus;cytoplasm;mitochondrion;cytosol;plasma membrane;microtubule cytoskeleton;dendrite;growth cone;motile cilium;neuronal cell body;apical part of cell;basal part of cell;perinuclear region of cytoplasm	magnesium ion binding;adenylate cyclase activity;ATP binding;manganese ion binding;ATPase binding;bicarbonate binding	TPR[30021884];	167825532
375	chr1	186050402	A	G	chr1:186050402	HMCN1	hemicentin 1	SNV	0/1	0.35	15_8	23	99	rs141564494	EXONIC	YES	NM_031935.3	Transcript	protein_coding	missense_variant		56/107	NM_031935.3:c.8663A>G	NP_114141.2:p.Lys2888Arg		1.0	Immunoglobulin I-set&Immunoglobulin-like domain&Immunoglobulin subtype 2&Immunoglobulin subtype				{Macular degeneration, age-related, 1}, 603075 (3), Autosomal dominant	.	.	Choroidal neovascularization;Progressive visual loss;Macular hemorrhage;Autosomal dominant inheritance;Macular degeneration;Foveal hypopigmentation;Macular drusen;Geographic atrophy		6.57108e-06	1.0	152182.0	0.0	32	0.95	PASS	nfe	1.46985e-05	1.0	1.46985e-05	1.0	1.19568e-05	3.0	250904.0	0.0	100	1.0	PASS	sas	3.26627e-05	1.0	1.76591e-05	2.0	0.0000129	2			9e-05	1		18.55	1.846068	0.053	3	15	18	MutationTaster_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	HMCN1	0.0	0.0	0.0	0.0	-46.0	-35.0	17.0	-46.0						0.675	0.0	0.000000000	0.983	1.312	.			ciliary ganglion;subthalamic nucleus;dorsal root ganglion;skin;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;globus pallidus;cerebellum;	.	cell cycle;homophilic cell adhesion via plasma membrane adhesion molecules;heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules;visual perception;response to bacterium;cell division	basement membrane;cell-cell adherens junction;cell cortex;cleavage furrow;collagen-containing extracellular matrix;extracellular exosome	extracellular matrix structural constituent;calcium ion binding;signaling receptor activity;protein homodimerization activity;cell adhesion molecule binding	B2M[30021884];	186050402
385	chr1	197390257	T	C	chr1:197390257	CRB1	crumbs 1, cell polarity complex component	SNV	0/1	0.61	9_14	23	99	rs1032057202	EXONIC	YES	NM_201253.3	Transcript	protein_coding	synonymous_variant		6/12	NM_201253.3:c.1299T>C	NP_957705.1:p.Tyr433%3D		1.0		Likely_benign	criteria_provided,_single_submitter	Retinitis_pigmentosa_12|Leber_congenital_amaurosis_8	Leber congenital amaurosis 8, 613835 (3), Autosomal recessive; Retinitis pigmentosa-12, 600105 (3), Autosomal recessive; Pigmented paravenous chorioretinal atrophy, 172870 (3), Autosomal dominant	Retinitis pigmentosa;Pigmented paravenous retinochoroidal atrophy;Leber congenital amaurosis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Pendular nystagmus;Autosomal recessive inheritance;Cataract;Undetectable electroretinogram;Keratoconus;High hypermetropia;Choriocapillaris atrophy;Reduced visual acuity;Deeply set eye;Visual impairment;Abnormality of neuronal migration;Severely reduced visual acuity;Aplasia/Hypoplasia of the cerebellar vermis;Encephalocele;Seizure;Abnormal electroretinogram;Muscular hypotonia;Abnormality of retinal pigmentation;Abnormality of the optic disc;Nystagmus;Global developmental delay;Cataract;Hearing impairment;Keratoconus;Intellectual disability;Hemiplegia/hemiparesis;Strabismus;Microphthalmia;Abnormality of retinal pigmentation;Abnormal choroid morphology;Glaucoma;High hypermetropia;Childhood onset;Autosomal recessive inheritance;Rod-cone dystrophy;Nyctalopia;Nystagmus;Hyperinsulinemia;Optic atrophy;Nystagmus;Abnormal retinal vascular morphology;Obesity;Hypoplasia of penis;Cataract;Abnormality of retinal pigmentation;Keratoconus;Progressive night blindness;Ophthalmoplegia;Abnormal testis morphology;Atypical scarring of skin;Hyperreflexia;Sensorineural hearing impairment;Blindness;Type II diabetes mellitus;Conductive hearing impairment;Photophobia;Intellectual disability;Anteverted nares;Abnormal electroretinogram;Wide nasal bridge;Hypogonadism;Glaucoma;Esotropia;Vitreoretinopathy;Hypermetropia;Paravenous chorioretinal atrophy;Bone spicule pigmentation of the retina;Autosomal dominant inheritance;X-linked inheritance		1.9705e-05	3.0	152246.0	0.0	33	0.97	PASS	nfe	4.40878e-05	3.0	4.40878e-05	3.0	3.97735e-06	1.0	251424.0	0.0	100	1.0	PASS	nfe	8.79477e-06	1.0	8.79477e-06	1.0					0.00018	2		8.878	0.446071		0	0	0			CRB1	0.0	0.0	0.0	0.0	-9.0	5.0	34.0	-23.0						0.0401	0.0	7.947566600			endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; mortality/aging ; pigmentation phenotype; nervous system phenotype ; vision/eye phenotype; immune system phenotype; 			.	.	plasma membrane organization;heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules;establishment or maintenance of cell polarity;cell-cell signaling;eye photoreceptor cell development;establishment or maintenance of epithelial cell apical/basal polarity	photoreceptor inner segment;extracellular region;plasma membrane;microvillus;cell-cell adherens junction;integral component of membrane;apical plasma membrane;protein-containing complex	calcium ion binding;protein binding	EXT2[17353931];PATJ[11927608];TSC22D1[17353931];PSMD13[17353931];PRKAR1A[17353931];DDX56[17353931];ALB[15174051];CD2BP2[17353931];MPP5[11927608];	197390257
448	chr1	230846187	G	A	chr1:230846187	AGT	angiotensinogen	SNV	0/1	0.42	43_31	74	99	rs34829218	EXONIC	YES	NM_001382817.3	Transcript	protein_coding	missense_variant		2/5	NM_001382817.3:c.383C>T	NP_001369746.2:p.Thr128Met		-1.0	Serpin domain&Serpin domain&Angiotensinogen serpin domain	Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Renotubular_dysgenesis|not_provided	Renal tubular dysgenesis, 267430 (3), Autosomal recessive; {Preeclampsia, susceptibility to} (3); {Hypertension, essential, susceptibility to}, 145500 (3), Multifactorial	Renal tubular dysgenesis of genetic origin	Disease-causing germline mutation(s) in	Widely patent fontanelles and sutures;Renotubular dysgenesis;Potter facies;Microcephaly;Hypotension;Pulmonary hypoplasia;Respiratory insufficiency;Autosomal recessive inheritance;Oligohydramnios;Anuria;Abnormality of the urinary system;Elevated mean arterial pressure;Multifactorial inheritance;Elevated systolic blood pressure;Elevated diastolic blood pressure	25278896	0.00321881	490.0	152230.0	2.0	33	0.98	PASS	sas	0.00621375	30.0	0.00520359	354.0	0.00321308	808.0	251472.0	2.0	100	1.0	PASS	sas	0.00597727	183.0	0.00457143	520.0	0.0031703	493	0.001	4.0	0.00184	21		5.314	0.165304	0.025	2	18	20	M-CAP_pred,FATHMM_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	AGT	0.0	0.0	0.0	0.0	46.0	-39.0	46.0	-39.0						0.0694	0.0	0.000000000	0.0	-0.548	behavior/neurological phenotype ; liver/biliary system phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; nervous system phenotype ; immune system phenotype; renal/urinary system phenotype; growth/size/body region phenotype; adipose tissue phenotype ; muscle phenotype; homeostasis/metabolism phenotype; 			.	Renin-angiotensin system	regulation of cell growth;positive regulation of cytokine production;kidney development;blood vessel remodeling;regulation of blood volume by renin-angiotensin;renin-angiotensin regulation of aldosterone production;regulation of renal output by angiotensin;regulation of heart rate;regulation of blood vessel diameter by renin-angiotensin;renal system process;angiotensin-mediated drinking behavior;positive regulation of extracellular matrix constituent secretion;protein import into nucleus;cellular sodium ion homeostasis;cell surface receptor signaling pathway;G protein-coupled receptor signaling pathway;G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger;phospholipase C-activating G protein-coupled receptor signaling pathway;activation of phospholipase C activity;positive regulation of cytosolic calcium ion concentration;nitric oxide mediated signal transduction;cell-cell signaling;female pregnancy;aging;regulation of blood pressure;associative learning;regulation of signaling receptor activity;positive regulation of activation of Janus kinase activity;positive regulation of endothelial cell migration;positive regulation of cardiac muscle hypertrophy;positive regulation of cardiac muscle cell apoptotic process;positive regulation of macrophage derived foam cell differentiation;positive regulation of cholesterol esterification;negative regulation of endopeptidase activity;positive regulation of neuron projection development;regulation of norepinephrine secretion;positive regulation of phosphatidylinositol 3-kinase signaling;artery smooth muscle contraction;response to muscle activity involved in regulation of muscle adaptation;negative regulation of angiogenesis;regulation of lipid metabolic process;regulation of vasoconstriction;negative regulation of cell growth;positive regulation of cellular protein metabolic process;response to estradiol;positive regulation of superoxide anion generation;positive regulation of NAD(P)H oxidase activity;negative regulation of tissue remodeling;low-density lipoprotein particle remodeling;operant conditioning;regulation of renal sodium excretion;positive regulation of renal sodium excretion;regulation of cell population proliferation;vasodilation;positive regulation of nitric oxide biosynthetic process;positive regulation of epidermal growth factor receptor signaling pathway;positive regulation of blood pressure;positive regulation of transcription, DNA-templated;positive regulation of insulin receptor signaling pathway;fibroblast proliferation;positive regulation of fibroblast proliferation;regulation of long-term neuronal synaptic plasticity;smooth muscle cell proliferation;cytokine secretion;positive regulation of inflammatory response;positive regulation of peptidyl-tyrosine phosphorylation;positive regulation of NF-kappaB transcription factor activity;negative regulation of neurotrophin TRK receptor signaling pathway;stress-activated MAPK cascade;regulation of calcium ion transport;regulation of transmission of nerve impulse;cell growth involved in cardiac muscle cell development;positive regulation of protein tyrosine kinase activity;ERK1 and ERK2 cascade;uterine smooth muscle contraction;cellular response to mechanical stimulus;positive regulation of branching involved in ureteric bud morphogenesis;regulation of extracellular matrix assembly;positive regulation of gap junction assembly;regulation of cardiac conduction;cellular response to angiotensin;positive regulation of vascular smooth muscle cell proliferation;positive regulation of vascular associated smooth muscle cell migration;positive regulation of L-lysine import across plasma membrane;positive regulation of L-arginine import across plasma membrane;positive regulation of reactive oxygen species metabolic process;positive regulation of extrinsic apoptotic signaling pathway	extracellular region;extracellular space;cytosol;extracellular exosome;blood microparticle	serine-type endopeptidase inhibitor activity;hormone activity;protein binding;growth factor activity;type 1 angiotensin receptor binding;type 2 angiotensin receptor binding	GSDMB[21988832];EWSR1[16189514];AGTR1[23597562];GRB2[18624398];PRCP[20517885];REN[20927107];AGTR2[23597562];	230846187
463	chr1	237870323	G	A	chr1:237870323	RYR2	ryanodine receptor 2	SNV	0/1	0.31	33_15	48	99	rs371147744,CM1411479,COSV63687970	EXONIC	YES	NM_001035.3	Transcript	protein_coding	missense_variant		68/105	NM_001035.3:c.9655G>A	NP_001026.2:p.Val3219Met		1.0	.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Cardiomyopathy|Arrhythmogenic_right_ventricular_dysplasia,_familial,_2|Catecholaminergic_polymorphic_ventricular_tachycardia_type_1|Catecholaminergic_polymorphic_ventricular_tachycardia|Inborn_genetic_diseases|not_specified|not_provided	Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3), Autosomal dominant; Ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, 115000 (3), Autosomal dominant; Arrhythmogenic right ventricular dysplasia 2, 600996 (3), Autosomal dominant	Catecholaminergic polymorphic ventricular tachycardia;Familial isolated arrhythmogenic ventricular dysplasia, right dominant form;Familial isolated arrhythmogenic ventricular dysplasia, biventricular form;Familial isolated arrhythmogenic ventricular dysplasia, left dominant form	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Sudden death;Right ventricular cardiomyopathy;Ventricular arrhythmia;Effort-induced polymorphic ventricular tachycardia;Dilatation of the ventricular cavity;Autosomal dominant inheritance;Syncope;Ventricular tachycardia;Sudden cardiac death;Vertigo;Seizure;Syncope;Ventricular tachycardia;Atrial fibrillation;Sudden death;Atrial standstill;Autosomal dominant inheritance;Left ventricular dysfunction	24033266,25356970,25041964	9.86271e-05	15.0	152088.0	0.0	32	0.96	PASS	nfe	0.00020581	14.0	0.00020581	14.0	7.62636e-05	19.0	249136.0	0.0	86	1.0	PASS	amr	0.000260688	9.0	7.08667e-05	8.0	0.0000707	11			0.0007	8		21.3	2.181459	0.036	4	16	20	M-CAP_pred,FATHMM_pred,LIST-S2_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	RYR2	0.0	0.0	0.0	0.0	10.0	-18.0	4.0	13.0						0.0489	1.0	0.000000000	0.892	0.245	homeostasis/metabolism phenotype; muscle phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; embryo phenotype; immune system phenotype; nervous system phenotype ; neoplasm; mortality/aging ; normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; behavior/neurological phenotype ; 			pons;caudate nucleus;amygdala;temporal lobe;occipital lobe;subthalamic nucleus;prefrontal cortex;cingulate cortex;globus pallidus;medulla oblongata;	Calcium signaling pathway	response to hypoxia;regulation of heart rate;embryonic heart tube morphogenesis;left ventricular cardiac muscle tissue morphogenesis;cardiac muscle hypertrophy;detection of calcium ion;calcium ion transport;cellular calcium ion homeostasis;positive regulation of heart rate;regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion;regulation of cardiac muscle contraction by calcium ion signaling;release of sequestered calcium ion into cytosol by sarcoplasmic reticulum;response to muscle activity;calcium-mediated signaling;BMP signaling pathway;response to caffeine;ion transmembrane transport;calcium-mediated signaling using intracellular calcium source;response to muscle stretch;release of sequestered calcium ion into cytosol;positive regulation of sequestering of calcium ion;regulation of cytosolic calcium ion concentration;response to redox state;regulation of cardiac muscle contraction;cardiac muscle contraction;canonical Wnt signaling pathway;calcium ion transport into cytosol;sarcoplasmic reticulum calcium ion transport;cellular response to caffeine;cellular response to epinephrine stimulus;establishment of protein localization to endoplasmic reticulum;ventricular cardiac muscle cell action potential;Purkinje myocyte to ventricular cardiac muscle cell signaling;cell communication by electrical coupling involved in cardiac conduction;type B pancreatic cell apoptotic process;positive regulation of the force of heart contraction;regulation of AV node cell action potential;regulation of SA node cell action potential;regulation of atrial cardiac muscle cell action potential;regulation of ventricular cardiac muscle cell action potential;positive regulation of calcium-transporting ATPase activity;regulation of cardiac conduction	smooth endoplasmic reticulum;plasma membrane;junctional sarcoplasmic reticulum membrane;membrane;sarcoplasmic reticulum;Z disc;cytoplasmic vesicle membrane;protein-containing complex;sarcoplasmic reticulum membrane;calcium channel complex;sarcolemma	ryanodine-sensitive calcium-release channel activity;calcium channel activity;calcium ion binding;protein binding;calmodulin binding;calcium-release channel activity;enzyme binding;protein kinase A catalytic subunit binding;protein kinase A regulatory subunit binding;identical protein binding;protein self-association;suramin binding;ion channel binding;calcium-induced calcium release activity	FKBP1A[11237759];GOLGA2[30021884];CAMK2D[20479242];ALB[15174051];FKBP1B[11237759;10830164;23233753];MDM2[20195357];HSPB2[26465331];AKAP6[10830164];PRKACA[10830164];SMAD5[15231748];CFTR[17110338];	237870323
590	chr10	112838337	G	A	chr10:112838337	ADRA2A	adrenoceptor alpha 2A	SNV	0/1	0.5	103_104	207	99	rs200592713,COSV54528144	EXONIC	YES	NM_000681.4	Transcript	protein_coding	missense_variant		1/1	NM_000681.4:c.583G>A	NP_000672.3:p.Gly195Ser		1.0						.	.	.		0.000283783	43.0	151524.0	0.0	33	0.97	PASS	amr	0.000328127	5.0	0.000221135	15.0	0.000379418	84.0	221392.0	1.0	25	0.62	PASS	amr	0.000543235	17.0	0.000194087	19.0	0.0003087	48			0.00026	3		19.45	1.963992	0.075	2	13	15	M-CAP_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	ADRA2A	0.0	0.0	0.01	0.0	-18.0	9.0	46.0	41.0								0.000000000	0.323	1.092	nervous system phenotype ; cardiovascular system phenotype ; normal phenotype; mortality/aging ; embryo phenotype; behavior/neurological phenotype ; homeostasis/metabolism phenotype; 			ciliary ganglion;trigeminal ganglion;atrioventricular node;	Neuroactive ligand-receptor interaction	positive regulation of cytokine production;regulation of smooth muscle contraction;G protein-coupled receptor signaling pathway;adenylate cyclase-modulating G protein-coupled receptor signaling pathway;adenylate cyclase-activating G protein-coupled receptor signaling pathway;adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway;Ras protein signal transduction;Rho protein signal transduction;positive regulation of cell population proliferation;negative regulation of norepinephrine secretion;regulation of vasoconstriction;actin cytoskeleton organization;platelet activation;positive regulation of cell migration;activation of protein kinase activity;activation of protein kinase B activity;negative regulation of epinephrine secretion;cellular response to hormone stimulus;receptor transactivation;glucose homeostasis;positive regulation of potassium ion transport;positive regulation of MAP kinase activity;positive regulation of MAPK cascade;positive regulation of epidermal growth factor-activated receptor activity;negative regulation of calcium ion-dependent exocytosis;negative regulation of insulin secretion;regulation of insulin secretion;intestinal absorption;negative regulation of lipid catabolic process;positive regulation of membrane protein ectodomain proteolysis;negative regulation of calcium ion transport;negative regulation of insulin secretion involved in cellular response to glucose stimulus;adrenergic receptor signaling pathway;adenylate cyclase-activating adrenergic receptor signaling pathway;adenylate cyclase-inhibiting adrenergic receptor signaling pathway;phospholipase C-activating adrenergic receptor signaling pathway;positive regulation of wound healing;negative regulation of calcium ion transmembrane transporter activity	cytoplasm;plasma membrane;integral component of plasma membrane;basolateral plasma membrane;receptor complex	adrenergic receptor activity;alpha2-adrenergic receptor activity;protein binding;protein kinase binding;alpha-1B adrenergic receptor binding;alpha-2C adrenergic receptor binding;thioesterase binding;heterotrimeric G-protein binding;protein homodimerization activity;protein heterodimerization activity;epinephrine binding;norepinephrine binding	SH3GL3[25517094];PSMD2[25036637];SH3GL2[25517094];SH3GL1[25517094];	112838337
637	chr11	1471906	G	A	chr11:1471906	BRSK2	BR serine/threonine kinase 2	SNV	0/1	0.48	21_19	40	99	rs144438382	EXONIC	YES	NM_001256630.1	Transcript	protein_coding	synonymous_variant		14/20	NM_001256630.1:c.1515G>A	NP_001243559.1:p.Thr505%3D		1.0						.	.	.		0.00485584	739.0	152188.0	1.0	34	0.98	PASS	nfe	0.00765974	521.0	0.00765974	521.0	0.00567236	1322.0	233060.0	5.0	24	0.7	PASS	nfe	0.0084229	862.0	0.0084229	862.0	0.0057941	901	0.003	9.0	0.00333	38		5.995	0.210449		0	0	0			BRSK2	0.15	0.0	0.0	0.0	24.0	-41.0	24.0	-5.0						0.286	0.78	0.599620294			behavior/neurological phenotype ; normal phenotype; mortality/aging ; nervous system phenotype ; integument phenotype ; cellular phenotype; 			amygdala;prefrontal cortex;whole brain;parietal lobe;cerebellum peduncles;cerebellum;	.	G2/M transition of mitotic cell cycle;protein phosphorylation;exocytosis;axonogenesis;regulation of neuron projection development;peptidyl-serine phosphorylation;establishment of cell polarity;neuron differentiation;actin cytoskeleton reorganization;intracellular signal transduction;ERAD pathway;regulation of ATPase activity;regulation of axonogenesis;cell division;regulation of insulin secretion involved in cellular response to glucose stimulus;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;microtubule cytoskeleton organization involved in establishment of planar polarity;regulation of retrograde protein transport, ER to cytosol;regulation of synaptic vesicle clustering	nucleus;cytoplasm;endoplasmic reticulum;centrosome;perinuclear region of cytoplasm;distal axon	magnesium ion binding;protein serine/threonine kinase activity;ATP binding;protein kinase binding;tau protein binding;tau-protein kinase activity;ATPase binding;ATPase regulator activity	TRAF6[unassigned1304];KBTBD7[20562859];	1471906
945	chr11	47333332	C	T	chr11:47333332	MADD	MAP kinase activating death domain	SNV	0/1	0.25	55_18	73	99	rs759842048,COSV100212037	EXONIC	YES	NM_001376571.1	Transcript	protein_coding	missense_variant		29/37	NM_001376571.1:c.4208C>T	NP_001363500.1:p.Ser1403Leu		1.0	.,.,.,.,.,.,.,.,.,.				Neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), Autosomal recessive; DEEAH syndrome, 619004 (3), Autosomal recessive	.	.	.		3.2858e-05	5.0	152170.0	0.0	32	0.96	PASS	amr	6.54365e-05	1.0	4.40917e-05	3.0	1.98929e-05	5.0	251346.0	0.0	53	1.0	PASS	amr	2.89486e-05	1.0	2.63857e-05	3.0	0.0000129	2			9e-05	1		24.8	3.449277	0.7	13	5	18	LRT_pred,M-CAP_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HDIV_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred	MADD	0.0	0.0	0.01	0.0	-40.0	-49.0	-23.0	37.0						0.861	0.0	0.000000000	0.995	1.026	homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; integument phenotype ; mortality/aging ; nervous system phenotype ; behavior/neurological phenotype ; respiratory system phenotype; 			temporal lobe;amygdala;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;cingulate cortex;testis;cerebellum peduncles;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;parietal lobe;globus pallidus;medulla oblongata;	.	activation of MAPK activity;cell surface receptor signaling pathway;regulation of tumor necrosis factor-mediated signaling pathway;regulation of Rab protein signal transduction;regulation of apoptotic process;regulation of cell cycle;execution phase of apoptosis;regulation of extrinsic apoptotic signaling pathway via death domain receptors;regulation of extrinsic apoptotic signaling pathway	cytoplasm;cytosol;plasma membrane;integral component of membrane	death receptor binding;protein binding;Rab guanyl-nucleotide exchange factor activity;protein kinase activator activity	PTPRB[30021884];WNK1[20936779];THRAP3[30021884];PTPRN[16273344];RB1CC1[25640309];VPS13D[12421765];RIPK4[26972000];ZNF625[30021884];POT1[21044950];YWHAZ[16959763];NUP37[30021884];	47333332
1059	chr11	75298830	A	G	chr11:75298830	MAP6	microtubule associated protein 6	SNV	0/1	0.75	3_9	12	59	rs61739609	EXONIC	YES	NM_033063.2	Transcript	protein_coding	synonymous_variant		4/4	NM_033063.2:c.1716T>C	NP_149052.1:p.Asn572%3D		-1.0						.	.	.		0.00107797	164.0	152138.0	0.0	31	0.96	PASS	amr	0.00274905	42.0	0.00097036	66.0	0.00111356	280.0	251446.0	1.0	100	1.0	PASS	amr	0.00199514	69.0	0.00104621	119.0	0.0007588	118	0.003	9.0	0.00343	39		7.684	0.337295		0	0	0			MAP6	0.0	0.0	0.0	0.0	7.0	-20.0	35.0	-37.0							0.01	35.288785949			nervous system phenotype ; behavior/neurological phenotype ; mortality/aging ; 			pons;dorsal root ganglion;superior cervical ganglion;atrioventricular node;globus pallidus;	.	microtubule cytoskeleton organization;cytoskeleton-dependent intracellular transport;lysosome localization;dendrite morphogenesis;positive regulation of axonogenesis;regulation of microtubule cytoskeleton organization	Golgi-associated vesicle;cis-Golgi network;microtubule;axon;dendrite;transport vesicle membrane;perinuclear region of cytoplasm	protein binding;calmodulin binding;microtubule binding	.	75298830
1096	chr11	113815354	T	G	chr11:113815354	HTR3B	5-hydroxytryptamine receptor 3B	SNV	0/1	0.49	26_25	51	99	rs78418698,COSV99492414	EXONIC	YES	NM_006028.4	Transcript	protein_coding	missense_variant		8/9	NM_006028.4:c.967T>G	NP_006019.1:p.Leu323Val		1.0	Neurotransmitter-gated ion-channel transmembrane domain,.	Likely_benign	criteria_provided,_single_submitter	not_provided		.	.	.		0.00316081	481.0	152176.0	2.0	32	0.96	PASS	sas	0.004756	23.0	0.00461629	314.0	0.00336846	847.0	251450.0	0.0	70	1.0	PASS	sas	0.0046381	142.0	0.00431717	491.0	0.0032346	503	0.009	30.0	0.00827	94		0.018	-0.711071	0.018	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	HTR3B	0.02	0.0	0.0	0.0	-19.0	27.0	-14.0	-2.0						0.416	0.0	0.000000000	0.157	-0.606	growth/size/body region phenotype; behavior/neurological phenotype ; skeleton phenotype; 			.	.	signal transduction;serotonin receptor signaling pathway;chemical synaptic transmission;ion transmembrane transport;regulation of membrane potential;nervous system process	plasma membrane;integral component of plasma membrane;cell surface;neuron projection;synapse;postsynaptic membrane;serotonin-activated cation-selective channel complex	transmembrane signaling receptor activity;extracellular ligand-gated ion channel activity;serotonin-gated cation-selective channel activity	HTR3A[16116092;17392525];	113815354
1103	chr11	118220583	A		chr11:118220583	CD3G	CD3g molecule	deletion	0/1	0.18	18_4	22	54	rs570768621,CM983819,COSV52675786	EXONIC	YES	NM_000073.3	Transcript	protein_coding	frameshift_variant		3/7	NM_000073.3:c.213del	NP_000064.1:p.Lys71AsnfsTer40		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Immunodeficiency_17	Immunodeficiency 17, CD3 gamma deficient, 615607 (3), Autosomal recessive	Combined immunodeficiency due to CD3gamma deficiency	Disease-causing germline mutation(s) in	Immunodeficiency;Failure to thrive;Autoimmune hemolytic anemia;Decreased proportion of CD8-positive T cells;Autosomal recessive inheritance;Recurrent otitis media;Variable expressivity;Eczema;Recurrent respiratory infections;Recurrent gastroenteritis;Abnormal intestine morphology		8.62103e-05	13.0	150794.0	0.0	31	0.96	PASS	eas	0.0011655	6.0	7.39076e-05	5.0	0.000105288	26.0	246942.0	0.0	100	1.0	RF	eas	0.000663497	12.0	9.84798e-05	11.0	0.0000193	3			9e-05	1		13.79	1.053994		0	0	0			CD3G	0.0	0.0	0.0	0.0	-31.0	44.0	22.0	47.0						0.823	0.03	0.000000000			hematopoietic system phenotype; immune system phenotype; endocrine/exocrine gland phenotype; cellular phenotype; 			thymus;	Hematopoietic cell lineage;T cell receptor signaling pathway	adaptive immune response;establishment or maintenance of cell polarity;cell surface receptor signaling pathway;protein transport;T cell differentiation;Fc-gamma receptor signaling pathway involved in phagocytosis;T cell activation;positive thymic T cell selection;regulation of immune response;T cell receptor signaling pathway;protein homooligomerization;membrane organization;protein-containing complex assembly;regulation of lymphocyte apoptotic process	plasma membrane;integral component of plasma membrane;external side of plasma membrane;clathrin-coated vesicle membrane;T cell receptor complex;alpha-beta T cell receptor complex	transmembrane signaling receptor activity;receptor signaling complex scaffold activity;T cell receptor binding;protein homodimerization activity;protein heterodimerization activity	TMEM54[unassigned1304];TMEM203[unassigned1304];MAL[unassigned1304];EMP1[unassigned1304];CD3E[20890284];TMEM262[unassigned1304];LAT[unassigned1304];KTN1[unassigned1304];	118220582
1109	chr11	118896035	C	G	chr11:118896035	SLC37A4	solute carrier family 37 member 4	SNV	0/1	0.31	18_8	26	99	rs782282206	EXONIC	YES	NM_001164278.2	Transcript	protein_coding	missense_variant		11/12	NM_001164278.2:c.1055G>C	NP_001157750.1:p.Trp352Ser		-1.0	Major facilitator superfamily domain&Major facilitator superfamily domain,Major facilitator superfamily domain&Major facilitator superfamily domain,Major facilitator superfamily domain&Major facilitator superfamily domain,Major facilitator superfamily domain&Major facilitator superfamily domain	Uncertain_significance	criteria_provided,_single_submitter	Glucose-6-phosphate_transport_defect	Glycogen storage disease Ib, 232220 (3), Autosomal recessive; Congenital disorder of glycosylation, type IIw, 619525 (3), Autosomal dominant; Glycogen storage disease Ic, 232240 (3), Autosomal recessive	Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib	Disease-causing germline mutation(s) in	Hyperuricemia;Hypoglycemia;Gout;Spider hemangioma;Hyperlipidemia;Decreased glomerular filtration rate;Hepatomegaly;Hyperketonemia;Delayed puberty;Hypertension;Chronic pancreatitis;Autosomal recessive inheritance;Hepatoblastoma;Renal insufficiency;Focal segmental glomerulosclerosis;Xanthelasma;Proteinuria;Hematuria;Pulmonary arterial hypertension;Lactic acidosis;Hepatocellular carcinoma;Metabolic acidosis;Xanthomatosis;Enlarged kidney;Lactic acidosis;Short stature;Doll-like facies;Lipemia retinalis;Delayed puberty;Hypoglycemia;Protuberant abdomen;Proteinuria;Decreased glomerular filtration rate;Focal segmental glomerulosclerosis;Xanthomatosis;Xanthelasma;Gout;Hepatocellular carcinoma;Hyperlipidemia;Hyperuricemia;Hepatomegaly;Oral ulcer;Hypertension;Osteoporosis;Recurrent bacterial infections;Nephrolithiasis;Neutropenia;Pancreatitis;Autosomal recessive inheritance;Elevated hepatic transaminase						33	0.98							8.3757e-06	2.0	238786.0	0.0	28	0.69	PASS	amr	2.99473e-05	1.0	0.0	0.0	0.0000129	2	0.0	1.0	9e-05	1		29.8	4.246282	0.738	8	4	12	SIFT,M-CAP_pred,MutationTaster_pred,MetaRNN_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PolyPhen,PrimateAI_pred,DEOGEN2_pred,LIST-S2_pred	SLC37A4	0.0	0.0	0.0	0.0	-18.0	49.0	-46.0	-7.0							0.0	0.000000000	1.0	1.026	hematopoietic system phenotype; mortality/aging ; liver/biliary system phenotype; behavior/neurological phenotype ; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; nervous system phenotype ; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; 			kidney;liver;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;	.	glucose metabolic process;gluconeogenesis;carbohydrate transport;glucose-6-phosphate transport;phosphate ion transmembrane transport	endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane;integral component of endoplasmic reticulum membrane	transporter activity;glucose-6-phosphate transmembrane transporter activity;glucose 6-phosphate:inorganic phosphate antiporter activity	TCTN3[26638075];BIK[unassigned1304];GPR35[28298427];	118896035
1119	chr11	121000636	A	G	chr11:121000636	TBCEL-TECTA		SNV	0/1	0.46	38_33	71	99	rs146175803,CM115245,COSV50713002	EXONIC	YES	NM_001378761.1	Transcript	protein_coding	missense_variant		16/30	NM_001378761.1:c.3614A>G	NP_001365690.1:p.Asn1205Ser		1.0	von Willebrand factor, type D domain,von Willebrand factor, type D domain,von Willebrand factor, type D domain	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Deafness,_autosomal_dominant_12|Deafness,_autosomal_recessive_21|not_specified|not_provided					24033266,25262649,21520338	0.000604555	92.0	152178.0	0.0	33	0.97	PASS	nfe	0.000955489	65.0	0.000955489	65.0	0.000475095	119.0	250476.0	0.0	73	0.96	PASS	nfe	0.000821381	93.0	0.000821381	93.0	0.0004244	66	0.003	11.0	0.00176	20		23.6	3.011115	0.385	8	11	19	Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,MutationAssessor_pred,MutationTaster_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	M-CAP_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	TECTA	0.0	0.0	0.0	0.0	1.0	-10.0	1.0	6.0								0.000000000	0.772	1.309										121000636
1120	chr11	121000636	A	G	chr11:121000636	TECTA	tectorin alpha	SNV	0/1	0.46	38_33	71	99	rs146175803,CM115245,COSV50713002	EXONIC	YES	NM_005422.4	Transcript	protein_coding	missense_variant		10/24	NM_005422.4:c.2657A>G	NP_005413.2:p.Asn886Ser		1.0	von Willebrand factor, type D domain,von Willebrand factor, type D domain,von Willebrand factor, type D domain	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Deafness,_autosomal_dominant_12|Deafness,_autosomal_recessive_21|not_specified|not_provided	Deafness, autosomal dominant 8/12, 601543 (3), Autosomal dominant; Deafness, autosomal recessive 21, 603629 (3), Autosomal recessive	Autosomal dominant non-syndromic sensorineural deafness type DFNA;Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Sensorineural hearing impairment;Autosomal dominant inheritance;Sensorineural hearing impairment;Autosomal recessive inheritance	24033266,25262649,21520338	0.000604555	92.0	152178.0	0.0	33	0.97	PASS	nfe	0.000955489	65.0	0.000955489	65.0	0.000475095	119.0	250476.0	0.0	73	0.96	PASS	nfe	0.000821381	93.0	0.000821381	93.0	0.0004244	66	0.003	11.0	0.00176	20		23.6	3.011115	0.385	9	12	21	PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,MutationAssessor_pred,MutationTaster_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,M-CAP_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	TECTA	0.0	0.0	0.0	0.0	1.0	-10.0	1.0	6.0						0.229	0.0	0.000000000	0.772	1.309	hearing/vestibular/ear phenotype; nervous system phenotype ; behavior/neurological phenotype ; 			atrioventricular node;superior cervical ganglion;skeletal muscle;	.	cell-matrix adhesion;sensory perception of sound	extracellular region;plasma membrane;anchored component of membrane;collagen-containing extracellular matrix;extracellular exosome	extracellular matrix structural constituent	NEK4[25798074];	121000636
1211	chr12	6630988	A	G	chr12:6630988	NCAPD2	non-SMC condensin I complex subunit D2	SNV	0/1	0.23	10_3	13	66	rs17725914	EXONIC	YES	NM_014865.4	Transcript	protein_coding	missense_variant		15/32	NM_014865.4:c.1739A>G	NP_055680.3:p.Lys580Arg		1.0	.,.	Likely_benign	criteria_provided,_single_submitter	not_provided	?Microcephaly 21, primary, autosomal recessive, 617983 (3), Autosomal recessive	.	.	Sloping forehead;Short stature;Microcephaly;Absent speech;Intellectual disability, moderate;Autosomal recessive inheritance		0.00518301	789.0	152228.0	3.0	32	0.96	PASS	nfe	0.00923095	628.0	0.00923095	628.0	0.0050882	1279.0	251366.0	5.0	64	1.0	PASS	nfe	0.00851678	968.0	0.00851678	968.0	0.0055818	868	0.01	34.0	0.00728	83		13.97	1.083961	0.07	1	18	19	fathmm-MKL_coding_pred	SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-XF_coding_pred	NCAPD2	0.0	0.0	0.0	0.0	-18.0	-15.0	-30.0	47.0						0.771	0.0	0.000000000	0.262	0.944	.			tumor;testis;heart;	.	mitotic chromosome condensation;meiotic chromosome condensation;cell division;chromosome separation	nuclear chromosome;condensed chromosome, centromeric region;condensed chromosome;condensin complex;condensin core heterodimer;nuclear condensin complex;nucleus;nucleoplasm;cytoplasm;cytosol;membrane	chromatin binding;protein binding;histone binding	FOXB1[25609649];CSNK2A1[22113938];KSR1[27086506];NEK6[17353931];FOXG1[25609649];CEP120[26638075];AKAP8[10791967];NCAPG[17268547];CDC5L[20467437];FOXL1[25609649];RRP1B[20926688];NCAPH[17268547;26496610];CNN1[27107012];SNW1[20467437];KATNAL2[26929214];ANG[28777577];	6630988
1322	chr12	103352160	A	T	chr12:103352160	ASCL1	achaete-scute family bHLH transcription factor 1	SNV	0/1	0.42	54_39	93	99	rs552552603	EXONIC	YES	NM_004316.4	Transcript	protein_coding	synonymous_variant		1/2	NM_004316.4:c.138A>T	NP_004307.2:p.Ala46%3D		1.0		Likely_benign	criteria_provided,_single_submitter	not_specified		Haddad syndrome	Disease-causing germline mutation(s) in	Central sleep apnea;Muscular hypotonia;Oligohydramnios;Central hypoventilation;Failure to thrive;Decreased fetal movement;Small for gestational age;Polyhydramnios;Sensorineural hearing impairment;Seizure;Neuroblastoma;Intellectual disability;Abnormal autonomic nervous system physiology;Aganglionic megacolon;Gastroesophageal reflux;Breathing dysregulation;Strabismus;Death in infancy;Ganglioneuroma;Hyperhidrosis;Autosomal dominant inheritance;Low-set ears;Posteriorly rotated ears;Hypoventilation;Abnormality of temperature regulation;Abnormality of the mouth;Hypercapnia;Ganglioneuroma;Ganglioneuroblastoma;Constipation;Apnea;Abnormality of the cardiovascular system;Feeding difficulties;Hypoxemia;Downslanted palpebral fissures;Aganglionic megacolon;Central hypoventilation	24033266	0.00455	674.0	148132.0	3.0	33	0.95	PASS	amr	0.00886785	133.0	0.00618312	416.0	0.00474559	399.0	84078.0	0.0	5	0.19	PASS	nfe	0.00767742	230.0	0.00767742	230.0	0.0006817	106	0.007	24.0	0.01115	126		6.783	0.267011		0	0	0			ASCL1	0.0	0.0	0.0	0.0	7.0	-28.0	48.0	5.0							0.36				nervous system phenotype ; vision/eye phenotype; behavior/neurological phenotype ; respiratory system phenotype; mortality/aging ; normal phenotype; taste/olfaction phenotype; pigmentation phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; growth/size/body region phenotype; integument phenotype ; 			ciliary ganglion;thymus;amygdala;appendix;prefrontal cortex;cingulate cortex;trigeminal ganglion;superior cervical ganglion;pons;fetal brain;whole brain;parietal lobe;skeletal muscle;globus pallidus;	.	negative regulation of transcription by RNA polymerase II;neuron migration;noradrenergic neuron development;noradrenergic neuron fate commitment;regulation of transcription by RNA polymerase II;Notch signaling pathway;regulation of mitotic cell cycle;neuroblast fate determination;neuroblast proliferation;sensory organ development;heart development;response to lithium ion;regulation of gene expression;oligodendrocyte development;spinal cord association neuron differentiation;spinal cord oligodendrocyte cell fate specification;vestibular nucleus development;cerebral cortex GABAergic interneuron differentiation;commitment of neuronal cell to specific neuron type in forebrain;central nervous system neuron development;cerebral cortex development;neurogenesis;neuron differentiation;regulation of epithelial cell differentiation;response to retinoic acid;negative regulation of apoptotic process;positive regulation of neuron apoptotic process;negative regulation of neuron differentiation;positive regulation of neuron differentiation;positive regulation of Notch signaling pathway;positive regulation of cell cycle;negative regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;cell maturation;sympathetic nervous system development;neuron fate commitment;neuron fate specification;neuron development;regulation of neurogenesis;musculoskeletal movement, spinal reflex action;response to folic acid;subpallium neuron fate commitment;regulation of timing of subpallium neuron differentiation;olfactory pit development;lung epithelial cell differentiation;ventral spinal cord interneuron fate commitment;lung neuroendocrine cell differentiation;stomach neuroendocrine cell differentiation;carotid body glomus cell differentiation;adrenal chromaffin cell differentiation;sympathetic ganglion development;response to epidermal growth factor;cellular response to magnetism;positive regulation of neural precursor cell proliferation	nucleus;neuronal cell body;RNA polymerase II transcription factor complex	RNA polymerase II regulatory region sequence-specific DNA binding;RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;chromatin binding;DNA-binding transcription factor activity;protein binding;transcription factor binding;protein homodimerization activity;bHLH transcription factor binding;E-box binding	MTNR1A[26514267];USP20[unassigned1304];UBQLN1[unassigned1304];TCF4[10903890];TCF3[10903890];UBQLN2[unassigned1304];	103352160
1324	chr12	109017773	G	A	chr12:109017773	SELPLG	selectin P ligand	SNV	0/1	0.34	63_32	95	99	rs147444406,COSV99947267	EXONIC	YES	NM_001206609.2	Transcript	protein_coding	missense_variant		2/2	NM_001206609.2:c.359C>T	NP_001193538.1:p.Thr120Met		-1.0	.,.,.					.	.	.		0.00127467	194.0	152196.0	4.0	32	0.97	PASS	amr	0.00209451	32.0	0.00113199	77.0	0.000723917	182.0	251410.0	0.0	100	1.0	PASS	amr	0.00150332	52.0	0.00100269	114.0	0.0005080	79	0.003	11.0	0.0036	41		0.003	-0.949903	0.053	0	19	19		SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SELPLG	0.0	0.0	0.0	0.0	-5.0	-42.0	-13.0	-41.0						0.784	0.0	0.000000000	0.0	-3.163	homeostasis/metabolism phenotype; cellular phenotype; integument phenotype ; renal/urinary system phenotype; immune system phenotype; hematopoietic system phenotype; mortality/aging ; 			white blood cells;superior cervical ganglion;whole blood;spinal cord;skeletal muscle;bone marrow;	Cell adhesion molecules (CAMs)	cell adhesion;viral entry into host cell;leukocyte migration;leukocyte tethering or rolling;leukocyte adhesive activation;cellular response to interleukin-6	uropod;plasma membrane;integral component of plasma membrane;membrane;integral component of membrane;plasma membrane raft	virus receptor activity;signaling receptor binding;protein binding	SELP[11081633;26627825;19118202];MAGEA1[25416956;25910212];FLOT2[24167781];SNX20[18196517];	109017773
1338	chr12	113416431	C	T	chr12:113416431	OAS2	2'-5'-oligoadenylate synthetase 2	SNV	0/1	0.65	6_11	17	99	rs45562438,COSV100660288	EXONIC	YES	NM_016817.3	Transcript	protein_coding	synonymous_variant		1/11	NM_016817.3:c.18C>T	NP_058197.2:p.Ser6%3D		1.0						.	.	.		0.00176209	268.0	152092.0	1.0	32	0.96	PASS	nfe	0.00286723	195.0	0.00286723	195.0	0.00179929	452.0	251210.0	1.0	53	0.98	PASS	nfe	0.00248993	283.0	0.00248993	283.0	0.0016077	250	0.003	10.0	0.00368	42		2.437	-0.012617		0	0	0			OAS2	0.01	0.0	0.0	0.0	46.0	-30.0	31.0	-30.0						0.983	0.0	17.284441283			endocrine/exocrine gland phenotype; integument phenotype ; cellular phenotype; 			ciliary ganglion;appendix;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;	.	nucleobase-containing compound metabolic process;RNA catabolic process;response to virus;response to bacterium;defense response to virus;interferon-gamma-mediated signaling pathway;type I interferon signaling pathway;regulation of ribonuclease activity;regulation of lactation	nucleus;nucleoplasm;cytosol;membrane;intracellular membrane-bounded organelle;perinuclear region of cytoplasm	2'-5'-oligoadenylate synthetase activity;double-stranded RNA binding;protein binding;ATP binding;metal ion binding	FBXO17[unassigned1304];CLK3[25416956;unassigned1304];	113416431
1386	chr13	23908169	T	C	chr13:23908169	SACS	sacsin molecular chaperone	SNV	0/1	0.35	20_11	31	99	rs61753111,COSV66546410	EXONIC	YES	NM_014363.6	Transcript	protein_coding	synonymous_variant		10/10	NM_014363.6:c.9846A>G	NP_055178.3:p.Pro3282%3D		-1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Spastic_paraplegia|Charlevoix-Saguenay_spastic_ataxia|Hereditary_spastic_paraplegia|not_provided	Spastic ataxia, Charlevoix-Saguenay type, 270550 (3), Autosomal recessive	Autosomal recessive spastic ataxia of Charlevoix-Saguenay	Disease-causing germline mutation(s) in	Dysmetria;Lower limb spasticity;Mitral valve prolapse;Absent Achilles reflex;Abnormality of the foot;Impaired tactile sensation;Hypermyelinated retinal nerve fibers;Hypoplasia of the corpus callosum;Dysphagia;Foot dorsiflexor weakness;Cerebellar vermis hypoplasia;Arachnoid cyst;Abnormal motor evoked potentials;Impaired vibratory sensation;Behavioral abnormality;Cerebellar atrophy;Demyelinating peripheral neuropathy;Urinary incontinence;Difficulty walking;Babinski sign;Impotence;Sensorimotor neuropathy;Intention tremor;Abnormality of the pons;Unsteady gait;Abnormality of the cerebellar peduncle;Parietal cortical atrophy;Dysarthria;Progressive cerebellar ataxia;Gaze-evoked horizontal nystagmus;Distal amyotrophy;Gait ataxia;Scanning speech;Scoliosis;Distal sensory impairment;Urinary urgency;Peroneal muscle atrophy;Spastic ataxia;Autosomal recessive inheritance;Pes cavus;Nystagmus;Infantile onset;Progressive truncal ataxia;Decreased number of large peripheral myelinated nerve fibers;Loss of Purkinje cells in the cerebellar vermis;Hyperactive patellar reflex;Decreased sensory nerve conduction velocity;Impaired smooth pursuit;Distal muscle weakness;Hammertoe;Hyperreflexia;Impaired vibration sensation in the lower limbs;Progressive gait ataxia;Upper motor neuron dysfunction;Spastic gait;Decreased motor nerve conduction velocity;Cerebellar vermis atrophy;Swan neck-like deformities of the fingers;Hypermyelinated retinal nerve fibers;Ataxia;Dysarthria;Onion bulb formation;Falls;Babinski sign;Absent Achilles reflex;Intellectual disability;Distal amyotrophy;Dysmetria		0.00271343	413.0	152206.0	0.0	33	0.97	PASS	nfe	0.00435115	296.0	0.00435115	296.0	0.00292169	733.0	250882.0	1.0	91	1.0	PASS	nfe	0.00467686	530.0	0.00467686	530.0	0.0032604	507	0.002	6.0	0.00132	15		8.045	0.368109		0	0	0			SACS	0.0	0.0	0.0	0.0	16.0	-2.0	-8.0	-1.0						0.0165	0.0	59.179255320			cellular phenotype; muscle phenotype; behavior/neurological phenotype ; nervous system phenotype ; 			.	.	protein folding;negative regulation of inclusion body assembly	nucleus;cytoplasm;mitochondrion;axon;dendrite;cell body fiber	Hsp70 protein binding;chaperone binding;proteasome binding	TSC22D4[16713569];PLK1[26496610];ACTN4[16713569];ADRB2[28298427];PPP1CA[19389623];PTBP3[22575643];SOD1[30021884];ZNRD1[16713569];TRIM29[26496610];P4HA2[30021884];MYC[21150319];ALB[15174051];PICK1[16713569];TP63[20085233];HNRNPA0[30021884];	23908169
1399	chr13	32953896	G	A	chr13:32953896	BRCA2	BRCA2, DNA repair associated	SNV	0/1	0.42	7_5	12	99	rs778052683,COSV66464073	EXONIC	YES	NM_000059.4	Transcript	protein_coding	missense_variant		23/27	NM_000059.4:c.8963G>A	NP_000050.3:p.Ser2988Asn		1.0	.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	Fanconi anemia, complementation group D1, 605724 (3), Autosomal recessive; {Glioblastoma 3}, 613029 (3), Autosomal recessive; {Medulloblastoma}, 155255 (3), Autosomal recessive, Somatic mutation, Autosomal dominant; {Prostate cancer}, 176807 (3), Somatic mutation, Autosomal dominant; {Breast-ovarian cancer, familial, 2}, 612555 (3), Autosomal dominant; {Breast cancer, male, susceptibility to}, 114480 (3), Somatic mutation, Autosomal dominant; {Pancreatic cancer 2}, 613347 (3); Wilms tumor, 194070 (3), Somatic mutation, Autosomal dominant	Fanconi anemia;Nephroblastoma;Familial prostate cancer;Hereditary site-specific ovarian cancer syndrome;Hereditary breast and ovarian cancer syndrome;Hereditary breast cancer;Familial pancreatic carcinoma;Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations	Disease-causing germline mutation(s) in;Candidate gene tested in;Major susceptibility factor in;Major susceptibility factor in;Disease-causing germline mutation(s) (loss of function) in;Major susceptibility factor in;Major susceptibility factor in;Disease-causing germline mutation(s) in	Somatic mutation;Autosomal dominant inheritance;Heterogeneous;Breast carcinoma;Microcephaly;Chromosomal breakage induced by crosslinking agents;Autosomal recessive inheritance;Bone marrow hypocellularity;Cafe-au-lait spot;Intrauterine growth retardation;Short stature;Anal atresia;T-cell acute lymphoblastic leukemias;Short thumb;Failure to thrive;Acute myeloid leukemia;Hematuria;Neoplasm of the liver;Hypertension;Abdominal pain;Nephroblastoma;Neoplasm of the lung;Weight loss;Lymphadenopathy;Fever;Aniridia;Autosomal recessive inheritance;Glioblastoma multiforme;Astrocytoma;Medulloblastoma;Elevated hepatic transaminase;Breast carcinoma;Weight loss;Melanoma;Poor appetite;Ovarian carcinoma;Colon cancer;Nausea and vomiting;Back pain;Hepatosplenomegaly;Functional intestinal obstruction;Peritoneal abscess;Diabetes mellitus;Exocrine pancreatic insufficiency;Pancreatic adenocarcinoma;Anorexia;Intermittent diarrhea;Extrahepatic cholestasis;Neoplasm of the liver;Intestinal pseudo-obstruction;Abdominal pain;Lymphadenopathy;Jaundice;Chronic fatigue;Medulloblastoma;Autosomal dominant inheritance;Incomplete penetrance;Autosomal recessive inheritance;Primary peritoneal carcinoma;Melanoma;Neoplasm of the pancreas;Prostate cancer;Breast carcinoma;Ovarian neoplasm;Abnormal fallopian tube morphology;Hydroureter;Hypopigmented skin patches;Cranial nerve paralysis;Umbilical hernia;Epicanthus;Weight loss;Choanal atresia;Myelodysplasia;Hypogonadism;Scoliosis;Hip dislocation;Recurrent urinary tract infections;Abnormality of the hypothalamus-pituitary axis;Short palpebral fissure;Hypertrophic cardiomyopathy;High palate;Aplasia/Hypoplasia of the iris;Decreased fertility in males;Aplasia/Hypoplasia of fingers;Toe syndactyly;Irregular hyperpigmentation;Almond-shaped palpebral fissure;Tetralogy of Fallot;Astigmatism;Pyridoxine-responsive sideroblastic anemia;Meckel diverticulum;Hypertelorism;Sloping forehead;Ptosis;Anal atresia;Cryptorchidism;Intellectual disability;Facial asymmetry;Visual impairment;Upslanted palpebral fissure;Duodenal stenosis;Abnormality of the liver;Aplasia/Hypoplasia of the uvula;Abnormal carotid artery morphology;Hypospadias;Nystagmus;Multiple cafe-au-lait spots;Renal insufficiency;Clinodactyly of the 5th finger;Bicornuate uterus;Abnormality of chromosome stability;Strabismus;Micrognathia;Hypoplasia of the ulna;Proptosis;Atrial septal defect;Abnormal aortic valve morphology;Abnormality of femur morphology;Cataract;Microphthalmia;Hydrocephalus;Ventriculomegaly;Aganglionic megacolon;Absent testis;Hearing impairment;Arteriovenous malformation;Azoospermia;Renal hypoplasia/aplasia;Thrombocytopenia;Finger syndactyly;Oligohydramnios;External ear malformation;Global developmental delay;Aplasia/Hypoplasia of the radius;Reduced bone mineral density;Clubbing of toes;Microcephaly;Abnormal aortic morphology;Frontal bossing;Dolichocephaly;Spina bifida;Leukopenia;Tracheoesophageal fistula;Patent ductus arteriosus;Abnormality of the preputium;Hyperreflexia;Short stature;Abnormal localization of kidney;Cleft palate;Triphalangeal thumb;Intrauterine growth retardation;Pes planus;Autosomal dominant inheritance;Somatic mutation;Prostate cancer;Neoplasm of the pancreas;Nephroblastoma;Somatic mutation;Autosomal dominant inheritance;Heterogeneous;Multifactorial inheritance;Breast carcinoma;Ovarian neoplasm;Autosomal dominant inheritance						32	0.98							3.98781e-06	1.0	250764.0	0.0	68	0.99	PASS				0.0	0.0	0.0000064	1			9e-05	1		18.6	1.852722	0.166	3	13	16	M-CAP_pred,MutationTaster_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	BRCA2	0.01	0.03	0.0	0.0	-9.0	42.0	45.0	-1.0						0.0896	0.0	0.000000000	0.99	1.176	limbs/digits/tail phenotype; nervous system phenotype ; digestive/alimentary phenotype; immune system phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype ; normal phenotype; mortality/aging ; reproductive system phenotype; hematopoietic system phenotype; neoplasm; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; integument phenotype ; growth/size/body region phenotype; 			.	Homologous recombination;Pancreatic cancer	mitotic cytokinesis;telomere maintenance via recombination;double-strand break repair via homologous recombination;oocyte maturation;inner cell mass cell proliferation;nucleotide-excision repair;double-strand break repair;DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator;male meiosis I;brain development;cell aging;response to X-ray;response to UV-C;response to gamma radiation;hemopoiesis;regulation of cytokinesis;negative regulation of mammary gland epithelial cell proliferation;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;histone H3 acetylation;histone H4 acetylation;positive regulation of transcription, DNA-templated;positive regulation of mitotic cell cycle;replication fork protection;centrosome duplication;establishment of protein localization to telomere;mitotic recombination-dependent replication fork processing	nuclear chromosome, telomeric region;lateral element;nucleus;nucleoplasm;centrosome;cytosol;secretory granule;protein-containing complex;BRCA2-MAGE-D1 complex	protease binding;single-stranded DNA binding;histone acetyltransferase activity;protein binding;protein C-terminus binding;H3 histone acetyltransferase activity;H4 histone acetyltransferase activity;identical protein binding;gamma-tubulin binding	MDC1[29656893];PCNA[22293751];USP11[26649820];BRCA1[22193777;19369211;29656893];PDS5B[22293751];BRCA2[21601571;25282148];SMC3[22293751];CDC45[22293751];XPO1[24013206];RAD21[22293751];ABL1[17474147];HMG20B[21399666];ZC3H18[29298432];FYN[17474147];TP53BP1[29656893];MTA2[19703393];MAPK6[26972000];POLH[24485656];EGLN3[26972000];PARP1[18990703];XRCC3[24141787;26496610];RPA1[12527904];RPA2[12527904];RAD23A[16712842];PALB2[19609323;22193777;22293751;24141787;24485656;17420451;19369211;26649820];SEM1[10373512;22293751;16205630;24013206];NEURL4[29426014];RAD51[12442171;10551859;9560268;15800615;17541404;19303847;21601571;21399666;22116401;22293751;17515903;17515904;18264088;19628690;20729832;20729859;25282148];RAD51C[24141787];FANCD2[15115758;18212739];KATNAL2[26929214];NCL[30021884];DMC1[17541404;20729832];GRB2[17474147];SYCP3[22116401];TP53[20421506];	32953896
1634	chr14	92549605	AA		chr14:92549605-92549606	ATXN3	ataxin 3	deletion	0/1	0.18	9_2	11	47	rs146481848	SPLICING	YES	NM_004993.6	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	6/10		NM_004993.6:c.476-4_476-3del			-1.0					Machado-Joseph disease, 109150 (3), Autosomal dominant	Machado-Joseph disease type 1;Machado-Joseph disease type 3;Machado-Joseph disease type 2	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Proptosis;Dysarthria;Vocal cord paralysis;Dystonia;Hyperreflexia;Peripheral neuropathy;Vestibular dysfunction;Muscle spasm;Spinocerebellar tract degeneration;Memory impairment;Abnormality of extrapyramidal motor function;Supranuclear ophthalmoplegia;Delayed speech and language development;Degeneration of the striatum;Distal lower limb amyotrophy;Diplopia;Spasticity;Sleep disturbance;Cerebellar atrophy;Progressive gait ataxia;Babinski sign;Progressive cerebellar ataxia;Neurogenic bladder;Facial-lingual fasciculations;Progressive external ophthalmoplegia;Dilated fourth ventricle;Gaze-evoked nystagmus;Clumsiness;Substantia nigra gliosis;Dysphagia;Abnormality of temperature regulation;Supranuclear ophthalmoplegia;Abnormality of temperature regulation;Proptosis;Diplopia;Dystonia;Dilated fourth ventricle;Facial-lingual fasciculations;Dysarthria;Gaze-evoked nystagmus;Spasticity;Dysphagia;Hyperreflexia;Memory impairment;Neurogenic bladder;Vestibular dysfunction;Sleep disturbance;Degeneration of anterior horn cells;Cerebellar atrophy;Progressive gait ataxia;Degeneration of the striatum;Progressive external ophthalmoplegia;Distal lower limb amyotrophy;Muscle spasm;EMG abnormality;Substantia nigra gliosis;Vocal cord paralysis;Delayed speech and language development;Abnormality of extrapyramidal motor function;Peripheral axonal neuropathy;Abnormal lower motor neuron morphology;Distal muscle weakness;Spinocerebellar tract degeneration;Babinski sign;Clumsiness;Progressive cerebellar ataxia;Dystonia;Progressive cerebellar ataxia;Neurogenic bladder;Memory impairment;Spinocerebellar tract degeneration;Substantia nigra gliosis;Cerebellar atrophy;Abnormality of extrapyramidal motor function;Abnormality of temperature regulation;Peripheral neuropathy;Diplopia;Gaze-evoked nystagmus;Hyperreflexia;Proptosis;Supranuclear ophthalmoplegia;Delayed speech and language development;Dysarthria;Dysphagia;Degeneration of the striatum;Vocal cord paralysis;Clumsiness;Progressive gait ataxia;Sleep disturbance;Spasticity;Babinski sign;Dilated fourth ventricle;Muscle spasm;Facial-lingual fasciculations;Vestibular dysfunction;Distal lower limb amyotrophy;Progressive external ophthalmoplegia;Abnormal autonomic nervous system physiology;Dystonia;Fasciculations;Diplopia;Distal amyotrophy;Parkinsonism;Muscle spasm;Ptosis;Babinski sign;Chronic pain;Autosomal dominant inheritance;Gliosis;Supranuclear ophthalmoplegia;Dysphagia;Truncal ataxia;Spinocerebellar tract degeneration;External ophthalmoplegia;Dementia;Postural instability;Progressive cerebellar ataxia;Dilated fourth ventricle;Impaired vibratory sensation;Spasticity;Facial-lingual fasciculations;Dysmetric saccades;Absent Achilles reflex;Genetic anticipation;Limb ataxia;Ataxia;Gaze-evoked nystagmus;Dysarthria;Urinary bladder sphincter dysfunction;Proptosis;Progressive;Bradykinesia;Cerebellar atrophy;Impaired horizontal smooth pursuit;Abnormal electrooculogram;Rigidity		0.0	0.0	143186.0	0.0	32	0.94	AC0				0.0	0.0	3.35666e-05	4.0	119166.0	0.0	33	0.78	RF	sas	8.37942e-05	1.0	1.70224e-05	1.0	0.0000064	1			9e-05	1		13.46	1.004213		0	0	0			ATXN3	0.41	0.0	0.0	0.0	-25.0	-2.0	-25.0	3.0						0.895	0.18				homeostasis/metabolism phenotype; nervous system phenotype ; hematopoietic system phenotype; behavior/neurological phenotype ; 			ciliary ganglion;temporal lobe;appendix;testis - interstitial;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;	.	microtubule cytoskeleton organization;nucleotide-excision repair;ubiquitin-dependent protein catabolic process;protein quality control for misfolded or incompletely synthesized proteins;chemical synaptic transmission;nervous system development;regulation of cell-substrate adhesion;protein deubiquitination;actin cytoskeleton organization;cellular response to heat;monoubiquitinated protein deubiquitination;exploration behavior;proteasome-mediated ubiquitin-dependent protein catabolic process;intermediate filament cytoskeleton organization;protein K63-linked deubiquitination;histone H3 deacetylation;protein K48-linked deubiquitination;cellular response to misfolded protein;positive regulation of ERAD pathway;protein localization to cytosolic proteasome complex involved in ERAD pathway	nucleus;nucleoplasm;nucleolus;cytoplasm;mitochondrial matrix;endoplasmic reticulum membrane;cytosol;plasma membrane;nuclear matrix;mitochondrial membrane;nuclear inclusion body	RNA polymerase II regulatory region DNA binding;histone deacetylase activity;thiol-dependent ubiquitin-specific protease activity;protein binding;ubiquitin protein ligase binding;thiol-dependent ubiquitinyl hydrolase activity;ATPase binding;Lys63-specific deubiquitinase activity;Lys48-specific deubiquitinase activity	OTUB2[19615732];USP13[19615732];PRKN[24063750];GSK3B[21900206];BECN1[28445460];VCP[12944474;16525503;20414249];CDKN1A[21900206];SDC2[26496610];ARHGAP19[16713569];RSF1[26496610];SLC3A2[26496610];SRI[26496610];ATXN3[16525503;22129356];PSMD7[12944474];UBB[16525503];MKNK1[21900206];BCL7C[26496610];UBC[14559776;19153604];RPS6KA1[21900206];UBQLN1[17082820];ANXA7[21900206];TK1[21900206];C16orf70[16713569];TEX11[16713569];TIMM23[26496610];RAD23A[16713569;unassigned1304];UBE4B[16525503];HLA-A[26496610];RAD23B[16713569;16712842];DNM2[21900206];TMCO1[26496610];CAMSAP3[26496610];NFKBIA[26496610];CNOT6[26496610];PSRC1[26496610];EWSR1[16713569];KCTD10[19615732];CANX[26496610];NDUFAF2[26496610];PICK1[16713569];HAP1[21386698];	92549604
1749	chr15	42167165	T	C	chr15:42167165	SPTBN5	spectrin beta, non-erythrocytic 5	SNV	0/1	0.48	56_51	107	99	rs111958620	EXONIC	YES	NM_016642.4	Transcript	protein_coding	synonymous_variant		23/68	NM_016642.4:c.4377A>G	NP_057726.4:p.Lys1459%3D		-1.0						.	.	.		0.00407412	620.0	152180.0	3.0	33	0.98	PASS	sas	0.00765412	37.0	0.00510234	347.0	0.00567976	1410.0	248250.0	12.0	70	0.99	PASS	sas	0.00804132	246.0	0.00590593	663.0	0.0052410	815	0.006	21.0	0.0057	65		0.768	-0.18995		0	0	0			SPTBN5	0.0	0.0	0.01	0.0	15.0	-13.0	-19.0	-2.0							0.0	16.866632416			.			ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	.	MAPK cascade;endoplasmic reticulum to Golgi vesicle-mediated transport;Golgi organization;lysosomal transport;axon guidance;actin cytoskeleton organization;protein homooligomerization;actin filament capping	cytoplasm;microtubule organizing center;cytosol;spectrin;membrane;filamentous actin;photoreceptor connecting cilium;photoreceptor disc membrane	actin binding;Ras guanyl-nucleotide exchange factor activity;kinesin binding;spectrin binding;myosin tail binding;dynactin binding;protein self-association;dynein intermediate chain binding	FBF1[26638075];CANX[29568061];SBDS[30021884];	42167165
1814	chr15	65312615	AAA		chr15:65312615-65312617	MTFMT	mitochondrial methionyl-tRNA formyltransferase	deletion	0/1	0.33	4_2	6	54	rs372515409	SPLICING	YES	NM_139242.4	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	4/8		NM_139242.4:c.646-7_646-5del			-1.0					Combined oxidative phosphorylation deficiency 15, 614947 (3), Autosomal recessive; Mitochondrial complex I deficiency, nuclear type 27, 618248 (3), Autosomal recessive	Leigh syndrome with leukodystrophy;Combined oxidative phosphorylation defect type 15	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Global developmental delay;Optic atrophy;Infantile onset;Generalized hypotonia;Autosomal recessive inheritance;Neurogenic bladder;Spasticity;Intellectual disability, severe;Increased serum lactate;Ophthalmoplegia;Apnea;Nystagmus;Global developmental delay;Decreased activity of mitochondrial respiratory chain;Emotional lability;Seizure;Hyperreflexia;Ventricular septal defect;Decreased activity of the pyruvate dehydrogenase complex;Focal T2 hyperintense basal ganglia lesion;Failure to thrive;Pigmentary retinopathy;Ptosis;Hypertrichosis;Anemia;Increased CSF lactate;Optic atrophy;Hearing impairment;Muscular hypotonia;Dysarthria;Progressive spastic paraplegia;Progressive cerebellar ataxia;Strabismus;Peripheral neuropathy;Dystonia;Hypertrophic cardiomyopathy;Leukodystrophy;Optic atrophy;Seizure;Abnormality of the cerebral white matter;Unsteady gait;Short stature;Increased CSF lactate;Global developmental delay;Ataxia;Tremor;Ventricular septal defect;Obesity;Delayed speech and language development;Generalized hypotonia;Nystagmus;Ventricular septal hypertrophy;Wolff-Parkinson-White syndrome;Increased serum lactate;Abnormal pyramidal sign;Microcephaly;Strabismus;Reduced visual acuity;Cognitive impairment;Incoordination;Autosomal recessive inheritance		1.29557e-05	1.0	77186.0	0.0	31	0.87	PASS	afr	4.44919e-05	1.0	0.0	0.0	0.00057217	60.0	104864.0	0.0	26	0.69	InbreedingCoeff	sas	0.00127877	19.0	0.000545579	24.0	0.0002315,0.0000064	36,1			0.0022	25		11.1	0.693368		0	0	0			MTFMT	0.05	0.0	0.0	0.0	-14.0	8.0	-4.0	6.0						0.817	0.0				mortality/aging ; 			ciliary ganglion;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;	Methionine metabolism;One carbon pool by folate;Aminoacyl-tRNA biosynthesis	translational initiation;conversion of methionyl-tRNA to N-formyl-methionyl-tRNA	mitochondrion	methionyl-tRNA formyltransferase activity	PTPMT1[27499296];HDHD5[27499296];MAIP1[27499296];	65312614
1836	chr15	66777468	G	C	chr15:66777468	MAP2K1	mitogen-activated protein kinase kinase 1	SNV	0/1	0.25	12_4	16	50	COSV100199245	EXONIC	YES	NM_002755.4	Transcript	protein_coding	missense_variant		7/11	NM_002755.4:c.834G>C	NP_002746.1:p.Gln278His		1.0	Protein kinase domain&Protein kinase domain&Protein kinase domain,Protein kinase domain&Protein kinase domain&Protein kinase domain				Cardiofaciocutaneous syndrome 3, 615279 (3), Autosomal dominant; Melorheostosis, isolated, somatic mosaic, 155950 (3)	Cardiofaciocutaneous syndrome	Disease-causing germline mutation(s) (gain of function) in	Curly hair;Muscular hypotonia;Pectus excavatum;Global developmental delay;Seizure;Hyperhidrosis;Reduced bone mineral density;Abnormality of the palpebral fissures;Wide mouth;Pulmonic stenosis;Scoliosis;Hypertrophic cardiomyopathy;Heat intolerance;Failure to thrive;Nystagmus;Hyperkeratosis pilaris;Hydrocephalus;Myopia;Deep palmar crease;Lymphedema;Long palpebral fissure;Hyperextensible skin;Biparietal narrowing;Abnormality of vision;Sparse or absent eyelashes;Full cheeks;Hypertelorism;Cryptorchidism;Sparse hair;Long philtrum;Thickened helices;Genu valgum;High forehead;Dry skin;Long face;Macrocephaly;Abnormal heart valve morphology;Palmoplantar keratoderma;Hypertrophic cardiomyopathy;Ichthyosis;Muscular hypotonia;Fine hair;Ptosis;Depressed nasal bridge;Short neck;Multiple cafe-au-lait spots;Anteverted nares;Scoliosis;Short stature;Feeding difficulties in infancy;Redundant skin;Slow-growing hair;Cavernous hemangioma;Macrotia;Cerebral cortical atrophy;Hypoplasia of the zygomatic bone;Brittle hair;Failure to thrive in infancy;Global developmental delay;Pectus excavatum;Premature birth;Nystagmus;Strabismus;Abnormality of the ulna;Intellectual disability;Atrial septal defect;Excessive wrinkled skin;Submucous cleft hard palate;Downslanted palpebral fissures;Epicanthus;Cubitus valgus;Functional abnormality of the gastrointestinal tract;Webbed neck;Short nose;Hydronephrosis;Pulmonic stenosis;Aplasia/Hypoplasia of the eyebrow;High palate;Dysarthria;Underdeveloped supraorbital ridges;Multiple lentigines;Generalized hyperpigmentation;Frontal bossing;EEG abnormality;Low-set, posteriorly rotated ears;Low posterior hairline;Dystrophic fingernails;Optic atrophy;Coarse facial features;Failure to thrive in infancy;Ptosis;Short neck;Brachydactyly;Shield chest;Neoplasm;Male infertility;Coarctation of aorta;Kyphoscoliosis;Pulmonic stenosis;High palate;Triangular face;Short stature;Cryptorchidism;Patent ductus arteriosus;Cubitus valgus;Hypertelorism;Autosomal dominant inheritance;Downslanted palpebral fissures;Superior pectus carinatum;Sensorineural hearing impairment;Epicanthus;High, narrow palate;Pectus excavatum of inferior sternum;Abnormality of the vertebral column;Lymphedema;Ventricular septal defect;Cystic hygroma;Webbed neck;Intellectual disability;Neurofibrosarcoma;Myopia;Reduced factor XII activity;Low-set, posteriorly rotated ears;Clinodactyly;Dental malocclusion;Low posterior hairline;Synovitis;Radial deviation of finger;Hypogonadism;Atrial septal defect;Postnatal growth retardation;Abnormal bleeding;Amegakaryocytic thrombocytopenia;Hypertrophic cardiomyopathy;Heterogeneous;Reduced factor XIII activity;Micrognathia						32	0.97											91	1.0											9e-05	1		14.92	1.249658	0.121	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MAP2K1	0.04	0.0	0.0	0.0	-34.0	1.0	-13.0	0.0						0.0532	0.99	76.530214162	0.422	-2.778	digestive/alimentary phenotype; hearing/vestibular/ear phenotype; nervous system phenotype ; vision/eye phenotype; skeleton phenotype; embryo phenotype; cardiovascular system phenotype ; mortality/aging ; integument phenotype ; normal phenotype; endocrine/exocrine gland phenotype; neoplasm; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; 			caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;cerebellum;occipital lobe;subthalamic nucleus;whole brain;parietal lobe;globus pallidus;hypothalamus;medulla oblongata;thalamus;	MAPK signaling pathway;ErbB signaling pathway;VEGF signaling pathway;Focal adhesion;Gap junction;Toll-like receptor signaling pathway;Natural killer cell mediated cytotoxicity;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	MAPK cascade;activation of MAPK activity;protein phosphorylation;chemotaxis;cell cycle arrest;signal transduction;heart development;negative regulation of cell population proliferation;positive regulation of gene expression;negative regulation of gene expression;peptidyl-threonine phosphorylation;peptidyl-tyrosine phosphorylation;cerebellar cortex formation;signal transduction by protein phosphorylation;neuron differentiation;keratinocyte differentiation;thyroid gland development;stress-activated protein kinase signaling cascade;activation of protein kinase activity;regulation of stress-activated MAPK cascade;positive regulation of transcription, DNA-templated;thymus development;regulation of axon regeneration;cell motility;positive regulation of axonogenesis;Bergmann glial cell differentiation;face development;trachea formation;epithelial cell proliferation involved in lung morphogenesis;placenta blood vessel development;labyrinthine layer development;ERK1 and ERK2 cascade;positive regulation of ERK1 and ERK2 cascade;positive regulation of protein serine/threonine kinase activity;regulation of Golgi inheritance;cellular senescence;positive regulation of production of miRNAs involved in gene silencing by miRNA;regulation of early endosome to late endosome transport	nucleus;cytoplasm;mitochondrion;early endosome;late endosome;endoplasmic reticulum;Golgi apparatus;microtubule organizing center;cytosol;plasma membrane;focal adhesion	protein kinase activity;protein serine/threonine kinase activity;MAP kinase kinase activity;protein serine/threonine/tyrosine kinase activity;protein tyrosine kinase activity;protein binding;ATP binding;protein C-terminus binding;protein serine/threonine kinase activator activity;protein N-terminus binding;scaffold protein binding	YWHAE[17979178];PLEKHF2[unassigned1304];YWHAB[17979178;24255178];ARAF[17979178;24746704;26496610];PTPRJ[24412244];HSCB[28380382];STK11[24412244];CDH1[24412244];PEBP4[19197339];MYC[26496610];TCTN1[26638075];MAP3K8[12832462];BTRC[24211253];TCP11[unassigned1304];RBM33[26496610];KSR1[17979178;26496610;27086506];FBXW7[24412244];HLA-B[17353931];VRK2[20679487;22752157];THOC2[26496610];KSR2[27086506];YWHAZ[17979178];PDGFRL[24412244];TGFBR2[24412244];MSH6[24412244];PKM[24606918];PIK3CA[24412244];POC5[26638075];TRIB3[15299019];BIRC6[18329369];TRIB1[15299019];RAF1[17979178;19197339;24746704;25155755;26496610;17724343;23934108];BLVRA[18463290];TLR2[24412244];ZNF277[26496610];GLYR1[unassigned1304];YAP1[24211253];PSMD10[24338975];SRC[24412244];ODC1[24412244];SKA3[26496610];AURKA[24412244];ERBB2[24412244];CTNNA1[24412244];MAPK1[17255949;23241949];BUB1[24412244];MAPK3[19197339];BANP[25416956;unassigned1304];SMAD2[24412244];HSPA8[17979178];MAP3K1[17110930];CDKN2A[24412244];BRAF[17979178;24746704;25155755;25600339;26496610;23934108;25437913];CFLAR[17110930];MLH3[24412244];CEP170P1[26496610];APC[24412244];WNK1[20936779];BAX[24412244];PIN1[20179161];CALR[22752157];DCP1A[26496610];HSPA1A[17979178];BMPR1A[24412244];	66777468
1876	chr15	81225763	G	A	chr15:81225763	CEMIP	cell migration inducing hyaluronidase 1	SNV	0/1	0.28	13_5	18	99	rs750368243,COSV99586282	EXONIC	YES	NM_001293298.2	Transcript	protein_coding	missense_variant		23/30	NM_001293298.2:c.2971G>A	NP_001280227.1:p.Asp991Asn		1.0	.,.,.					.	.	.		5.91475e-05	9.0	152162.0	0.0	33	0.97	PASS	amr	6.54622e-05	1.0	5.87924e-05	4.0	5.96654e-05	15.0	251402.0	0.0	87	1.0	PASS	nfe	5.27704e-05	6.0	5.27704e-05	6.0	0.0000386	6			9e-05	1		23.0	2.747231	0.215	14	7	21	PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,MetaRNN_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PROVEAN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	CEMIP	0.0	0.0	0.01	0.02	-31.0	-45.0	-31.0	21.0								0.000000000	0.47	1.146	homeostasis/metabolism phenotype; nervous system phenotype ; 			.	.	sensory perception of sound;positive regulation of peptidyl-threonine phosphorylation;hyaluronan biosynthetic process;hyaluronan catabolic process;positive regulation of cell migration;positive regulation of release of sequestered calcium ion into cytosol;positive regulation of protein targeting to membrane;positive regulation of protein kinase C activity	extracellular region;nucleus;cytoplasm;endoplasmic reticulum;plasma membrane;clathrin-coated pit;clathrin-coated vesicle membrane;clathrin-coated endocytic vesicle	hyalurononglucosaminidase activity;protein binding;hyaluronic acid binding;clathrin heavy chain binding;ER retention sequence binding	HSPA8[30021884];PLXNA2[12421765];	81225763
1924	chr15	99646201	C	T	chr15:99646201	SYNM	synemin	SNV	0/1	0.41	108_74	182	99	rs140039713,COSV100153158	EXONIC	YES	NM_145728.3	Transcript	protein_coding	missense_variant		2/5	NM_145728.3:c.794C>T	NP_663780.2:p.Ala265Val		1.0	.,Intermediate filament, rod domain&Intermediate filament, rod domain&Intermediate filament, rod domain,Intermediate filament, rod domain&Intermediate filament, rod domain&Intermediate filament, rod domain					.	.	.		0.00341647	520.0	152204.0	3.0	33	0.98	PASS	nfe	0.00530695	361.0	0.00530695	361.0	0.00430189	342.0	79500.0	1.0	6	0.17	PASS	nfe	0.0060067	183.0	0.0060067	183.0	0.0011254	175	0.003	10.0	0.00816	93		10.17	0.584353		1	14	15	FATHMM_pred	SIFT,PolyPhen,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SYNM	0.0	0.0	0.12	0.02	-2.0	-15.0	-2.0	13.0							0.0		0.818	0.875	growth/size/body region phenotype; muscle phenotype; behavior/neurological phenotype ; cardiovascular system phenotype ; 			ciliary ganglion;dorsal root ganglion;trigeminal ganglion;superior cervical ganglion;atrioventricular node;prostate;spinal cord;skeletal muscle;	.	fast-twitch skeletal muscle fiber contraction;intermediate filament cytoskeleton organization	intermediate filament;adherens junction;sarcolemma;costamere;neurofilament cytoskeleton	structural constituent of cytoskeleton;protein binding;structural constituent of muscle;vinculin binding;intermediate filament binding	DTNA[11353857];CEP135[26638075];CSNK2A2[26496610];FGFR1OP[26496610];FLNC[25447537];DISC1[25447537];SKA1[26496610];TTN[25447537];	99646201
1960	chr16	1248710	G	A	chr16:1248710	CACNA1H	calcium voltage-gated channel subunit alpha1 H	SNV	0/1	0.32	38_18	56	99	rs768157656,COSV100672035	EXONIC	YES	NM_021098.3	Transcript	protein_coding	missense_variant		6/35	NM_021098.3:c.739G>A	NP_066921.2:p.Val247Ile		1.0	Ion transport domain,Ion transport domain,.,.				{Epilepsy, childhood absence, susceptibility to, 6}, 611942 (3); Hyperaldosteronism, familial, type IV, 617027 (3), Autosomal dominant; {Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3)	Childhood absence epilepsy	Disease-causing germline mutation(s) in	Intellectual disability;Uncontrolled eye movements;Impaired visuospatial constructive cognition;Hyperventilation;Low self esteem;Myoclonic absence seizure;Pallor;Punding;Jerky head movements;EEG with spike-wave complexes (2.5-3.5 Hz);Urinary incontinence;Depressivity;Typical absence seizure;Bilateral tonic-clonic seizure;Anxiety;Attention deficit hyperactivity disorder;Limb myoclonus;Abnormal social behavior;Febrile seizure (within the age range of 3 months to 6 years);Dyslexia;Hypertension;Autosomal dominant inheritance		1.31477e-05	2.0	152118.0	0.0	33	0.98	PASS	afr	2.41558e-05	1.0	0.0	0.0	8.03994e-06	2.0	248758.0	0.0	84	1.0	PASS	sas	3.26776e-05	1.0	0.0	0.0	0.0000064	1			0.00026	3		20.0	2.032989	0.041	10	9	19	M-CAP_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,LRT_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred	CACNA1H	0.0	0.0	0.0	0.0	-1.0	12.0	-32.0	-6.0						0.0051	0.76	0.000000000	0.995	1.079	nervous system phenotype ; skeleton phenotype; respiratory system phenotype; behavior/neurological phenotype ; cardiovascular system phenotype ; muscle phenotype; growth/size/body region phenotype; 			pons;testis - seminiferous tubule;superior cervical ganglion;	MAPK signaling pathway;Calcium signaling pathway	muscle contraction;muscle organ development;myoblast fusion;regulation of heart contraction;neuronal action potential;aldosterone biosynthetic process;cellular response to hormone stimulus;cortisol biosynthetic process;regulation of ion transmembrane transport;cellular response to potassium ion;regulation of membrane potential;positive regulation of calcium ion-dependent exocytosis;calcium ion import;calcium ion transmembrane transport;membrane depolarization during action potential;inorganic cation transmembrane transport;positive regulation of acrosome reaction	plasma membrane;integral component of plasma membrane;voltage-gated calcium channel complex;integral component of membrane	voltage-gated ion channel activity;protein binding;low voltage-gated calcium channel activity;metal ion binding;scaffold protein binding	PPP3CB[23669360];NEK4[25798074];MAPK15[23602568];CCR4[28298427];	1248710
1967	chr16	1411894	G	A	chr16:1411894	GNPTG	N-acetylglucosamine-1-phosphate transferase subunit gamma	SNV	0/1	0.4	18_12	30	99	rs76594024,COSV99201420	EXONIC	YES	NM_032520.5	Transcript	protein_coding	synonymous_variant		5/11	NM_032520.5:c.255G>A	NP_115909.1:p.Pro85%3D		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Mucolipidosis_type_III_gamma|not_provided	Mucolipidosis III gamma, 252605 (3), Autosomal recessive	Mucolipidosis type III gamma	Disease-causing germline mutation(s) (loss of function) in	Autosomal recessive inheritance;Dysostosis multiplex;Aortic regurgitation;Increased serum iduronate sulfatase level;Abnormality of the hand;Intellectual disability, mild;Joint stiffness;Scoliosis;Abnormality of the rib cage;Hyperlordosis;Short neck;Myopia;Arthralgia;Short stature;Genu valgum;Opacification of the corneal stroma;Pectus carinatum;Flat capital femoral epiphysis;Coarse facial features;Kyphosis;Increased serum beta-hexosaminidase;Flared iliac wings;Aortic valve stenosis		0.00579409	882.0	152224.0	1.0	33	0.98	PASS	nfe	0.00921544	627.0	0.00921544	627.0	0.00490727	1232.0	251056.0	6.0	100	1.0	PASS	nfe	0.00841964	956.0	0.00841964	956.0	0.0054468	847	0.01	33.0	0.01061	121		0.068	-0.536013		0	0	0			GNPTG	0.0	0.0	0.0	0.0	19.0	-21.0	-22.0	49.0						0.331	0.0	16.788866872			homeostasis/metabolism phenotype; 			pons;amygdala;adrenal gland;globus pallidus;	.	N-glycan processing to lysosome;carbohydrate phosphorylation	Golgi membrane;Golgi apparatus;extracellular exosome	UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity;protein homodimerization activity	UPF1[15231747];ANAPC15[26496610];SRPK1[23602568];	1411894
1997	chr16	2331230	C	T	chr16:2331230	ABCA3	ATP binding cassette subfamily A member 3	SNV	0/1	0.39	34_22	56	99	rs138769732	SPLICING	YES	NM_001089.3	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	27/32		NM_001089.3:c.4165-8G>A			-1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Surfactant_metabolism_dysfunction,_pulmonary,_3|not_specified|not_provided	Surfactant metabolism dysfunction, pulmonary, 3, 610921 (3), Autosomal recessive	Idiopathic pulmonary fibrosis;Interstitial lung disease due to ABCA3 deficiency;Infant acute respiratory distress syndrome	Candidate gene tested in;Disease-causing germline mutation(s) (loss of function) in;Candidate gene tested in	Bronchiectasis;Pulmonary insufficiency;Exertional dyspnea;Clubbing of fingers;Reticular pattern on pulmonary HRCT;Gastroesophageal reflux;Ground-glass opacification on pulmonary HRCT;Cough;Pulmonary fibrosis;Crackles;Honeycomb lung;Autosomal recessive inheritance;Alveolar proteinosis;Respiratory failure;Apnea;Failure to thrive;Congenital onset;Respiratory distress;Tachypnea;Heterogeneous;Desquamative interstitial pneumonitis		0.00748906	1140.0	152222.0	11.0	32	0.96	PASS	nfe	0.0092745	631.0	0.0092745	631.0	0.00824003	2065.0	250606.0	15.0	100	1.0	PASS	nfe	0.0090647	1025.0	0.0090647	1025.0	0.0078519	1221	0.008	26.0	0.00754	85		0.101	-0.482477		0	0	0			ABCA3	0.0	0.13	0.0	0.0	-20.0	29.0	3.0	-7.0	9.24049225474954e-05	0.024	9.088	0.666	9.754	0.0274	0.0				cardiovascular system phenotype ; mortality/aging ; respiratory system phenotype; behavior/neurological phenotype ; homeostasis/metabolism phenotype; 			.	ABC transporters	lipid transport;response to drug;cellular protein metabolic process;response to glucocorticoid;transmembrane transport	extracellular space;plasma membrane;membrane;integral component of membrane;intracellular membrane-bounded organelle;alveolar lamellar body;lamellar body membrane;alveolar lamellar body membrane	transporter activity;lipid transporter activity;ATP binding;ATPase activity, coupled to transmembrane movement of substances	LAMP3[20863830];CANX[20863830];HTR2B[28298427];	2331230
2002	chr16	3639398	G	A	chr16:3639398	SLX4	SLX4 structure-specific endonuclease subunit	SNV	0/1	0.42	25_18	43	99	rs140892471	EXONIC	YES	NM_032444.4	Transcript	protein_coding	missense_variant		12/15	NM_032444.4:c.4241C>T	NP_115820.2:p.Pro1414Leu		-1.0		Benign	criteria_provided,_multiple_submitters,_no_conflicts	Fanconi_anemia|not_specified	Fanconi anemia, complementation group P, 613951 (3), Autosomal recessive	Fanconi anemia	Disease-causing germline mutation(s) in	Pelvic kidney;Anemia;Horseshoe kidney;Squamous cell carcinoma;Blepharophimosis;Short thumb;Variable expressivity;Microcephaly;Pancytopenia;Short palpebral fissure;Autosomal recessive inheritance;Hearing impairment;Vitiligo;Hypoplasia of the radius;Absent thumb;Cryptorchidism;Bulbous nose;Short stature;Micrognathia;Cafe-au-lait spot;Hydroureter;Hypopigmented skin patches;Cranial nerve paralysis;Umbilical hernia;Epicanthus;Weight loss;Choanal atresia;Myelodysplasia;Hypogonadism;Scoliosis;Hip dislocation;Recurrent urinary tract infections;Abnormality of the hypothalamus-pituitary axis;Short palpebral fissure;Hypertrophic cardiomyopathy;High palate;Aplasia/Hypoplasia of the iris;Decreased fertility in males;Aplasia/Hypoplasia of fingers;Toe syndactyly;Irregular hyperpigmentation;Almond-shaped palpebral fissure;Tetralogy of Fallot;Astigmatism;Pyridoxine-responsive sideroblastic anemia;Meckel diverticulum;Hypertelorism;Sloping forehead;Ptosis;Anal atresia;Cryptorchidism;Intellectual disability;Facial asymmetry;Visual impairment;Upslanted palpebral fissure;Duodenal stenosis;Abnormality of the liver;Aplasia/Hypoplasia of the uvula;Abnormal carotid artery morphology;Hypospadias;Nystagmus;Multiple cafe-au-lait spots;Renal insufficiency;Clinodactyly of the 5th finger;Bicornuate uterus;Abnormality of chromosome stability;Strabismus;Micrognathia;Hypoplasia of the ulna;Proptosis;Atrial septal defect;Abnormal aortic valve morphology;Abnormality of femur morphology;Cataract;Microphthalmia;Hydrocephalus;Ventriculomegaly;Aganglionic megacolon;Absent testis;Hearing impairment;Arteriovenous malformation;Azoospermia;Renal hypoplasia/aplasia;Thrombocytopenia;Finger syndactyly;Oligohydramnios;External ear malformation;Global developmental delay;Aplasia/Hypoplasia of the radius;Reduced bone mineral density;Clubbing of toes;Microcephaly;Abnormal aortic morphology;Frontal bossing;Dolichocephaly;Spina bifida;Leukopenia;Tracheoesophageal fistula;Patent ductus arteriosus;Abnormality of the preputium;Hyperreflexia;Short stature;Abnormal localization of kidney;Cleft palate;Triphalangeal thumb;Intrauterine growth retardation;Pes planus	25741868	0.00280626	427.0	152160.0	0.0	32	0.96	PASS	afr	0.00970827	402.0	2.93927e-05	2.0	0.00071791	176.0	245156.0	1.0	100	0.88	PASS	afr	0.0094093	144.0	2.71155e-05	3.0	0.0007588	118			0.0008	9		5.832	0.199427	0.057	0	18	18		SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SLX4	0.0	0.0	0.0	0.0	-10.0	-40.0	32.0	8.0							0.0	0.000000000	0.0	-1.524	growth/size/body region phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; skeleton phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; nervous system phenotype ; limbs/digits/tail phenotype; vision/eye phenotype; 			ciliary ganglion;whole brain;superior cervical ganglion;	.	meiotic DNA double-strand break processing;resolution of meiotic recombination intermediates;double-strand break repair via homologous recombination;DNA replication;DNA repair;nucleotide-excision repair;DNA double-strand break processing involved in repair via single-strand annealing;interstrand cross-link repair;positive regulation of catalytic activity;telomeric D-loop disassembly;response to intra-S DNA damage checkpoint signaling;t-circle formation;negative regulation of telomere maintenance via telomere lengthening;positive regulation of t-circle formation	chromosome, telomeric region;nuclear chromosome, telomeric region;nuclear chromatin;nucleoplasm;cytosol;cell junction;Slx1-Slx4 complex;Holliday junction resolvase complex;ERCC4-ERCC1 complex	endodeoxyribonuclease activity;protein binding;enzyme activator activity;crossover junction endodeoxyribonuclease activity;5'-flap endonuclease activity;3'-flap endonuclease activity	MDC1[29656893];AHCYL2[19596235];AHCYL1[19596235];RNH1[19596235];NUP188[19596235];VARS[19596235];CALML5[19596235];HP[19596235];KEAP1[19596235];CALML3[19596235];GPATCH4[19596235];PARK7[19596235];IPO7[19596235];PDCD2L[19596235];DCAF1[19596235;24412650];ALKBH2[19596235];EME1[19596235;19596236];CHEK1[19596235];PLS3[19596235];KPNA4[19596235];KPNA3[19596235];TGM3[19596235];KPNA1[19596235];PRKCI[19596235];TSPYL1[19596235];KRT4[19596235];CSNK2A1[19596235];ZNF282[19596235];SLX4IP[19596235];SCRIB[19596235];HCFC1[19596235];SMAP[19596235];NUP93[19596235];GNPAT[19596235];DDX39A[19596235];HOXB9[19596235];MSH2[19596235];MSH3[19596235];DMWD[19596235];TIPRL[19596235];CSNK2B[19596235];SLX1A[19596235;19596236];RAD54L2[19596235];TTLL12[19596235];DSC1[19596235];SQSTM1[19596235];S100A8[19596235];ATP5MD[19596235];FLG[19596235];ANKRD17[19596235];FTO[19596235];SEH1L[19596235];MAGED1[19596235];UBA5[19596235];MEPCE[19596235];NMD3[19596235];MRPL15[19596235];SLC5A3[19596235];CNN3[19596235];BAG5[19596235];UBR5[19596235];EPB41L3[19596235];MYH11[19596235];FAM192A[19596235];TP53BP1[29656893];IGHA1[19596235];HOXC9[19596235];ATG7[19596235];CDSN[19596235];NUP155[19596235];PLK1[19596235;25852190];NRDC[19596235];LARP7[19596235];TIMM44[19596235];NUP153[19596235];CWC15[19596235];GPN3[19596235];TF[19596235];ALB[19596235];UBE2O[19596235];PIN1[19596235];FARSB[19596235];MUS81[19596235;19596236;25416956;unassigned1304];SLC25A1[19596235];SRPX[19596235];IGHM[19596235];GFM1[19596235];SERPINA1[19596235];MRPS16[19596235];GFM2[19596235];MRPS11[19596235];HSPB1[19596235];BRCA1[29656893];GPHN[19596235];LRRC1[19596235];MRPL41[19596235];SART1[19596235];GYS1[19596235];AKAP11[19596235];IGLC1[19596235];TK1[19596235];MRPL9[19596235];SERPINB4[19596235];PARP1[19596235];TEX10[19596235];MRPS21[19596235];RANGAP1[19596235];TERF2[19596235;19596236];SERPINB5[19596235];MRPL44[19596235];F7[19596235];DEPDC7[19596235];CTTN[19596235];TBC1D4[19596235];NUP50[19596235];PEX5[19596235];SDE2[19596235];TERF2IP[19596235];PGAM5[19596235];DNAJC9[19596235];MICU1[19596235];SLC25A13[19596235];DDX24[19596235];MRPS31[19596235];RRBP1[19596235];MRPL58[19596235];PPM1G[19596235];AP3M1[19596235];PSMB4[19596235];CAND1[19596235];DNAJB6[19596235];TCOF1[19596235];RNF138[19596235];FLNA[19596235];POLR2G[19596235];DCAF10[19596235];AASDHPPT[19596235];EGLN3[26972000];IGKV1-5[19596235];RANBP9[19596235];PNMA2[19596235];PPP2R3A[19596235];ASPRV1[19596235];MKLN1[19596235];MYO1C[19596235];FABP5[19596235];PPP2R2C[19596235];ERCC4[19596235;19596236];ERCC1[19596235;19596236];GID8[19596235];PPP2R2D[19596235];ATP5PO[19596235];ZYX[19596235];PRPF31[19596235];COPG1[19596235];NCAPD3[19596235];NOP53[19596235];RAN[19596235];	3639398
2005	chr16	3646198	G	A	chr16:3646198	SLX4	SLX4 structure-specific endonuclease subunit	SNV	0/1	0.46	33_28	61	99	rs774683778	EXONIC	YES	NM_032444.4	Transcript	protein_coding	missense_variant		8/15	NM_032444.4:c.1880C>T	NP_115820.2:p.Pro627Leu		-1.0		Uncertain_significance	criteria_provided,_single_submitter	Fanconi_anemia	Fanconi anemia, complementation group P, 613951 (3), Autosomal recessive	Fanconi anemia	Disease-causing germline mutation(s) in	Pelvic kidney;Anemia;Horseshoe kidney;Squamous cell carcinoma;Blepharophimosis;Short thumb;Variable expressivity;Microcephaly;Pancytopenia;Short palpebral fissure;Autosomal recessive inheritance;Hearing impairment;Vitiligo;Hypoplasia of the radius;Absent thumb;Cryptorchidism;Bulbous nose;Short stature;Micrognathia;Cafe-au-lait spot;Hydroureter;Hypopigmented skin patches;Cranial nerve paralysis;Umbilical hernia;Epicanthus;Weight loss;Choanal atresia;Myelodysplasia;Hypogonadism;Scoliosis;Hip dislocation;Recurrent urinary tract infections;Abnormality of the hypothalamus-pituitary axis;Short palpebral fissure;Hypertrophic cardiomyopathy;High palate;Aplasia/Hypoplasia of the iris;Decreased fertility in males;Aplasia/Hypoplasia of fingers;Toe syndactyly;Irregular hyperpigmentation;Almond-shaped palpebral fissure;Tetralogy of Fallot;Astigmatism;Pyridoxine-responsive sideroblastic anemia;Meckel diverticulum;Hypertelorism;Sloping forehead;Ptosis;Anal atresia;Cryptorchidism;Intellectual disability;Facial asymmetry;Visual impairment;Upslanted palpebral fissure;Duodenal stenosis;Abnormality of the liver;Aplasia/Hypoplasia of the uvula;Abnormal carotid artery morphology;Hypospadias;Nystagmus;Multiple cafe-au-lait spots;Renal insufficiency;Clinodactyly of the 5th finger;Bicornuate uterus;Abnormality of chromosome stability;Strabismus;Micrognathia;Hypoplasia of the ulna;Proptosis;Atrial septal defect;Abnormal aortic valve morphology;Abnormality of femur morphology;Cataract;Microphthalmia;Hydrocephalus;Ventriculomegaly;Aganglionic megacolon;Absent testis;Hearing impairment;Arteriovenous malformation;Azoospermia;Renal hypoplasia/aplasia;Thrombocytopenia;Finger syndactyly;Oligohydramnios;External ear malformation;Global developmental delay;Aplasia/Hypoplasia of the radius;Reduced bone mineral density;Clubbing of toes;Microcephaly;Abnormal aortic morphology;Frontal bossing;Dolichocephaly;Spina bifida;Leukopenia;Tracheoesophageal fistula;Patent ductus arteriosus;Abnormality of the preputium;Hyperreflexia;Short stature;Abnormal localization of kidney;Cleft palate;Triphalangeal thumb;Intrauterine growth retardation;Pes planus						32	0.98							6.63192e-06	1.0	150786.0	0.0	35	0.56	RF	sas	4.34707e-05	1.0	0.0	0.0	0.0000129	2			9e-05	1		12.29	0.843236	0.152	2	18	20	MutationTaster_pred,PROVEAN_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SLX4	0.0	0.0	0.0	0.0	-13.0	40.0	-44.0	-11.0							0.0	60.588807349	0.008	-0.26	growth/size/body region phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; skeleton phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; nervous system phenotype ; limbs/digits/tail phenotype; vision/eye phenotype; 			ciliary ganglion;whole brain;superior cervical ganglion;	.	meiotic DNA double-strand break processing;resolution of meiotic recombination intermediates;double-strand break repair via homologous recombination;DNA replication;DNA repair;nucleotide-excision repair;DNA double-strand break processing involved in repair via single-strand annealing;interstrand cross-link repair;positive regulation of catalytic activity;telomeric D-loop disassembly;response to intra-S DNA damage checkpoint signaling;t-circle formation;negative regulation of telomere maintenance via telomere lengthening;positive regulation of t-circle formation	chromosome, telomeric region;nuclear chromosome, telomeric region;nuclear chromatin;nucleoplasm;cytosol;cell junction;Slx1-Slx4 complex;Holliday junction resolvase complex;ERCC4-ERCC1 complex	endodeoxyribonuclease activity;protein binding;enzyme activator activity;crossover junction endodeoxyribonuclease activity;5'-flap endonuclease activity;3'-flap endonuclease activity	MDC1[29656893];AHCYL2[19596235];AHCYL1[19596235];RNH1[19596235];NUP188[19596235];VARS[19596235];CALML5[19596235];HP[19596235];KEAP1[19596235];CALML3[19596235];GPATCH4[19596235];PARK7[19596235];IPO7[19596235];PDCD2L[19596235];DCAF1[19596235;24412650];ALKBH2[19596235];EME1[19596235;19596236];CHEK1[19596235];PLS3[19596235];KPNA4[19596235];KPNA3[19596235];TGM3[19596235];KPNA1[19596235];PRKCI[19596235];TSPYL1[19596235];KRT4[19596235];CSNK2A1[19596235];ZNF282[19596235];SLX4IP[19596235];SCRIB[19596235];HCFC1[19596235];SMAP[19596235];NUP93[19596235];GNPAT[19596235];DDX39A[19596235];HOXB9[19596235];MSH2[19596235];MSH3[19596235];DMWD[19596235];TIPRL[19596235];CSNK2B[19596235];SLX1A[19596235;19596236];RAD54L2[19596235];TTLL12[19596235];DSC1[19596235];SQSTM1[19596235];S100A8[19596235];ATP5MD[19596235];FLG[19596235];ANKRD17[19596235];FTO[19596235];SEH1L[19596235];MAGED1[19596235];UBA5[19596235];MEPCE[19596235];NMD3[19596235];MRPL15[19596235];SLC5A3[19596235];CNN3[19596235];BAG5[19596235];UBR5[19596235];EPB41L3[19596235];MYH11[19596235];FAM192A[19596235];TP53BP1[29656893];IGHA1[19596235];HOXC9[19596235];ATG7[19596235];CDSN[19596235];NUP155[19596235];PLK1[19596235;25852190];NRDC[19596235];LARP7[19596235];TIMM44[19596235];NUP153[19596235];CWC15[19596235];GPN3[19596235];TF[19596235];ALB[19596235];UBE2O[19596235];PIN1[19596235];FARSB[19596235];MUS81[19596235;19596236;25416956;unassigned1304];SLC25A1[19596235];SRPX[19596235];IGHM[19596235];GFM1[19596235];SERPINA1[19596235];MRPS16[19596235];GFM2[19596235];MRPS11[19596235];HSPB1[19596235];BRCA1[29656893];GPHN[19596235];LRRC1[19596235];MRPL41[19596235];SART1[19596235];GYS1[19596235];AKAP11[19596235];IGLC1[19596235];TK1[19596235];MRPL9[19596235];SERPINB4[19596235];PARP1[19596235];TEX10[19596235];MRPS21[19596235];RANGAP1[19596235];TERF2[19596235;19596236];SERPINB5[19596235];MRPL44[19596235];F7[19596235];DEPDC7[19596235];CTTN[19596235];TBC1D4[19596235];NUP50[19596235];PEX5[19596235];SDE2[19596235];TERF2IP[19596235];PGAM5[19596235];DNAJC9[19596235];MICU1[19596235];SLC25A13[19596235];DDX24[19596235];MRPS31[19596235];RRBP1[19596235];MRPL58[19596235];PPM1G[19596235];AP3M1[19596235];PSMB4[19596235];CAND1[19596235];DNAJB6[19596235];TCOF1[19596235];RNF138[19596235];FLNA[19596235];POLR2G[19596235];DCAF10[19596235];AASDHPPT[19596235];EGLN3[26972000];IGKV1-5[19596235];RANBP9[19596235];PNMA2[19596235];PPP2R3A[19596235];ASPRV1[19596235];MKLN1[19596235];MYO1C[19596235];FABP5[19596235];PPP2R2C[19596235];ERCC4[19596235;19596236];ERCC1[19596235;19596236];GID8[19596235];PPP2R2D[19596235];ATP5PO[19596235];ZYX[19596235];PRPF31[19596235];COPG1[19596235];NCAPD3[19596235];NOP53[19596235];RAN[19596235];	3646198
2050	chr16	21716516	A	G	chr16:21716516	OTOA	otoancorin	SNV	0/1	0.4	37_25	62	99	rs145119450	EXONIC	YES	NM_144672.4	Transcript	protein_coding	missense_variant		12/29	NM_144672.4:c.1007A>G	NP_653273.3:p.Asn336Ser		1.0	.,.,.,.,.				Deafness, autosomal recessive 22, 607039 (3), Autosomal recessive	Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing germline mutation(s) in	Sensorineural hearing impairment;Autosomal recessive inheritance		3.94384e-05	6.0	152136.0	0.0	32	0.97	PASS	amr	0.000327354	5.0	1.4699e-05	1.0	9.94684e-05	25.0	251336.0	0.0	100	1.0	PASS	amr	0.000578202	20.0	2.64019e-05	3.0	0.0000772	12	0.0	1.0	0.00018	2		22.2	2.361239	0.079	3	16	19	SIFT,M-CAP_pred,fathmm-MKL_coding_pred	PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-XF_coding_pred	OTOA	0.32	0.32	0.0	0.0	1.0	-26.0	1.0	-14.0						0.616	0.0	0.000000000	0.989	1.298	nervous system phenotype ; hearing/vestibular/ear phenotype; 			.	.	cell-matrix adhesion;sensory perception of sound;transmission of nerve impulse	extracellular region;plasma membrane;cell surface;apical plasma membrane;anchored component of membrane	.	.	21716516
2060	chr16	28877787	A	T	chr16:28877787	SH2B1	SH2B adaptor protein 1	SNV	0/1	0.42	74_54	128	99	rs766836953	EXONIC	YES	NM_001387430.1	Transcript	protein_coding	synonymous_variant		1/8	NM_001387430.1:c.372A>T	NP_001374359.1:p.Arg124%3D		1.0						Distal 16p11.2 microdeletion syndrome;Proximal 16p11.2 microdeletion syndrome;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency	Role in the phenotype of;Role in the phenotype of;Disease-causing germline mutation(s) (loss of function) in	Autism;Scoliosis;Feeding difficulties;Micrognathia;Hemivertebrae;Attention deficit hyperactivity disorder;Anophthalmia;Hand polydactyly;Broad forehead;EEG abnormality;Atrial septal defect;Gastroesophageal reflux;Seizure;Malar flattening;Global developmental delay;Hypertelorism;Microphthalmia;Psychosis;Optic nerve coloboma;Macrocephaly;Strabismus;Ventriculomegaly;Aortic regurgitation;Cleft palate;Language impairment;Pyloric stenosis;Congenital diaphragmatic hernia;Syringomyelia;Muscular hypotonia;Myopia;Obesity;Intellectual disability;Obesity;Hyperinsulinemia;No social interaction;Delayed speech and language development;Aggressive behavior;Short stature;Polyphagia;Aganglionic megacolon;Attention deficit hyperactivity disorder;Prominent nasal bridge;Global developmental delay;Intellectual disability;Rod-cone dystrophy;Moderate receptive language delay;Autistic behavior;Renal agenesis;Seizure;Vesicoureteral reflux;Narrow mouth;Chronic constipation;Neonatal hypotonia;Chronic kidney disease;Arachnodactyly;Obesity;Oval face;Hyperuricemia;Proteinuria;Low anterior hairline;Kyphosis;Migraine						32	0.96							7.97296e-06	2.0	250848.0	0.0	65	1.0	PASS	amr	5.7857e-05	2.0	0.0	0.0	0.0000064	1			0.00026	3		11.71	0.76994		0	0	0			SH2B1	0.0	0.0	0.02	0.0	38.0	-42.0	-36.0	36.0						0.667	0.96	16.719672762			growth/size/body region phenotype; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; mortality/aging ; reproductive system phenotype; 			ciliary ganglion;pons;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;cerebellum;	.	transmembrane receptor protein tyrosine kinase signaling pathway;blood coagulation;positive regulation of signal transduction;lamellipodium assembly;intracellular signal transduction;positive regulation of mitotic nuclear division;regulation of DNA biosynthetic process	nucleus;cytosol;plasma membrane	transmembrane receptor protein tyrosine kinase adaptor activity;protein binding	MEF2A[25609649];INSR[9742218];STAT3[24396070];FRS2[24396070];GRB2[unassigned1304];JAK2[17565041;15767667];CSAD[25814554];KIAA0319[12421765];RHBG[21988832];MET[24728074];FRS3[25814554];EGFR[16273093;24658140];	28877787
2088	chr16	57003915	T	A	chr16:57003915	CETP	cholesteryl ester transfer protein	SNV	0/1	0.32	17_8	25	99		SPLICING	YES	NM_000078.3	Transcript	protein_coding	splice_donor_variant	5/15		NM_000078.3:c.527+2T>A			1.0					[High density lipoprotein cholesterol level QTL 10], 143470 (3), Autosomal dominant; Hyperalphalipoproteinemia, 143470 (3), Autosomal dominant	Cholesterol-ester transfer protein deficiency	Disease-causing germline mutation(s) in	Hypercholesterolemia;Hyperlipidemia;Increased HDL cholesterol concentration;Hypotriglyceridemia;Increased HDL cholesterol concentration;Autosomal dominant inheritance						33	0.96											100	0.9											9e-05	1		24.2	3.255633		0	0	0			CETP	0.0	0.21	0.03	0.98	50.0	-30.0	44.0	-2.0	0.999909215603194	0.762	1.17	8.183	9.354	0.97	0.0				.			ciliary ganglion;liver;lymph node;atrioventricular node;trigeminal ganglion;superior cervical ganglion;placenta;fetal liver;skeletal muscle;	.	triglyceride metabolic process;lipid transport;cholesterol metabolic process;negative regulation of macrophage derived foam cell differentiation;regulation of cholesterol efflux;phospholipid transport;cholesterol transport;triglyceride transport;very-low-density lipoprotein particle remodeling;low-density lipoprotein particle remodeling;high-density lipoprotein particle remodeling;cholesterol homeostasis;reverse cholesterol transport;phosphatidylcholine metabolic process;lipid homeostasis;phospholipid homeostasis;triglyceride homeostasis	extracellular region;extracellular space;vesicle;high-density lipoprotein particle;extracellular exosome	lipid transporter activity;phospholipid transporter activity;lipid binding;cholesterol binding;cholesterol transporter activity;triglyceride binding;phosphatidylcholine binding	ARPC3[16169070];EWSR1[16189514];PRKACG[21988832];	57003915
2093	chr16	67203258	G	A	chr16:67203258	HSF4	heat shock transcription factor 4	SNV	0/1	0.48	17_16	33	99		SPLICING	YES	NM_001040667.3	Transcript	protein_coding	splice_region_variant,intron_variant	14/14		NM_001040667.3:c.1324+7G>A			1.0					Cataract 5, multiple types, 116800 (3), Autosomal dominant	Early-onset lamellar cataract;Total early-onset cataract	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Autosomal dominant inheritance;Nuclear cataract;Anterior polar cataract;Pulverulent cataract;Lamellar cataract						32	0.98											100	0.8											9e-05	1		9.878	0.551801		0	0	0			HSF4	0.01	0.0	0.04	0.0	-6.0	-1.0	-7.0	-1.0	0.0005753293520159	0.046				0.209	0.0				vision/eye phenotype; 			pons;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	.	negative regulation of transcription by RNA polymerase II;regulation of transcription, DNA-templated;visual perception;positive regulation of cell population proliferation;histone H3-K9 demethylation;cellular response to heat;camera-type eye development;positive regulation of cell differentiation;cell development;positive regulation of transcription from RNA polymerase II promoter in response to heat stress;protein homotrimerization	nucleus;nuclear speck	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;transcription corepressor activity;sequence-specific DNA binding	INTS11[unassigned1304];ZBED8[21900206];tmp_locus_54[unassigned1304];AKAP8L[unassigned1304];TIMM13[25036637];FOXI1[unassigned1304];UFSP1[unassigned1304];KRT40[unassigned1304];FAM168B[unassigned1304];ALKBH4[23145062];HSF2[25036637];HSF1[25036637];NUP62[unassigned1304];KRTAP6-2[unassigned1304];OIP5[unassigned1304];C10orf55[unassigned1304];KRTAP3-1[unassigned1304];PITX1[unassigned1304];LINC01600[unassigned1304];C19orf54[unassigned1304];YTHDF1[unassigned1304];NHLRC4[unassigned1304];TPM3[unassigned1304];FOXH1[unassigned1304];KRT31[unassigned1304];KRTAP19-6[unassigned1304];SOX10[unassigned1304];TARBP1[25036637];KRTAP19-7[unassigned1304];NUDT21[21900206];RABEP1[25036637];PPFIBP2[unassigned1304];BCL6[16147992];GFOD1[unassigned1304];MYO15A[25036637];SESTD1[25036637;unassigned1304];KRT38[unassigned1304];HGS[unassigned1304];KRT37[unassigned1304];PLA2G10[unassigned1304];CDK2AP2[21900206];PIH1D2[unassigned1304];MKRN3[unassigned1304];SUGT1[25036637];ZMYND12[unassigned1304];FKBP5[25036637];	67203258
2102	chr16	67229794	GCA		chr16:67229794-67229796	E2F4	E2F transcription factor 4	deletion	0/1	0.37	12_7	19	99	rs3830472	EXONIC	YES	NM_001950.4	Transcript	protein_coding	inframe_deletion		7/10	NM_001950.4:c.956_958del	NP_001941.2:p.Ser319del		1.0						.	.	.		0.00364136	546.0	149944.0	2.0	32	0.87	PASS	amr	0.00431779	65.0	0.00406155	274.0					100	1.0							0.0029774,0.1770630	463,27534			0.12335	1175		15.4	1.340797		0	0	0			E2F4	0.06	0.13	0.0	0.0	10.0	4.0	13.0	44.0						0.126	0.32	0.000000000			behavior/neurological phenotype ; respiratory system phenotype; embryo phenotype; neoplasm; cardiovascular system phenotype ; hematopoietic system phenotype; mortality/aging ; normal phenotype; reproductive system phenotype; digestive/alimentary phenotype; hearing/vestibular/ear phenotype; skeleton phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype ; craniofacial phenotype; 			.	TGF-beta signaling pathway	regulation of transcription involved in G1/S transition of mitotic cell cycle;negative regulation of transcription by RNA polymerase II;epithelial cell development;cell volume homeostasis;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;blood circulation;animal organ morphogenesis;regulation of cell population proliferation;motile cilium assembly;positive regulation of transcription by RNA polymerase II;regulation of cell cycle;centriole assembly;multi-ciliated epithelial cell differentiation	nuclear chromatin;nucleus;nucleoplasm;RNA polymerase II transcription factor complex	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;protein binding;transcription factor binding;protein domain specific binding;sequence-specific DNA binding;protein dimerization activity;promoter-specific chromatin binding	RB1[16360038];LIN54[17531812];L3MBTL3[17517653];LIN37[17531812];TRRAP[11418595];LRRK2[29513927];LIN9[17159899;17531812];PML[22002537];RBL2[17531812;22002537;20133863];MFHAS1[29513927];PCM1[21988832];TFDP1[16360038;27705803;unassigned1304];RBL1[16360038];TFDP2[10090723;16360038;unassigned1304];KAT5[unassigned1304];CDK4[27173435;unassigned1312];CDK2[25852190];CHMP2A[21988832];POLR1D[21988832];PIN1[unassigned1304];MYBL2[17159899];AP3S2[21988832];	67229793
2111	chr16	68391049	T	C	chr16:68391049	PRMT7	protein arginine methyltransferase 7	SNV	0/1	0.27	63_23	86	99	rs751267550	EXONIC	YES	NM_001351143.3	Transcript	protein_coding	synonymous_variant		19/20	NM_001351143.3:c.2001T>C	NP_001338072.1:p.Thr667%3D		1.0					Short stature, brachydactyly, intellectual developmental disability, and seizures, 617157 (3), Autosomal recessive	Short stature-brachydactyly-obesity-global developmental delay syndrome	Disease-causing germline mutation(s) (loss of function) in	Infantile onset;Intellectual disability;Thin vermilion border;Malar flattening;Short metatarsal;Microcephaly;Wide nasal bridge;Strabismus;Delayed myelination;Obesity;Underdeveloped supraorbital ridges;Epicanthus;Seizure;Astigmatism;Delayed speech and language development;Short metacarpal;High palate;Delayed ability to walk;Long philtrum;Frontal bossing;Global developmental delay;Pseudohypoparathyroidism;Retrognathia;Broad nasal tip;Brachydactyly;Generalized hypotonia;Short palpebral fissure;Short neck;Depressed nasal bridge;Autosomal recessive inheritance;Short stature;Deeply set eye;Short fourth metatarsal;Intellectual disability, moderate;Flat face;Depressed nasal ridge;Anteverted nares;Coloboma;Intellectual disability, mild;Global developmental delay;Short neck;Seizure;Sensorineural hearing impairment;Hypertelorism;Deeply set eye;Blue sclerae;Laryngomalacia;Cryptorchidism;Brachydactyly;Obesity;Preauricular skin tag;Sleep apnea;Strabismus;Gingival overgrowth;Microcephaly;Long philtrum;Hypoplasia of the corpus callosum;Vesicoureteral reflux;Renal hypoplasia;Dacryocystitis;Prominent forehead;Pseudohypoparathyroidism;Infantile muscular hypotonia;Retrognathia;Thin vermilion border;Intellectual disability, severe;Thick corpus callosum;Specific learning disability;Patellar hypoplasia;Abnormal conus terminalis morphology;Eczema;Feeding difficulties						33	0.98							3.97937e-06	1.0	251296.0	0.0	63	1.0	PASS	nfe	8.80003e-06	1.0	8.80003e-06	1.0	0.0000064	1			9e-05	1		0.231	-0.365921		0	0	0			PRMT7	0.0	0.0	0.0	0.0	-42.0	35.0	12.0	50.0						0.663	0.0	6.709702002			neoplasm; cardiovascular system phenotype ; hematopoietic system phenotype; liver/biliary system phenotype; embryo phenotype; skeleton phenotype; immune system phenotype; nervous system phenotype ; endocrine/exocrine gland phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; 			skeletal muscle;globus pallidus;	Androgen and estrogen metabolism;Histidine metabolism;Tyrosine metabolism;Tryptophan metabolism;Aminophosphonate metabolism;Selenoamino acid metabolism	spliceosomal snRNP assembly;regulation of gene expression by genetic imprinting;regulation of transcription, DNA-templated;histone methylation;peptidyl-arginine methylation;peptidyl-arginine methylation, to symmetrical-dimethyl arginine;peptidyl-arginine methylation, to asymmetrical-dimethyl arginine;cell differentiation;histone arginine methylation;DNA methylation involved in gamete generation;regulation of protein binding;histone H4-R3 methylation	fibrillar center;nucleus;nucleoplasm;cytosol	histone-arginine N-methyltransferase activity;S-adenosylmethionine-dependent methyltransferase activity;protein-arginine N-methyltransferase activity;[myelin basic protein]-arginine N-methyltransferase activity;protein-arginine omega-N monomethyltransferase activity;protein-arginine omega-N asymmetric methyltransferase activity;protein-arginine omega-N symmetric methyltransferase activity;histone binding;ribonucleoprotein complex binding;histone methyltransferase activity (H4-R3 specific)	ICE1[26496610];H3F3C[23455924];ZBTB24[23455924];SSR3[26496610];DDIT4L[unassigned1304];UBE3A[unassigned1304];EIF2S1[unassigned1304];PIK3CG[20562859];GANAB[26496610];REPS2[26496610];ZNF438[unassigned1304];POT1[21044950];MNDA[23455924];EZR[29568061];NFKBID[unassigned1304];	68391049
2129	chr16	68853297	G	C	chr16:68853297	CDH1	cadherin 1	SNV	0/1	0.38	20_12	32	99	rs35741240,COSV55731541	EXONIC	YES	NM_004360.5	Transcript	protein_coding	synonymous_variant		11/16	NM_004360.5:c.1680G>C	NP_004351.1:p.Thr560%3D		1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Hereditary_diffuse_gastric_cancer|Hereditary_cancer-predisposing_syndrome|not_specified|Breast_and/or_ovarian_cancer|not_provided	Ovarian cancer, somatic, 167000 (3); Blepharocheilodontic syndrome 1, 119580 (3), Autosomal dominant; Diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, 137215 (3), Autosomal dominant; Endometrial carcinoma, somatic, 608089 (3); Breast cancer, lobular, somatic, 114480 (3); {Prostate cancer, susceptibility to}, 176807 (3), Somatic mutation, Autosomal dominant	Cleft lip/palate;Blepharo-cheilo-odontic syndrome;Hereditary diffuse gastric cancer	Major susceptibility factor in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Somatic mutation;Autosomal dominant inheritance;Heterogeneous;Breast carcinoma;High anterior hairline;Flat face;Ectropion of lower eyelids;Cleft upper lip;Hypodontia;Hypertelorism;Distichiasis;Anal atresia;Cutaneous syndactyly;Neural tube defect;Conical tooth;Clinodactyly;Sparse hair;Autosomal dominant inheritance;High forehead;Choanal atresia;Small nail;Cleft upper lip;Chronic atrophic gastritis;Stomach cancer;Autosomal dominant inheritance;Cleft palate;Conductive hearing impairment;Ectropion of lower eyelids;Conical tooth;Abnormal hair quantity;Anal atresia;Distichiasis;Euryblepharon;Epidermoid cyst;Hypertelorism;Bilateral cleft lip and palate;Abnormality of vision;Finger syndactyly;Carious teeth;Nasal speech;Peg-shaped maxillary lateral incisors;Conductive hearing impairment;Velopharyngeal insufficiency;Malnutrition;Abnormality of dental eruption;Abnormal number of permanent teeth;Poor suck;Delayed speech and language development;Bilateral cleft palate;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Recurrent otitis media;Unilateral cleft palate;Speech articulation difficulties;Palate fistula;Dental malocclusion;Agenesis of lateral incisor;Endometrial carcinoma;Somatic mutation;Autosomal dominant inheritance;Somatic mutation;Prostate cancer;Abnormality of metabolism/homeostasis;Breast carcinoma;Somatic mutation;Autosomal dominant inheritance;Ovarian papillary adenocarcinoma;Dysgerminoma	30642281	0.00261642	398.0	152116.0	0.0	32	0.96	PASS	sas	0.00497925	24.0	0.00398389	271.0	0.00337201	848.0	251482.0	4.0	99	1.0	PASS	sas	0.00686005	210.0	0.00449191	511.0	0.0035755	556	0.004	13.0	0.00254	29		0.029	-0.651298		0	0	0			CDH1	0.0	0.0	0.0	0.0	8.0	-1.0	31.0	-1.0						0.329	0.34				digestive/alimentary phenotype; immune system phenotype; embryo phenotype; neoplasm; reproductive system phenotype; mortality/aging ; normal phenotype; integument phenotype ; cardiovascular system phenotype ; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; 			olfactory bulb;trachea;skin;fetal liver;fetal lung;fetal thyroid;salivary gland;lung;kidney;thyroid;beta cell islets;pancreas;dorsal root ganglion;placenta;prostate;	Cell adhesion molecules (CAMs);Adherens junction;Pathogenic Escherichia coli infection;EPEC;Endometrial cancer;Thyroid cancer;Melanoma;Bladder cancer	cell morphogenesis;cell-cell junction assembly;homophilic cell adhesion via plasma membrane adhesion molecules;synapse assembly;response to toxic substance;regulation of gene expression;calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules;pituitary gland development;negative regulation of cell-cell adhesion;extracellular matrix organization;negative regulation of cell migration;neuron projection development;adherens junction organization;entry of bacterium into host cell;positive regulation of protein import into nucleus;cell-cell adhesion mediated by cadherin;positive regulation of transcription, DNA-templated;cellular response to lithium ion;cellular response to indole-3-methanol;protein localization to plasma membrane;cell-cell adhesion;regulation of protein catabolic process at postsynapse, modulating synaptic transmission	extracellular region;cytoplasm;endosome;trans-Golgi network;plasma membrane;cell-cell adherens junction;cytoplasmic side of plasma membrane;cell surface;actin cytoskeleton;integral component of membrane;lateral plasma membrane;catenin complex;flotillin complex;lamellipodium;cell junction;cortical actin cytoskeleton;apical junction complex;perinuclear region of cytoplasm;extracellular exosome;postsynapse;glutamatergic synapse	calcium ion binding;protein binding;beta-catenin binding;cytoskeletal protein binding;ankyrin binding;GTPase activating protein binding;identical protein binding;protein homodimerization activity;gamma-catenin binding;cadherin binding;cell adhesion molecule binding	GALNT12[24412244];GSK3B[25241761];ACADVL[16212417];CTNND1[20371349;24424122];ILK[25852190];MSANTD3[24412244];PVR[17717529];CCND1[20439707];CDH1[24725409;19114658;19646884;21300292;23112161];C1QBP[16212417];CASP3[25241761];CDC27[20951947;20802534];RACK1[21685945];EPSTI1[25640309];AKT1[24412244];SKP2[18239684;22770219];NANS[24412244];TNS3[19732724];HRAS[24412244];AP2M1[24189400];TGM2[16212417];TMOD1[24412244];HSP90AA1[16212417];MAP2K1[24412244];RALBP1[28851898];KRT1[16212417];SCRIB[21701506];ACTN4[16212417];NIPSNAP1[16212417];KRT9[16212417];NIPSNAP2[16212417];DKK3[25640309];FRMD5[22846708];SFRP2[24412244];AOPEP[24412244];MAPKAPK3[24412244];PRKD1[15695390];KIFC3[19041755];CBLL1[21685945];CRYAB[22158051];ZNF510[24412244];CFTR[17110338];YAP1[21376238];HEMGN[24412244];HDAC2[25241761];SET[16212417];PHLPP1[21701506];BEX1[25640309];STX17[24412244];SRC[21685945];HSD17B3[24412244];PSEN1[11953314];NDRG1[17220478];EGFR[25241761;24189400;24658140];HSPD1[16212417];CYP17A1[25640309];PSMC3IP[25640309];LIMA1[18093941];RACGAP1[22750944];CCL5[25640309];LMNA[16212417];POLR2E[16212417];CTNNA1[16212417;19016843;22750944];TP53BP2[25344754];IGHA1[16212417];ECT2[22750944];MTA3[25640309];RALGDS[23175184];XRCC5[16212417];PLEKHA7[19041755;28877994];PPP1CA[17274640];CCT6A[16212417];CDK8[24412244];NAT2[25640309];CTNNB1[12640114;16212417;17220478;11401320;19016843;22158051;18593713;24424122;16983094;22056988;25344754];BLID[25640309];THRSP[25640309];ANP32B[16212417];HSPA1A[16212417];FGFR1[11401320;25241761];	68853297
2143	chr16	72832619	AA		chr16:72832619-72832620	ZFHX3	zinc finger homeobox 3	deletion	0/1	0.6	2_3	5	63	rs75174704	SPLICING	YES	NM_001386735.1	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	15/16		NM_001386735.1:c.3968-7_3968-6del			-1.0					Prostate cancer, somatic, 176807 (3)	.	.	Autosomal dominant inheritance;Somatic mutation;Prostate cancer		7.14306e-05	10.0	139996.0	0.0	32	0.82	PASS	amr	0.000140568	2.0	6.27924e-05	4.0	0.00686702	797.0	116062.0	0.0	22	0.54	InbreedingCoeff	sas	0.00888202	92.0	0.00725446	429.0	0.0000193,0.0000064	3,1			0.01976	219		6.022	0.212306		0	0	0			ZFHX3	0.01	0.0	0.0	0.0	-14.0	-9.0	-5.0	-16.0						0.086	1.0				neoplasm; reproductive system phenotype; mortality/aging ; normal phenotype; behavior/neurological phenotype ; renal/urinary system phenotype; nervous system phenotype ; growth/size/body region phenotype; homeostasis/metabolism phenotype; 			fetal thyroid;superior cervical ganglion;prostate;	.	negative regulation of transcription by RNA polymerase II;regulation of transcription, DNA-templated;transcription by RNA polymerase II;brain development;muscle organ development;circadian regulation of gene expression;regulation of neuron differentiation;positive regulation of cell adhesion;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;response to transforming growth factor beta;regulation of locomotor rhythm	nucleus;nucleoplasm;transcription factor complex;cytoplasm;nuclear body	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;zinc ion binding;enzyme binding;transcription regulatory region DNA binding	TTC23[unassigned1304];USHBP1[unassigned1304];C11orf49[unassigned1304];DEUP1[unassigned1304];KRT40[25416956];LMNB2[unassigned1304];GOLGA2[unassigned1304];GOLGA6L9[unassigned1304];ALKBH4[23145062];MYC[21150319];CEP70[unassigned1304];TRIM27[unassigned1304];NINL[16189514];PIBF1[unassigned1304];ZNF620[unassigned1304];RBM11[unassigned1304];POU2F1[unassigned1304];MSX2[unassigned1304];POU6F2[unassigned1304];MTUS2[unassigned1304];KRT34[unassigned1304];KRT31[unassigned1304];AES[unassigned1304];COPS6[unassigned1304];CNOT2[unassigned1304];BHLHE40[unassigned1304];SPECC1L[unassigned1304];PICK1[unassigned1304];TACC1[unassigned1304];EFHC2[unassigned1304];TRIM54[unassigned1304];WRAP53[26496610];	72832618
2148	chr16	72991712	GCCACCGCCGCCGCC		chr16:72991712-72991726	ZFHX3	zinc finger homeobox 3	deletion	0/1	0.45	36_29	65	99	rs746659616	EXONIC	YES	NM_001386735.1	Transcript	protein_coding	inframe_deletion		9/17	NM_001386735.1:c.2319_2333del	NP_001373664.1:p.Val777_Ala781del		-1.0					Prostate cancer, somatic, 176807 (3)	.	.	Autosomal dominant inheritance;Somatic mutation;Prostate cancer		0.00010608	16.0	150830.0	2.0	33	0.96	PASS	amr	0.000461559	7.0	7.42523e-05	5.0	6.41827e-05	15.0	233708.0	0.0	78	0.96	PASS	amr	0.000205786	7.0	4.88081e-05	5.0	0.0000064	1			0.00167	19		18.31	1.814934		0	0	0																	0.086	1.0				neoplasm; reproductive system phenotype; mortality/aging ; normal phenotype; behavior/neurological phenotype ; renal/urinary system phenotype; nervous system phenotype ; growth/size/body region phenotype; homeostasis/metabolism phenotype; 			fetal thyroid;superior cervical ganglion;prostate;	.	negative regulation of transcription by RNA polymerase II;regulation of transcription, DNA-templated;transcription by RNA polymerase II;brain development;muscle organ development;circadian regulation of gene expression;regulation of neuron differentiation;positive regulation of cell adhesion;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;response to transforming growth factor beta;regulation of locomotor rhythm	nucleus;nucleoplasm;transcription factor complex;cytoplasm;nuclear body	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;zinc ion binding;enzyme binding;transcription regulatory region DNA binding	TTC23[unassigned1304];USHBP1[unassigned1304];C11orf49[unassigned1304];DEUP1[unassigned1304];KRT40[25416956];LMNB2[unassigned1304];GOLGA2[unassigned1304];GOLGA6L9[unassigned1304];ALKBH4[23145062];MYC[21150319];CEP70[unassigned1304];TRIM27[unassigned1304];NINL[16189514];PIBF1[unassigned1304];ZNF620[unassigned1304];RBM11[unassigned1304];POU2F1[unassigned1304];MSX2[unassigned1304];POU6F2[unassigned1304];MTUS2[unassigned1304];KRT34[unassigned1304];KRT31[unassigned1304];AES[unassigned1304];COPS6[unassigned1304];CNOT2[unassigned1304];BHLHE40[unassigned1304];SPECC1L[unassigned1304];PICK1[unassigned1304];TACC1[unassigned1304];EFHC2[unassigned1304];TRIM54[unassigned1304];WRAP53[26496610];	72991711
2165	chr16	84203741	CCCGCCACCTGTGGAGGTTAAAGGAGAGGATGGAGATCAAGAGCCAGAGGGGACCCTCCCAGCTGAGACCCTGCTACTGTCACCGCCTGTGAAGGTTAAAGGAGAGGATGGAGATCGAGAGCCAGAGGGGACCCTCCCAGCTGAGGCCCCACCACC		chr16:84203741-84203896	DNAAF1	dynein axonemal assembly factor 1	deletion	0/1	0.78	5_18	23	60		EXONIC	YES	NM_178452.6	Transcript	protein_coding	inframe_deletion		8/12	NM_178452.6:c.1347_1502del	NP_848547.4:p.Pro452_Pro503del		1.0					Ciliary dyskinesia, primary, 13, 613193 (3), Autosomal recessive	Primary ciliary dyskinesia	Disease-causing germline mutation(s) in	Hydrocephalus;Pectus excavatum;Chronic otitis media;Tachypnea;Impaired nasal mucociliary clearance;Delayed speech and language development;Asthma;Atelectasis;Headache;Ectopic pregnancy;Nasal polyposis;Clubbing of fingers;Pulmonary obstruction;Asplenia;Scoliosis;Reduced sperm motility;Respiratory distress;Immotile cilia;Chronic sinusitis;Infertility;Chronic bronchitis;Corneal dystrophy;Glue ear;Pneumonia;Spontaneous abortion;Conductive hearing impairment;Recurrent respiratory infections;Situs inversus totalis;Cough;Bronchiectasis;Ventriculomegaly;Rhinitis;Halitosis;Infertility;Bronchiectasis;Recurrent bronchitis;Sinusitis;Absent outer dynein arms;Autosomal recessive inheritance;Situs inversus totalis;Absent inner dynein arms;Recurrent otitis media;Ciliary dyskinesia		0.000537497	80.0	148838.0	0.0	32	0.93	PASS	afr	0.00124384	50.0	0.000179056	12.0					100	0.99											0.00526	60		12.6	0.883905		0	0	0																		0.0	0.000000000,2.001801699,0.000000000,23.536853263,0.000000000,6.586176324,0.000000000,54.938639654,0.000000000			nervous system phenotype ; craniofacial phenotype; mortality/aging ; skeleton phenotype; 			testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;fetal lung;testis;skeletal muscle;hypothalamus;	.	heart looping;cilium movement;regulation of cilium beat frequency;lung development;determination of pancreatic left/right asymmetry;outer dynein arm assembly;inner dynein arm assembly;motile cilium assembly;cilium assembly;epithelial cilium movement involved in determination of left/right asymmetry;left/right pattern formation;axonemal dynein complex assembly;determination of digestive tract left/right asymmetry;determination of liver left/right asymmetry	spindle pole;cytoplasm;cytosol;plasma membrane;axoneme;nuclear speck	dynein complex binding	ANKMY2[27173435;unassigned1312];GLRX3[27173435;unassigned1312];XPNPEP3[27173435;unassigned1312];STOM[27173435;unassigned1312];FADD[unassigned1774];OBSL1[27173435;unassigned1312];	84203740
2167	chr16	85697117	C	T	chr16:85697117	GSE1	Gse1 coiled-coil protein	SNV	0/1	0.5	43_43	86	99	rs144238002	EXONIC	YES	NM_014615.5	Transcript	protein_coding	synonymous_variant		11/16	NM_014615.5:c.2541C>T	NP_055430.1:p.Thr847%3D		1.0						.	.	.		0.000170954	26.0	152088.0	0.0	33	0.97	PASS	amr	0.000981804	15.0	7.35208e-05	5.0	0.000139256	35.0	251336.0	0.0	100	1.0	PASS	amr	0.000491443	17.0	0.0001408	16.0	0.0000900	14	0.002	5.0	0.0014	16		9.317	0.490908		0	0	0			GSE1	0.0	0.0	0.0	0.0	9.0	44.0	18.0	-41.0								34.893533698			hematopoietic system phenotype; skeleton phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; 			.	.	.	.	protein binding	C1orf94[25416956;unassigned1304];BECN1[22081109];HDAC2[21258344;23752268];RBM48[16169070];KDM1A[21258344];ZMYND19[unassigned1304];HDAC1[21258344;23752268;26496610];TULP3[23414517];LENG8[unassigned1304];CFAP206[25416956];GOLGA2[25416956;unassigned1304;29568061];NUDT18[16189514];GSE1[25416956];TEKT4[25416956];HMG20A[26496610];TRIM27[unassigned1304];NINL[26638075];RUNX1T1[25416956];MAPK3[26496610];CARD10[unassigned1304];XRCC6[16169070];RALBP1[25416956];RBPMS[16189514];SFMBT1[27705803];CADPS[unassigned1304];HIST2H2BC[30021884];CDC5L[17043677];TFIP11[unassigned1304];TRAF2[unassigned1304];TRIP6[25416956];TCF4[25609649];CEP63[17043677];RCOR3[16189514;19060904;25416956;unassigned1304];	85697117
2169	chr16	88496719	G	A	chr16:88496719	ZNF469	zinc finger protein 469	SNV	0/1	0.42	50_36	86	99	rs150435442,COSV104714896	EXONIC	YES	NM_001367624.2	Transcript	protein_coding	synonymous_variant		3/3	NM_001367624.2:c.2841G>A	NP_001354553.1:p.Arg947%3D		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	not_specified|not_provided	Brittle cornea syndrome 1, 229200 (3), Autosomal recessive	Brittle cornea syndrome	Disease-causing germline mutation(s) in	Visual loss;Myalgia;Scoliosis;Hyperextensible skin;Mitral valve prolapse;Sensorineural hearing impairment;Blue sclerae;Joint hyperflexibility;High myopia;Hernia;Abnormality of hair pigmentation;Corneal scarring;Glaucoma;Retinal detachment;Bruising susceptibility;Hallux valgus;Corneal erosion;Neonatal hypotonia;Conductive hearing impairment;Corneal dystrophy;Abnormality of epiphysis morphology;Pulmonic stenosis;Arachnodactyly;Hip dysplasia;Keratoglobus;Cleft palate;Soft skin;Camptodactyly;Osteoporosis;Gait disturbance;Increased susceptibility to fractures;Abnormality of the dentition;Pes planus;Dentinogenesis imperfecta;Keratoglobus;Decreased corneal thickness;Autosomal recessive inheritance;Blue sclerae;Keratoconus;Spondylolisthesis;Disproportionate tall stature;Scoliosis;Congenital hip dislocation;Red hair;Myopia;Molluscoid pseudotumors;Mitral valve prolapse;Epicanthus;Visual loss;Atypical scarring of skin;Palmoplantar cutis laxa;Joint laxity;Hearing impairment;Macrocephaly		0.00317902	484.0	152248.0	3.0	34	0.98	PASS	amr	0.00647482	99.0	0.00460051	313.0	0.00276078	323.0	116996.0	2.0	10	0.32	PASS	nfe	0.00481895	214.0	0.00481895	214.0	0.0004244	66	0.006	21.0	0.00704	79		1.393	-0.101477		0	0	0			ZNF469	0.0	0.0	0.0	0.0	-21.0	-17.0	1.0	-17.0											.			.	.	regulation of transcription by RNA polymerase II	nucleus	DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;metal ion binding	HIST1H2BL[30021884];RIPK4[26972000];HIST1H2BH[30021884];	88496719
2199	chr16	89598356	C	T	chr16:89598356	SPG7	SPG7, paraplegin matrix AAA peptidase subunit	SNV	0/1	0.35	35_19	54	99	rs116319889,COSV51948138	EXONIC	YES	NM_001363850.1	Transcript	protein_coding	synonymous_variant		8/18	NM_001363850.1:c.1032C>T	NP_001350779.1:p.Gly344%3D		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Hereditary_spastic_paraplegia_7|Hereditary_spastic_paraplegia|not_specified|not_provided	Spastic paraplegia 7, autosomal recessive, 607259 (3), Autosomal recessive, Autosomal dominant	Primary lateral sclerosis;Spastic paraplegia type 7	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Hyperreflexia;Memory impairment;Autosomal recessive inheritance;Dysarthria;Cerebral cortical atrophy;Cerebellar atrophy;Spastic gait;Spastic paraplegia;Babinski sign;Degeneration of the lateral corticospinal tracts;Dysphagia;Optic atrophy;Impaired vibration sensation in the lower limbs;Pes cavus;Urinary bladder sphincter dysfunction;Urinary incontinence;Lower limb spasticity;Lower limb muscle weakness;Urinary urgency;Scoliosis;Adult onset;Gait ataxia;Nystagmus;Autosomal dominant inheritance;Optic atrophy;Dysarthria;Supranuclear gaze palsy;Pes cavus;Lower limb hyperreflexia;Abnormal mitochondrial morphology;Scoliosis;Cerebellar atrophy;Upper limb muscle weakness;Cerebral cortical atrophy;Spastic gait;Lower limb pain;Ragged-red muscle fibers;Dysphagia;Optic disc pallor;Memory impairment;Attention deficit hyperactivity disorder;Nystagmus;Nasal speech;Lower limb hypertonia;Urinary urgency;Slowed slurred speech;Impaired vibration sensation in the lower limbs;Abnormality of the cerebral white matter;Babinski sign;Specific learning disability;Lower limb muscle weakness;Loss of speech;Spastic dysarthria;Pseudobulbar signs;Cervical spinal cord atrophy;Spastic gait;Progressive spastic paraparesis;Abnormal upper motor neuron morphology;Motor axonal neuropathy;EMG: chronic denervation signs;Dysphagia;Generalized hyperreflexia;Babinski sign		0.0045522	693.0	152234.0	5.0	32	0.97	PASS	nfe	0.00724638	493.0	0.00724638	493.0	0.00494378	1240.0	250820.0	10.0	94	0.99	PASS	nfe	0.00775468	878.0	0.00775468	878.0	0.0051253	797	0.007	23.0	0.00678	77		1.057	-0.142505		0	0	0			SPG7	0.02	0.01	0.0	0.0	-23.0	-44.0	-2.0	-42.0						0.103	0.0	1.990387946			growth/size/body region phenotype; skeleton phenotype; behavior/neurological phenotype ; nervous system phenotype ; 			amygdala;thyroid;subthalamic nucleus;prefrontal cortex;whole brain;cingulate cortex;testis;	.	proteolysis;mitochondrial calcium ion transmembrane transport;mitochondrion organization;nervous system development;anterograde axonal transport;regulation of mitochondrial membrane permeability;mitochondrial outer membrane permeabilization involved in programmed cell death	mitochondrion;mitochondrial inner membrane;m-AAA complex;mitochondrial permeability transition pore complex;axon cytoplasm	metalloendopeptidase activity;protein binding;ATP binding;peptidase activity;zinc ion binding;unfolded protein binding	KHDRBS2[25416956];RIF1[16169070];CERK[26496610];HSF2BP[unassigned1304];CCNDBP1[25416956];KRT40[25416956];PSTPIP1[25416956];HTR7[19486527];CYSRT1[unassigned1304];TRIM28[16169070];PNMA1[21516116;25416956;unassigned1304];EMC2[26496610];BDKRB2[28298427];RALY[16169070];C6orf203[27499296];MAPK6[21900206];LZTS2[25416956];PDK1[26496610];KRTAP5-9[21516116];KRTAP10-7[25416956];RBPMS[25416956];SPATS1[21988832];KRTAP10-9[25416956];MTUS2[21516116;25416956];NOTCH2NLA[25416956;unassigned1304];PLSCR1[16189514];HNRNPK[25416956;unassigned1304];ELF3[17353931];KRTAP4-12[16189514];PSME3[25416956];STAMBP[21988832];MDFI[16189514;25416956;unassigned1304];	89598356
2205	chr16	89809240	G	T	chr16:89809240	FANCA	FA complementation group A	SNV	0/1	0.21	22_6	28	99	rs745665658	EXONIC	YES	NM_000135.4	Transcript	protein_coding	missense_variant		37/43	NM_000135.4:c.3733C>A	NP_000126.2:p.Gln1245Lys		-1.0	.,.,.	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Fanconi_anemia,_complementation_group_A|Fanconi_anemia|not_specified	Fanconi anemia, complementation group A, 227650 (3), Autosomal recessive	Fanconi anemia	Disease-causing germline mutation(s) in	Hydroureter;Hypopigmented skin patches;Cranial nerve paralysis;Umbilical hernia;Epicanthus;Weight loss;Choanal atresia;Myelodysplasia;Hypogonadism;Scoliosis;Hip dislocation;Recurrent urinary tract infections;Abnormality of the hypothalamus-pituitary axis;Short palpebral fissure;Hypertrophic cardiomyopathy;High palate;Aplasia/Hypoplasia of the iris;Decreased fertility in males;Aplasia/Hypoplasia of fingers;Toe syndactyly;Irregular hyperpigmentation;Almond-shaped palpebral fissure;Tetralogy of Fallot;Astigmatism;Pyridoxine-responsive sideroblastic anemia;Meckel diverticulum;Hypertelorism;Sloping forehead;Ptosis;Anal atresia;Cryptorchidism;Intellectual disability;Facial asymmetry;Visual impairment;Upslanted palpebral fissure;Duodenal stenosis;Abnormality of the liver;Aplasia/Hypoplasia of the uvula;Abnormal carotid artery morphology;Hypospadias;Nystagmus;Multiple cafe-au-lait spots;Renal insufficiency;Clinodactyly of the 5th finger;Bicornuate uterus;Abnormality of chromosome stability;Strabismus;Micrognathia;Hypoplasia of the ulna;Proptosis;Atrial septal defect;Abnormal aortic valve morphology;Abnormality of femur morphology;Cataract;Microphthalmia;Hydrocephalus;Ventriculomegaly;Aganglionic megacolon;Absent testis;Hearing impairment;Arteriovenous malformation;Azoospermia;Renal hypoplasia/aplasia;Thrombocytopenia;Finger syndactyly;Oligohydramnios;External ear malformation;Global developmental delay;Aplasia/Hypoplasia of the radius;Reduced bone mineral density;Clubbing of toes;Microcephaly;Abnormal aortic morphology;Frontal bossing;Dolichocephaly;Spina bifida;Leukopenia;Tracheoesophageal fistula;Patent ductus arteriosus;Abnormality of the preputium;Hyperreflexia;Short stature;Abnormal localization of kidney;Cleft palate;Triphalangeal thumb;Intrauterine growth retardation;Pes planus;Abnormality of cardiovascular system morphology;Abnormality of skin pigmentation;Leukemia;Chromosomal breakage induced by crosslinking agents;Cafe-au-lait spot;Bruising susceptibility;Male infertility;Duplicated collecting system;Pancytopenia;Complete duplication of thumb phalanx;Absent radius;Short stature;Thrombocytopenia;Anemic pallor;Cryptorchidism;Deficient excision of UV-induced pyrimidine dimers in DNA;Absent thumb;Hypergonadotropic hypogonadism;Abnormal heart morphology;Renal agenesis;Hearing impairment;Intellectual disability;Prolonged G2 phase of cell cycle;Microphthalmia;Short thumb;Autosomal recessive inheritance;Neutropenia;Horseshoe kidney;Strabismus;Anemia;Microcephaly;Ectopic kidney;Small for gestational age;Reticulocytopenia		1.31427e-05	2.0	152176.0	0.0	32	0.96	PASS	amr	6.5505e-05	1.0	0.0	0.0	5.96483e-05	15.0	251474.0	1.0	86	1.0	PASS	amr	0.000317993	11.0	8.79105e-06	1.0	0.0000257	4	0.001	2.0	0.00245	28		2.449	-0.011839	0.152	2	17	19	M-CAP_pred,FATHMM_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	FANCA	0.0	0.0	0.03	0.0	23.0	-3.0	-32.0	-29.0						0.0821	0.0	0.000000000	0.002	0.15	mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; embryo phenotype; skeleton phenotype; vision/eye phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; 			temporal lobe;testis - seminiferous tubule;testis - interstitial;tumor;superior cervical ganglion;trigeminal ganglion;testis;parietal lobe;	Tyrosine metabolism;Styrene degradation	DNA repair;male meiotic nuclear division;male gonad development;female gonad development;interstrand cross-link repair;regulation of cell population proliferation;regulation of regulatory T cell differentiation;regulation of inflammatory response;regulation of DNA-binding transcription factor activity;protein-containing complex assembly;regulation of CD40 signaling pathway	nucleus;nucleoplasm;cytoplasm;Fanconi anaemia nuclear complex	protein binding	FANCM[17396147;17289582];FANCL[17396147;17289582];SRC[17474147];TOP3A[21240188];FANCA[12649160];FAAP24[17289582];FANCC[10627486;9742112];BRCA1[12354784;21240188;29656893];FANCB[17396147;17289582];PIK3R1[17474147];FANCE[12093742];FAAP20[22266823];FANCG[10373536;10468606;10627486;10652215;11157805;11063725;16189514;17396147;12649160;17289582];SMARCA4[11726552];FANCF[11063725;12649160];FYN[17474147];GRB2[17474147];PLCG1[17474147];SPTAN1[10551855];CRK[17474147];FAAP100[17396147];NCK1[17474147];	89809240
2213	chr16	89986091	G	A	chr16:89986091	MC1R	melanocortin 1 receptor	SNV	0/1	0.52	138_149	287	99	rs11547464,CM994355	EXONIC	YES	NM_002386.4	Transcript	protein_coding	missense_variant		1/1	NM_002386.4:c.425G>A	NP_002377.4:p.Arg142His		1.0	GPCR, rhodopsin-like, 7TM,GPCR, rhodopsin-like, 7TM,GPCR, rhodopsin-like, 7TM,.	Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Cutaneous_malignant_melanoma_5|not_provided	[Analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3); [Skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3), Autosomal recessive; [Skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3), Autosomal recessive; {Melanoma, cutaneous malignant, 5}, 613099 (3); {Albinism, oculocutaneous, type II, modifier of}, 203200 (3), Autosomal recessive; {UV-induced skin damage}, 266300 (3), Autosomal recessive	Large congenital melanocytic nevus;Familial melanoma;Oculocutaneous albinism type 2	Modifying germline mutation in;Major susceptibility factor in;Modifying germline mutation in	Nystagmus;Albinism;Basal cell carcinoma;Squamous cell carcinoma of the skin;Photophobia;Visual impairment;Abnormality of the optic nerve;Freckling;Iris hypopigmentation;Strabismus;Melanoma;Congenital giant melanocytic nevus;Hypopigmented skin patches;Cutaneous melanoma;Pruritus;Seizure;Subcutaneous nodule;Hydrocephalus;Generalized hirsutism;Rhabdomyosarcoma;Retinopathy;Neoplasm of the stomach;Abnormality of the lymphatic system;Neoplasm of the breast;Freckling;Neoplasm of the pancreas;Abnormality of extrapyramidal motor function;Dry skin;Melanoma;Nevus;Abnormal hair morphology;Exotropia;Strabismus;Myopia;Albinism;Hypopigmentation of the fundus;Blue irides;Reduced visual acuity;Red hair;Autosomal recessive inheritance;Freckles in sun-exposed areas;Nystagmus;Hypoplasia of the fovea	21197618,26547235,25945350,19710684,20585627,18366057,21128237,27488084,19585506,26848990,31612033,10403794,19924138,22095742,20457063,26103569,30531825,29774366,29340229,25963972,27766958,23843775,23317428,28500464	0.0047106	717.0	152210.0	1.0	33	0.98	PASS	nfe	0.00688033	468.0	0.00688033	468.0	0.00532294	1298.0	243850.0	7.0	98	1.0	PASS	nfe	0.00697472	784.0	0.00697472	784.0	0.0048680	757	0.008	26.0	0.00929	106		27.6	3.990441	0.556	17	2	19	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaRNN_pred,ClinPred_pred	MC1R	0.0	0.0	0.0	0.0	37.0	-47.0	-2.0	-26.0							0.0	0.000000000,0.000000000	0.455	1.146	growth/size/body region phenotype; integument phenotype ; cellular phenotype; craniofacial phenotype; hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; pigmentation phenotype; neoplasm; hematopoietic system phenotype; behavior/neurological phenotype ; immune system phenotype; 			.	Neuroactive ligand-receptor interaction;Melanogenesis	G protein-coupled receptor signaling pathway;G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger;adenylate cyclase-activating G protein-coupled receptor signaling pathway;multicellular organism development;UV protection;positive regulation of protein kinase A signaling;sensory perception of pain;negative regulation of tumor necrosis factor production;intracellular signal transduction;melanin biosynthetic process;pigmentation;positive regulation of transcription by RNA polymerase II;positive regulation of protein kinase B signaling;UV-damage excision repair;positive regulation of protein kinase C signaling	plasma membrane;integral component of plasma membrane	melanocortin receptor activity;melanocyte-stimulating hormone receptor activity;protein binding;G protein-coupled peptide receptor activity;ubiquitin protein ligase binding	MRAP[19329486];PSMD2[25036637];MRAP2[19329486];	89986091
2218	chr17	1381390	C	T	chr17:1381390	MYO1C	myosin IC	SNV	0/1	0.41	58_40	98	99	rs142534772	EXONIC	YES	NM_001080779.2	Transcript	protein_coding	synonymous_variant		12/32	NM_001080779.2:c.1392G>A	NP_001074248.1:p.Glu464%3D		-1.0						Autosomal dominant non-syndromic sensorineural deafness type DFNA	Disease-causing germline mutation(s) in	.		0.00044664	68.0	152248.0	0.0	32	0.98	PASS	sas	0.00227649	11.0	0.000764166	52.0	0.000600981	151.0	251256.0	0.0	100	1.0	PASS	sas	0.00192735	59.0	0.000712928	81.0	0.0004373	68	0.001	2.0	0.00035	4		11.65	0.761656		0	0	0			MYO1C	0.0	0.0	0.01	0.18	-2.0	-10.0	-1.0	13.0						0.0331	0.0	23.536853263			skeleton phenotype; hearing/vestibular/ear phenotype; nervous system phenotype ; hematopoietic system phenotype; 			ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	.	protein targeting;protein targeting to membrane;vesicle transport along actin filament;positive regulation of cell migration;positive regulation of actin filament polymerization;positive regulation of cell migration by vascular endothelial growth factor signaling pathway;Fc-gamma receptor signaling pathway involved in phagocytosis;positive regulation of gene expression, epigenetic;mRNA transport;cellular response to interferon-gamma;positive regulation of protein targeting to membrane;positive regulation of cellular response to insulin stimulus;positive regulation of vascular endothelial growth factor signaling pathway;regulation of bicellular tight junction assembly	stress fiber;nuclear pore;nucleoplasm;nucleolus;cytoplasm;cytosol;plasma membrane;microvillus;brush border;basal plasma membrane;membrane;lateral plasma membrane;unconventional myosin complex;nuclear body;cytoplasmic vesicle membrane;filamentous actin;ruffle membrane;membrane raft;phagocytic vesicle;stereocilium membrane;extracellular exosome	microfilament motor activity;signaling receptor binding;protein binding;calmodulin binding;ATP binding;protein C-terminus binding;Ral GTPase binding;actin-dependent ATPase activity;actin filament binding	EIF4A2[17353931];TRIR[26496610];DIXDC1[26496610];CCAR1[26496610];ACTG1[26496610];PYCARD[24407287];PPP1CB[26496610];GOLGA2[29568061];FBL[16514417];CHCHD3[26496610];MPRIP[26496610];BASP1[26496610];TUBB3[27291054];CFL2[26496610];CFL1[26496610];BAP18[26496610];SYNPO[26496610];PHLDA3[17353931];TMOD1[26496610];CARD10[26496610];PDGFRA[26496610];PPTC7[28330616];TMOD3[26496610];AFAP1[26496610];OCRL[25107275];ACTN4[26496610];GTF2F1[26496610];CDC25C[28330616];DDX39B[26496610];PPP1R3C[28330616];KCTD10[26496610];SRSF2[26496610];ZSCAN26[26496610];PTPRCAP[28330616];PHLDB2[26496610];HDGFL2[26496610];VCL[26496610];RAI14[26496610];SHC1[19380743];COX15[29128334];FLII[26496610];TWF2[26496610];TWF1[26496610];FBXO46[26496610];IQGAP1[26496610];CIAO1[17353931];CORO1C[26496610];ARHGAP21[26496610];SAFB2[26496610];PNPO[26496610];SPTBN1[26496610];RBM10[26496610];SPTBN2[26496610];SPECC1[26496610];UVRAG[26496610];ITPRID2[26496610];JUN[25609649];NEK6[17353931];DSTN[26496610];MYO5A[26496610];CORO2A[26496610];LARP4[26496610];ESR1[21182205];ESR2[21182203];FBXO30[26496610];SSH1[26496610];CHERP[26496610];ANLN[26496610];ARPC3[26496610];GIPC1[17353931];JMY[26496610];TADA3[26496610];CDK2[26496610];GRB2[12577067];CALM1[26496610];ARHGAP11A[26496610];MCM7[23764002];CCDC127[26496610];WDR1[26496610];LRRK2[24725412];ARPC1B[26496610];DOCK7[26496610];HMGB2[26496610];ARRB1[17620599];ARRB2[17620599];KIF11[26496610];MED16[26496610];SIPA1L3[26496610];MED15[26496610];TRIOBP[26496610];MED12[26496610];TUBA1A[27291054];MYO18A[26496610];IKBKG[14743216];SPTAN1[26496610];RBM5[26496610];RBM33[26496610];TPRN[26496610];ILKAP[28330616];IQCB1[21565611];PLEKHG3[26496610];UNC45A[26496610];SUN2[22555292];RBM17[26496610];PPP1R12A[26496610];TIMM29[26496610];RIPK3[14743216];KSR1[27086506];SPHK1[25216046];COBL[26496610];DUSP7[28330616];GAK[26496610];WRAP73[17353931];PTP4A3[17353931];INF2[26496610];DUSP21[28330616];PSMA1[29568061];PALLD[26496610];POLR1B[16514417];POLR1E[16514417];MYH9[26496610];NCBP3[26496610];NSRP1[26496610];DBN1[26496610];PPP1R15A[29109149];RALA[26496610];SF3B2[26496610];TIMM13[26496610];NEXN[26496610];CSTF2T[26496610];DLST[29128334];CRIP2[26496610];MRM1[26496610];ADD1[26496610];MRPL55[26496610];PCNP[26496610];AP3M1[26496610];LIMA1[26496610];SCAF8[26496610];ABLIM1[26496610];SLX4[19596235];FLNA[26496610];E2F3[22157815];SF3B1[26496610];MISP[26496610];PDLIM7[26496610];CLASP1[26496610];TIMM8B[26496610];MAP3K3[14743216];SVIL[26496610];FARP1[26496610];USP20[19615732];CDKN2A[26496610];RIOK3[26496610];SQOR[26496610];SORBS2[26496610];RRP1B[20926688];OXR1[26496610];MYO19[26496610];U2SURP[26496610];PPP1CA[26496610];TJP1[26496610];MYO1B[26496610];IMPDH1[26496610];IMPDH2[26496610];EIF3I[26496610];CAPZA2[26496610];AGGF1[26496610];CEP162[26496610];SIPA1[26496610];BCAR1[28007913];PTPN2[28330616];EIF3B[26496610];TJP2[26496610];	1381390
2246	chr17	4536572	G	A	chr17:4536572	ALOX15	arachidonate 15-lipoxygenase	SNV	0/1	0.36	28_16	44	99	rs147073659	EXONIC	YES	NM_001140.5	Transcript	protein_coding	synonymous_variant		10/14	NM_001140.5:c.1287C>T	NP_001131.3:p.Leu429%3D		-1.0						.	.	.		0.000157683	24.0	152204.0	0.0	32	0.96	PASS	afr	0.000410232	17.0	8.81756e-05	6.0	0.000107482	27.0	251204.0	0.0	54	0.99	PASS	afr	0.000184752	3.0	0.000158434	18.0	0.0000836	13	0.001	2.0	0.00079	9		3.277	0.041113		0	0	0			ALOX15	0.14	0.0	0.0	0.0	-30.0	38.0	26.0	-2.0						0.935	0.0	34.893533698			cellular phenotype; homeostasis/metabolism phenotype; integument phenotype ; endocrine/exocrine gland phenotype; neoplasm; immune system phenotype; mortality/aging ; cardiovascular system phenotype ; hematopoietic system phenotype; 			pons;ciliary ganglion;appendix;trachea;dorsal root ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	Arachidonic acid metabolism;Linoleic acid metabolism	ossification;negative regulation of adaptive immune response;phosphatidylethanolamine biosynthetic process;leukotriene metabolic process;inflammatory response;positive regulation of cell-substrate adhesion;cytokine-mediated signaling pathway;arachidonic acid metabolic process;lipoxygenase pathway;bone mineralization;positive regulation of actin filament polymerization;positive regulation of heterotypic cell-cell adhesion;response to endoplasmic reticulum stress;regulation of peroxisome proliferator activated receptor signaling pathway;cellular response to interleukin-13;wound healing;long-chain fatty acid biosynthetic process;apoptotic cell clearance;hepoxilin biosynthetic process;oxidation-reduction process;positive regulation of ERK1 and ERK2 cascade;cellular response to calcium ion;regulation of engulfment of apoptotic cell;lipoxin A4 biosynthetic process	lipid droplet;cytosol;plasma membrane;membrane;extrinsic component of cytoplasmic side of plasma membrane	arachidonate 12-lipoxygenase activity;iron ion binding;protein binding;phosphatidylinositol-4,5-bisphosphate binding;hepoxilin-epoxide hydrolase activity;arachidonate 15-lipoxygenase activity;hepoxilin A3 synthase activity;eoxin A4 synthase activity	KSR1[27086506];PEBP1[21831839];	4536572
2258	chr17	7096390	G	A	chr17:7096390	DLG4	discs large MAGUK scaffold protein 4	SNV	0/1	0.42	38_27	65	99	rs35441057	EXONIC	YES	NM_001365.4	Transcript	protein_coding	synonymous_variant		19/22	NM_001365.4:c.1869C>T	NP_001356.1:p.Tyr623%3D		-1.0		Benign	criteria_provided,_single_submitter	not_provided	Intellectual developmental disorder 62, 618793 (3), Autosomal dominant	.	.	.		0.00380686	579.0	152094.0	1.0	31	0.95	PASS	nfe	0.00592612	403.0	0.00592612	403.0	0.00406439	1008.0	248008.0	3.0	84	1.0	PASS	nfe	0.00599188	670.0	0.00599188	670.0	0.0036977	575	0.009	28.0	0.00693	66		10.54	0.626375		0	0	0			DLG4	0.16	0.01	0.0	0.0	-22.0	46.0	-23.0	18.0						0.424	1.0	75.529919781			nervous system phenotype ; behavior/neurological phenotype ; growth/size/body region phenotype; integument phenotype ; mortality/aging ; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; 			caudate nucleus;pons;ciliary ganglion;temporal lobe;amygdala;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;parietal lobe;medulla oblongata;cerebellum;	Tight junction	MAPK cascade;negative regulation of receptor internalization;signal transduction;positive regulation of cytosolic calcium ion concentration;chemical synaptic transmission;nervous system development;learning;synaptic vesicle maturation;protein localization to synapse;cellular response to potassium ion;receptor clustering;establishment of protein localization;regulation of long-term neuronal synaptic plasticity;positive regulation of synaptic transmission;dendritic spine morphogenesis;positive regulation of protein tyrosine kinase activity;protein-containing complex assembly;AMPA glutamate receptor clustering;receptor localization to synapse;cell-cell adhesion;postsynaptic neurotransmitter receptor diffusion trapping;positive regulation of neuron projection arborization;regulation of NMDA receptor activity;positive regulation of excitatory postsynaptic potential	cytoplasm;endoplasmic reticulum;cytosol;plasma membrane;synaptic vesicle;voltage-gated potassium channel complex;ionotropic glutamate receptor complex;postsynaptic density;cell junction;endocytic vesicle membrane;cortical cytoskeleton;extrinsic component of cytoplasmic side of plasma membrane;neuromuscular junction;AMPA glutamate receptor complex;dendrite cytoplasm;neuron projection;dendritic spine;juxtaparanode region of axon;neuron projection terminus;neuron spine;synapse;postsynaptic membrane;excitatory synapse;postsynaptic density membrane	Ras guanyl-nucleotide exchange factor activity;protein binding;protein C-terminus binding;kinase binding;protein phosphatase binding;PDZ domain binding;beta-1 adrenergic receptor binding;D1 dopamine receptor binding;P2Y1 nucleotide receptor binding;acetylcholine receptor binding;ionotropic glutamate receptor binding;protein-containing complex binding;neuroligin family protein binding;scaffold protein binding	APP[20573181];NLGN1[11937501];LRP1[17360663];FRMPD4[30126976];KCNA1[11937501];CTNND2[30126976];KCNA4[11937501];HSPD1[30021884];GRIN2A[11937501;17360663];SIPA1L1[22117215];CYSLTR2[30126976];ERBB4[10725395;16767099];KIF13B[10859302];KIF1B[12097473];DLGAP1[22117215];SPRR2A[18155796];NTRK2[23424281];GUCY1A2[30126976];RALBP1[30126976];CRIPT[11937501;20018661];CDC5L[30126976];GRIN2C[11937501];GRIN2B[11937501;20018661];GRIN1[11937501];GRIN2D[11937501];MED28[16964398];NET1[30126976];TANC1[30126976];ARC[23424281];MDM2[23260144];GRB2[17474147];PKP4[30126976];	7096390
2316	chr17	17697094		CAGCAG	chr17:17697093-17697094	RAI1	retinoic acid induced 1	insertion	0/1	0.29	49_20	69	99	rs371983878	EXONIC	YES	NM_030665.4	Transcript	protein_coding	inframe_insertion		3/6	NM_030665.4:c.867_872dup	NP_109590.3:p.Gln290_Gln291dup		1.0		Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	History_of_neurodevelopmental_disorder|not_provided	Smith-Magenis syndrome, 182290 (3), Isolated cases, Autosomal dominant	Smith-Magenis syndrome;Smith-Magenis syndrome;17p11.2 microduplication syndrome;PMP22-RAI1 contiguous gene duplication syndrome	Disease-causing germline mutation(s) in;Role in the phenotype of;Role in the phenotype of;Role in the phenotype of	Morphological abnormality of the middle ear;Abnormality of the thyroid gland;Short palm;Deeply set eye;Midface retrusion;Onychotillomania;Increased body weight;Abnormality of the dentition;Areflexia;EEG abnormality;Hearing impairment;Constipation;Brachydactyly;Abnormality of the urinary system;Ventriculomegaly;Stereotypy;Hoarse voice;Velopharyngeal insufficiency;Abnormality of the forearm;Sporadic;Self-mutilation;Abnormal tracheobronchial morphology;Head-banging;Sleep-wake inversion;Hoarse voice;Broad palm;Hypercholesterolemia;Abnormality of cardiovascular system morphology;Brachycephaly;Abnormal renal morphology;Abnormality of the outer ear;Autosomal dominant inheritance;Broad face;Seizure;Stereotypy;Retinal detachment;Delayed speech and language development;Pes planus;Short stature;Hypertriglyceridemia;Hyperacusis;Impaired pain sensation;Abnormality of the immune system;Hyporeflexia;Oral cleft;Everted upper lip vermilion;Global developmental delay;Abnormal heart morphology;Polyembolokoilamania;Generalized hypotonia;Wide nasal bridge;Mandibular prognathia;Hyperactivity;Abnormality of the larynx;Intellectual disability;Scoliosis;Synophrys;Self hugging;Malar flattening;Sleep disturbance;Downslanted palpebral fissures;Double outlet right ventricle;Smooth philtrum;Foot dorsiflexor weakness;Syringomyelia;Pes valgus;Joint laxity;Pes planus;Failure to thrive in infancy;Delayed speech and language development;Sensory neuropathy;Aortic aneurysm;Abnormality of the pinna;Persistent left superior vena cava;Triangular face;Thin upper lip vermilion;Long philtrum;Broad-based gait;Decreased number of peripheral myelinated nerve fibers;Sandal gap;Delayed ability to walk;Brain imaging abnormality;Ventricular septal defect;Feeding difficulties in infancy;Bicuspid aortic valve;Decreased/absent ankle reflexes;Global developmental delay;Distal sensory impairment;Strabismus;Chronic constipation;Decreased nerve conduction velocity;Abnormal renal morphology;Wide nose;2-3 toe syndactyly;Talipes equinovarus;Distal amyotrophy;Infantile muscular hypotonia;Patent foramen ovale;Distal muscle weakness;Overriding aorta;Autism;Intellectual disability, mild;Low-set, posteriorly rotated ears;Oral-pharyngeal dysphagia;Dysarthria;Muscular hypotonia;Abnormality of chromosome segregation;Triangular face;Failure to thrive;Poor fine motor coordination;High hypermetropia;Hypertelorism;Hypoplasia of the corpus callosum;Global developmental delay;Short stature;Dysphasia;Hearing impairment;Scoliosis;Attention deficit hyperactivity disorder;Micrognathia;Downslanted palpebral fissures;Microcephaly;Anxiety;Broad forehead;Abnormality of cardiovascular system morphology;EEG abnormality;Echolalia;Gastroesophageal reflux;Open bite;Abnormality of dental morphology;Speech apraxia;Wide mouth;Expressive language delay;Sleep apnea;Precocious puberty;Renal hypoplasia/aplasia;Neurological speech impairment;Hand polydactyly;Strabismus;Global developmental delay;Sleep disturbance;Short nose;Broad forehead;Wide nasal bridge;Hyperacusis;Muscular hypotonia;Aplasia/Hypoplasia of the corpus callosum;Gait disturbance;Short philtrum;Anteverted nares;Synophrys;Open mouth;Deeply set eye;Upslanted palpebral fissure;Hypercholesterolemia;Micrognathia;Taurodontia;EEG abnormality;Conductive hearing impairment;Failure to thrive in infancy;Brachycephaly;Hyporeflexia;Delayed puberty;Hypertelorism;Abnormal form of the vertebral bodies;Anxiety;Abnormality of cardiovascular system morphology;Stereotypy;Joint stiffness;Abnormality of the ureter;Cleft palate;Pes planus;Midface retrusion;Clinodactyly of the 5th finger;Feeding difficulties in infancy;Brachydactyly;Hoarse voice;Ventriculomegaly;Corticospinal tract hypoplasia;Mandibular prognathia;Tented upper lip vermilion;Delayed eruption of primary teeth;Large face;Intellectual disability;Constipation;Hypertriglyceridemia;Seizure;Short stature;Cleft upper lip;Toe syndactyly;Frontal bossing;Abnormal localization of kidney;Self-injurious behavior;Retinal detachment;Delayed speech and language development;Depressed nasal bridge;Attention deficit hyperactivity disorder;Decreased fetal movement;Abnormal tracheobronchial morphology;Microcephaly;Myopia;Scoliosis;Gastroesophageal reflux;Microcornea;Chronic otitis media;Hypothyroidism;Obesity;Impaired pain sensation;Precocious puberty;Renal hypoplasia/aplasia;Neurological speech impairment;Hand polydactyly;Strabismus;Global developmental delay;Sleep disturbance;Short nose;Broad forehead;Wide nasal bridge;Hyperacusis;Muscular hypotonia;Aplasia/Hypoplasia of the corpus callosum;Gait disturbance;Short philtrum;Anteverted nares;Synophrys;Open mouth;Deeply set eye;Upslanted palpebral fissure;Hypercholesterolemia;Micrognathia;Taurodontia;EEG abnormality;Conductive hearing impairment;Failure to thrive in infancy;Brachycephaly;Hyporeflexia;Delayed puberty;Hypertelorism;Abnormal form of the vertebral bodies;Anxiety;Abnormality of cardiovascular system morphology;Stereotypy;Joint stiffness;Abnormality of the ureter;Cleft palate;Pes planus;Midface retrusion;Clinodactyly of the 5th finger;Feeding difficulties in infancy;Brachydactyly;Hoarse voice;Ventriculomegaly;Corticospinal tract hypoplasia;Mandibular prognathia;Tented upper lip vermilion;Delayed eruption of primary teeth;Large face;Intellectual disability;Constipation;Hypertriglyceridemia;Seizure;Short stature;Cleft upper lip;Toe syndactyly;Frontal bossing;Abnormal localization of kidney;Self-injurious behavior;Retinal detachment;Delayed speech and language development;Depressed nasal bridge;Attention deficit hyperactivity disorder;Decreased fetal movement;Abnormal tracheobronchial morphology;Microcephaly;Myopia;Scoliosis;Gastroesophageal reflux;Microcornea;Chronic otitis media;Hypothyroidism;Obesity;Impaired pain sensation	25741868	0.00277806	219.0	78832.0	1.0	8	0.35	PASS	afr	0.00631526	150.0	0.00126356	48.0					80	0.98							0.0000193	3			0.00123	14					0	0	0																	0.202	1.0	0.000000000			homeostasis/metabolism phenotype; craniofacial phenotype; adipose tissue phenotype ; endocrine/exocrine gland phenotype; growth/size/body region phenotype; respiratory system phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype ; normal phenotype; mortality/aging ; behavior/neurological phenotype ; 			pons;trigeminal ganglion;superior cervical ganglion;skeletal muscle;globus pallidus;	Urea cycle and metabolism of amino groups;beta-Alanine metabolism;Glutathione metabolism	skeletal system development;circadian regulation of gene expression;negative regulation of multicellular organism growth;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II	nucleus;nucleoplasm;mitochondrion	DNA-binding transcription factor activity;protein binding;enhancer binding;transcription regulatory region DNA binding;metal ion binding	GSK3B[21900206];CDKN1A[21900206];DAXX[26496610];GADD45A[21900206];TESC[16189514];PYHIN1[25665578];TCF20[26496610];MAPK8IP2[21900206];RPS6KA5[21900206];TTR[21900206];PIN1[16189514;25416956];CASP2[21900206];CDK2AP1[26496610];RPL13[30021884];HMG20A[26496610];HIST1H2BH[30021884];	17697093
2351	chr17	20135619	G	C	chr17:20135619	SPECC1	sperm antigen with calponin homology and coiled-coil domains 1	SNV	0/1	0.52	22_24	46	99	rs781522996,COSV54962991	EXONIC	YES	NM_001386083.1	Transcript	protein_coding	missense_variant		9/17	NM_001386083.1:c.2276G>C	NP_001373012.1:p.Arg759Thr		1.0	.,.,.,.,.,.,.					.	.	.						32	0.97							3.98191e-06	1.0	251136.0	0.0	97	1.0	PASS	sas	3.26627e-05	1.0	0.0	0.0	0.0000064	1			0.0001	1		24.7	3.406448	0.574	11	8	19	Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaLR_pred,MetaSVM_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	SPECC1	0.0	0.0	0.0	0.0	-19.0	1.0	-8.0	33.0							0.11	0.000000000	0.999	0.227	.			ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;	.	actin cytoskeleton organization	nucleus;microtubule organizing center;membrane;filamentous actin	.	CBX7[21282530];ACTR2[26496610];ATP6AP2[26496610];IQGAP1[26496610];KSR2[27086506];MYO19[26496610];PLEKHA7[28877994];PPP1CB[26496610];ANLN[26496610];LIMA1[26496610];MYO1C[26496610];MYO5C[26496610];CAPZA2[26496610];WDR5[27705803];MYO18A[26496610];MYH9[26496610];FLNA[26496610];GRB2[12577067];SYNPO[26496610];MAPRE1[26496610];RAB5A[26496610];DBN1[26496610];	20135619
2410	chr17	21318595	G	C	chr17:21318595	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.39	20_13	33	99	rs58780973,COSV59168601	SPLICING	YES	NM_021012.5	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	2/2		NM_021012.5:c.-56-4G>C			1.0						.	.	.						64	1.0											0	0.0							0.1701039	4487	0.069	179.0	0.49181	4685		6.709	0.261468		0	0	0			KCNJ12	0.0	0.01	0.0	0.0	7.0	4.0	7.0	-1.0	6.79726635997955e-05	0.214	10.444	-0.253	10.191	0.0599	0.0				.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21318595
2414	chr17	21318698	C	T	chr17:21318698	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.28	168_66	234	99	rs1657738,COSV59162518	EXONIC	YES	NM_021012.5	Transcript	protein_coding	missense_variant		3/3	NM_021012.5:c.44C>T	NP_066292.2:p.Ser15Leu		1.0	Potassium channel, inwardly rectifying, Kir, N-terminal,Potassium channel, inwardly rectifying, Kir, N-terminal					.	.	.		6.56659e-05	10.0	152286.0	0.0	68	1.0	PASS	sas	0.000206697	1.0	7.34711e-05	5.0	0.499594	121776.0	243750.0	1.0	100	1.0	InbreedingCoeff	amr	0.499853	17018.0	0.499719	55097.0	0.0317162	4932	0.153	444.0	0.49507	4716		23.1	2.799047	0.206	5	14	19	SIFT,LRT_pred,MutationTaster_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PolyPhen,Polyphen2_HDIV_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	KCNJ12	0.0	0.0	0.0	0.0	5.0	-11.0	-6.0	22.0						0.0599	0.0	74.840780568	0.359	1.021	.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21318698
2416	chr17	21318897	G	C	chr17:21318897	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.26	171_59	230	99	rs1657739,COSV59166881	EXONIC	YES	NM_021012.5	Transcript	protein_coding	synonymous_variant		3/3	NM_021012.5:c.243G>C	NP_066292.2:p.Arg81%3D		1.0						.	.	.		5.25472e-05	8.0	152244.0	0.0	68	1.0	PASS	eas	0.000384172	2.0	2.93902e-05	2.0	0.49992	124803.0	249646.0	0.0	100	1.0	InbreedingCoeff_RF	afr	0.5	8052.0	0.499947	56460.0	0.0286424	4454	0.137	402.0	0.49916	4755		11.19	0.704788		0	0	0			KCNJ12	0.0	0.0	0.0	0.0	4.0	-1.0	3.0	-1.0						0.0599	0.0	6.586176324			.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21318897
2418	chr17	21319007	G	A	chr17:21319007	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.25	141_46	187	99	rs1657740,COSV59162539	EXONIC	YES	NM_021012.5	Transcript	protein_coding	missense_variant		3/3	NM_021012.5:c.353G>A	NP_066292.2:p.Arg118Gln		1.0	.,.					.	.	.		3.94021e-05	6.0	152276.0	0.0	54	1.0	PASS	amr	6.53851e-05	1.0	5.87769e-05	4.0	0.499828	124644.0	249374.0	0.0	100	1.0	InbreedingCoeff	sas	0.499967	15237.0	0.499858	56434.0	0.0302436	4703	0.158	460.0	0.49927	4756		11.93	0.796593	0.088	1	17	18	FATHMM_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	KCNJ12	0.0	0.0	0.0	0.0	2.0	26.0	2.0	-25.0						0.0599	0.0	0.235039220	0.73	1.169	.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319007
2420	chr17	21319121	C	T	chr17:21319121	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.33	163_82	245	99	rs1714864,COSV59162867	EXONIC	YES	NM_021012.5	Transcript	protein_coding	missense_variant		3/3	NM_021012.5:c.467C>T	NP_066292.2:p.Pro156Leu		1.0	.,.					.	.	.		0.0	0.0	152296.0	0.0	57	1.0	AC0				0.0	0.0	0.499868	124541.0	249148.0	0.0	100	1.0	InbreedingCoeff	eas	0.5	9177.0	0.499965	56577.0	0.0290153	4512	0.185	563.0	0.49937	4757		28.8	4.119805	0.632	14	6	20	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaLR_pred,MetaSVM_pred,MetaRNN_pred,DEOGEN2_pred,ClinPred_pred,LIST-S2_pred	KCNJ12	0.0	0.0	0.0	0.0	-43.0	-4.0	-17.0	1.0						0.0599	0.0	26.103281974	0.951	1.021	.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319121
2421	chr17	21319230	G	C	chr17:21319230	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.33	139_67	206	99	rs1657742,COSV59162549	EXONIC	YES	NM_021012.5	Transcript	protein_coding	missense_variant		3/3	NM_021012.5:c.576G>C	NP_066292.2:p.Gln192His		1.0	.,.					.	.	.		1.9734e-05	3.0	152022.0	0.0	44	0.99	PASS,InbreedingCoeff	amr,amr	6.54536e-05	1.0	1.46968e-05	1.0	0.499264	120747.0	241850.0	0.0	100	1.0	InbreedingCoeff	eas	0.49989	9127.0	0.499163	54253.0	0.0268160	4170	0.115	324.0	0.49822	4746		23.1	2.802329	0.262	11	7	18	SIFT,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PolyPhen,LRT_pred,PROVEAN_pred,MetaRNN_pred,DEOGEN2_pred,ClinPred_pred,LIST-S2_pred	KCNJ12	0.0	0.0	0.0	0.0	15.0	-26.0	-24.0	43.0						0.0599	0.0	93.824270006	1.0	1.17	.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319230
2423	chr17	21319302	T	C	chr17:21319302	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.37	164_98	262	99	rs1657743,COSV59168745	EXONIC	YES	NM_021012.5	Transcript	protein_coding	synonymous_variant		3/3	NM_021012.5:c.648T>C	NP_066292.2:p.Gly216%3D		1.0						.	.	.		0.000193372	26.0	134456.0	0.0	37	0.96	AS_VQSR	eas	0.00167304	7.0	9.93049e-05	6.0	0.500004	125645.0	251288.0	1.0	100	1.0	InbreedingCoeff	nfe	0.500009	56813.0	0.500009	56813.0	0.0300185	4668	0.146	432.0	0.5	4763		11.92	0.795386		0	0	0			KCNJ12	0.0	0.0	0.0	0.0	46.0	-1.0	33.0	-6.0						0.0599	0.0	11.487689946			.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319302
2426	chr17	21319473	G	A	chr17:21319473	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.34	119_61	180	99	rs1657744,COSV59168799	EXONIC	YES	NM_021012.5	Transcript	protein_coding	synonymous_variant		3/3	NM_021012.5:c.819G>A	NP_066292.2:p.Glu273%3D		1.0						.	.	.		1.31351e-05	2.0	152264.0	0.0	60	1.0	PASS	afr	4.82556e-05	2.0	0.0	0.0	0.499868	125299.0	250664.0	0.0	100	1.0	InbreedingCoeff	sas	0.499967	15298.0	0.499965	56805.0	0.0336519	5233	0.167	527.0	0.49979	4761		12.29	0.843956		0	0	0			KCNJ12	0.0	0.0	0.0	0.0	15.0	1.0	-27.0	1.0						0.0599	0.0				.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319473
2427	chr17	21319767	C	T	chr17:21319767	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.23	126_38	164	99	rs1612176,COSV59162626,COSV59163167	EXONIC	YES	NM_021012.5	Transcript	protein_coding	synonymous_variant		3/3	NM_021012.5:c.1113C>T	NP_066292.2:p.Ser371%3D		1.0						.	.	.		1.31313e-05	2.0	152308.0	0.0	68	1.0	PASS	sas	0.000206697	1.0	0.0	0.0	0.471801	116179.0	246246.0	0.0	100	1.0	InbreedingCoeff	amr	0.486025	16624.0	0.475152	53256.0	0.2347464	36504	0.075	225.0	0.479	4563		7.46	0.319315		0	0	0			KCNJ12	0.0	0.0	0.0	0.0	22.0	-39.0	-27.0	-39.0						0.0599	0.0				.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319767
2428	chr17	21319785	C	T	chr17:21319785	KCNJ12	potassium voltage-gated channel subfamily J member 12	SNV	0/1	0.17	120_25	145	99	rs1657745,COSV59168851	EXONIC	YES	NM_021012.5	Transcript	protein_coding	synonymous_variant		3/3	NM_021012.5:c.1131C>T	NP_066292.2:p.Tyr377%3D		1.0						.	.	.		0.000111631	17.0	152288.0	0.0	73	1.0	PASS	afr	0.000265278	11.0	4.40813e-05	3.0	0.499992	125441.0	250886.0	0.0	100	1.0	InbreedingCoeff	nfe	0.5	56746.0	0.5	56746.0	0.0336454	5232	0.146	438.0	0.49685	4733		3.68	0.065319		0	0	0			KCNJ12	0.0	0.0	0.0	0.0	24.0	4.0	-45.0	8.0						0.0599	0.0				.			occipital lobe;skeletal muscle;cerebellum peduncles;cerebellum;	.	potassium ion transport;muscle contraction;regulation of heart contraction;regulation of ion transmembrane transport;protein homotetramerization;potassium ion import across plasma membrane	plasma membrane;integral component of membrane;intrinsic component of membrane	inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity	DLG1[24550280];SCRIB[24550280;30126976];EMD[unassigned1304];	21319785
2474	chr17	38567394	T	C	chr17:38567394	TOP2A	DNA topoisomerase II alpha	SNV	0/1	0.24	47_15	62	99	rs34370875	EXONIC	YES	NM_001067.4	Transcript	protein_coding	synonymous_variant		10/35	NM_001067.4:c.1170A>G	NP_001058.2:p.Ser390%3D		-1.0		Benign	criteria_provided,_single_submitter	not_provided	DNA topoisomerase II, resistance to inhibition of, by amsacrine (3)	Neuroblastoma	Biomarker tested in	Elevated urinary catecholamines;Neoplasm of the nervous system		0.00362043	551.0	152192.0	1.0	32	0.97	PASS	nfe	0.005056	344.0	0.005056	344.0	0.0037953	934.0	246094.0	5.0	31	0.81	PASS	nfe	0.0053406	596.0	0.0053406	596.0	0.0033504	521	0.005	15.0	0.00735	70		12.14	0.824363		0	0	0			TOP2A	0.03	0.0	0.0	0.0	41.0	-33.0	-33.0	-8.0						0.689	1.0	67.552498716			.			testis - seminiferous tubule;tumor;testis - interstitial;fetal liver;testis;	.	resolution of meiotic recombination intermediates;sister chromatid segregation;hematopoietic progenitor cell differentiation;DNA topological change;DNA ligation;cellular response to DNA damage stimulus;chromosome segregation;female meiotic nuclear division;apoptotic chromosome condensation;embryonic cleavage;regulation of circadian rhythm;positive regulation of apoptotic process;mitotic DNA integrity checkpoint;positive regulation of single stranded viral RNA replication via double stranded DNA intermediate;positive regulation of transcription by RNA polymerase II;rhythmic process;negative regulation of DNA duplex unwinding	nuclear chromosome;condensed chromosome;nucleus;nucleoplasm;nucleolus;centriole;DNA topoisomerase complex (ATP-hydrolyzing);viral integration complex;protein-containing complex;ribonucleoprotein complex	magnesium ion binding;DNA binding;chromatin binding;RNA binding;DNA topoisomerase type II (ATP-hydrolyzing) activity;protein kinase C binding;protein binding;ATP binding;protein C-terminus binding;DNA-dependent ATPase activity;drug binding;DNA binding, bending;enzyme binding;protein homodimerization activity;histone deacetylase binding;ubiquitin binding;protein heterodimerization activity	L3MBTL3[26496610];SMARCB1[30108113];RPL10[26496610];PRKDC[20085707];AIRE[20085707];COX15[29128334];DDX21[15034300];HNRNPU[26496610];DLST[29128334];BRCA1[15965487];MAGT1[30021884];KIAA1551[30021884];FOXM1[15965487];RNF2[26496610];YY1[23531880];METTL14[29507755];XPO1[19955415];TFG[26496610];MYC[17314511];DHX16[30021884];RANBP2[18394993];NOP56[26496610];FOXD3[25609649];JUN[25609649];DAXX[26496610];VCAM1[22623428];PARP1[20085707];CSNK2A1[22113938];XRCC5[20085707];H2AFX[20085707];PRKCD[16611985];SPICE1[26638075];ARID1A[23698369];FBXL13[30021884];ESR1[21182205];CKAP5[26496610];FOXP1[25609649];SMARCA4[23698369];AGO2[19955415];HIST3H3[30021884];PIN1[11940573];CTNNB1[17983804];TCF4[17983804];VDAC1[29128334];HIST1H2BH[30021884];TOP1[15848144];	38567394
2480	chr17	39768635	A	C	chr17:39768635	KRT16	keratin 16	SNV	0/1	0.58	5_7	12	99	rs151282702,COSV56967106	EXONIC	YES	NM_005557.4	Transcript	protein_coding	missense_variant		1/8	NM_005557.4:c.306T>G	NP_005548.2:p.Phe102Leu		-1.0		Likely_benign	criteria_provided,_single_submitter	not_provided	Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3), Autosomal dominant; Pachyonychia congenita 1, 167200 (3), Autosomal dominant	Epidermolytic palmoplantar keratoderma;Pachyonychia congenita;Isolated focal non-epidermolytic palmoplantar keratoderma	Candidate gene tested in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Localized epidermolytic hyperkeratosis;Verrucae;Hyperhidrosis;Abnormal fingernail morphology;Eczema;Palmoplantar keratoderma;Erythema;Autosomal dominant inheritance;Keratosis pilaris;Palmoplantar keratoderma;Abnormal blistering of the skin;Cognitive impairment;Palmoplantar keratoderma;Nail dystrophy;Epidermoid cyst;Laryngomalacia;Hepatomegaly;Corneal dystrophy;Abnormal fingernail morphology;Abnormality of nail color;Alopecia;Oral leukoplakia;Anonychia;Hyperhidrosis;Ichthyosis;Carious teeth;Onychogryposis;Skin plaque;Cataract;Respiratory insufficiency;Follicular hyperkeratosis;Palmoplantar hyperkeratosis;Heterogeneous;Autosomal dominant inheritance;Oral leukoplakia;Onychogryposis		0.000466915	71.0	152062.0	0.0	32	0.97	PASS	nfe	0.000882379	60.0	0.000882379	60.0	0.000401696	101.0	251434.0	0.0	100	1.0	PASS	nfe	0.00074741	85.0	0.00074741	85.0	0.0000129	2	0.0	1.0	0.00123	14		0.214	-0.376744	0.424	1	18	19	PROVEAN_pred	SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	KRT16	0.0	0.0	0.0	0.0	-42.0	-5.0	11.0	-33.0						0.12	0.0		0.007	-1.08	behavior/neurological phenotype ; mortality/aging ; digestive/alimentary phenotype; integument phenotype ; growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; 			tongue;skin;skeletal muscle;	Cell Communication	morphogenesis of an epithelium;inflammatory response;cytoskeleton organization;aging;cell population proliferation;epidermis development;keratinocyte differentiation;negative regulation of cell migration;keratinization;hair cycle;innate immune response;intermediate filament cytoskeleton organization;keratinocyte migration;establishment of skin barrier;cornification	nucleus;cytosol;cytoskeleton;intermediate filament;extracellular exosome	structural constituent of cytoskeleton;protein binding	TTC23[unassigned1304];PUS10[unassigned1304];EIF4A3[23084401];CCNC[unassigned1304];SGF29[unassigned1304];PPP1R18[unassigned1304];AMOT[unassigned1304];TCHP[unassigned1304];EPM2AIP1[unassigned1304];IGHG1[15174051];MAP1LC3B[20562859];METTL14[29507755];ARFIP2[unassigned1304];POLL[unassigned1304];CCHCR1[unassigned1304];KRT6C[unassigned1304];KRT6A[unassigned1304];LMO1[unassigned1304];KRT71[unassigned1304];GABARAPL2[20562859];GABARAPL1[20562859];KRT4[unassigned1304];KRT3[unassigned1304];KRT2[unassigned1304];KRT1[unassigned1304];METTL3[29507755];KRT8[unassigned1304];KRT79[unassigned1304];APOA1[15174051];KRT78[unassigned1304];KRT5[unassigned1304];KRT76[unassigned1304];KRT74[unassigned1304];KRT73[unassigned1304];KRT72[unassigned1304];TXLNB[unassigned1304];HGS[unassigned1304];KIFC3[unassigned1304];C1orf216[unassigned1304];GAS8[unassigned1304];WHAMMP3[unassigned1304];SMARCD1[unassigned1304];KRT81[unassigned1304];KRT80[unassigned1304];TSG101[unassigned1304];PRKAA2[unassigned1304];USHBP1[unassigned1304];CCDC146[unassigned1304];KRT86[unassigned1304];TANK[14743216];KRT85[unassigned1304];GABARAP[20562859];KRT83[unassigned1304];KLC4[unassigned1304];GNG10[unassigned1304];CYTH4[unassigned1304];C1orf109[unassigned1304];MAPK6[26972000];PRPH[unassigned1304];MBD3[unassigned1304];SMARCE1[unassigned1304];CDK18[unassigned1304];CCDC17[unassigned1304];VCAM1[22623428];SNAPIN[unassigned1304];WTAP[29507755];CARD9[unassigned1304];SEMA4C[unassigned1304];PPP2R2B[19156129];ALB[15174051];LNX1[unassigned1304];PKN1[unassigned1304];	39768635
2506	chr17	42084810	G	A	chr17:42084810	NAGS	N-acetylglutamate synthase	SNV	0/1	0.35	83_44	127	99	rs140481641	EXONIC	YES	NM_153006.3	Transcript	protein_coding	missense_variant		5/7	NM_153006.3:c.1216G>A	NP_694551.1:p.Asp406Asn		1.0	Vertebrate-like NAGS Gcn5-related N-acetyltransferase (GNAT) domain&Vertebrate-like NAGS Gcn5-related N-acetyltransferase (GNAT) domain,Vertebrate-like NAGS Gcn5-related N-acetyltransferase (GNAT) domain&Vertebrate-like NAGS Gcn5-related N-acetyltransferase (GNAT) domain	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Hyperammonemia,_type_III	N-acetylglutamate synthase deficiency, 237310 (3), Autosomal recessive	Hyperammonemia due to N-acetylglutamate synthase deficiency	Disease-causing germline mutation(s) in	Vomiting;Autosomal recessive inheritance;Confusion;Respiratory distress;Hyperammonemia;Seizure;Coma;Failure to thrive;Lethargy;Aggressive behavior;Cognitive impairment;Increased level of L-glutamic acid in blood;Lethargy;Poor speech;Coma;Microcephaly;Global developmental delay;Hepatomegaly;Echolalia;Cognitive impairment;Stereotypy;Fatigue;Psychotic episodes;Failure to thrive;Cerebral ischemia;Nausea;Agitation;Stroke;Reye syndrome-like episodes;Ataxia;Polyneuropathy;Hyperalaninemia;Drowsiness;Myelodysplasia;Acute hyperammonemia;Mood changes;Delirium;Anxiety;Hyperglutaminemia;Feeding difficulties;Headache;Diarrhea;Infantile muscular hypotonia;Paraplegia;Respiratory distress;Seizure;Encephalopathy;Loss of consciousness;Vomiting;Poor appetite;Insomnia		0.0012815	195.0	152166.0	1.0	32	0.97	PASS	amr	0.00202853	31.0	0.000632204	43.0	0.00141109	353.0	250162.0	0.0	94	0.99	PASS	amr	0.00173661	60.0	0.00093812	106.0	0.0010868	169	0.001	3.0	0.00114	13		32.0	4.530473	0.269	14	7	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,DEOGEN2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	NAGS	0.0	0.0	0.0	0.0	-4.0	-22.0	50.0	-5.0						0.216	0.0	0.000000000	0.995	1.101	growth/size/body region phenotype; integument phenotype ; homeostasis/metabolism phenotype; mortality/aging ; behavior/neurological phenotype ; 			ciliary ganglion;atrioventricular node;trigeminal ganglion;globus pallidus;	Urea cycle and metabolism of amino groups	urea cycle;arginine biosynthetic process;glutamate metabolic process;phosphorylation	mitochondrion;mitochondrial matrix	acetylglutamate kinase activity;acetyl-CoA:L-glutamate N-acetyltransferase activity;arginine binding;methione N-acyltransferase activity	TMEM39B[16169070];	42084810
2520	chr17	48264045	C	T	chr17:48264045	COL1A1	collagen type I alpha 1 chain	SNV	0/1	0.44	50_40	90	99	rs775462973,COSV99867741	EXONIC	YES	NM_000088.4	Transcript	protein_coding	missense_variant		48/51	NM_000088.4:c.3770G>A	NP_000079.2:p.Arg1257His		-1.0					Osteogenesis imperfecta, type II, 166210 (3), Autosomal dominant; Caffey disease, 114000 (3), Autosomal dominant; Ehlers-Danlos syndrome, arthrochalasia type, 1, 130060 (3), Autosomal dominant; Osteogenesis imperfecta, type I, 166200 (3), Autosomal dominant; {Bone mineral density variation QTL, osteoporosis}, 166710 (3), Autosomal dominant; Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1, 619115 (3), Autosomal dominant; Osteogenesis imperfecta, type IV, 166220 (3), Autosomal dominant; Osteogenesis imperfecta, type III, 259420 (3), Autosomal dominant	Caffey disease;Osteogenesis imperfecta type 1;Osteogenesis imperfecta type 2;Osteogenesis imperfecta type 3;Osteogenesis imperfecta type 4;Ehlers-Danlos/osteogenesis imperfecta syndrome;Ehlers-Danlos syndrome, vascular-like type;High bone mass osteogenesis imperfecta;Dermatofibrosarcoma protuberans;Ehlers-Danlos syndrome type 2;Ehlers-Danlos syndrome type 1;Ehlers-Danlos syndrome type 7A	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Part of a fusion gene in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Erythema;Fibrosarcoma;Neoplasm of the skin;Subcutaneous nodule;Skin ulcer;Thickened skin;Joint laxity;Bruising susceptibility;Joint subluxation;Muscular hypotonia;Generalized hypotonia;Hyperextensible skin;Premature osteoarthritis;Breech presentation;Malar flattening;Delayed gross motor development;Mild short stature;Soft skin;Congenital bilateral hip dislocation;Increased susceptibility to fractures;Osteopenia;Midface retrusion;Poor wound healing;Scoliosis;Autosomal dominant inheritance;Kyphosis;Atrophic scars;Platyspondyly;Disproportionate short-limb short stature;Congestive heart failure;Nonimmune hydrops fetalis;Broad long bones;Crumpled long bones;Large fontanelles;Abnormality of pelvic girdle bone morphology;Convex nasal ridge;Blue sclerae;Premature birth;Beaded ribs;Recurrent fractures;Pulmonary insufficiency;Small for gestational age;Multiple prenatal fractures;Tibial bowing;Autosomal dominant inheritance;Thin skin;Respiratory insufficiency;Wormian bones;Absent ossification of calvaria;Femoral bowing;Aortic aneurysm;Mitral valve prolapse;Increased susceptibility to fractures;Autosomal dominant inheritance;Growth abnormality;Biconcave flattened vertebrae;Hearing impairment;Wormian bones;Osteopenia;Joint hypermobility;Dentinogenesis imperfecta;Thin skin;Bruising susceptibility;Otosclerosis;Blue sclerae;Recurrent fractures;Triangular face;Biconcave vertebral bodies;Dentinogenesis imperfecta;Blue sclerae;Kyphosis;Pulmonary arterial hypertension;Platybasia;Autosomal dominant inheritance;Abnormality of the thorax;Protrusio acetabuli;Recurrent fractures;Bowing of limbs due to multiple fractures;Multiple prenatal fractures;Tibial bowing;Wormian bones;Micrognathia;Scoliosis;Frontal bossing;Wide anterior fontanel;Basilar impression;Abnormality of the nervous system;Autosomal recessive inheritance;Decreased calvarial ossification;Severe generalized osteoporosis;Hearing impairment;Slender long bone;Neonatal short-limb short stature;Autosomal dominant inheritance;Tibial bowing;Fever;Calvarial hyperostosis;Periosteal thickening of long tubular bones;Cortical irregularity;Joint hyperflexibility;Hip dysplasia;Retrognathia;Severe short stature;Micrognathia;Abnormality of subcutaneous fat tissue;Thin skin;Coxa vara;Joint stiffness;Hyperextensible skin;Coxa valga;Aphasia;Scoliosis;Inguinal hernia;Hip dislocation;Avascular necrosis of the capital femoral epiphysis;Scarring;Mutism;Femoral hernia;Epicanthus;Echolalia;Muscular hypotonia;Dysphasia;Depressed nasal bridge;Hypertelorism;Muscle flaccidity;Osteoporosis;Autosomal dominant inheritance;Recurrent fractures;Femoral bowing present at birth, straightening with time;Otosclerosis;Reduced bone mineral density;Autosomal dominant inheritance;Scoliosis;Biconcave flattened vertebrae;Blue sclerae;Kyphosis;Wormian bones;Bowing of limbs due to multiple fractures;Dentinogenesis imperfecta;Hearing impairment;Short stature;Ectopia lentis;Myopia;Atrial septal defect;Narrow face;Blue sclerae;Abnormality of the gingiva;Triangular face;Retinal detachment;Microcornea;Premature birth;Hypertension;Fatigue;High, narrow palate;Abnormal renal tubule morphology;Eczema;Joint dislocation;Hyperextensible skin;Erythema;Aplasia/Hypoplasia of the abdominal wall musculature;Muscular hypotonia;Malar prominence;Corneal dystrophy;Inguinal hernia;Cognitive impairment;Open bite;Wide nasal bridge;Umbilical hernia;Shagreen patch;Epicanthus;Reduced number of teeth;Reduced consciousness/confusion;Microdontia;Kyphosis;Pectus carinatum;Long thorax;Atypical scarring of skin;Papule;Pes planus;Hypotension;Dental malocclusion;Keratoglobus;Cachexia;Urticaria;Migraine;Abnormal nasal morphology;Asthma;Arachnodactyly;Pneumothorax;Arterial dissection;Joint hyperflexibility;Osteoarthritis;Genital hernia;Mitral valve prolapse;Petechiae;Hiatus hernia;Hypoplasia of the ear cartilage;Acrocyanosis;Venous insufficiency;Hyperlordosis;Emphysema;Muscle weakness;Ascending tubular aorta aneurysm;Myalgia;Glaucoma;Thin skin;Bruising susceptibility;Tricuspid valve prolapse;Abnormality of the tongue;Spina bifida occulta;Striae distensae;Scoliosis;Short stature;Facial asymmetry;Cortical thickening of long bone diaphyses;Feeding difficulties in infancy;Behavioral abnormality;Calvarial hyperostosis;Proptosis;Respiratory insufficiency;Scoliosis;Periosteal thickening of long tubular bones;Increased circulating antibody level;Cellulitis;Hyperesthesia;Cortical irregularity;Fever		1.31513e-05	2.0	152076.0	0.0	32	0.97	PASS	sas	0.000207211	1.0	0.0	0.0	1.99629e-05	5.0	250464.0	0.0	100	1.0	PASS	sas	6.53253e-05	2.0	8.82503e-06	1.0	0.0000064	1			9e-05	1		29.3	4.182691	0.978	13	2	15	SIFT,PolyPhen,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	FATHMM_pred,PrimateAI_pred	COL1A1	0.0	0.0	0.0	0.01	-2.0	46.0	-8.0	-41.0						0.00406	1.0	0.000000000	1.0	1.026	growth/size/body region phenotype; integument phenotype ; adipose tissue phenotype ; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; vision/eye phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; normal phenotype; mortality/aging ; reproductive system phenotype; pigmentation phenotype; neoplasm; embryo phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; respiratory system phenotype; immune system phenotype; renal/urinary system phenotype; skeleton phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; nervous system phenotype ; hearing/vestibular/ear phenotype; 			fetal thyroid;uterus;adipose tissue;atrioventricular node;smooth muscle;uterus corpus;superior cervical ganglion;placenta;fetal lung;heart;	Cell Communication;Focal adhesion;ECM-receptor interaction	skeletal system development;ossification;blood vessel development;osteoblast differentiation;intramembranous ossification;endochondral ossification;blood coagulation;visual perception;sensory perception of sound;response to mechanical stimulus;positive regulation of epithelial to mesenchymal transition;negative regulation of cell-substrate adhesion;protein transport;platelet activation;extracellular matrix organization;collagen fibril organization;positive regulation of cell migration;response to corticosteroid;response to estradiol;collagen biosynthetic process;protein localization to nucleus;tooth mineralization;collagen-activated tyrosine kinase receptor signaling pathway;response to hydrogen peroxide;response to peptide hormone;skin development;skin morphogenesis;cellular response to fibroblast growth factor stimulus;tooth eruption;positive regulation of transcription, DNA-templated;embryonic skeletal system development;regulation of immune response;leukocyte migration;response to cAMP;response to hyperoxia;face morphogenesis;bone trabecula formation;cartilage development involved in endochondral bone morphogenesis;protein heterotrimerization;cellular response to amino acid stimulus;cellular response to mechanical stimulus;cellular response to retinoic acid;cellular response to vitamin E;cellular response to tumor necrosis factor;cellular response to epidermal growth factor stimulus;cellular response to transforming growth factor beta stimulus;positive regulation of canonical Wnt signaling pathway;cellular response to fluoride	extracellular region;collagen type I trimer;extracellular space;cytoplasm;endoplasmic reticulum lumen;Golgi apparatus;secretory granule;extracellular matrix;collagen-containing extracellular matrix	protease binding;extracellular matrix structural constituent;protein binding;extracellular matrix structural constituent conferring tensile strength;identical protein binding;metal ion binding;platelet-derived growth factor binding	TFAP2A[24835590];TFAP2C[24835590];ANXA1[23754495];LOX[21690299];COL5A1[20979576];FN1[25290767;20541508];KEAP1[unassigned1304];ATP13A2[22645275];COCH[19013156];PTBP3[22575643];ZNF16[21874239];OTUB1[26752685];	48264045
2576	chr18	3126784	T	C	chr18:3126784	MYOM1	myomesin 1	SNV	0/1	0.47	9_8	17	99	rs200780735	EXONIC	YES	NM_003803.4	Transcript	protein_coding	missense_variant		19/38	NM_003803.4:c.2906A>G	NP_003794.3:p.Tyr969Cys		-1.0	Fibronectin type III&Fibronectin type III&Fibronectin type III&Fibronectin type III,Fibronectin type III&Fibronectin type III&Fibronectin type III&Fibronectin type III,.	Uncertain_significance	criteria_provided,_single_submitter	Hypertrophic_cardiomyopathy		.	.	.		0.000118256	18.0	152212.0	0.0	31	0.94	PASS	amr	0.000457995	7.0	0.000132252	9.0	8.43563e-05	21.0	248944.0	0.0	42	0.97	PASS	afr	0.000129316	2.0	0.000124026	14.0	0.0000707	11	0.001	2.0	0.00053	6		25.0	3.500324	0.753	13	8	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,FATHMM_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	MYOM1	0.0	0.0	0.0	0.0	40.0	33.0	1.0	-16.0							0.0	0.000000000	1.0	1.138	.			dorsal root ganglion;skeletal muscle;	.	extraocular skeletal muscle development;muscle contraction;positive regulation of gene expression;protein kinase A signaling;skeletal muscle thin filament assembly;skeletal muscle myosin thick filament assembly;sarcomere organization;cardiac muscle fiber development;positive regulation of protein secretion;cardiac myofibril assembly;cardiac muscle tissue morphogenesis;striated muscle myosin thick filament assembly	striated muscle myosin thick filament;striated muscle thin filament;sarcomere;Z disc;M band	protein binding;structural constituent of muscle;kinase binding;identical protein binding;protein homodimerization activity;actin filament binding;muscle alpha-actinin binding	ANKRD28[23414517];MYOM1[18059477;22347812];KRTAP5-7[unassigned1304];PPP1R16A[unassigned1304];DYSF[23414517];MTUS2[unassigned1304];PDE4DIP[unassigned1304];TFIP11[unassigned1304];C1QTNF9[23414517];KRT31[unassigned1304];SYNE1[23414517];TTN[23414517];DNAJB6[23414517];KRTAP1-1[unassigned1304];TRIM23[unassigned1304];	3126784
2578	chr18	3135690	C	T	chr18:3135690	MYOM1	myomesin 1	SNV	0/1	0.56	21_27	48	99	rs374462999	EXONIC	YES	NM_003803.4	Transcript	protein_coding	synonymous_variant		15/38	NM_003803.4:c.2064G>A	NP_003794.3:p.Thr688%3D		-1.0		Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Hypertrophic_cardiomyopathy|not_specified		.	.	.	24033266	0.000512868	78.0	152086.0	0.0	31	0.95	PASS	nfe	0.000823287	56.0	0.000823287	56.0	0.000421494	105.0	249114.0	0.0	49	0.99	PASS	eas	0.000890373	16.0	0.000593361	67.0	0.0003794	59	0.001	4.0	0.00158	18		5.756	0.194379		0	0	0			MYOM1	0.0	0.01	0.0	0.0	-49.0	38.0	38.0	-32.0							0.0	1.893316461			.			dorsal root ganglion;skeletal muscle;	.	extraocular skeletal muscle development;muscle contraction;positive regulation of gene expression;protein kinase A signaling;skeletal muscle thin filament assembly;skeletal muscle myosin thick filament assembly;sarcomere organization;cardiac muscle fiber development;positive regulation of protein secretion;cardiac myofibril assembly;cardiac muscle tissue morphogenesis;striated muscle myosin thick filament assembly	striated muscle myosin thick filament;striated muscle thin filament;sarcomere;Z disc;M band	protein binding;structural constituent of muscle;kinase binding;identical protein binding;protein homodimerization activity;actin filament binding;muscle alpha-actinin binding	ANKRD28[23414517];MYOM1[18059477;22347812];KRTAP5-7[unassigned1304];PPP1R16A[unassigned1304];DYSF[23414517];MTUS2[unassigned1304];PDE4DIP[unassigned1304];TFIP11[unassigned1304];C1QTNF9[23414517];KRT31[unassigned1304];SYNE1[23414517];TTN[23414517];DNAJB6[23414517];KRTAP1-1[unassigned1304];TRIM23[unassigned1304];	3135690
2780	chr18	77475188	GGA		chr18:77475188-77475190	CTDP1	CTD phosphatase subunit 1	deletion	0/1	0.12	60_8	68	99	rs3833180	EXONIC	YES	NM_004715.5	Transcript	protein_coding	inframe_deletion		8/13	NM_004715.5:c.1746_1748del	NP_004706.3:p.Glu582del		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	not_provided	Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3), Autosomal recessive	Congenital cataracts-facial dysmorphism-neuropathy syndrome	Disease-causing germline mutation(s) (loss of function) in	Pes cavus;Decreased testicular size;Ataxia;Decreased motor nerve conduction velocity;Global developmental delay;Genu recurvatum;Axonal degeneration;Talipes equinovarus;Developmental cataract;Decreased serum estradiol;Peripheral demyelination;Abnormality of the dentition;Abnormal facial shape;Malar prominence;Cognitive impairment;Kyphoscoliosis;Short stature;Hypergonadotropic hypogonadism;Motor delay;Nystagmus;Autosomal recessive inheritance;Babinski sign;Microcornea;Peripheral hypomyelination;Split hand;Intellectual disability;Cerebral atrophy;Global developmental delay;Chorea;Hypogonadotropic hypogonadism;Acute rhabdomyolysis;Primary amenorrhea;Infantile onset;Motor polyneuropathy;Abnormal pyramidal sign;Short stature;Intellectual disability, mild;Hypogonadotropic hypogonadism;Microcornea;Intrauterine growth retardation;Strabismus;Abnormality of the cervical spine;Cataract;Scoliosis;Hypoglycemia;Abnormality of peripheral nerve conduction;Intention tremor;Motor axonal neuropathy;Malar prominence;Ventriculomegaly;Kyphosis;Long eyelashes;Global developmental delay;Paresthesia;Microphthalmia;Cerebral cortical atrophy;Micrognathia;Osteoporosis;Camptodactyly of finger;Nystagmus;Dysmetria;Acute rhabdomyolysis		9.24385e-05	14.0	151452.0	0.0	33	0.96	PASS	eas	0.000390168	2.0	2.94916e-05	2.0	0.000649886	153.0	235426.0	0.0	100	0.85	PASS	afr	0.0011984	18.0	0.000733331	78.0	0.0000707,0.0006559,0.0028038,0.0000322	11,102,436,5			0.0014	16		14.78	1.223579		0	0	0			CTDP1	0.0	0.0	0.0	0.01	-44.0	5.0	24.0	-22.0						0.251	0.92				.			testis;	.	transcription by RNA polymerase II;transcription elongation from RNA polymerase II promoter;protein dephosphorylation;exit from mitosis;positive regulation by host of viral transcription;cell division;negative regulation of cell growth involved in cardiac muscle cell development;dephosphorylation of RNA polymerase II C-terminal domain	spindle pole;nucleus;nucleoplasm;cytoplasm;centrosome;spindle;midbody;protein-containing complex;intracellular membrane-bounded organelle;spindle midzone	TFIIF-class transcription factor complex binding;phosphoprotein phosphatase activity;protein binding;RNA polymerase II CTD heptapeptide repeat phosphatase activity;Tat protein binding	PRMT5[15670829];LTN1[26496610];IWS1[26496610];ETS2[26496610];WDR77[15670829];CDK8[26496610];DSN1[26496610];POLR2A[14576432];POLR2B[15670829];POLR2C[18562274];STK38[15670829];NUF2[26496610];POLR2F[26496610];ERH[15670829];POLR2G[26496610];	77475187
2785	chr19	856130	C	T	chr19:856130	ELANE	elastase, neutrophil expressed	SNV	0/1	0.39	25_16	41	99	rs17216663,CM082608	EXONIC	YES	NM_001972.4	Transcript	protein_coding	missense_variant		5/5	NM_001972.4:c.770C>T	NP_001963.1:p.Pro257Leu		1.0	.,.	Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Cyclical_neutropenia|Neutropenia,_severe_congenital_1,_autosomal_dominant|not_specified|not_provided	Neutropenia, cyclic, 162800 (3), Autosomal dominant; Neutropenia, severe congenital 1, autosomal dominant, 202700 (3), Autosomal dominant	Autosomal dominant severe congenital neutropenia;Cyclic neutropenia	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Overlapping toe;Anemia;Lymphadenopathy;Oral ulcer;Abdominal pain;Carious teeth;Recurrent skin infections;Periodontitis;Recurrent respiratory infections;Neutropenia;Abnormal eosinophil morphology;Recurrent aphthous stomatitis;Fatigue;Thrombocytopenia;Sepsis;Fever;Cyclic neutropenia;Neutropenia;Autosomal dominant inheritance;Abnormality of the mouth;Thrombocytosis;Increased circulating antibody level;Acute monocytic leukemia;Autosomal dominant inheritance;Growth abnormality;Anemia;Neutropenia;Eosinophilia;Infantile onset;Recurrent bacterial infections;Congenital agranulocytosis;Monocytosis;Lymphopenia;Osteopenia;Premature loss of teeth;Pyoderma gangrenosum;Cellulitis;Pharyngitis;Recurrent skin infections;Gingivitis;Recurrent aphthous stomatitis;Recurrent sinopulmonary infections;Fever;Rhinitis;Eosinophilia;Acute myeloid leukemia;Periodontitis;Abdominal pain;Oral ulcer;Recurrent infection of the gastrointestinal tract;Monocytosis;Recurrent ear infections;Myelodysplasia;Hemangioma;Pneumonia;Recurrent bacterial infections;Antineutrophil antibody positivity;Neutropenia;Acute lymphoblastic leukemia;Diarrhea;Recurrent viral infections;Aplastic anemia	25741868	0.00586574	893.0	152240.0	6.0	32	0.97	PASS	nfe	0.00906926	617.0	0.00906926	617.0	0.0063991	1596.0	249410.0	13.0	100	0.99	PASS	nfe	0.00854907	959.0	0.00854907	959.0	0.0060320	938	0.021	62.0	0.01385	158		15.41	1.341845	0.075	2	15	17	SIFT,FATHMM_pred	PolyPhen,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	ELANE	0.0	0.0	0.0	0.0	-19.0	11.0	-5.0	-10.0						0.0124	0.77	0.000000000	0.002	0.957	homeostasis/metabolism phenotype; neoplasm; hematopoietic system phenotype; mortality/aging ; normal phenotype; immune system phenotype; 			bone marrow;	Systemic lupus erythematosus	negative regulation of transcription by RNA polymerase II;response to yeast;acute inflammatory response to antigenic stimulus;leukocyte migration involved in inflammatory response;biosynthetic process of antibacterial peptides active against Gram-negative bacteria;proteolysis;cellular calcium ion homeostasis;phagocytosis;response to UV;antimicrobial humoral response;extracellular matrix disassembly;protein catabolic process;response to lipopolysaccharide;defense response to bacterium;neutrophil degranulation;positive regulation of MAP kinase activity;negative regulation of growth of symbiont in host;negative regulation of chemokine biosynthetic process;negative regulation of interleukin-8 biosynthetic process;positive regulation of interleukin-8 biosynthetic process;positive regulation of smooth muscle cell proliferation;negative regulation of inflammatory response;positive regulation of immune response;negative regulation of chemotaxis;neutrophil mediated killing of gram-negative bacterium;neutrophil mediated killing of fungus;positive regulation of leukocyte tethering or rolling	extracellular region;extracellular space;cytoplasm;cell surface;transcriptional repressor complex;secretory granule;azurophil granule lumen;specific granule lumen;collagen-containing extracellular matrix;extracellular exosome	protease binding;transcription corepressor activity;endopeptidase activity;serine-type endopeptidase activity;protein binding;heparin binding;peptidase activity;cytokine binding	SERPINA1[16321984];SLPI[18421166];GZMB[9404514];	856130
2802	chr19	2249682	G	C	chr19:2249682	AMH	anti-Mullerian hormone	SNV	0/1	0.35	35_19	54	99		EXONIC	YES	NM_000479.5	Transcript	protein_coding	synonymous_variant		1/5	NM_000479.5:c.351G>C	NP_000470.3:p.Arg117%3D		1.0					Persistent Mullerian duct syndrome, type I, 261550 (3), Autosomal recessive	Persistent Mllerian duct syndrome	Disease-causing germline mutation(s) in	Bilateral cryptorchidism;Inguinal hernia;Autosomal recessive inheritance;Abnormality of male internal genitalia;Male infertility;Abnormal circulating hormone level;Cryptorchidism;Male pseudohermaphroditism;Inguinal hernia						33	0.98											10	0.26											0.00028	3		0.284	-0.336664		0	0	0			AMH	0.0	0.0	0.0	0.0	-27.0	1.0	-4.0	-28.0							0.0	46.682792552			endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; reproductive system phenotype; neoplasm; 			superior cervical ganglion;testis;skeletal muscle;	Cytokine-cytokine receptor interaction;TGF-beta signaling pathway	preantral ovarian follicle growth;urogenital system development;Mullerian duct regression;cell-cell signaling;gonadal mesoderm development;sex determination;sex differentiation;aging;regulation of signaling receptor activity;positive regulation of gene expression;response to organic cyclic compound;BMP signaling pathway;response to drug;positive regulation of NF-kappaB transcription factor activity;negative regulation of ovarian follicle development	extracellular region;extracellular space	signaling receptor binding;transforming growth factor beta receptor binding;hormone activity;growth factor activity	ZMAT2[21988832];PHACTR3[28330616];ETV5[21988832];ARL8B[21988832];	2249682
2850	chr19	7975658	C	A	chr19:7975658	MAP2K7	mitogen-activated protein kinase kinase 7	SNV	0/1	0.36	34_19	53	99	rs117765980,COSV67607601,COSV67609547	EXONIC	YES	NM_001297555.2	Transcript	protein_coding	synonymous_variant		7/12	NM_001297555.2:c.693C>A	NP_001284484.1:p.Pro231%3D		1.0		Benign	criteria_provided,_single_submitter	not_provided		.	.	.		0.00338782	514.0	151720.0	2.0	33	0.98	PASS	nfe	0.00539563	367.0	0.00539563	367.0	0.00407356	983.0	241312.0	1.0	67	0.8	PASS	nfe	0.0059493	644.0	0.0059493	644.0	0.0039549	615	0.001	4.0	0.00525	50		4.857	0.136321		0	0	0			MAP2K7	0.0	0.0	0.0	0.0	2.0	-29.0	27.0	30.0						0.0231	0.99	56.471442430			nervous system phenotype ; vision/eye phenotype; behavior/neurological phenotype ; hematopoietic system phenotype; mortality/aging ; normal phenotype; neoplasm; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; integument phenotype ; 			.	MAPK signaling pathway;ErbB signaling pathway;Toll-like receptor signaling pathway;Fc epsilon RI signaling pathway;GnRH signaling pathway	activation of MAPK activity;apoptotic process;response to osmotic stress;signal transduction;activation of JUN kinase activity;response to heat;response to UV;peptidyl-tyrosine phosphorylation;signal transduction by protein phosphorylation;stress-activated protein kinase signaling cascade;activation of protein kinase activity;positive regulation of telomere maintenance via telomerase;response to tumor necrosis factor;positive regulation of transcription, DNA-templated;stress-activated MAPK cascade;positive regulation of telomerase activity;positive regulation of ERK1 and ERK2 cascade;positive regulation of telomere capping	nucleus;cytoplasm;cytosol	magnesium ion binding;protein serine/threonine kinase activity;MAP kinase kinase activity;protein tyrosine kinase activity;protein binding;ATP binding;JUN kinase kinase activity;enzyme binding;protein kinase binding;protein phosphatase binding	RPL30[21988832];MAP3K1[17110930];HSP90AB1[22939624];GADD45B[25314077];LRRK2[20067578];CDC5L[20467437];CFLAR[17110930];VRK2[18286207];PIK3R1[25284480];HSCB[28380382];ARR3[16169070];MAPK8IP1[18286207;16840345];MAPK8[16533805;25241761;25284480];SNW1[20467437];LPXN[21988832];TRIB3[15299019];MAP3K7[17110930;17709393;25241761];MAP3K5[17110930];ATF4[21988832];	7975658
2882	chr19	11152156	C	T	chr19:11152156	SMARCA4	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	SNV	0/1	0.34	74_38	112	99	rs200087760,COSV104654163	EXONIC	YES	NM_001128849.3	Transcript	protein_coding	synonymous_variant		31/36	NM_001128849.3:c.4440C>T	NP_001122321.1:p.Ala1480%3D		1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Rhabdoid_tumor_predisposition_syndrome_2|Intellectual_disability,_autosomal_dominant_16|Hereditary_cancer-predisposing_syndrome|not_provided	Coffin-Siris syndrome 4, 614609 (3), Autosomal dominant; {Rhabdoid tumor predisposition syndrome 2}, 613325 (3), Autosomal dominant	Coffin-Siris syndrome;Familial rhabdoid tumor;Small cell carcinoma of the ovary;SMARCA4-deficient sarcoma of thorax	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing somatic mutation(s) in	Hypoplasia of the corpus callosum;Wide mouth;Feeding difficulties in infancy;Wide nasal bridge;Aplasia/Hypoplasia of the distal phalanx of the 5th finger;Depressed nasal ridge;Intrauterine growth retardation;Ectopic kidney;Joint hyperflexibility;Bilateral single transverse palmar creases;Abnormality of the intervertebral disk;Congenital diaphragmatic hernia;Partial agenesis of the corpus callosum;Hypoplastic fifth toenail;Strabismus;Scoliosis;Microcephaly;Epicanthus;Depressed nasal bridge;Abnormality of the clavicle;Muscular hypotonia;Cryptorchidism;Lacrimation abnormality;Long eyelashes;Dandy-Walker malformation;Short distal phalanx of finger;Aplasia/Hypoplasia of the patella;Thick eyebrow;Global developmental delay;Cataract;Cutis marmorata;Spina bifida occulta;Kyphosis;Renal hypoplasia/aplasia;Coarse facial features;Cleft palate;Short philtrum;Aplasia/Hypoplasia of the distal phalanx of the 5th toe;Recurrent respiratory infections;Coxa valga;Abnormality of the hip bone;Abnormality of the dentition;Elbow dislocation;Hydronephrosis;Thick lower lip vermilion;Generalized hirsutism;Hearing impairment;Short stature;Ptosis;Abnormality of cardiovascular system morphology;Seizure;Hypoplastic fifth fingernail;Aplasia/Hypoplasia of the cerebellum;Nystagmus;Slow-growing hair;Intellectual disability;Seizure;Feeding difficulties;Abnormal corpus callosum morphology;Generalized hypotonia;Global developmental delay;Macroglossia;Abnormal heart morphology;Scoliosis;Thick nasal alae;Sparse scalp hair;Aplasia/Hypoplasia of the distal phalanges of the hand;Thick eyebrow;Visual impairment;Dandy-Walker malformation;Intrauterine growth retardation;Microcephaly;Coarse facial features;Anteverted nares;Autosomal dominant inheritance;Long eyelashes;Wide mouth;Short stature;Abnormality of cardiovascular system morphology;Hypertrichosis;Delayed skeletal maturation;Depressed nasal bridge;Wide nose;Hirsutism;Hearing impairment;Intellectual disability;Carcinoma;Autosomal dominant inheritance;Neoplasm of the central nervous system		8.54611e-05	13.0	152116.0	0.0	32	0.96	PASS	nfe	0.000117616	8.0	0.000117616	8.0	6.40856e-05	16.0	249666.0	0.0	68	0.99	PASS	sas	0.000130702	4.0	7.99844e-05	9.0	0.0000514	8	0.0	1.0	0.00018	2		3.354	0.045809		0	0	0			SMARCA4	0.0	0.0	0.0	0.0	37.0	-26.0	40.0	6.0						0.000689	1.0	46.985606744			renal/urinary system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; limbs/digits/tail phenotype; nervous system phenotype ; digestive/alimentary phenotype; neoplasm; pigmentation phenotype; normal phenotype; mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; liver/biliary system phenotype; respiratory system phenotype; embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; muscle phenotype; endocrine/exocrine gland phenotype; integument phenotype ; growth/size/body region phenotype; 			caudate nucleus;temporal lobe;amygdala;testis - seminiferous tubule;prefrontal cortex;cingulate cortex;testis;cerebellum peduncles;pons;fetal brain;testis - interstitial;tumor;subthalamic nucleus;whole brain;prostate;parietal lobe;skeletal muscle;globus pallidus;thalamus;	.	negative regulation of transcription by RNA polymerase II;RNA polymerase I preinitiation complex assembly;neural retina development;chromatin organization;nucleosome disassembly;chromatin remodeling;regulation of transcription by RNA polymerase II;nervous system development;positive regulation of Wnt signaling pathway;negative regulation of cell growth;interleukin-7-mediated signaling pathway;ATP-dependent chromatin remodeling;positive regulation by host of viral transcription;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;positive regulation of DNA-binding transcription factor activity;negative regulation of androgen receptor signaling pathway;positive regulation of transcription of nucleolar large rRNA by RNA polymerase I;positive regulation of glucose mediated signaling pathway;positive regulation of pri-miRNA transcription by RNA polymerase II;beta-catenin-TCF complex assembly	nuclear chromatin;extracellular space;nucleus;nucleoplasm;nucleolus;membrane;SWI/SNF complex;protein-containing complex;npBAF complex;nBAF complex	RNA polymerase II proximal promoter sequence-specific DNA binding;RNA polymerase II distal enhancer sequence-specific DNA binding;RNA polymerase I CORE element sequence-specific DNA binding;p53 binding;transcription coactivator activity;transcription corepressor activity;RNA binding;helicase activity;protein binding;ATP binding;DNA-dependent ATPase activity;transcription factor binding;Tat protein binding;nucleosomal DNA binding;protein N-terminus binding;androgen receptor binding;DNA polymerase binding;lysine-acetylated histone binding	TOP2A[23698369];SMARCB1[12368262;15985610;10078207;23540691;19164553;22140357;30108113];KDM1A[28420882];MAML1[23022380];CHD7[20130577];HSPB1[25277244];CHD4[28977666];NR2E1[28420882];CHD3[28977666];NR3C1[9590696];GLI1[25609649];RBPJ[23022380];TENT4B[26496610];ACTB[15985610];STK11[14676191];NUDCD1[29021621];MYC[17353931];DPF1[22334708];DPF2[23540691;22334708];SNIP1[15378006];DPF3[22334708;18765789];HIF1AN[29426014];ARID2[15985610;22140357];IKBKE[17353931];KPNA1[26496610];GABARAPL2[20562859];SS18[23540691];SMARCC1[12368262;15985610;12917342;18303029;10078207;23540691;24434208;28420882];PBRM1[12368262;15985610;11780067;22140357];SMARCC2[12368262;15985610;10078207;23540691];ACTL6A[15985610;11780067];H2AFX[20224553];TET2[23353889];ARID1A[12368262;11988099;15985610;11780067;12200431;23540691;22140357;23698369];ARID1B[12200431];YWHAZ[20129940];WDR77[20951943];NEIL3[26496610];NCOR1[11013263];CAT[26496610;29568061];PPARG[14701856];TP53[18303029];CHMP5[16730941];SMARCD1[15985610;12917342;18303029];SMARCD2[12368262];HDAC2[12192000];DDX5[17011493];RAB5C[26496610];NOTCH1[23022380];SMARCD3[18765789];HDAC1[12192000];TAF9[20195357];ATL2[26496610];RRBP1[30021884];FOXO1[25609649];RELB[14743216];PARD6A[26496610];PABPN1[11371506];TERT[24550003;19571879];SRGAP3[12368262];MARK4[14676191];SMARCE1[12368262;12192000;19164553];JUN[25609649];CBX5[19498464;20562864];VCAM1[22623428];PHF10[22334708];CBX3[21888893];CBX1[21888893];STAT3[15286705];FANCA[11726552];CDC5L[20467437];NFATC1[25609649];NFKB2[14743216];SMARCA4[12917342];REST[12192000];SNW1[20467437];REEP5[26496610];VAPA[26496610];SP1[20969766];HIST3H3[20224553];HNRNPA2B1[30021884];UBE2O[19549727];SS18/SSX1 fusion[23540691];CTNNB1[19571879];SYT-SSX1[23540691];SYT-SSX2[23540691];RCOR2[28420882];HNRNPA1L2[30021884];RCOR1[12192000];TRIM33[20603019];MPHOSPH6[15231747];	11152156
2925	chr19	35773520	CTC		chr19:35773520-35773522	HAMP	hepcidin antimicrobial peptide	deletion	0/1	0.17	24_5	29	99	rs760383487	EXONIC	YES	NM_021175.4	Transcript	protein_coding	inframe_deletion		1/3	NM_021175.4:c.52_54del	NP_066998.1:p.Leu18del		1.0					Hemochromatosis, type 2B, 613313 (3), Autosomal recessive	Hemochromatosis type 2	Disease-causing germline mutation(s) in	Anemia;Autosomal recessive inheritance;Cirrhosis;Hypogonadism;Increased serum iron;Cardiomyopathy;Splenomegaly;Increased serum ferritin;Congestive heart failure;Abnormality of iron homeostasis;Hepatomegaly;Elevated hepatic transaminase;Diabetes mellitus;Elevated transferrin saturation;Generalized hyperpigmentation;Muscle weakness;Abnormality of endocrine pancreas physiology;Dilated cardiomyopathy;Elevated hepatic transaminase;Hypogonadism;Congenital hepatic fibrosis;Arthropathy;Impotence;Osteoporosis;Lethargy;Increased serum ferritin		1.97138e-05	3.0	152178.0	0.0	33	0.98	PASS	nfe	2.93988e-05	2.0	2.93988e-05	2.0	3.19685e-05	8.0	250246.0	0.0	100	1.0	RF	nfe	6.20843e-05	7.0	6.20843e-05	7.0	0.0000322,0.0000965,0.0000450	5,15,7			0.00053	6		16.58	1.554457		0	0	0			HAMP	0.0	0.0	0.0	0.0	21.0	-46.0	-44.0	-36.0						0.438	0.04	0.000000000			immune system phenotype; mortality/aging ; hematopoietic system phenotype; liver/biliary system phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; 			liver;trigeminal ganglion;atrioventricular node;fetal liver;	.	negative regulation of transcription by RNA polymerase II;cellular iron ion homeostasis;acute-phase response;immune response;aging;response to iron ion;response to zinc ion;regulation of signaling receptor activity;killing of cells of other organism;response to vitamin A;negative regulation of iron ion transmembrane transport;response to erythropoietin;defense response to bacterium;response to ethanol;defense response to fungus;multicellular organismal iron ion homeostasis;positive regulation of cell growth involved in cardiac muscle cell development;cellular response to lipopolysaccharide;cellular response to interleukin-6;cellular response to tumor necrosis factor;cellular response to X-ray;liver regeneration;cellular response to bile acid;negative regulation of intestinal absorption;response to iron ion starvation	extracellular region;extracellular space;intercalated disc;apical cortex	hormone activity	CKAP4[21988832];	35773519
2959	chr19	41354561	C	T	chr19:41354561	CYP2A6	cytochrome P450 family 2 subfamily A member 6	SNV	0/1	0.52	45_48	93	99	rs60996254	EXONIC	YES	NM_000762.6	Transcript	protein_coding	missense_variant		3/9	NM_000762.6:c.451G>A	NP_000753.3:p.Glu151Lys		-1.0					{Lung cancer, resistance to}, 211980 (3), Somatic mutation, Autosomal dominant; Coumarin resistance, 122700 (3), Autosomal dominant; {Nicotine addiction, protection from}, 188890 (3)	Familial mesial temporal lobe epilepsy with febrile seizures;Benign familial mesial temporal lobe epilepsy	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (gain of function) in	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Somatic mutation;Alveolar cell carcinoma;Autosomal dominant inheritance;Autosomal recessive inheritance		2.63696e-05	4.0	151690.0	0.0	32	0.93	PASS	nfe	5.88201e-05	4.0	5.88201e-05	4.0	1.99521e-05	5.0	250600.0	0.0	78	0.99	PASS	amr	8.67804e-05	3.0	8.81694e-06	1.0	0.0000064	1	0.0	1.0	0.00061	7		24.6	3.367558	0.431	9	7	16	SIFT,PolyPhen,M-CAP_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred	MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-XF_coding_pred	CYP2A6	0.0	0.0	0.0	0.0	-3.0	0.0	-42.0	34.0						0.916	0.0		0.994	0.921	homeostasis/metabolism phenotype; 			liver;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;	Caffeine metabolism;Retinol metabolism;Drug metabolism - cytochrome P450;Drug metabolism - other enzymes	organic acid metabolic process;xenobiotic metabolic process;steroid metabolic process;coumarin metabolic process;drug metabolic process;epoxygenase P450 pathway;exogenous drug catabolic process;coumarin catabolic process;oxidation-reduction process	cytoplasm;endoplasmic reticulum membrane;cytoplasmic microtubule;organelle membrane;intracellular membrane-bounded organelle	iron ion binding;coumarin 7-hydroxylase activity;arachidonic acid epoxygenase activity;steroid hydroxylase activity;oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen;enzyme binding;heme binding	YWHAZ[30021884];	41354561
2977	chr19	46280843	G	A	chr19:46280843	DMPK	DM1 protein kinase	SNV	0/1	0.46	32_27	59	99	rs147815859	EXONIC	YES	NM_001288764.2	Transcript	protein_coding	synonymous_variant		9/16	NM_001288764.2:c.966C>T	NP_001275693.1:p.His322%3D		-1.0					Myotonic dystrophy 1, 160900 (3), Autosomal dominant	Steinert myotonic dystrophy	Disease-causing germline mutation(s) in	Testicular atrophy;Hypogonadism;Muscular hypotonia;Muscle weakness;Respiratory distress;Feeding difficulties in infancy;Cerebral atrophy;Intellectual disability, severe;Myotonia;First degree atrioventricular block;Polyhydramnios;Excessive daytime sleepiness;Dysphagia;Frontal balding;Facial diplegia;Atrial fibrillation;Decreased fetal movement;Atrial flutter;Intellectual disability, progressive;Cataract;Generalized hypotonia;Obsessive-compulsive trait;Autosomal dominant inheritance;Cholelithiasis;Constipation;Alopecia;Prolonged QRS complex;Male hypogonadism;EMG: myotonic discharges;Prolonged PR interval;Diarrhea;Elevated hepatic transaminase;Colon cancer;Decreased fetal movement;Atrial fibrillation;Myotonia with warm-up phenomenon;Posterior subcapsular cataract;Inability to walk;Peripheral axonal neuropathy;Respiratory failure requiring assisted ventilation;Dysarthria;Diaphragmatic weakness;Mood changes;Hypersomnia;Nasogastric tube feeding in infancy;Decreased fertility;Proximal muscle weakness;Insulin resistance;Intellectual disability, mild;Abnormality of thyroid physiology;Dilated cardiomyopathy;Intestinal pseudo-obstruction;Oral-pharyngeal dysphagia;Excessive daytime somnolence;Cardiac conduction abnormality;Left ventricular systolic dysfunction;Hypercholesterolemia;Fatigue;Astigmatism;Talipes equinovarus;Falls;Intellectual disability, borderline;Cholelithiasis;Choroidal melanoma;Impaired visuospatial constructive cognition;Ovarian carcinoma;Facial diplegia;Hypergonadotropic hypogonadism;Tented upper lip vermilion;Neck flexor weakness;Limited extraocular movements;Non-medullary thyroid carcinoma;Growth hormone deficiency;Neonatal hypotonia;Decreased serum testosterone level;Distal amyotrophy;Aggressive behavior;Abnormal rapid eye movement sleep;Hyperinsulinemia;Pelvic girdle muscle weakness;Mild fetal ventriculomegaly;Myotonia of the jaw;Impotence;Short attention span;Poor fine motor coordination;Paranoia;Myotonia of the upper limb;Autism;Supraventricular tachycardia;Cerebral cortical atrophy;Brain neoplasm;Abnormality of the tongue muscle;Global developmental delay;Obstructive sleep apnea;Shoulder girdle muscle weakness;Abnormality of the cerebral white matter;Testicular atrophy;Secondary hyperparathyroidism;Respiratory failure;Foot dorsiflexor weakness;Hypermetropia;Endometrial carcinoma;Diabetes mellitus;Abnormality of masticatory muscle;Depressivity;Myalgia;Handgrip myotonia;Early balding;Respiratory insufficiency due to muscle weakness;Bilateral ptosis;Anxiety;Polyhydramnios;Reduced visual acuity;Obsessive-compulsive trait;Fatigable weakness of bulbar muscles;Neoplasm of the skin;Ophthalmoplegia;Distal muscle weakness;Mental deterioration		0.000105088	16.0	152254.0	0.0	32	0.98	PASS	nfe	4.40891e-05	3.0	4.40891e-05	3.0	0.000148276	37.0	249534.0	0.0	72	0.98	PASS	nfe	2.67256e-05	3.0	2.67256e-05	3.0	0.0000900	14			0.00018	2		12.84	0.917191		0	0	0			DMPK	0.21	0.0	0.0	0.0	-26.0	8.0	-27.0	47.0						0.638	0.03	28.854279525			homeostasis/metabolism phenotype; muscle phenotype; normal phenotype; cardiovascular system phenotype ; 			pons;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	.	protein phosphorylation;cellular calcium ion homeostasis;nuclear envelope organization;regulation of heart contraction;muscle cell apoptotic process;regulation of myotube differentiation;regulation of skeletal muscle contraction by calcium ion signaling;peptidyl-serine phosphorylation;intracellular signal transduction;regulation of phosphoprotein phosphatase activity;regulation of cardiac conduction	nuclear outer membrane;endoplasmic reticulum membrane;cytosol;plasma membrane;integral component of mitochondrial outer membrane;nuclear membrane;sarcoplasmic reticulum membrane	protein serine/threonine kinase activity;protein binding;ATP binding;myosin phosphatase regulator activity;metal ion binding	PPP1R12A[11287000;21457715];HSP90AB1[22939624];ATN1[16713569];GABARAP[16169070];PLN[15598648];ATXN1[16713569];GEMIN4[21988832];ANXA7[21900206];PIN1[21900206];SMN1[21900206];TK1[21900206];UBQLN4[16713569];RPS10[21900206];	46280843
3006	chr19	51323221	G	A	chr19:51323221	KLK1	kallikrein 1	SNV	0/1	0.29	17_7	24	99	rs3212857	EXONIC	YES	NM_002257.4	Transcript	protein_coding	synonymous_variant		4/5	NM_002257.4:c.567C>T	NP_002248.1:p.His189%3D		-1.0		Benign	criteria_provided,_single_submitter	not_provided	[Kallikrein, decreased urinary activity of], 615953 (3)	.	.	.		0.00368604	561.0	152196.0	3.0	32	0.96	PASS	nfe	0.00649694	442.0	0.00649694	442.0	0.00325357	818.0	251416.0	3.0	58	1.0	PASS	nfe	0.005707	649.0	0.005707	649.0	0.0033311	518	0.005	16.0	0.0071	81		3.264	0.040365		0	0	0			KLK1	0.0	0.05	0.0	0.03	-7.0	47.0	49.0	-9.0						0.401	0.0	0.000000000			.			salivary gland;kidney;beta cell islets;pancreas;trigeminal ganglion;superior cervical ganglion;	.	regulation of systemic arterial blood pressure;zymogen activation	nucleus;secretory granule;extracellular exosome	serine-type endopeptidase activity	.	51323221
3021	chr19	55494126	A	G	chr19:55494126	NLRP2	NLR family pyrin domain containing 2	SNV	0/1	0.39	49_31	80	99	rs61735077,COSV99672859	EXONIC	YES	NM_001174081.3	Transcript	protein_coding	missense_variant		6/13	NM_001174081.3:c.1060A>G	NP_001167552.1:p.Ile354Val		1.0	NACHT nucleoside triphosphatase&NACHT nucleoside triphosphatase,.,.,NACHT nucleoside triphosphatase&NACHT nucleoside triphosphatase,.,.,NACHT nucleoside triphosphatase&NACHT nucleoside triphosphatase	Likely_benign	criteria_provided,_single_submitter	not_provided		.	.	.	25988833	0.00493508	751.0	152176.0	2.0	32	0.96	PASS	amr	0.00765707	117.0	0.0075713	515.0	0.00506446	1272.0	251162.0	4.0	87	0.99	PASS	nfe	0.00789988	897.0	0.00789988	897.0	0.0050224	781	0.012	39.0	0.01307	149		0.001	-1.636558	0.009	1	16	17	FATHMM_pred	SIFT,PolyPhen,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	NLRP2	0.0	0.0	0.0	0.0	-1.0	-43.0	-1.0	5.0						0.955	0.0		0.0	-3.592	.			pons;superior cervical ganglion;atrioventricular node;placenta;testis;	Homologous recombination	apoptotic process;inflammatory response;negative regulation of NF-kappaB transcription factor activity;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;innate immune response;positive regulation of interleukin-1 beta secretion	nuclear chromosome, telomeric region;cytoplasm;Golgi apparatus;cytosol;intracellular membrane-bounded organelle	protein binding;ATP binding;Pyrin domain binding	BECN1[26496610];WRN[15733840];TAF13[26496610];H2AFX[15733840];BCL7B[26496610];NLRP5[26496610];CRIPT[26496610];PYDC2[17178784];TPP1[26496610];RBBP6[26496610];SUGT1[17420470];TTF1[26496610];	55494126
3074	chr2	24521687	A		chr2:24521687	ITSN2	intersectin 2	deletion	0/1	0.56	4_5	9	71	rs747412792	SPLICING	YES	NM_006277.3	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	12/39		NM_006277.3:c.1345-4del			-1.0						.	.	.		9.00389e-05	13.0	144382.0	0.0	31	0.92	PASS	nfe	0.000136899	9.0	0.000136899	9.0	0.0098193	1127.0	114774.0	0.0	34	0.68	RF	eas	0.0127525	101.0	0.00950362	556.0	0.0393495	6119			0.00827	94		9.58	0.519008		0	0	0			ITSN2	0.07	0.0	0.0	0.0	-7.0	-3.0	-14.0	-15.0						0.926	0.02				homeostasis/metabolism phenotype; growth/size/body region phenotype; integument phenotype ; nervous system phenotype ; renal/urinary system phenotype; behavior/neurological phenotype ; hematopoietic system phenotype; 			ciliary ganglion;appendix;tongue;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;thyroid;dorsal root ganglion;atrioventricular node;skeletal muscle;globus pallidus;medulla oblongata;	.	endocytosis;positive regulation of signal transduction;viral process;regulation of Rho protein signal transduction;positive regulation of dendrite extension	cytoplasm;centrosome;extracellular exosome	SH3/SH2 adaptor activity;Rho guanyl-nucleotide exchange factor activity;calcium ion binding;protein binding	MEGF10[unassigned5];GOLT1B[26496610];FBF1[26638075];BCCIP[16169070];FASLG[19807924];PTN[16169070];EGFR[24658140];TM9SF4[26496610];TGOLN2[29568061];KIAA1549[12421765];LAMP1[29568061];MRPL9[26496610];NINL[26638075];MAP4K3[20936779];YTHDF1[18654987];SEMA6A[12421765];VCAM1[22623428];MCRS1[17353931];PPP4R3A[26496610];SYNJ2[12421765];RNF41[26496610];LSM8[15231747];TBL3[16169070];SOS1[20936779];EZR[29568061];EZH2[26496610];	24521686
3104	chr2	26693554	CTT		chr2:26693554-26693556	OTOF	otoferlin	deletion	0/1	0.16	16_3	19	78	rs368148603	EXONIC	YES	NM_194248.3	Transcript	protein_coding	inframe_deletion		32/47	NM_194248.3:c.3928_3930del	NP_919224.1:p.Lys1310del		-1.0		Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	not_specified|not_provided	Auditory neuropathy, autosomal recessive, 1, 601071 (3), Autosomal recessive; Deafness, autosomal recessive 9, 601071 (3), Autosomal recessive	Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing germline mutation(s) in	Sensorineural hearing impairment;Autosomal recessive inheritance;Absent brainstem auditory responses;Absence of acoustic reflex		0.00044748	68.0	151962.0	0.0	33	0.97	PASS	afr	0.000604069	25.0	0.000529599	36.0	0.000584225	145.0	248192.0	0.0	100	1.0	RF	afr	0.000991449	16.0	0.000650972	73.0	0.0001929,0.0012540,0.0006045	30,195,94	0.001	4.0	0.00412	47	1.0	20.4	2.072718		0	0	0			OTOF	0.03	0.0	0.0	0.0	36.0	39.0	-11.0	-26.0						0.315	0.0				hearing/vestibular/ear phenotype; nervous system phenotype ; behavior/neurological phenotype ; 			.	.	sensory perception of sound;synaptic vesicle exocytosis;membrane fusion	endoplasmic reticulum membrane;cytosol;integral component of membrane;basolateral plasma membrane;cell junction;synaptic vesicle membrane	molecular_function;calcium ion binding	HMGB2[30021884];HIST1H2BH[30021884];B2M[30021884];HIST2H2BE[30021884];	26693553
3212	chr2	44051124	C	T	chr2:44051124	ABCG5	ATP binding cassette subfamily G member 5	SNV	0/1	0.37	53_31	84	99	rs1279466034	EXONIC	YES	NM_022436.3	Transcript	protein_coding	missense_variant		9/13	NM_022436.3:c.1252G>A	NP_071881.1:p.Asp418Asn		-1.0	ABC-2 type transporter,ABC-2 type transporter				Sitosterolemia 2, 618666 (3), Autosomal recessive	Sitosterolemia;Homozygous familial hypercholesterolemia	Disease-causing germline mutation(s) in;Candidate gene tested in	Myocardial infarction;Mitral regurgitation;Sudden cardiac death;Aortic atherosclerotic lesion;Coronary artery aneurysm;Hepatic steatosis;Premature coronary artery atherosclerosis;Left ventricular dysfunction;Hyperlipidemia;Dyspnea;Cerebral artery atherosclerosis;Tendon xanthomatosis;Supravalvular aortic stenosis;Premature arteriosclerosis;Abnormal nervous system physiology;Hypertension;Abnormal eye physiology;Precocious atherosclerosis;Hypercholesterolemia;Increased LDL cholesterol concentration;Abnormal internal carotid artery morphology;Angina pectoris;Arthralgia;Myocardial steatosis;Renal steatosis;Heart murmur;Renal artery stenosis;Peripheral arterial stenosis;Calcification of the aorta;Optic neuropathy						32	0.97							3.9764e-06	1.0	251484.0	0.0	100	1.0	PASS	nfe	8.79013e-06	1.0	8.79013e-06	1.0					0.00018	2		23.6	3.032726	0.182	8	13	21	PolyPhen,M-CAP_pred,MutationTaster_pred,MetaRNN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	ABCG5	0.0	0.03	0.05	0.0	41.0	25.0	-5.0	-48.0						0.359	0.0	0.000000000	0.957	1.026	muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; digestive/alimentary phenotype; immune system phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; mortality/aging ; reproductive system phenotype; 			liver;testis - interstitial;fetal liver;	ABC transporters	drug transmembrane transport;response to nutrient;excretion;response to ionizing radiation;negative regulation of intestinal phytosterol absorption;intestinal cholesterol absorption;cholesterol efflux;cholesterol homeostasis;negative regulation of intestinal cholesterol absorption;transmembrane transport	plasma membrane;integral component of plasma membrane;apical plasma membrane;ATP-binding cassette (ABC) transporter complex;receptor complex	protein binding;ATP binding;ATPase activity;cholesterol transporter activity;ATPase activity, coupled to transmembrane movement of substances;metal ion binding;protein heterodimerization activity	ABCG8[16870176;27144356];PIK3R1[17474147];ABCG1[16870176];NCK1[17474147];	44051124
3341	chr2	96780785	G	A	chr2:96780785	ADRA2B	adrenoceptor alpha 2B	SNV	0/1	0.36	75_42	117	99	rs976762879,COSV69787247	EXONIC	YES	NM_000682.7	Transcript	protein_coding	synonymous_variant		1/1	NM_000682.7:c.1113C>T	NP_000673.2:p.Phe371%3D		-1.0						Benign adult familial myoclonic epilepsy	Disease-causing germline mutation(s) (gain of function) in	EEG abnormality;Amaurosis fugax;Hand tremor;Focal-onset seizure;Intellectual disability;Headache;Generalized-onset seizure;Myoclonus		1.31404e-05	2.0	152202.0	0.0	33	0.97	PASS	nfe	2.93979e-05	2.0	2.93979e-05	2.0	2.42187e-05	6.0	247742.0	0.0	100	0.94	PASS	eas	0.000111297	2.0	8.95031e-06	1.0	0.0000257	4			9e-05	1	1.0	9.338	0.493081		0	0	0			ADRA2B	0.0	0.0	0.0	0.0	26.0	47.0	-6.0	-38.0						0.761	0.0	75.641263512			respiratory system phenotype; embryo phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; muscle phenotype; 			.	Neuroactive ligand-receptor interaction	activation of MAPK activity;regulation of vascular smooth muscle contraction;G protein-coupled receptor signaling pathway;adenylate cyclase-modulating G protein-coupled receptor signaling pathway;cell-cell signaling;female pregnancy;negative regulation of norepinephrine secretion;platelet activation;activation of protein kinase B activity;negative regulation of epinephrine secretion;receptor transactivation;positive regulation of MAPK cascade;positive regulation of neuron differentiation;positive regulation of blood pressure;positive regulation of uterine smooth muscle contraction;adrenergic receptor signaling pathway;adenylate cyclase-activating adrenergic receptor signaling pathway	plasma membrane;integral component of plasma membrane;cell surface	adrenergic receptor activity;alpha2-adrenergic receptor activity;protein binding;epinephrine binding	RAB26[23105096];SH3GL2[25517094];SH3GL1[25517094];	96780785
3343	chr2	96780987		TCCTCCTCT	chr2:96780986-96780987	ADRA2B	adrenoceptor alpha 2B	insertion	1/1	1.0	0_72	72	99	rs1204257059,rs4066772	EXONIC	YES	NM_000682.7	Transcript	protein_coding	inframe_insertion		1/1	NM_000682.7:c.903_911dup	NP_000673.2:p.Glu304_Glu306dup		-1.0						Benign adult familial myoclonic epilepsy	Disease-causing germline mutation(s) (gain of function) in	EEG abnormality;Amaurosis fugax;Hand tremor;Focal-onset seizure;Intellectual disability;Headache;Generalized-onset seizure;Myoclonus	20051907					28	0.73											18	0.49							0.0209448,0.5142826	3257,79973			0.68086	7740		16.79	1.590496		0	0	0																	0.761	0.0	43.832499795			respiratory system phenotype; embryo phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; muscle phenotype; 			.	Neuroactive ligand-receptor interaction	activation of MAPK activity;regulation of vascular smooth muscle contraction;G protein-coupled receptor signaling pathway;adenylate cyclase-modulating G protein-coupled receptor signaling pathway;cell-cell signaling;female pregnancy;negative regulation of norepinephrine secretion;platelet activation;activation of protein kinase B activity;negative regulation of epinephrine secretion;receptor transactivation;positive regulation of MAPK cascade;positive regulation of neuron differentiation;positive regulation of blood pressure;positive regulation of uterine smooth muscle contraction;adrenergic receptor signaling pathway;adenylate cyclase-activating adrenergic receptor signaling pathway	plasma membrane;integral component of plasma membrane;cell surface	adrenergic receptor activity;alpha2-adrenergic receptor activity;protein binding;epinephrine binding	RAB26[23105096];SH3GL2[25517094];SH3GL1[25517094];	96780986
3348	chr2	98994191	C	T	chr2:98994191	CNGA3	cyclic nucleotide gated channel alpha 3	SNV	0/1	0.43	31_23	54	99	rs62156348	EXONIC	YES	NM_001298.3	Transcript	protein_coding	missense_variant		3/8	NM_001298.3:c.143C>T	NP_001289.1:p.Pro48Leu		1.0	.,.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Achromatopsia_2|not_specified|not_provided	Achromatopsia 2, 216900 (3), Autosomal recessive	Cone rod dystrophy;Achromatopsia	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Blindness;Photophobia;Achromatopsia;Nystagmus;Hemeralopia;Autosomal recessive inheritance;Dyschromatopsia;Attenuation of retinal blood vessels;Hypoplasia of the fovea;Abnormal electroretinogram;Exotropia;Hypermetropia;Granular macular appearance;Retinal pigment epithelial atrophy;Blue cone monochromacy;Central scotoma;Photophobia;Pendular nystagmus;Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia		0.004304	655.0	152184.0	4.0	33	0.97	PASS	nfe	0.00686543	467.0	0.00686543	467.0	0.00430656	1078.0	250316.0	4.0	57	0.95	PASS	nfe	0.00721307	816.0	0.00721307	816.0	0.0049709	773	0.006	20.0	0.00421	48		5.534	0.179659	0.094	1	17	18	LIST-S2_pred	SIFT,PolyPhen,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	CNGA3	0.0	0.0	0.0	0.0	-39.0	-41.0	-28.0	-37.0						0.0506	0.0	0.000000000	0.001	-0.352	vision/eye phenotype; nervous system phenotype ; behavior/neurological phenotype ; taste/olfaction phenotype; 			pituitary;ciliary ganglion;appendix;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;spinal cord;skeletal muscle;globus pallidus;	Olfactory transduction	cation transport;signal transduction;visual perception;response to corticosteroid;response to magnesium ion;response to cAMP;inorganic cation import across plasma membrane	cytoplasm;plasma membrane;dendrite;axon initial segment;perikaryon;glial cell projection;transmembrane transporter complex	intracellular cAMP-activated cation channel activity;intracellular cGMP-activated cation channel activity;protein C-terminus binding;ligand-gated ion channel activity;cGMP binding	MIS18A[unassigned1304];HNRNPU[30021884];ARRB1[17620599];	98994191
3378	chr2	128177493	C	T	chr2:128177493	PROC	protein C, inactivator of coagulation factors Va and VIIIa	SNV	0/1	0.49	26_25	51	99	rs41269833	EXONIC	YES	NM_001375607.1	Transcript	protein_coding	missense_variant		2/8	NM_001375607.1:c.94C>T	NP_001362536.1:p.Leu32Phe		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Thrombophilia,_hereditary,_due_to_protein_C_deficiency,_autosomal_dominant|not_provided	Thrombophilia 3 due to protein C deficiency, autosomal dominant, 176860 (3), Autosomal dominant; Thrombophilia 3 due to protein C deficiency, autosomal recessive, 612304 (3), Autosomal recessive	Severe hereditary thrombophilia due to congenital protein C deficiency	Disease-causing germline mutation(s) in	Venous thrombosis;Thin skin;Purpura;Gangrene;Warfarin-induced skin necrosis;Venous insufficiency;Pulmonary embolism;Abnormality of skin pigmentation;Abnormality of the cerebral vasculature;Seizure;Pulmonary embolism;Cerebral palsy;Global developmental delay;Autosomal recessive inheritance;Reduced protein C activity;Purpura;Variable expressivity;Vitreous hemorrhage;Hypercoagulability;Deep venous thrombosis;Superficial thrombophlebitis;Pulmonary embolism;Hypercoagulability;Autosomal dominant inheritance;Abnormality of the nervous system;Warfarin-induced skin necrosis;Deep venous thrombosis;Cerebral venous thrombosis;Reduced protein C activity;Abnormality of the eye;Superficial thrombophlebitis		0.0018329	279.0	152218.0	1.0	33	0.98	PASS	sas	0.0031043	15.0	0.00282237	192.0	0.00218655	549.0	251080.0	0.0	95	1.0	PASS	nfe	0.00302352	343.0	0.00302352	343.0	0.0022507	350	0.003	11.0	0.00342	39		13.32	0.984254		0	0	0			PROC	0.16	0.03	0.0	0.0	5.0	-47.0	8.0	-31.0	0.0009306119801753					0.097	0.03				immune system phenotype; nervous system phenotype ; mortality/aging ; cardiovascular system phenotype ; hematopoietic system phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; respiratory system phenotype; homeostasis/metabolism phenotype; muscle phenotype; growth/size/body region phenotype; 			kidney;liver;atrioventricular node;superior cervical ganglion;fetal liver;fetal lung;	Complement and coagulation cascades	proteolysis;endoplasmic reticulum to Golgi vesicle-mediated transport;blood coagulation;negative regulation of blood coagulation;negative regulation of apoptotic process;post-translational protein modification;cellular protein metabolic process;negative regulation of inflammatory response;negative regulation of coagulation;positive regulation of establishment of endothelial barrier	extracellular region;extracellular space;endoplasmic reticulum;endoplasmic reticulum lumen;Golgi apparatus;Golgi lumen	serine-type endopeptidase activity;calcium ion binding;protein binding	CYSRT1[unassigned1304];MMP15[15248212];CSNK2B[21900206];MATR3[30021884];TK1[21900206];	128177493
3480	chr2	206480193	G	A	chr2:206480193	PARD3B	par-3 family cell polarity regulator beta	SNV	0/1	0.62	8_13	21	99	rs774103122	EXONIC	YES	NM_001302769.2	Transcript	protein_coding	missense_variant		23/23	NM_001302769.2:c.3274G>A	NP_001289698.1:p.Asp1092Asn		1.0	.,.,.,.,.,.,.					.	.	.		8.54409e-05	13.0	152152.0	0.0	32	0.95	PASS	amr	0.000327354	5.0	8.82119e-05	6.0	4.97467e-05	12.0	241222.0	0.0	57	0.78	PASS	amr	9.01713e-05	3.0	8.20285e-05	9.0	0.0000193	3			0.00035	4		17.11	1.642975	0.094	2	18	20	LIST-S2_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	PARD3B	0.0	0.04	0.0	0.0	10.0	-13.0	-13.0	0.0						0.94	0.0	0.000000000	0.014	1.146	behavior/neurological phenotype ; cardiovascular system phenotype ; 			ciliary ganglion;temporal lobe;subthalamic nucleus;trigeminal ganglion;atrioventricular node;superior cervical ganglion;globus pallidus;	.	microtubule cytoskeleton organization;cell cycle;cell adhesion;protein localization;establishment of cell polarity;establishment or maintenance of epithelial cell apical/basal polarity;cell division;establishment of centrosome localization	nucleoplasm;cytoplasm;adherens junction;cell-cell adherens junction;bicellular tight junction;cell cortex;endomembrane system;apical plasma membrane;nuclear body;cell junction;protein-containing complex;apical junction complex	protein binding;phosphatidylinositol binding	SFN[15778465];PRPF4B[30021884];YWHAG[15324660];HIST1H1B[30021884];	206480193
3499	chr2	207631446	G	C	chr2:207631446	FASTKD2	FAST kinase domains 2	SNV	0/1	0.19	21_5	26	62	rs147727753	EXONIC	YES	NM_001136194.2	Transcript	protein_coding	missense_variant		2/12	NM_001136194.2:c.29G>C	NP_001129666.1:p.Ser10Thr		1.0	.,.,.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Mitochondrial_complex_IV_deficiency|not_specified|not_provided	Combined oxidative phosphorylation deficiency 44, 618855 (3), Autosomal recessive	FASTKD2-related infantile mitochondrial encephalomyopathy	Disease-causing germline mutation(s) (loss of function) in	.	25741868	0.00453339	690.0	152204.0	3.0	32	0.97	PASS	nfe	0.00801047	545.0	0.00801047	545.0	0.00402738	1012.0	251280.0	4.0	69	1.0	PASS	nfe	0.00744482	846.0	0.00744482	846.0	0.0045015	700	0.003	10.0	0.00297	32		13.09	0.951404	0.061	0	20	20		SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	FASTKD2	0.0	0.0	0.0	0.0	-47.0	-44.0	-38.0	-1.0						0.885	0.0	0.000000000	0.048	1.176	.			ciliary ganglion;dorsal root ganglion;trigeminal ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;	.	protein phosphorylation;cellular respiration;positive regulation of mitochondrial translation;mitochondrial large ribosomal subunit assembly	nucleus;mitochondrion;ribonucleoprotein granule;mitochondrial nucleoid;intercellular bridge	RNA binding;protein kinase activity;rRNA binding	MRPL50[26496610];USP7[26496610];TSC22D1[17353931];MYC[17353931];TRAF6[17353931];FASTKD3[20869947];MRPL58[20186120];HSCB[28380382];PHLDA3[17353931];	207631446
3532	chr2	211521333	A	G	chr2:211521333	CPS1	carbamoyl-phosphate synthase 1	SNV	0/1	0.3	7_3	10	57	rs141373204,CM071659,COSV51822452	EXONIC	YES	NM_001369256.1	Transcript	protein_coding	missense_variant		31/39	NM_001369256.1:c.3676A>G	NP_001356185.1:p.Ile1226Val		1.0	.,Carbamoyl-phosphate synthetase large subunit-like, ATP-binding domain&ATP-grasp fold,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Congenital_hyperammonemia,_type_I|Pulmonary_hypertension,_neonatal,_susceptibility_to|not_specified|not_provided	Carbamoylphosphate synthetase I deficiency, 237300 (3), Autosomal recessive; {Pulmonary hypertension, neonatal, susceptibility to}, 615371 (3)	Carbamoyl-phosphate synthetase 1 deficiency	Disease-causing germline mutation(s) (loss of function) in	Irritability;Vomiting;Hyperammonemia;Stroke;Hypoargininemia;Protein avoidance;Seizure;Cerebral edema;Ataxia;Intellectual disability;Coma;Failure to thrive;Episodic ammonia intoxication;Lethargy;Low plasma citrulline;Global developmental delay;Respiratory alkalosis;Autosomal recessive inheritance;Muscular hypotonia;Hypoargininemia;Aminoaciduria;Seizure;Episodic ammonia intoxication;Hyperammonemia;Respiratory insufficiency	25741868	0.00125682	188.0	149584.0	2.0	28	0.85	PASS	amr	0.00235437	35.0	0.000944454	64.0	0.00159456	401.0	251480.0	1.0	71	1.0	PASS	amr	0.00179253	62.0	0.00116911	133.0	0.0014405	224	0.002	7.0	0.00303	34		22.8	2.642021	0.438	9	9	18	M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,FATHMM_pred,DEOGEN2_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HDIV_pred,LRT_pred,MutationAssessor_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,ClinPred_pred,LIST-S2_pred	CPS1	0.0	0.0	0.01	0.0	-50.0	-7.0	-1.0	-45.0						0.0148	0.08	0.000000000	0.995	0.268	homeostasis/metabolism phenotype; mortality/aging ; 			ciliary ganglion;liver;dorsal root ganglion;superior cervical ganglion;atrioventricular node;skin;trigeminal ganglion;fetal lung;fetal liver;	Urea cycle and metabolism of amino groups;Glutamate metabolism;Arginine and proline metabolism;Nitrogen metabolism	urea cycle;proteolysis;arginine biosynthetic process;nitrogen compound metabolic process;midgut development;response to zinc ion;response to amine;citrulline biosynthetic process;triglyceride catabolic process;response to food;response to lipopolysaccharide;vasodilation;response to starvation;response to amino acid;cellular response to fibroblast growth factor stimulus;nitric oxide metabolic process;homocysteine metabolic process;anion homeostasis;response to growth hormone;hepatocyte differentiation;carbamoyl phosphate biosynthetic process;cellular response to glucagon stimulus;cellular response to oleic acid;response to dexamethasone;cellular response to ammonia	nucleolus;cytoplasm;mitochondrial inner membrane;mitochondrial matrix;protein-containing complex;mitochondrial nucleoid	carbamoyl-phosphate synthase (ammonia) activity;endopeptidase activity;calcium ion binding;protein binding;ATP binding;phospholipid binding;glutamate binding;protein-containing complex binding;modified amino acid binding	HSPA5[26496610];FOXF1[25609649];FOXG1[25609649];FASTKD3[20869947];H2AFX[20000738];XRCC3[26496610];ARAF[12620389];TUBG1[26496610];YWHAZ[15161933;20618440];TANK[unassigned1774];TUBA1C[26496610];METTL14[29507755];DNAJC7[26496610];ARMC6[26496610];AP1S2[26496610];TCF4[25609649];C6orf203[27499296];RAF1[12620389];	211521333
3537	chr2	212578380	AA		chr2:212578380-212578381	ERBB4	erb-b2 receptor tyrosine kinase 4	sequence_alteration	1/2	0.44	1_4_4	9	68	rs67894136	SPLICING	YES	NM_005235.3	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	7/27		NM_005235.3:c.884-8_884-7del			-1.0		Benign	criteria_provided,_single_submitter	not_provided	Amyotrophic lateral sclerosis 19, 615515 (3), Autosomal dominant	Amyotrophic lateral sclerosis	Disease-causing germline mutation(s) in	Laryngospasm;Nausea and vomiting;Dyspnea;Anxiety;Pain;Paralysis;Agitation;Generalized muscle weakness;Depressivity;Amyotrophic lateral sclerosis;Xerostomia;Fatigable weakness of respiratory muscles;Muscle spasm;Fatigable weakness of swallowing muscles;Skeletal muscle atrophy;Neurodegeneration;Emotional lability;Spasticity;Respiratory failure;Fatigue;Respiratory insufficiency due to muscle weakness;Loss of ability to walk;Adult onset;Autosomal dominant inheritance;Amyotrophic lateral sclerosis	26919099	0.000536251	75.0	139860.0	0.0	0	0.42	PASS	afr	0.000685184	26.0	0.000342125	22.0	0.0279945	4599.0	164282.0	0.0	30	0.75	InbreedingCoeff	sas	0.0400786	816.0	0.0297554	2236.0	0.0000257,0.0000965	4,15			0.05312	582		0.022	-0.684169		0	0	0			ERBB4	0.01	0.0	0.0	0.0	-21.0	-6.0	-16.0	-34.0						0.147	1.0				behavior/neurological phenotype ; respiratory system phenotype; embryo phenotype; mortality/aging ; normal phenotype; reproductive system phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; nervous system phenotype ; cellular phenotype; immune system phenotype; endocrine/exocrine gland phenotype; integument phenotype ; muscle phenotype; 			ciliary ganglion;caudate nucleus;pons;amygdala;occipital lobe;dorsal root ganglion;cingulate cortex;superior cervical ganglion;trigeminal ganglion;parietal lobe;medulla oblongata;	ErbB signaling pathway;Calcium signaling pathway	MAPK cascade;neural crest cell migration;positive regulation of protein phosphorylation;signal transduction;transmembrane receptor protein tyrosine kinase signaling pathway;nervous system development;synapse assembly;heart development;lactation;cell population proliferation;positive regulation of cell population proliferation;negative regulation of cell population proliferation;embryonic pattern specification;positive regulation of phosphatidylinositol 3-kinase signaling;cell migration;peptidyl-tyrosine phosphorylation;central nervous system morphogenesis;olfactory bulb interneuron differentiation;regulation of cell migration;ERBB2 signaling pathway;positive regulation of tyrosine phosphorylation of STAT protein;mitochondrial fragmentation involved in apoptotic process;cell fate commitment;positive regulation of transcription, DNA-templated;positive regulation of JAK-STAT cascade;protein autophosphorylation;phosphatidylinositol phosphorylation;positive regulation of protein kinase B signaling;positive regulation of cardiac muscle cell proliferation;mammary gland epithelial cell differentiation;mammary gland alveolus development;cardiac muscle tissue regeneration;positive regulation of ERK1 and ERK2 cascade;cellular response to epidermal growth factor stimulus;positive regulation of protein localization to cell surface;regulation of cell motility;negative regulation of neuron migration	extracellular region;nucleus;nucleoplasm;mitochondrion;mitochondrial matrix;cytosol;plasma membrane;integral component of plasma membrane;basal plasma membrane;basolateral plasma membrane;receptor complex;postsynaptic membrane;glutamatergic synapse;GABA-ergic synapse;integral component of presynaptic membrane;integral component of postsynaptic density membrane	protein tyrosine kinase activity;transmembrane receptor protein tyrosine kinase activity;Ras guanyl-nucleotide exchange factor activity;epidermal growth factor receptor binding;protein binding;ATP binding;protein homodimerization activity;transcription regulatory region DNA binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity	YAP1[25283809];HSP90AB1[22939624];SHC1[16729043;16273093;24658140];TROAP[17360433];PIK3R2[16729043];EGFR[10572067];HDAC6[20029029];CRKL[16729043];TRO[21191175];ERBB3[10572067;20227043];NUDCD1[25036637];ERBB4[18334220];ERBB2[10572067;16767099;24557338;21203579];CFL1[24658140];NCK2[16729043];ABL1[16273093];ABL2[16273093];ANKS1A[16273093];ANKS1B[16273093];STAT5B[16729043];WWOX[16061658];HSP90AA1[24658140];SYK[16273093];GOLM1[27569582];PTPN11[16729043];HSPE1[30021884];GRIN1[16767099];BYSL[17360433];DLG1[24550280];ITCH[18334649];DLG2[10725395];DLG3[10725395];DLG4[10725395;16767099];RASA1[16273093];GRB2[16729043;24658140];GAPDH[24658140];SNTB2[10725395];	212578379
3591	chr2	223084911	G	A	chr2:223084911	PAX3	paired box 3	SNV	0/1	0.39	19_12	31	99	rs45607236,COSV60592088	EXONIC	YES	NM_181459.4	Transcript	protein_coding	missense_variant		7/10	NM_181459.4:c.1121C>T	NP_852124.1:p.Ser374Leu		-1.0	.,.,.,.,.,Paired box protein 7, C-terminal				Craniofacial-deafness-hand syndrome, 122880 (3), Autosomal dominant; Waardenburg syndrome, type 3, 148820 (3), Autosomal recessive, Autosomal dominant; Waardenburg syndrome, type 1, 193500 (3), Autosomal dominant; Rhabdomyosarcoma 2, alveolar, 268220 (3), Somatic mutation	Waardenburg syndrome type 3;Waardenburg syndrome type 1;Craniofacial-deafness-hand syndrome;Alveolar rhabdomyosarcoma	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Part of a fusion gene in	Telecanthus;Sprengel anomaly;Congenital sensorineural hearing impairment;Blue irides;Partial albinism;Hypertelorism;Mandibular prognathia;Spina bifida;Myelomeningocele;Heterochromia iridis;Blepharophimosis;Synophrys;Premature graying of hair;Wide nasal bridge;Smooth philtrum;Supernumerary ribs;Hypopigmentation of the fundus;Autosomal dominant inheritance;Hypoplastic iris stroma;Oral cleft;Underdeveloped nasal alae;White forelock;Supernumerary vertebrae;Thick eyebrow;White eyebrow;Aplasia of the vagina;White eyelashes;Autosomal dominant contiguous gene syndrome;Brachydactyly;Aganglionic megacolon;Camptodactyly of finger;Wide nasal bridge;Intellectual disability;Clinodactyly;Spastic paraplegia;White forelock;Prominent nasal bridge;Telecanthus;Hypopigmented skin patches;Mandibular prognathia;Carpal synostosis;Joint contracture of the hand;Microcephaly;Variable expressivity;Partial albinism;Autosomal recessive inheritance;Synophrys;Cutaneous finger syndactyly;Premature graying of hair;Heterochromia iridis;Blepharophimosis;Scapular winging;Sensorineural hearing impairment;Blue irides;Strabismus;Underdeveloped nasal alae;White forelock;Tented upper lip vermilion;Synophrys;Hypopigmented skin patches;White eyelashes;White hair;Congenital sensorineural hearing impairment;Lacrimation abnormality;Meningocele;Abnormality of vision;Scoliosis;Premature graying of hair;Mandibular prognathia;Cleft upper lip;Short nose;Aganglionic megacolon;Sprengel anomaly;Wide nasal bridge;Telecanthus;Thick eyebrow;White eyebrow;Ptosis;Heterochromia iridis;Abnormality of cardiovascular system morphology;Cleft palate;Microcephaly;Atrial septal defect;Tented upper lip vermilion;Narrow nasal bridge;Downslanted palpebral fissures;Intellectual disability;Atelectasis;Blepharophimosis;Telecanthus;Hearing impairment;Synostosis of carpal bones;Joint stiffness;Thick eyebrow;Acrocyanosis;Cutaneous finger syndactyly;Camptodactyly of finger;White hair;Tracheomalacia;Spastic paraplegia;Narrow mouth;Hypertelorism;Short nose;Camptodactyly of finger;Narrow face;Ulnar deviation of the wrist;Depressed nasal bridge;Hypoplasia of the maxilla;Blepharophimosis;Flat face;Depressed nasal ridge;Lacrimal duct atresia;Ulnar deviation of finger;Sensorineural hearing impairment;Aplasia/Hypoplasia involving the nose;Downslanted palpebral fissures;Flat face;Malar flattening;Sensorineural hearing impairment;Autosomal dominant inheritance;Ulnar deviation of the hand or of fingers of the hand;Short nose;Ulnar deviation of the hand;Hypertelorism;Hypoplasia of the maxilla;Somatic mutation;Alveolar rhabdomyosarcoma;Autosomal recessive inheritance		0.000111767	17.0	152102.0	0.0	32	0.97	PASS	amr	0.00111329	17.0	0.0	0.0	3.18776e-05	8.0	250960.0	0.0	100	1.0	PASS	amr	0.000231616	8.0	0.0	0.0	0.0000064	1			0.00018	2		24.0	3.171675	0.275	8	12	20	SIFT,M-CAP_pred,PROVEAN_pred,DEOGEN2_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PolyPhen,Polyphen2_HDIV_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,ClinPred_pred	PAX3	0.0	0.0	0.0	0.0	42.0	47.0	42.0	-50.0						0.00923	0.9	0.000000000	0.441	1.176	homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype ; endocrine/exocrine gland phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; respiratory system phenotype; immune system phenotype; skeleton phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; nervous system phenotype ; vision/eye phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; normal phenotype; mortality/aging ; pigmentation phenotype; neoplasm; embryo phenotype; 			ciliary ganglion;appendix;skin;atrioventricular node;superior cervical ganglion;	.	transcription by RNA polymerase II;apoptotic process;nervous system development;muscle organ development;sensory perception of sound;animal organ morphogenesis;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II	nucleoplasm	DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;sequence-specific DNA binding;HMG box domain binding	IPO13[unassigned1304];FOXE1[25609649];SRC[17474147];KRTAP8-1[unassigned1304];MEOX2[11423130];SOX10[11029584];POU3F2[11029584];SKI[26977879];ABL1[17474147];KRTAP6-2[unassigned1304];FYN[17474147];GRB2[17474147];NCK1[17474147];	223084911
3622	chr2	233201179	G	T	chr2:233201179	DIS3L2	DIS3 like 3'-5' exoribonuclease 2	SNV	0/1	0.54	22_26	48	99		SPLICING	YES	NM_152383.5	Transcript	protein_coding	missense_variant,splice_region_variant		21/21	NM_152383.5:c.2497G>T	NP_689596.4:p.Val833Phe		1.0	.,.				Perlman syndrome, 267000 (3), Autosomal recessive	Nephroblastoma;Perlman syndrome	Major susceptibility factor in;Disease-causing germline mutation(s) in	Hematuria;Neoplasm of the liver;Hypertension;Abdominal pain;Nephroblastoma;Neoplasm of the lung;Weight loss;Lymphadenopathy;Fever;Aniridia;Nephroblastomatosis;Micrognathia;Autosomal recessive inheritance;Agenesis of corpus callosum;Renal hamartoma;Polyhydramnios;Abnormality of the cardiovascular system;Volvulus;Open mouth;Low-set ears;Growth abnormality;Visceromegaly;Wide nasal bridge;Pancreatic islet-cell hyperplasia;Ascites;Nephrogenic rest;Long upper lip;Large for gestational age;Abnormal facial shape;Nephroblastoma;Depressed nasal bridge;Global developmental delay;Interrupted aortic arch;Tented upper lip vermilion;Cryptorchidism;Hypoplasia of the abdominal wall musculature;Edema;Congenital diaphragmatic hernia;Distal ileal atresia;Open mouth;Epicanthus;Macrocephaly;Nephroblastoma;High, narrow palate;Femoral hernia;Status epilepticus;Capillary hemangioma;Specific learning disability;Ptosis;Tall stature;Inguinal hernia;Anteverted nares;Global developmental delay;Round face;Hepatomegaly;Abnormal pancreas morphology;High forehead;Bilateral single transverse palmar creases;Smooth philtrum;Hypoplasia of penis;Short nose;Retrognathia;Micrognathia;Hyperinsulinemia;Deeply set eye;Intellectual disability;Cryptorchidism;Wide nasal bridge;Muscular hypotonia;Dolichocephaly;Posteriorly rotated ears;Low-set ears;Naevus flammeus of the eyelid;Broad alveolar ridges;Thickened helices						33	0.97											96	0.73											9e-05	1		32.0	4.534087	0.614	13	8	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,M-CAP_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HVAR_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred,DEOGEN2_pred,LIST-S2_pred	DIS3L2	0.13	0.42	0.0	0.0	17.0	0.0	26.0	-1.0	0.998333625321143	0.902	4.166	1.741	5.907	0.559	0.86		0.993	1.172	.			ciliary ganglion;trigeminal ganglion;superior cervical ganglion;	.	mitotic cell cycle;nuclear-transcribed mRNA catabolic process, exonucleolytic;rRNA processing;RNA catabolic process;negative regulation of cell population proliferation;miRNA catabolic process;stem cell population maintenance;nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5';cell division;mitotic sister chromatid separation;RNA phosphodiester bond hydrolysis, exonucleolytic;polyuridylation-dependent mRNA catabolic process	exosome (RNase complex);P-body;cytoplasm;polysome	3'-5'-exoribonuclease activity;magnesium ion binding;ribonuclease activity;protein binding;poly(U) RNA binding	PDIA3[30021884];COPS6[16169070];FEZ1[16169070];CBX2[21282530];VIM[16169070];	233201179
3653	chr2	242138819	G	A	chr2:242138819	ANO7	anoctamin 7	SNV	0/1	0.38	66_40	106	99	rs149743431,COSV51472695	EXONIC	YES	NM_001370694.2	Transcript	protein_coding	missense_variant		5/25	NM_001370694.2:c.398G>A	NP_001357623.1:p.Arg133His		1.0	Anoctamin, dimerisation domain,.					.	.	.		0.00117587	179.0	152228.0	0.0	33	0.98	PASS	nfe	0.00191081	130.0	0.00191081	130.0	0.00109119	274.0	251102.0	0.0	91	1.0	PASS	nfe	0.00178008	202.0	0.00178008	202.0	0.0010096	157	0.002	7.0	0.00307	35		17.11	1.643116	0.065	1	19	20	LIST-S2_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	ANO7	0.0	0.0	0.0	0.0	-6.0	-41.0	4.0	19.0						0.987	0.0	0.000000000	0.989	0.891	.			ciliary ganglion;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;fetal liver;prostate;skeletal muscle;globus pallidus;	.	chloride transport;ion transmembrane transport;calcium activated phosphatidylserine scrambling;calcium activated phosphatidylcholine scrambling;calcium activated galactosylceramide scrambling	endoplasmic reticulum;cytosol;plasma membrane;integral component of membrane;cell junction	intracellular calcium activated chloride channel activity;phospholipid scramblase activity;protein dimerization activity	.	242138819
3654	chr2	242149775	G	A	chr2:242149775	ANO7	anoctamin 7	SNV	0/1	0.32	40_19	59	99	rs141796681,COSV51472712	EXONIC	YES	NM_001370694.2	Transcript	protein_coding	synonymous_variant		14/25	NM_001370694.2:c.1425G>A	NP_001357623.1:p.Val475%3D		1.0		Benign	criteria_provided,_single_submitter	not_provided		.	.	.		0.00438107	667.0	152246.0	1.0	33	0.99	PASS	nfe	0.00677483	461.0	0.00677483	461.0	0.00446475	1121.0	251078.0	6.0	100	1.0	PASS	nfe	0.00626619	711.0	0.00626619	711.0	0.0044693	695	0.012	40.0	0.01271	145		8.345	0.395154		0	0	0			ANO7	0.0	0.0	0.01	0.04	6.0	33.0	-3.0	33.0						0.987	0.0	22.908947238			.			ciliary ganglion;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;fetal liver;prostate;skeletal muscle;globus pallidus;	.	chloride transport;ion transmembrane transport;calcium activated phosphatidylserine scrambling;calcium activated phosphatidylcholine scrambling;calcium activated galactosylceramide scrambling	endoplasmic reticulum;cytosol;plasma membrane;integral component of membrane;cell junction	intracellular calcium activated chloride channel activity;phospholipid scramblase activity;protein dimerization activity	.	242149775
3671	chr20	2635555	G	A	chr20:2635555	NOP56	NOP56 ribonucleoprotein	SNV	0/1	0.37	17_10	27	99	rs373127184	EXONIC	YES	NM_006392.4	Transcript	protein_coding	synonymous_variant		5/12	NM_006392.4:c.531G>A	NP_006383.2:p.Gln177%3D		1.0					Spinocerebellar ataxia 36, 614153 (3), Autosomal dominant	Spinocerebellar ataxia type 36	Disease-causing germline mutation(s) in	Blurred vision;Head tremor;Hyperreflexia;Loss of Purkinje cells in the cerebellar vermis;Babinski sign;Tongue fasciculations;Limb myoclonus;Dysphagia;Intention tremor;Bowel incontinence;Migraine;Attention deficit hyperactivity disorder;Tongue atrophy;Slow saccadic eye movements;Truncal ataxia;Hearing impairment;Dysmetria;Difficulty walking;Diplopia;Ptosis;Vertigo;Dysarthria;Skeletal muscle atrophy;Limb ataxia;Hand tremor;Progressive;Limb ataxia;Skeletal muscle atrophy;Cerebellar atrophy;Impaired smooth pursuit;Autosomal dominant inheritance;Babinski sign;Hearing impairment;Hyperreflexia;Vertical supranuclear gaze palsy;Hypertonia;Tongue atrophy;Dysphagia;Incoordination;Ptosis;Tongue fasciculations;Truncal ataxia;Muscle weakness;Slow saccadic eye movements;Nystagmus;Gait ataxia;Muscular hypotonia;EMG: neuropathic changes;Dysarthria		1.31396e-05	2.0	152212.0	0.0	32	0.97	PASS	nfe	2.93953e-05	2.0	2.93953e-05	2.0	6.76014e-05	17.0	251474.0	0.0	100	1.0	PASS	amr	0.000346901	12.0	2.63713e-05	3.0	0.0000965	15			0.00018	2		10.93	0.673617		0	0	0			NOP56	0.0	0.0	0.0	0.0	10.0	-20.0	33.0	38.0						0.285	0.97	81.617792582			.			.	.	rRNA processing	fibrillar center;nucleoplasm;nucleolus;small nucleolar ribonucleoprotein complex;cytoplasm;membrane;box C/D snoRNP complex;small-subunit processome;pre-snoRNP complex	RNA binding;protein binding;snoRNA binding;cadherin binding;histone methyltransferase binding	RPL4[26496610];RPL5[26496610];RPL30[26496610];RPL3[26496610];RPL32[26496610];POP1[26496610];HDAC11[23752268];PPAN[26496610];HNRNPU[26496610];JADE2[26496610];RPL8[26496610];NOC2L[26496610];RPL10A[26496610];MKI67[26496610];SOGA1[26496610];RPL6[26496610];RPL7[26496610];RRP9[30021884];FBL[26496610;29568061];RPS14[26496610];MYC[17353931;17314511];DHX57[26496610];RPL36[26496610];RPS12[26496610];DDX18[26496610];CSNK2A1[22113938];RPL23[26496610];RPS6[26496610;29568061];RPL22[26496610];CIRBP[26496610];WDR74[26496610];DDX10[26496610];IMP4[26496610];LEMD2[26496610];SDCBP2[unassigned1304];GTPBP4[26496610];EBNA1BP2[26496610];MRTO4[26496610];RPL24[26496610];VDAC1[29128334];GLYR1[26496610];L3MBTL1[27705803];DHX9[26496610];COX15[29128334];NOP2[26496610];MEPCE[26496610];SNU13[30021884];FXR1[26496610];DHX30[26496610];LARP1[26496610];DHX33[26496610];DHX37[26496610];BRIX1[26496610];H1FX[26496610];SMN1[19928837];LYAR[26496610];HMOX2[30021884];DECR1[26496610];SRPK3[23602568];EIF2B4[26496610];JUN[25609649];VCAM1[22623428];NOP16[26496610];NEK4[25798074];CCDC137[26496610];LARP7[18281698];CDC6[26496610];C8orf33[26496610];ESR1[21182205];ESR2[21182203];PRRC2A[26496610];RPS25[26496610];FAM111A[26496610];TBL3[26496610];IBTK[26496610];COQ2[29128334];RPS27[26496610];EIF2S3[26496610];RIOX1[26496610];AGO1[17932509];RIOX2[26496610];NMT1[26496610];NOP10[26496610];RPS24[26496610];TOP2A[26496610];RBM28[26496610];MCM7[23764002];WDR3[26496610];C7orf50[26496610];PINX1[26496610];RPLP0[26496610];CCDC124[26496610];MED19[15175163];NAT10[26496610];ARRB2[17620599];YBX1[25497084];KRI1[26496610];RPS4X[26496610];RPL7A[26496610];METTL14[29507755];RARS[26496610];UBTF[26496610];RRP12[26496610];EIF2B1[26496610];RRP15[26496610];RFC5[26496610];WDR36[26496610];RFC3[26496610];RFC4[26496610];RFC1[26496610];RFC2[26496610];DDX55[26496610];RPL13A[26496610];DDX54[26496610];URB2[26496610];RPS3A[26496610];URB1[26496610];GNL3[26496610];LSG1[26496610];PPP1R15A[29109149];NUFIP1[17636026];GTF3C4[26496610];DDX24[26496610];USP10[26496610];NIP7[26496610];RPL12[26496610];RPL11[26496610];DDX21[26496610];DLST[29128334];TPTE[28330616];MRM1[26496610];HSD17B10[26496610];NOL6[26496610];MLLT6[26496610];RPS15A[26496610];EXOSC9[26496610];RPS3[26496610];PCGF1[27505670];RPS2[26496610];SAMD1[26496610];C12orf43[26496610];RTRAF[26496610];ABCF1[26496610];NOP58[17636026;26496610];CENPV[26496610];NPM1[26496610];MAP3K1[26496610];TRMT10C[26496610];UTP4[26496610];ATAD5[26496610];PNMA3[26496610];RPL23A[26496610];DEK[26496610];SRP68[26496610];RRP1B[20926688];RSL1D1[26496610];MYBBP1A[26496610];TSR1[26496610];MNDA[25665578];ESYT2[26496610];CEBPZ[26496610];ERCC6[26496610];BCOR[27505670];	2635555
3696	chr20	10389422	T	C	chr20:10389422	MKKS	McKusick-Kaufman syndrome	SNV	0/1	0.41	13_9	22	99	rs137853909,CM021299	EXONIC	YES	NM_170784.3	Transcript	protein_coding	missense_variant		4/6	NM_170784.3:c.1015A>G	NP_740754.1:p.Ile339Val		-1.0	.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	McKusick-Kaufman_syndrome|Bardet-Biedl_syndrome_6|Bardet-Biedl_syndrome|not_specified|not_provided	McKusick-Kaufman syndrome, 236700 (3), Autosomal recessive; Bardet-Biedl syndrome 6, 605231 (3), Autosomal recessive	McKusick-Kaufman syndrome;Bardet-Biedl syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Postaxial foot polydactyly;Atrial septal defect;Urethral stricture;Tetralogy of Fallot;Urogenital sinus anomaly;Brachydactyly;Ventricular septal defect;Patent ductus arteriosus;Cleft palate;Tarsal synostosis;Cryptorchidism;Hypoplastic left heart;Hydrometrocolpos;Glandular hypospadias;Hydronephrosis;Global developmental delay;Renal hypoplasia/aplasia;Aganglionic megacolon;Failure to thrive;Anal atresia;Postaxial hand polydactyly;Multicystic kidney dysplasia;Finger syndactyly;High palate;Short stature;Abnormality of the metacarpal bones;Intellectual disability;Ectopic anus;Edema;Aganglionic megacolon;Hydronephrosis;Polycystic kidney dysplasia;Vaginal atresia;Cryptorchidism;Postaxial hand polydactyly;Hydrometrocolpos;Pedal edema;Transverse vaginal septum;Vesicovaginal fistula;Rectovaginal fistula;Anal atresia;Congenital hip dislocation;Abnormality of cardiovascular system morphology;Autosomal recessive inheritance;Syndactyly;Mesoaxial hand polydactyly;Pulmonary hypoplasia;Hydroureter;Rod-cone dystrophy;Syndactyly;Hypospadias;Obesity;External genital hypoplasia;Autosomal recessive inheritance;Diabetes mellitus;Intellectual disability;Renal cyst;Polydactyly;Hearing impairment;Cryptorchidism;Hypoplasia of the ovary;Low-set, posteriorly rotated ears;Hypogonadism;Nephrotic syndrome;Nystagmus;Multicystic kidney dysplasia;Generalized hirsutism;Short stature;Obesity;Abnormal electroretinogram;Hepatic fibrosis;Pigmentary retinopathy;Neurological speech impairment;Short neck;Downslanted palpebral fissures;Postaxial hand polydactyly;Finger syndactyly;Skeletal muscle atrophy;Hypertension;Intellectual disability;Prominent nasal bridge;Hypoplasia of penis;Medial flaring of the eyebrow	25741868,12107442,18094050	0.00364642	555.0	152204.0	1.0	32	0.96	PASS	nfe	0.00504115	343.0	0.00504115	343.0	0.00421768	1059.0	251086.0	8.0	46	0.98	PASS	sas	0.00585197	179.0	0.00503974	572.0	0.0041285	642	0.006	19.0	0.00503	57		1.678	-0.072919	0.026	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MKKS	0.0	0.01	0.0	0.0	5.0	29.0	1.0	-14.0						0.265	0.0	0.000000000	0.213	0.197	cardiovascular system phenotype ; mortality/aging ; reproductive system phenotype; behavior/neurological phenotype ; respiratory system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype ; taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; 			caudate nucleus;pons;temporal lobe;occipital lobe;subthalamic nucleus;prefrontal cortex;cingulate cortex;parietal lobe;globus pallidus;medulla oblongata;thalamus;	.	heart looping;protein folding;spermatid development;determination of left/right symmetry;heart development;visual perception;sensory perception of smell;gonad development;negative regulation of gene expression;artery smooth muscle contraction;striatum development;hippocampus development;cerebral cortex development;negative regulation of actin filament polymerization;melanosome transport;developmental process;negative regulation of GTPase activity;social behavior;negative regulation of appetite by leptin-mediated signaling pathway;positive regulation of multicellular organism growth;vasodilation;fat cell differentiation;photoreceptor cell maintenance;negative regulation of blood pressure;intracellular transport;brain morphogenesis;detection of mechanical stimulus involved in sensory perception of sound;chaperone-mediated protein complex assembly;cartilage development;regulation of stress fiber assembly;pigment granule aggregation in cell center;convergent extension involved in gastrulation;cilium assembly;regulation of cilium beat frequency involved in ciliary motility;face development;non-motile cilium assembly	nucleus;cytoplasm;centrosome;cytosol;motile cilium;ciliary basal body;kinociliary basal body	RNA polymerase II repressing transcription factor binding;protein binding;ATP binding;unfolded protein binding	TGIF1[17353931];BBS2[22500027;20080638];CCT2[22500027];ICA1[17353931];PTN[16169070];HSCB[28380382];CCDC28B[16327777];BBS10[22500027;20080638];BBS12[22500027;20080638];STK16[17353931];TCP1[22500027];ZBED1[unassigned1304];BBS7[22500027;20080638];CDR2[unassigned1304];	10389422
3728	chr20	39832625	G	A	chr20:39832625	ZHX3	zinc fingers and homeoboxes 3	SNV	0/1	0.34	23_12	35	99	rs143152968	EXONIC	YES	NM_001384325.1	Transcript	protein_coding	missense_variant		3/5	NM_001384325.1:c.932C>T	NP_001371254.1:p.Ala311Val		-1.0	Homeobox domain,Homeobox domain,.,Homeobox domain,Homeobox domain	Uncertain_significance	criteria_provided,_single_submitter	not_provided		.	.	.		0.000157633	24.0	152252.0	0.0	32	0.98	PASS	nfe	0.000293902	20.0	0.000293902	20.0	0.000119315	30.0	251436.0	1.0	84	1.0	PASS	nfe	0.000219823	25.0	0.000219823	25.0	0.0001479	23	0.001	2.0	0.00027	3		22.3	2.394446	0.198	6	13	19	LRT_pred,MutationTaster_pred,PROVEAN_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	ZHX3	0.0	0.0	0.0	0.0	-19.0	-3.0	2.0	9.0						0.291	0.35	0.000000000	0.903	-0.13	growth/size/body region phenotype; hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; behavior/neurological phenotype ; mortality/aging ; 			ciliary ganglion;pons;prefrontal cortex;trigeminal ganglion;	.	negative regulation of transcription by RNA polymerase II;cell differentiation;positive regulation of osteoblast differentiation;negative regulation of transcription, DNA-templated	nucleus;nucleoplasm	RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;transcription corepressor activity;protein binding;protein homodimerization activity;metal ion binding;protein heterodimerization activity	RPL7A[30021884];ATXN1[16713569];SH2D2A[25814554];NLK[21516116;25416956;unassigned1304];	39832625
3779	chr20	62641612	C	A	chr20:62641612	PRPF6	pre-mRNA processing factor 6	SNV	0/1	0.39	23_15	38	99		EXONIC	YES	NM_012469.4	Transcript	protein_coding	missense_variant		10/21	NM_012469.4:c.1246C>A	NP_036601.2:p.Pro416Thr		1.0		Uncertain_significance	criteria_provided,_single_submitter	Retinitis_pigmentosa	Retinitis pigmentosa 60, 613983 (3), Autosomal dominant	Retinitis pigmentosa	Disease-causing germline mutation(s) in	Hyperinsulinemia;Optic atrophy;Nystagmus;Abnormal retinal vascular morphology;Obesity;Hypoplasia of penis;Cataract;Abnormality of retinal pigmentation;Keratoconus;Progressive night blindness;Ophthalmoplegia;Abnormal testis morphology;Atypical scarring of skin;Hyperreflexia;Sensorineural hearing impairment;Blindness;Type II diabetes mellitus;Conductive hearing impairment;Photophobia;Intellectual disability;Anteverted nares;Abnormal electroretinogram;Wide nasal bridge;Hypogonadism;Glaucoma;Rod-cone dystrophy;Autosomal dominant inheritance;Pallor;Reduced visual acuity						33	0.97											100	1.0											0.00018	2		22.3	2.37243	0.509	12	8	20	LRT_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,BayesDel_noAF_pred	PRPF6	0.0	0.0	0.0	0.0	14.0	-17.0	-37.0	-45.0						0.461	0.28	68.581115215	0.998	1.022	hematopoietic system phenotype; behavior/neurological phenotype ; homeostasis/metabolism phenotype; 			pons;amygdala;liver;cingulate cortex;placenta;cerebellum;	.	spliceosomal tri-snRNP complex assembly;spliceosomal complex assembly;RNA splicing, via transesterification reactions;mRNA splicing, via spliceosome;RNA localization;RNA splicing;positive regulation of transcription by RNA polymerase II	nucleus;nucleoplasm;spliceosomal complex;U5 snRNP;membrane;nuclear speck;U4/U6 x U5 tri-snRNP complex;U2-type precatalytic spliceosome;catalytic step 2 spliceosome	transcription coactivator activity;RNA binding;protein binding;ribonucleoprotein complex binding;androgen receptor binding	NOTCH1[23022380];LRRK2[24725412];HDAC11[23752268];ARAF[12620389];DLST[29128334];DDX41[25920683];USP39[19615732];PRPF8[27173435;unassigned1312];GABARAP[20562859];EFTUD2[27173435;unassigned1312];MAP1LC3A[20562859];MYC[17353931;17314511;21150319];PSMD2[25036637];KIF21B[26496610];RIOK1[27173435;unassigned1312];PHLDA3[17353931];SRRM2[22365833];GABARAPL2[20562859];IK[22365833];JUN[25609649];SF3A2[17332742];RAB4B[26496610];PDHA1[29128334];CDC5L[20467437];PRPF4B[23602568];AARSD1[25036637];RRP1B[20926688];SMARCA2[16341228];SMU1[27173435;unassigned1312];PRPF4[19615732;26496610];SNRNP40[17353931];SNW1[20467437];RNF169[21252943];MDM2[20195357];CD2BP2[15840814;17353931;22365833;27173435;unassigned1312];RNPS1[17353931;26496610];PRPF31[22365833];SNRNP200[27173435;unassigned1312];SNRPB[17353931];SF1[26420826];	62641612
3831	chr21	45789179	G	C	chr21:45789179	TRPM2	transient receptor potential cation channel subfamily M member 2	SNV	0/1	0.48	50_46	96	99	rs759377341,COSV55967470	EXONIC	YES	NM_001320350.1	Transcript	protein_coding	missense_variant		5/33	NM_001320350.1:c.724G>C	NP_001307279.1:p.Ala242Pro		1.0	.,.,.,.					.	.	.		6.56996e-06	1.0	152208.0	0.0	33	0.97	PASS	nfe	1.46985e-05	1.0	1.46985e-05	1.0	8.0023e-06	2.0	249928.0	0.0	45	0.98	PASS	nfe	1.77453e-05	2.0	1.77453e-05	2.0					9e-05	1		25.7	3.679779	0.469	14	6	20	SIFT,PolyPhen,Polyphen2_HDIV_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred	TRPM2	0.0	0.0	0.0	0.01	-34.0	-46.0	-24.0	47.0						0.797	0.0	0.000000000	0.641	1.107	cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; immune system phenotype; nervous system phenotype ; mortality/aging ; normal phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; 			superior cervical ganglion;	.	temperature homeostasis;dendritic cell chemotaxis;calcium ion transport;response to purine-containing compound;calcium-mediated signaling using intracellular calcium source;sodium ion transmembrane transport;neutrophil degranulation;release of sequestered calcium ion into cytosol;regulation of filopodium assembly;cellular response to hydrogen peroxide;calcium ion transmembrane transport;cellular response to calcium ion;cellular response to purine-containing compound;cellular response to temperature stimulus;zinc ion transmembrane transport;dendritic cell differentiation;calcium ion transmembrane import into cytosol;calcium ion import across plasma membrane;regulation of actin cytoskeleton reorganization	lysosome;lysosomal membrane;plasma membrane;integral component of plasma membrane;cytoplasmic vesicle membrane;specific granule membrane;cell projection;perikaryon;tertiary granule membrane;ficolin-1-rich granule membrane	cation channel activity;calcium channel activity;sodium channel activity;calcium ion binding;calcium-release channel activity;hydrolase activity;ligand-gated calcium channel activity	PPP1R12A[28330616];	45789179
3859	chr21	47819594	A	T	chr21:47819594	PCNT	pericentrin	SNV	0/1	0.27	27_10	37	99	rs180775012,COSV100855602	EXONIC	YES	NM_006031.6	Transcript	protein_coding	missense_variant		25/47	NM_006031.6:c.4675A>T	NP_006022.3:p.Met1559Leu		1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Microcephalic_osteodysplastic_primordial_dwarfism_type_II|not_provided	Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3), Autosomal recessive	Seckel syndrome;Microcephalic osteodysplastic primordial dwarfism type II	Candidate gene tested in;Disease-causing germline mutation(s) (loss of function) in	Narrow pelvis bone;Sensorineural hearing impairment;Ventriculomegaly;Arterial stenosis;Stroke;Aplasia/Hypoplasia of the eyebrow;Dry skin;Attention deficit hyperactivity disorder;Wide nasal bridge;Aplasia/Hypoplasia of the earlobes;Abnormality of female external genitalia;Patent ductus arteriosus;Underdeveloped nasal alae;Abnormality of epiphysis morphology;Intrauterine growth retardation;Micromelia;Brachydactyly;Hypopigmented skin patches;Scoliosis;Microdontia;Hypoplasia of the corpus callosum;Prominent nose;Joint hyperflexibility;Hypoplastic iliac wing;Tracheal stenosis;Clinodactyly of the 5th finger;Recurrent respiratory infections;Disproportionate short stature;Downslanted palpebral fissures;Retrognathia;Delayed skeletal maturation;Full cheeks;Laryngomalacia;Reduced number of teeth;Low-set ears;Intellectual disability;Seizure;Dilatation;Atrial septal defect;Nasal speech;High pitched voice;Global developmental delay;Precocious puberty;Anemia;Coxa vara;Narrow palpebral fissure;Multiple cafe-au-lait spots;Microcephaly;Fine hair;Abnormality of the metaphysis;Truncal obesity;Retrognathia;Prominent nasal bridge;Tibial bowing;Sloping forehead;Cafe-au-lait spot;Sparse scalp hair;Intellectual disability;Narrow pelvis bone;Flared metaphysis;Areas of hypopigmentation and hyperpigmentation that do not follow Blaschko lines;Microdontia;Global developmental delay;Straight clavicles;Large sella turcica;Ulnar bowing;Microcephaly;Hypoplasia of dental enamel;Ivory epiphyses;Upslanted palpebral fissure;Slender long bone;Cone-shaped epiphysis;Long clavicles;Moyamoya phenomenon;Delayed skeletal maturation;Limited elbow extension;Truncal obesity;Type II diabetes mellitus;Pseudoepiphyses of the metacarpals;Clinodactyly of the 5th finger;Proximal femoral epiphysiolysis;Distal symphalangism;Hypermetropia;Hypoplastic scapulae;Disproportionate short stature;Hypospadias;Narrow chest;Intrauterine growth retardation;Short distal phalanx of finger;Brachydactyly;Coxa vara;Thin clavicles;Hypoplastic iliac wing;Microtia;Prominent nose;Radial bowing;Precocious puberty;Autosomal recessive inheritance;High pitched voice;Short middle phalanx of finger;Dilatation of the cerebral artery;Postnatal growth retardation;Short 1st metacarpal;Cachexia;Downslanted palpebral fissures;Narrow face;Micrognathia;Mild global developmental delay;Prematurely aged appearance;Sparse scalp hair;Microcephaly;Hip dysplasia;Joint hyperflexibility;Convex nasal ridge;Delayed skeletal maturation;Reduced number of teeth;Glaucoma;Abnormality of dental enamel;Intrauterine growth retardation;Short stature;Sandal gap;Cone-shaped epiphysis;Clinodactyly of the 5th finger;Scoliosis;Craniosynostosis;Absent earlobe;Intellectual disability;Cognitive impairment		0.000715824	109.0	152272.0	0.0	33	0.97	PASS	amr	0.002028	31.0	0.000925817	63.0	0.000922553	232.0	251476.0	0.0	100	1.0	PASS	amr	0.00161887	56.0	0.00106364	121.0	0.0008167	127	0.005	17.0	0.005	57		14.51	1.174034	0.019	0	19	19		SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PCNT	0.56	0.01	0.0	0.0	6.0	-27.0	6.0	-27.0						0.898	0.0	0.000000000	0.359	1.272	growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; respiratory system phenotype; behavior/neurological phenotype ; embryo phenotype; cardiovascular system phenotype ; mortality/aging ; vision/eye phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; nervous system phenotype ; renal/urinary system phenotype; skeleton phenotype; 			caudate nucleus;testis - seminiferous tubule;testis - interstitial;prefrontal cortex;testis;skeletal muscle;globus pallidus;medulla oblongata;	.	G2/M transition of mitotic cell cycle;microtubule cytoskeleton organization;mitotic spindle organization;signal transduction;regulation of G2/M transition of mitotic cell cycle;cilium assembly;positive regulation of intracellular protein transport;ciliary basal body-plasma membrane docking	centrosome;centriole;microtubule organizing center;cytosol;microtubule;membrane;centriolar satellite	protein binding;calmodulin binding;protein-containing complex scaffold activity	APP[30021884];PON2[26496610];C7orf50[26496610];MPV17L2[26496610];YBX1[21423216];OSBPL10[30021884];PCM1[26496610;24816561;26638075];PSMD4[17891176];RACGAP1[26496610];PRKAR2A[26496610];CNTRL[26638075];CEP72[26496610];STK38L[30108113];DISC1[15094396;12812986];MTA2[26496610];PIBF1[26496610];CEP290[26638075;18694559];CDK5RAP2[26496610;26297806];OFD1[26496610];CEP68[25503564];CCDC13[24816561];CEP152[26638075];CEP131[26496610];RITA1[21102556];CDC5L[20467437];PAX6[26496610];IMP4[26496610];RPGRIP1L[26638075];YWHAZ[26496610];WDR35[26496610];MIB1[26496610];CEP162[26638075];MAPRE1[26496610];CALM1[18694559];SLC25A4[26496610];	47819594
3930	chr22	26872985	T	C	chr22:26872985	HPS4	HPS4, biogenesis of lysosomal organelles complex 3 subunit 2	SNV	0/1	0.4	26_17	43	99	rs149830675	EXONIC	YES	NM_001349900.2	Transcript	protein_coding	missense_variant		4/15	NM_001349900.2:c.250A>G	NP_001336829.1:p.Ile84Val		-1.0	.,.,.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Hermansky-Pudlak_syndrome_4|Hermansky-Pudlak_syndrome|not_specified|not_provided	Hermansky-Pudlak syndrome 4, 614073 (3), Autosomal recessive	Hermansky-Pudlak syndrome with pulmonary fibrosis	Disease-causing germline mutation(s) in	Reduced visual acuity;Abnormal platelet granules;Autosomal recessive inheritance;Bruising susceptibility;Horizontal nystagmus;Hypoplasia of the fovea;Ocular albinism;Restrictive ventilatory defect;Epistaxis;Pulmonary fibrosis;Menorrhagia;Albinism	25741868	0.00342862	522.0	152248.0	3.0	32	0.97	PASS	sas	0.00827815	40.0	0.00393874	268.0	0.00470843	1184.0	251464.0	5.0	100	1.0	PASS	sas	0.00558531	171.0	0.00517839	589.0	0.0044500	692	0.008	27.0	0.00824	94		0.001	-1.946802	0.014	2	15	17	M-CAP_pred,FATHMM_pred	LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	HPS4	0.0	0.0	0.0	0.0	6.0	-2.0	1.0	28.0						0.125	0.0	0.000000000	0.01	-2.093	pigmentation phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; renal/urinary system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; growth/size/body region phenotype; integument phenotype ; homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; 			trigeminal ganglion;skeletal muscle;	Glycosphingolipid biosynthesis - lactoseries;Glycosphingolipid biosynthesis - neo-lactoseries;Glycan structures - biosynthesis 2	protein targeting;lysosome organization;blood coagulation;hemostasis;melanocyte differentiation;positive regulation of eye pigmentation;protein stabilization;melanosome assembly;positive regulation of protein targeting to mitochondrion	cytoplasm;lysosome;cytosol;membrane;BLOC-3 complex;melanosome;platelet dense granule	guanyl-nucleotide exchange factor activity;protein binding;Rab GTPase binding;protein homodimerization activity;protein dimerization activity	HPS1[12756248];RAC1[20936779];	26872985
3968	chr22	38119772	AAGCCTCCAGAACCTCCTCTCCCAATAGAGCCACACGAGACAACCCCAGAACATCCTGCGCCCAGCGGGACAATCCCAGAGCCTCCTCTCCCAGTAGAGCTACACGAGACAACCCCACAACATCCTGTGCCCAGCGGGACAATCCCA		chr22:38119772-38119918	TRIOBP	TRIO and F-actin binding protein	deletion	0/1	0.45	11_9	20	95		EXONIC	YES	NM_001039141.3	Transcript	protein_coding	inframe_deletion		7/24	NM_001039141.3:c.1238_1384del	NP_001034230.1:p.Lys413_Pro461del		1.0					Deafness, autosomal recessive 28, 609823 (3), Autosomal recessive	Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing germline mutation(s) in	Infantile onset;Severe sensorineural hearing impairment;Autosomal recessive inheritance		0.000112315	17.0	151360.0	0.0	25	0.73	AS_VQSR	sas	0.00020938	1.0	0.000117893	8.0	4.00702e-06	1.0	249562.0	0.0	97	1.0	RF	amr	2.89687e-05	1.0	0.0	0.0					0.00132	15		12.79	0.909454		0	0	0																	0.171	0.0				mortality/aging ; nervous system phenotype ; hearing/vestibular/ear phenotype; 			.	.	cell cycle;sensory perception of sound;actin modification;barbed-end actin filament capping;cell division;auditory receptor cell stereocilium organization;positive regulation of substrate adhesion-dependent cell spreading	nucleus;cytoplasm;microtubule organizing center;focal adhesion;actin cytoskeleton;midbody	GTP-Rho binding;ubiquitin protein ligase binding;myosin II binding;actin filament binding	IQGAP1[26496610];TRIOBP[17629495];PPP1CB[26496610;28330616];BAG6[26496610];SYNCRIP[26496610];LAMP1[29568061];MYO18A[26496610];POLR2F[26496610];IKBKG[21988832];PPP1R12A[28330616];SORT1[26496610];TMEM132A[26496610];GTF2H1[21988832];TERF1[17629495];HAUS2[26496610];PLEKHA7[28877994];ANLN[26496610];MYO1C[26496610];KIF2A[26496610];POLR1C[21988832];CAPZA2[26496610];MYH9[26496610];L1TD1[26496610];VIM[16169070];EZR[29568061];BCAR1[28007913];	38119771
3984	chr22	41077613	G	A	chr22:41077613	MCHR1	melanin concentrating hormone receptor 1	SNV	0/1	0.46	47_40	87	99	rs45439291,CM044005,COSV50762934	EXONIC	YES	NM_005297.4	Transcript	protein_coding	missense_variant		2/2	NM_005297.4:c.743G>A	NP_005288.4:p.Arg248Gln		1.0	GPCR, rhodopsin-like, 7TM,GPCR, rhodopsin-like, 7TM					.	.	.	28265093	0.00319898	487.0	152236.0	0.0	32	0.99	PASS	nfe	0.00468828	319.0	0.00468828	319.0	0.00343041	862.0	251282.0	3.0	100	1.0	PASS	nfe	0.005156	586.0	0.005156	586.0	0.0037684	586	0.005	16.0	0.00406	46		24.2	3.253949	0.266	6	13	19	LRT_pred,MutationTaster_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred	MCHR1	0.0	0.0	0.0	0.0	2.0	-10.0	1.0	16.0						0.699	0.0	0.000000000	1.0	1.176	homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype ; nervous system phenotype ; skeleton phenotype; behavior/neurological phenotype ; cardiovascular system phenotype ; 			pons;dorsal root ganglion;superior cervical ganglion;	Neuroactive ligand-receptor interaction	generation of precursor metabolites and energy;cell surface receptor signaling pathway;G protein-coupled receptor signaling pathway;adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway;positive regulation of cytosolic calcium ion concentration;neuropeptide signaling pathway;feeding behavior;positive regulation of calcium ion transport	plasma membrane;integral component of plasma membrane;ciliary membrane;non-motile cilium	G protein-coupled receptor activity;signaling receptor binding;protein C-terminus binding;neuropeptide receptor activity;melanin-concentrating hormone receptor activity;peptide binding;hormone binding;neuropeptide binding	.	41077613
4000	chr22	50216719	G	A	chr22:50216719	BRD1	bromodomain containing 1	SNV	0/1	0.49	46_44	90	99	rs778784084	EXONIC	YES	NM_001304808.3	Transcript	protein_coding	missense_variant		2/13	NM_001304808.3:c.1247C>T	NP_001291737.1:p.Ser416Leu		-1.0	.,.,.,.					.	.	.		2.62826e-05	4.0	152192.0	0.0	33	0.97	PASS	sas	0.000206954	1.0	0.0	0.0	3.97621e-06	1.0	251496.0	0.0	100	1.0	PASS	sas	3.26627e-05	1.0	0.0	0.0	0.0000064	1	0.001	2.0	0.00026	3		21.1	2.159285	0.054	2	17	19	LIST-S2_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	BRD1	0.0	0.0	0.0	0.0	-16.0	-28.0	20.0	-28.0						0.35	0.99	0.000000000	0.982	1.176	cellular phenotype; hematopoietic system phenotype; growth/size/body region phenotype; integument phenotype ; mortality/aging ; vision/eye phenotype; nervous system phenotype ; liver/biliary system phenotype; embryo phenotype; 			ciliary ganglion;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;cerebellum;	.	response to immobilization stress;histone H3 acetylation;response to electrical stimulus	nucleus;nuclear speck;dendrite;perikaryon;MOZ/MORF histone acetyltransferase complex	histone binding;metal ion binding	ZNF512B[15231748];YWHAE[27142060];CEP126[16169070];MRPS14[27142060];YWHAB[27142060];CLTC[27142060];PHB2[27142060];ING4[26496610;27142060];ING5[27142060];CASP8[unassigned1304];C1QBP[27142060];WDR7[27142060];KMT5B[27142060];KAT7[27142060];KPNA2[27142060];YWHAG[27142060];TMPO[26496610];KPNA1[27142060];YWHAH[27142060];RUBCN[unassigned1304];PBRM1[27142060];NSUN2[27142060];TFIP11[unassigned1304];YWHAZ[27142060];DIEXF[27142060];PICK1[unassigned1304];S100A4[26496610];MYH6[26496610];DNMT1[27142060];RPL10[26496610];MEAF6[27142060];HMBOX1[unassigned1304];PSMB2[27142060];CEP70[unassigned1304];ZNF226[27142060];MAGEA11[unassigned1304];DISC1[unassigned1304];LYAR[27142060];ZC3H15[27142060];QSER1[27142060];NPM1[27142060];ZRANB1[unassigned1304];ATP5PD[30021884];MCC[unassigned1304];NAP1L4[27142060];EIF3I[27142060];DRG1[27142060];RPL22L1[27142060];VIM[16169070];CNTROB[26496610];	50216719
4152	chr3	38645506	A	G	chr3:38645506	SCN5A	sodium voltage-gated channel alpha subunit 5	SNV	0/1	0.53	34_39	73	99	rs45624133	EXONIC	YES	NM_001099404.2	Transcript	protein_coding	synonymous_variant		12/28	NM_001099404.2:c.1587T>C	NP_001092874.1:p.Ile529%3D		-1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Cardiac_arrhythmia|Progressive_familial_heart_block,_type_1A|Brugada_syndrome_1|Dilated_cardiomyopathy_1E|Paroxysmal_familial_ventricular_fibrillation_1|Long_QT_syndrome_3|Brugada_syndrome|Sick_sinus_syndrome_1,_autosomal_recessive|not_specified|Cardiovascular_phenotype|not_provided	Ventricular fibrillation, familial, 1, 603829 (3); Heart block, progressive, type IA, 113900 (3), Autosomal dominant; Cardiomyopathy, dilated, 1E, 601154 (3), Autosomal dominant; Heart block, nonprogressive, 113900 (3), Autosomal dominant; Long QT syndrome 3, 603830 (3), Autosomal dominant; Sick sinus syndrome 1, 608567 (3), Autosomal recessive; Brugada syndrome 1, 601144 (3), Autosomal dominant; Atrial fibrillation, familial, 10, 614022 (3), Autosomal dominant; {Sudden infant death syndrome, susceptibility to}, 272120 (3), Autosomal recessive	Familial sick sinus syndrome;Familial isolated dilated cardiomyopathy;Atrial standstill;Familial progressive cardiac conduction defect;Idiopathic ventricular fibrillation, non Brugada type;Brugada syndrome;Familial atrial fibrillation;Romano-Ward syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) (gain of function) in	Atrioventricular block;Palpitations;Reduced systolic function;Atrial fibrillation;Right bundle branch block;Atrial flutter;Ventricular extrasystoles;Autosomal dominant inheritance;Dilated cardiomyopathy;Atrial standstill;Stroke;Left bundle branch block;Supraventricular tachycardia;Premature atrial contractions;Syncope;Left ventricular hypertrophy;Left atrial enlargement;Autosomal dominant inheritance;Atrial flutter;Tricuspid regurgitation;Paroxysmal atrial fibrillation;Paroxysmal atrial tachycardia;Syncope;Sudden cardiac death;Autosomal dominant inheritance;Heterogeneous;Ventricular fibrillation;Prolonged QT interval;Torsade de pointes;Syncope;Ventricular fibrillation;Tachycardia;Left anterior fascicular block;Dyspnea;Heterogeneous;Complete heart block with broad QRS complexes;Sudden death;Autosomal dominant inheritance;Right bundle branch block;Syncope;Sudden cardiac death;Left posterior fascicular block;Palmoplantar keratoderma;EMG abnormality;Lipoatrophy;Dilated cardiomyopathy;Elevated serum creatine kinase;Abnormality of neutrophils;Sensorineural hearing impairment;Myopathy;Autosomal recessive inheritance;Apneic episodes in infancy;Multifactorial inheritance;Sudden death;Malignant hyperthermia;Cardiac arrest;Ventricular fibrillation;Right bundle branch block;Autosomal dominant inheritance;Sudden death;Trifascicular block;Supraventricular tachycardia;Right bundle branch block;ST segment elevation;Syncope;Paroxysmal ventricular tachycardia;First degree atrioventricular block;Ventricular fibrillation;Cardiac arrest;Sick sinus syndrome;Atrioventricular block;Sinus bradycardia;Autosomal recessive inheritance;Prolonged QT interval;Sick sinus syndrome;Autosomal dominant inheritance;Ventricular escape rhythm;Congenital onset;Abdominal pain;Dyspnea;Arrhythmia;Vertigo;Bundle branch block;Congestive heart failure;Syncope;Abnormality of prenatal development or birth;Syncope;Torsade de pointes;Abnormal cardiac exercise stress test;Hypokalemia;Abnormal T-wave;Sudden cardiac death;Sinus bradycardia;Prolonged QTc interval;Abnormal autonomic nervous system physiology;Seizure	25741868,24033266	0.00552729	841.0	152154.0	5.0	32	0.97	PASS	amr	0.00955622	146.0	0.00671802	457.0	0.00555785	1371.0	246678.0	3.0	61	0.87	PASS	nfe	0.00721847	806.0	0.00721847	806.0	0.0053311	829	0.01	32.0	0.01043	119		10.53	0.625989		0	0	0			SCN5A	0.03	0.13	0.01	0.0	36.0	-15.0	-14.0	0.0						0.000413	1.0	9.361925911			growth/size/body region phenotype; muscle phenotype; behavior/neurological phenotype ; embryo phenotype; cardiovascular system phenotype ; mortality/aging ; normal phenotype; nervous system phenotype ; 			superior cervical ganglion;heart;	.	regulation of heart rate;cardiac ventricle development;brainstem development;sodium ion transport;positive regulation of sodium ion transport;response to denervation involved in regulation of muscle adaptation;neuronal action potential;telencephalon development;cerebellum development;sodium ion transmembrane transport;odontogenesis of dentin-containing tooth;positive regulation of action potential;positive regulation of epithelial cell proliferation;membrane depolarization;cardiac muscle contraction;regulation of ventricular cardiac muscle cell membrane repolarization;regulation of atrial cardiac muscle cell membrane depolarization;regulation of atrial cardiac muscle cell membrane repolarization;regulation of ventricular cardiac muscle cell membrane depolarization;cellular response to calcium ion;cardiac muscle cell action potential involved in contraction;regulation of cardiac muscle cell contraction;ventricular cardiac muscle cell action potential;membrane depolarization during action potential;membrane depolarization during cardiac muscle cell action potential;atrial cardiac muscle cell action potential;SA node cell action potential;AV node cell action potential;bundle of His cell action potential;membrane depolarization during AV node cell action potential;membrane depolarization during SA node cell action potential;membrane depolarization during Purkinje myocyte cell action potential;membrane depolarization during bundle of His cell action potential;AV node cell to bundle of His cell communication;regulation of heart rate by cardiac conduction;membrane depolarization during atrial cardiac muscle cell action potential;regulation of sodium ion transmembrane transport	voltage-gated sodium channel complex;endoplasmic reticulum;plasma membrane;caveola;cell surface;intercalated disc;integral component of membrane;lateral plasma membrane;Z disc;T-tubule;axon;sarcolemma;perinuclear region of cytoplasm	voltage-gated ion channel activity;voltage-gated sodium channel activity;protein binding;calmodulin binding;fibroblast growth factor binding;enzyme binding;protein kinase binding;protein domain specific binding;ankyrin binding;ubiquitin protein ligase binding;ion channel binding;nitric-oxide synthase binding;voltage-gated sodium channel activity involved in cardiac muscle cell action potential;voltage-gated sodium channel activity involved in AV node cell action potential;voltage-gated sodium channel activity involved in bundle of His cell action potential;voltage-gated sodium channel activity involved in Purkinje myocyte action potential;voltage-gated sodium channel activity involved in SA node cell action potential;scaffold protein binding	PRMT5[23912080];CAMK2D[22514276];ZMYND19[unassigned1304];PRMT1[23912080];PRMT3[23912080];ANK3[19805355];SNTG2[12429735];RGS2[16169070];DLG1[24550280];ALB[15174051];TEKT4[unassigned1304];GPD1L[19666841];CALM1[11807557;21167176;16505387;22705208];ANKS1A[unassigned1304];FGF13[22705208];FGF12[22705208];EMC9[unassigned1304];PTPN3[16930557];BANP[unassigned1304];SNTA1[18591664];	38645506
4157	chr3	38651442	G	A	chr3:38651442	SCN5A	sodium voltage-gated channel alpha subunit 5	SNV	0/1	0.4	36_24	60	99	rs41285129	EXONIC	YES	NM_001099404.2	Transcript	protein_coding	synonymous_variant		7/28	NM_001099404.2:c.717C>T	NP_001092874.1:p.Ile239%3D		-1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Cardiac_arrhythmia|Progressive_familial_heart_block,_type_1A|Brugada_syndrome_1|Dilated_cardiomyopathy_1E|Paroxysmal_familial_ventricular_fibrillation_1|Long_QT_syndrome_3|Brugada_syndrome|Sick_sinus_syndrome_1,_autosomal_recessive|not_specified|Cardiovascular_phenotype|not_provided	Ventricular fibrillation, familial, 1, 603829 (3); Heart block, progressive, type IA, 113900 (3), Autosomal dominant; Cardiomyopathy, dilated, 1E, 601154 (3), Autosomal dominant; Heart block, nonprogressive, 113900 (3), Autosomal dominant; Long QT syndrome 3, 603830 (3), Autosomal dominant; Sick sinus syndrome 1, 608567 (3), Autosomal recessive; Brugada syndrome 1, 601144 (3), Autosomal dominant; Atrial fibrillation, familial, 10, 614022 (3), Autosomal dominant; {Sudden infant death syndrome, susceptibility to}, 272120 (3), Autosomal recessive	Familial sick sinus syndrome;Familial isolated dilated cardiomyopathy;Atrial standstill;Familial progressive cardiac conduction defect;Idiopathic ventricular fibrillation, non Brugada type;Brugada syndrome;Familial atrial fibrillation;Romano-Ward syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) (gain of function) in	Atrioventricular block;Palpitations;Reduced systolic function;Atrial fibrillation;Right bundle branch block;Atrial flutter;Ventricular extrasystoles;Autosomal dominant inheritance;Dilated cardiomyopathy;Atrial standstill;Stroke;Left bundle branch block;Supraventricular tachycardia;Premature atrial contractions;Syncope;Left ventricular hypertrophy;Left atrial enlargement;Autosomal dominant inheritance;Atrial flutter;Tricuspid regurgitation;Paroxysmal atrial fibrillation;Paroxysmal atrial tachycardia;Syncope;Sudden cardiac death;Autosomal dominant inheritance;Heterogeneous;Ventricular fibrillation;Prolonged QT interval;Torsade de pointes;Syncope;Ventricular fibrillation;Tachycardia;Left anterior fascicular block;Dyspnea;Heterogeneous;Complete heart block with broad QRS complexes;Sudden death;Autosomal dominant inheritance;Right bundle branch block;Syncope;Sudden cardiac death;Left posterior fascicular block;Palmoplantar keratoderma;EMG abnormality;Lipoatrophy;Dilated cardiomyopathy;Elevated serum creatine kinase;Abnormality of neutrophils;Sensorineural hearing impairment;Myopathy;Autosomal recessive inheritance;Apneic episodes in infancy;Multifactorial inheritance;Sudden death;Malignant hyperthermia;Cardiac arrest;Ventricular fibrillation;Right bundle branch block;Autosomal dominant inheritance;Sudden death;Trifascicular block;Supraventricular tachycardia;Right bundle branch block;ST segment elevation;Syncope;Paroxysmal ventricular tachycardia;First degree atrioventricular block;Ventricular fibrillation;Cardiac arrest;Sick sinus syndrome;Atrioventricular block;Sinus bradycardia;Autosomal recessive inheritance;Prolonged QT interval;Sick sinus syndrome;Autosomal dominant inheritance;Ventricular escape rhythm;Congenital onset;Abdominal pain;Dyspnea;Arrhythmia;Vertigo;Bundle branch block;Congestive heart failure;Syncope;Abnormality of prenatal development or birth;Syncope;Torsade de pointes;Abnormal cardiac exercise stress test;Hypokalemia;Abnormal T-wave;Sudden cardiac death;Sinus bradycardia;Prolonged QTc interval;Abnormal autonomic nervous system physiology;Seizure	25741868,24033266	0.00388269	591.0	152214.0	3.0	33	0.98	PASS	nfe	0.00489504	333.0	0.00489504	333.0	0.00392158	977.0	249134.0	3.0	72	1.0	PASS	nfe	0.00535461	604.0	0.00535461	604.0	0.0038906	605	0.007	23.0	0.00798	91		11.48	0.740233		0	0	0			SCN5A	0.0	0.0	0.0	0.0	-19.0	13.0	13.0	-39.0						0.000413	1.0	83.653156295			growth/size/body region phenotype; muscle phenotype; behavior/neurological phenotype ; embryo phenotype; cardiovascular system phenotype ; mortality/aging ; normal phenotype; nervous system phenotype ; 			superior cervical ganglion;heart;	.	regulation of heart rate;cardiac ventricle development;brainstem development;sodium ion transport;positive regulation of sodium ion transport;response to denervation involved in regulation of muscle adaptation;neuronal action potential;telencephalon development;cerebellum development;sodium ion transmembrane transport;odontogenesis of dentin-containing tooth;positive regulation of action potential;positive regulation of epithelial cell proliferation;membrane depolarization;cardiac muscle contraction;regulation of ventricular cardiac muscle cell membrane repolarization;regulation of atrial cardiac muscle cell membrane depolarization;regulation of atrial cardiac muscle cell membrane repolarization;regulation of ventricular cardiac muscle cell membrane depolarization;cellular response to calcium ion;cardiac muscle cell action potential involved in contraction;regulation of cardiac muscle cell contraction;ventricular cardiac muscle cell action potential;membrane depolarization during action potential;membrane depolarization during cardiac muscle cell action potential;atrial cardiac muscle cell action potential;SA node cell action potential;AV node cell action potential;bundle of His cell action potential;membrane depolarization during AV node cell action potential;membrane depolarization during SA node cell action potential;membrane depolarization during Purkinje myocyte cell action potential;membrane depolarization during bundle of His cell action potential;AV node cell to bundle of His cell communication;regulation of heart rate by cardiac conduction;membrane depolarization during atrial cardiac muscle cell action potential;regulation of sodium ion transmembrane transport	voltage-gated sodium channel complex;endoplasmic reticulum;plasma membrane;caveola;cell surface;intercalated disc;integral component of membrane;lateral plasma membrane;Z disc;T-tubule;axon;sarcolemma;perinuclear region of cytoplasm	voltage-gated ion channel activity;voltage-gated sodium channel activity;protein binding;calmodulin binding;fibroblast growth factor binding;enzyme binding;protein kinase binding;protein domain specific binding;ankyrin binding;ubiquitin protein ligase binding;ion channel binding;nitric-oxide synthase binding;voltage-gated sodium channel activity involved in cardiac muscle cell action potential;voltage-gated sodium channel activity involved in AV node cell action potential;voltage-gated sodium channel activity involved in bundle of His cell action potential;voltage-gated sodium channel activity involved in Purkinje myocyte action potential;voltage-gated sodium channel activity involved in SA node cell action potential;scaffold protein binding	PRMT5[23912080];CAMK2D[22514276];ZMYND19[unassigned1304];PRMT1[23912080];PRMT3[23912080];ANK3[19805355];SNTG2[12429735];RGS2[16169070];DLG1[24550280];ALB[15174051];TEKT4[unassigned1304];GPD1L[19666841];CALM1[11807557;21167176;16505387;22705208];ANKS1A[unassigned1304];FGF13[22705208];FGF12[22705208];EMC9[unassigned1304];PTPN3[16930557];BANP[unassigned1304];SNTA1[18591664];	38651442
4254	chr3	58109344	C	T	chr3:58109344	FLNB	filamin B	SNV	0/1	0.36	27_15	42	99	rs771276246,COSV55871171,COSV99911611	EXONIC	YES	NM_001164317.2	Transcript	protein_coding	synonymous_variant		21/47	NM_001164317.2:c.3651C>T	NP_001157789.1:p.Pro1217%3D		1.0		Likely_benign	criteria_provided,_single_submitter	not_provided	Larsen syndrome, 150250 (3), Autosomal dominant; Atelosteogenesis, type I, 108720 (3), Autosomal dominant; Atelosteogenesis, type III, 108721 (3), Autosomal dominant; Spondylocarpotarsal synostosis syndrome, 272460 (3), Autosomal recessive; Boomerang dysplasia, 112310 (3), Autosomal dominant	Boomerang dysplasia;Atelosteogenesis type I;Spondylocarpotarsal synostosis;Larsen syndrome;Atelosteogenesis type III	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Respiratory insufficiency;Flat face;Large joint dislocations;Conductive hearing impairment;Prominent forehead;Hypertelorism;Short nail;Joint hyperflexibility;Depressed nasal bridge;Craniosynostosis;Abnormality of epiphysis morphology;Cryptorchidism;Intellectual disability;Malar flattening;Laryngotracheomalacia;Broad distal phalanx of finger;Short distal phalanx of finger;Vertebral segmentation defect;Accessory carpal bones;Brachydactyly;Broad thumb;Abnormality of the cervical spine;Cleft palate;Abnormality of the cardiovascular system;Scoliosis;Short stature;Finger syndactyly;Wide nasal bridge;Hypoplastic iliac body;Absent radius;Fibular aplasia;Neonatal death;Severe short stature;Autosomal dominant inheritance;Hypoplastic nasal septum;Underdeveloped nasal alae;Patellar dislocation;Short tubular bones of the hand;Absent radius;Laryngotracheomalacia;Hand clenching;Abnormal cervical curvature;Thoracolumbar kyphosis;Ulnar deviation of the wrist;Thoracic hypoplasia;Fibular aplasia;Micrognathia;Hip dislocation;Elbow dislocation;Absent humerus;Global developmental delay;Epiphyseal stippling of the humerus;Distal tapering femur;Respiratory insufficiency;Club-shaped distal femur;Vertebral hypoplasia;Polyhydramnios;Talipes equinovarus;Coronal cleft vertebrae;High palate;Short tibia;Knee dislocation;Talipes equinovarus;Autosomal dominant inheritance;Cleft palate;Hitchhiker thumb;Tibial bowing;Scoliosis;Radial bowing;Widened distal phalanges;Hypoplasia of the maxilla;Flat acetabular roof;Micrognathia;Frontal bossing;Elbow dislocation;Horizontal sacrum;Cervical kyphosis;Malar flattening;Midface retrusion;Short neck;Cervical segmentation defect;Tombstone-shaped proximal phalanges;Sandal gap;Rhizomelia;Prominent occiput;Depressed nasal bridge;Knee dislocation;Pectus carinatum;Tracheomalacia;Depressed nasal bridge;Autosomal dominant inheritance;Intellectual disability;Flat face;Scoliosis;Aortic aneurysm;Multiple carpal ossification centers;Talipes equinovalgus;Talipes equinovarus;Ventricular septal defect;Spondylolysis;Knee dislocation;Shallow orbits;Hypertelorism;Short metatarsal;Short stature;Intrauterine growth retardation;Cleft palate;Short metacarpal;Cryptorchidism;Conductive hearing impairment;Cleft upper lip;Spinal cord compression;Beaking of vertebral bodies;Bipartite calcaneus;Prominent forehead;Hypoplastic cervical vertebrae;Malar flattening;Atrial septal defect;Frontal bossing;Hypodontia;Tracheal stenosis;Pectus excavatum;Cervical kyphosis;Accessory carpal bones;Dislocated wrist;Joint laxity;Spina bifida occulta;Bronchomalacia;Spatulate thumbs;Short nail;Corneal opacity;Hip dislocation;Elbow dislocation;Abnormality of fibula morphology;Neonatal short-trunk short stature;Abnormal ossification involving the femoral head and neck;Joint dislocation;Coronal cleft vertebrae;Cleft palate;Malrotation of colon;Multiple renal cysts;Short femur;Brachydactyly;Absent or minimally ossified vertebral bodies;Hypertelorism;Laryngotracheal stenosis;Telecanthus;Narrow chest;Enlarged cisterna magna;Talipes equinovarus;Retinal dysplasia;Micrognathia;Pulmonary hypoplasia;Midface retrusion;Abnormal pancreatic duct morphology;Polyhydramnios;Proptosis;Scoliosis;Low-set ears;Platyspondyly;Rhizomelia;Severe short-limb dwarfism;Abnormality of the metacarpal bones;Growth hormone deficiency;Abnormality of tibia morphology;Aplasia/Hypoplasia of the lungs;Narrow chest;Polyhydramnios;Micromelia;Abnormality of the ulna;Poorly ossified vertebrae;Aplasia/Hypoplasia of the fibula;Abnormality of femur morphology;Aplasia/Hypoplasia of the abdominal wall musculature;Cryptorchidism;Hydrops fetalis;Abnormality of the humerus;Finger syndactyly;Omphalocele;Abnormality of the radius;Broad nasal tip;Coxa vara;Brachydactyly;Clinodactyly of the 5th finger;Preauricular skin tag;Pectus carinatum;Inguinal hernia;Frontal bossing;Short neck;Scapular winging;Cataract;Epiphyseal dysplasia;Pes planus;Broad face;Mixed hearing impairment;Abnormality of pelvic girdle bone morphology;Small foramen magnum;Bowed humerus;Restrictive ventilatory defect;Short nose;Carpal synostosis;Scoliosis;Hypoplasia of the odontoid process;Abnormality of retinal pigmentation;Talipes equinovarus;Tarsal synostosis;Platybasia;C2-C3 subluxation;Hypoplasia of dental enamel;Hypertelorism;Capitate-hamate fusion;Limited elbow extension;Sensorineural hearing impairment;Delayed skeletal maturation;Cleft palate;Disproportionate short-trunk short stature;Hyperlordosis;Failure of eruption of permanent teeth;Short metacarpal;Autosomal recessive inheritance;Renal cyst;Block vertebrae;Encephalocele;Depressed nasal bridge;Cleft palate;Laryngeal stenosis;Brachydactyly;Short femur;Short nose;Sporadic;Short metatarsal;Elbow dislocation;Aplasia/Hypoplasia of the ulna;Cryptorchidism;Premature birth;Autosomal dominant inheritance;Polyhydramnios;Fused cervical vertebrae;Thoracic platyspondyly;Distal tapering femur;Short metacarpal;Radial bowing;Clubbing;Coronal cleft vertebrae;11 pairs of ribs;Stillbirth;Malar flattening;Talipes equinovarus;Club-shaped proximal femur;Narrow chest;Fibular aplasia;Frontal bossing;Rhizomelia;Multinucleated giant chondrocytes in epiphyseal cartilage;Proptosis;Tibial bowing;Short humerus;Neonatal death;Micrognathia;Midface retrusion;Short neck		9.22254e-05	14.0	151802.0	0.0	30	0.89	PASS	afr	0.000145363	6.0	0.000117716	8.0	8.94316e-05	22.0	245998.0	0.0	68	0.96	PASS	nfe	0.000146164	16.0	0.000146164	16.0	0.0000772	12			0.00035	4		0.065	-0.541082		0	0	0			FLNB	0.0	0.0	0.0	0.0	-7.0	13.0	-31.0	12.0						0.00269	0.0	37.033812567			growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype ; respiratory system phenotype; mortality/aging ; cardiovascular system phenotype ; nervous system phenotype ; limbs/digits/tail phenotype; skeleton phenotype; 			lung;dorsal root ganglion;superior cervical ganglion;placenta;skeletal muscle;	MAPK signaling pathway;Focal adhesion	keratinocyte development;epithelial cell morphogenesis;cytoskeletal anchoring at plasma membrane;signal transduction;skeletal muscle tissue development;actin cytoskeleton organization;cellular response to interferon-gamma	stress fiber;cytoplasm;cytosol;plasma membrane;brush border;focal adhesion;cell cortex;actin cytoskeleton;integral component of membrane;Z disc;phagocytic vesicle;extracellular exosome	RNA binding;actin binding;protein binding;identical protein binding;cadherin binding	RALA[26496610];CAMK2D[29426014];PSEN2[9437013];HSPB1[25277244];UBE2L6[19270716];PSEN1[9437013];PIK3R1[17474147];IQGAP1[26496610];PPP1CB[26496610];LIMA1[26496610];MAPK8[19270716];MAP1LC3B[20562859];TUBA1A[27291054];TUBB3[27291054];G3BP1[19615732];MYO18A[26496610];FLNA[12393796;26496610];FLNB[12393796];PLCG1[17474147];RAC1[19270716];SYNPO[26496610];MAP3K4[19270716];NCK1[17474147];ATF7IP[15231748];GABARAPL1[20562859];MAP3K1[19270716];MYBPC2[23414517];VCAM1[22623428;19738201];SMURF2[15231748];KSR1[27086506];FN1[19738201];ISG15[19270716];MLH1[20706999];ESR1[21182205];MYO19[26496610];ESR2[21182203];ANLN[26496610];CAPZA2[26496610];MYH9[26496610];GRB2[12577067;17474147];PLEKHO1[18624398];CD247[24502978];CRK[17474147];OTUD1[19615732];DBN1[26496610];ITGB3BP[26496610];BCAR1[28007913];	58109344
4271	chr3	87313507	T	C	chr3:87313507	POU1F1	POU class 1 homeobox 1	SNV	0/1	0.19	22_5	27	74	rs143373007	EXONIC	YES	NM_001122757.3	Transcript	protein_coding	missense_variant		3/6	NM_001122757.3:c.448A>G	NP_001116229.1:p.Met150Val		-1.0	POU-specific domain&POU-specific domain,.,POU-specific domain	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Pituitary_hormone_deficiency,_combined,_1|not_specified|Combined_Pituitary_Hormone_Deficiency,_Recessive|not_provided	Pituitary hormone deficiency, combined or isolated, 1, 613038 (3), Autosomal recessive, Autosomal dominant	Hypothyroidism due to deficient transcription factors involved in pituitary development or function;Isolated growth hormone deficiency type II;Combined pituitary hormone deficiencies, genetic forms	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in	Deeply set eye;Short stature;Autosomal dominant inheritance;Autosomal recessive inheritance;Jaundice;Delayed cranial suture closure;Anteverted nares;Prominent forehead;Muscular hypotonia;Hypothyroidism;Severe postnatal growth retardation;Midface retrusion;Generalized hypotonia;Prolonged neonatal jaundice;Depressed nasal bridge;Macroglossia;Malar flattening;Intellectual disability;Frontal bossing;Short nose;Intellectual disability;Global developmental delay;Jaundice;Large fontanelles;Muscular hypotonia;Septo-optic dysplasia;Sleep disturbance;Coarse facial features;Oral cleft;Umbilical hernia;Central hypothyroidism;Constipation;Fatigue;Short stature;Abnormality of the hypothalamus-pituitary axis;Abdominal distention;Feeding difficulties;Aplasia/Hypoplasia of the breasts;Abnormal prolactin level;Hypoglycemia;Abnormality of secondary sexual hair;Pituitary dwarfism;Anterior pituitary agenesis;Pituitary hypothyroidism;Septo-optic dysplasia;Osteopenia;Decreased circulating ACTH level;Anterior pituitary hypoplasia;Holoprosencephaly;Amenorrhea;Fatigue;Ectopic anterior pituitary gland;Agenesis of corpus callosum;Polydactyly;Severe global developmental delay;Ectopic posterior pituitary;Delayed skeletal maturation;Delayed puberty;Decreased cervical spine mobility;Osteoporosis of vertebrae;Constipation;Absence of secondary sex characteristics;Median cleft lip and palate;Hypogonadotropic hypogonadism;Infertility;Decreased testicular size;Hypotension;Depressed nasal ridge;Seizure		0.00180111	274.0	152128.0	1.0	32	0.96	PASS	nfe	0.00249934	170.0	0.00249934	170.0	0.00197385	496.0	251286.0	0.0	89	1.0	PASS	nfe	0.00253512	288.0	0.00253512	288.0	0.0016977	264	0.002	5.0	0.00307	35		15.79	1.414273	0.23	5	14	19	LRT_pred,MutationTaster_pred,FATHMM_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	POU1F1	0.0	0.0	0.01	0.0	42.0	-50.0	-50.0	27.0						0.231	0.62	0.000000000	0.992	0.173	hematopoietic system phenotype; mortality/aging ; reproductive system phenotype; pigmentation phenotype; immune system phenotype; skeleton phenotype; nervous system phenotype ; hearing/vestibular/ear phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; 			pituitary;superior cervical ganglion;	.	negative regulation of transcription by RNA polymerase II;cell fate specification;regulation of transcription, DNA-templated;transcription by RNA polymerase II;positive regulation of cell population proliferation;negative regulation of cell population proliferation;determination of adult lifespan;B cell differentiation;positive regulation of inositol trisphosphate biosynthetic process;positive regulation of multicellular organism growth;regulation of insulin-like growth factor receptor signaling pathway;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;somatotropin secreting cell development	chromatin;nucleus;transcription factor complex	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;RNA polymerase II transcription factor binding;RNA polymerase II activating transcription factor binding;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;DNA-binding transcription factor activity	ARSA[unassigned1304];UBE2I[unassigned1304];MSX2[unassigned1304];KRTAP15-1[unassigned1304];KRTAP10-8[unassigned1304];ARID5A[unassigned1304];ETS1[9032233];LASP1[unassigned1304];FAM171A2[unassigned1304];OPA1[30021884];KIF5B[26496610];KRTAP6-1[unassigned1304];LHX4[unassigned1304];RAD54L2[unassigned1304];	87313507
4295	chr3	122056493	A	C	chr3:122056493	CSTA	cystatin A	SNV	0/1	0.21	15_4	19	53		SPLICING	YES	NM_005213.4	Transcript	protein_coding	missense_variant,splice_region_variant		2/3	NM_005213.4:c.166A>C	NP_005204.1:p.Lys56Gln		1.0	Cystatin domain&Proteinase inhibitor I25, cystatin, conserved site&Cystatin domain&Cystatin domain,Cystatin domain&Proteinase inhibitor I25, cystatin, conserved site&Cystatin domain&Cystatin domain				Peeling skin syndrome 4, 607936 (3), Autosomal recessive	Acral peeling skin syndrome;Exfoliative ichthyosis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in	Eczema;Ichthyosis;Scaling skin;Excessive wrinkling of palmar skin;High hypermetropia;Skin erosion;Allergy;Abnormal blistering of the skin;Macule;Papule;Hyperpigmentation of the skin;Erythema;Scaling skin;Nail dystrophy;Autosomal recessive inheritance;Orthokeratosis;Epidermal acanthosis;Lichenification;Ichthyosis;Palmoplantar keratoderma						32	0.97											78	0.99											9e-05	1		28.7	4.112785	0.745	13	7	20	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	CSTA	0.0	0.0	0.0	0.0	3.0	2.0	5.0	37.0	0.593031470615616	0.554	5.939	0.18	6.118	0.764	0.0	71.092525027	1.0	1.312	.			lung;tonsil;tongue;skin;whole blood;	.	negative regulation of peptidase activity;negative regulation of endopeptidase activity;peptide cross-linking;keratinocyte differentiation;negative regulation of proteolysis;cornification;cell-cell adhesion	cornified envelope;extracellular space;nucleus;cytoplasm;cytosol	protease binding;cysteine-type endopeptidase inhibitor activity;structural molecule activity;protein binding, bridging	GABARAPL2[20562859];USP53[19615732];WTAP[29507755];CD81[26212323];EHMT2[27705803];METTL3[29507755];ZNF518A[27705803];RASSF9[24366813];PTN[16169070];ZDHHC17[24705354];EGFR[24189400];SENP7[27705803];FOXR1[25609649];MAP1LC3B[20562859];RASSF10[24366813];OGT[27705803];CTSB[20860624];	122056493
4372	chr3	186450326	G	A	chr3:186450326	KNG1	kininogen 1	SNV	0/1	0.3	16_7	23	99	rs145150298,COSV99405849	EXONIC	YES	NM_001102416.3	Transcript	protein_coding	missense_variant		7/10	NM_001102416.3:c.793G>A	NP_001095886.1:p.Val265Met		1.0	.,Cystatin domain,.,.,Cystatin domain				[Kininogen deficiency], 228960 (3), Autosomal recessive; Angioedema, hereditary, 6, 619363 (3), Autosomal dominant; [High molecular weight kininogen deficiency], 228960 (3), Autosomal recessive	Congenital high-molecular-weight kininogen deficiency	Disease-causing germline mutation(s) in	.		0.000394384	60.0	152136.0	1.0	32	0.96	PASS	amr	0.00288373	44.0	8.81964e-05	6.0	0.000119337	30.0	251388.0	0.0	99	1.0	PASS	amr	0.000520412	18.0	5.27807e-05	6.0	0.0001286	20	0.001	3.0	0.00062	7		0.033	-0.632125	0.073	2	18	20	Polyphen2_HDIV_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred	KNG1	0.0	0.01	0.0	0.0	14.0	-35.0	-35.0	-6.0						0.92	0.0	0.000000000	0.003	-0.829	growth/size/body region phenotype; 			kidney;liver;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;fetal liver;fetal lung;skeletal muscle;	Complement and coagulation cascades	platelet degranulation;inflammatory response;negative regulation of cell adhesion;G protein-coupled receptor signaling pathway;positive regulation of cytosolic calcium ion concentration;blood coagulation, intrinsic pathway;negative regulation of endopeptidase activity;negative regulation of blood coagulation;vasodilation;positive regulation of apoptotic process;post-translational protein modification;cellular protein metabolic process;negative regulation of proteolysis	extracellular region;extracellular space;endoplasmic reticulum lumen;plasma membrane;platelet alpha granule lumen;collagen-containing extracellular matrix;extracellular exosome;blood microparticle	cysteine-type endopeptidase inhibitor activity;signaling receptor binding;protein binding;heparin binding;zinc ion binding	C1QBP[8710908];F12[8710908];BDKRB2[23597562];BDKRB1[23597562];FAM20C[22582013];KLKB1[17598838];	186450326
4406	chr3	189607152	C	A	chr3:189607152	TP63	tumor protein p63	SNV	0/1	0.38	8_5	13	99	rs148076109,COSV53216075,COSV53217531	EXONIC	YES	NM_003722.5	Transcript	protein_coding	missense_variant		12/14	NM_003722.5:c.1531C>A	NP_003713.3:p.Pro511Thr		1.0	.,.,.,.,.,.,.	Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Ectrodactyly,_ectodermal_dysplasia,_and_cleft_lip/palate_syndrome_3|Orofacial_cleft_8|not_specified|TP63-Related_Spectrum_Disorders|not_provided	Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), Autosomal dominant; Hay-Wells syndrome, 106260 (3), Autosomal dominant; Split-hand/foot malformation 4, 605289 (3), Autosomal dominant; Orofacial cleft 8, 618149 (3); Rapp-Hodgkin syndrome, 129400 (3), Autosomal dominant; ADULT syndrome, 103285 (3), Autosomal dominant; Limb-mammary syndrome, 603543 (3), Autosomal dominant	Isolated cleft lip;Cleft lip/palate;Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome;ADULT syndrome;Cleft lip and alveolus;EEC syndrome;Isolated split hand-split foot malformation;Limb-mammary syndrome;Bladder exstrophy	Major susceptibility factor in;Major susceptibility factor in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Major susceptibility factor in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Major susceptibility factor in	Decreased number of sweat glands;Progressive alopecia;Ptosis;Hypodontia;Sparse hair;Depressed nasal bridge;Narrow nose;Underdeveloped nasal alae;Cleft upper lip;Hearing impairment;Thin skin;Anhidrotic ectodermal dysplasia;Hypospadias;Small, conical teeth;Fine hair;Short stature;Absent lacrimal punctum;Narrow mouth;High forehead;Syndactyly;Hypoplastic labia majora;Bifid uvula;Hypohidrosis;Onychogryposis;Hypoplasia of the maxilla;Sparse hair;Velopharyngeal insufficiency;Recurrent otitis media;Pili canaliculi;Small nail;Autosomal dominant inheritance;Finger syndactyly;Abnormality of the voice;Protruding ear;Palmoplantar keratoderma;Hyperconvex fingernails;Coarse hair;Ventricular septal defect;Sparse eyelashes;Submucous cleft hard palate;Wide nasal bridge;Widely spaced teeth;Ankyloblepharon;Submucous cleft soft palate;Micrognathia;Abnormality of dental enamel;Absent lacrimal punctum;Conductive hearing impairment;Hypohidrosis;Delayed eruption of teeth;Generalized hyperpigmentation;Dystrophic toenail;Non-midline cleft lip;Supernumerary nipple;Sparse and thin eyebrow;Clinodactyly of the 5th finger;Conical tooth;Hypodontia;Dystrophic fingernails;Inguinal hernia;Recurrent urinary tract infections;Bowel incontinence;Hypoplasia of penis;Abnormality of the clitoris;Bladder exstrophy;Intestinal malrotation;Epispadias;Vesicoureteral reflux;Omphalocele;Umbilical hernia;Abnormality of the anus;Nasal speech;Peg-shaped maxillary lateral incisors;Conductive hearing impairment;Velopharyngeal insufficiency;Malnutrition;Abnormality of dental eruption;Abnormal number of permanent teeth;Poor suck;Delayed speech and language development;Bilateral cleft palate;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Recurrent otitis media;Unilateral cleft palate;Speech articulation difficulties;Palate fistula;Dental malocclusion;Agenesis of lateral incisor;Fair hair;Toe syndactyly;Hypoplastic nipples;Freckling;Cutaneous photosensitivity;Breast hypoplasia;Alopecia of scalp;Absent nipple;Dry skin;Nasolacrimal duct obstruction;Conjunctivitis;Oral cleft;Hypodontia;Split hand;Oligodontia;Ectodermal dysplasia;Thin skin;Dermal atrophy;Wide intermamillary distance;Adermatoglyphia;Microdontia;Sparse axillary hair;Sparse scalp hair;Premature loss of permanent teeth;Split foot;Eczema;Autosomal dominant inheritance;Nail pits;Sensorineural hearing impairment;Split hand;Absent hand;Finger syndactyly;Oligodactyly;Aniridia;Proximal placement of thumb;Photophobia;Xerostomia;Slow-growing hair;Hypohidrosis;Sparse and thin eyebrow;Entropion;Vesicoureteral reflux;Fine hair;Intellectual disability;Toe syndactyly;Generalized hypopigmentation;Split foot;Aplasia/Hypoplasia of the thumb;Finger syndactyly;Coarse hair;Keratitis;Microdontia;Short stature;Aplasia/Hypoplasia of the nipples;Taurodontia;Urethral atresia;Lacrimation abnormality;Carious teeth;External ear malformation;Aplasia/Hypoplasia of the skin;Cleft palate;Nail dystrophy;Nail pits;Blepharitis;Growth hormone deficiency;Renal hypoplasia/aplasia;Hypoplasia of the thymus;Split hand;Sensorineural hearing impairment;Reduced number of teeth;Thick eyebrow;Abnormality of dental enamel;Abnormality of the middle ear;Nevus;Hypospadias;Hyperkeratosis;Dry skin;Aplasia/Hypoplasia of the breasts;Corneal erosion;Hydronephrosis;Lymphoma;Choanal atresia;Protruding ear;Absent lacrimal punctum;Aplasia of the uterus;Psoriasiform dermatitis;Aplasia of the ovary;3-4 finger cutaneous syndactyly;Sparse eyebrow;Cleft hard palate;Dry skin;Malar flattening;Blepharitis;Breast aplasia;Alopecia;Absent nipple;Chronic irritative conjunctivitis;Hypoplastic nipples;Oligodactyly;Submucous cleft soft palate;Freckling;Toe syndactyly;Lacrimal duct atresia;Clinodactyly of the 5th finger;Cleft lip;Multiple cafe-au-lait spots;Bifid uvula;Nail dysplasia;Primary amenorrhea;Hypohidrosis;Hypodontia;Bilateral breast hypoplasia;Dysphagia;Abnormal nasal morphology;Disturbance of facial expression;Hypodontia;Lip pit;Abnormality of the nasal septum;Abnormal pattern of respiration;Impaired mastication;Abnormality of masticatory muscle;Nasal speech;Speech articulation difficulties;Melanocytic nevus;Hypoplastic nipples;Toenail dysplasia;Skin ulcer;Split foot;Dry skin;Abnormality of dental morphology;Absent nipple;Prominent nasal bridge;Nail pits;Sparse scalp hair;Fine hair;Wide nasal bridge;Freckling;Finger syndactyly;Thin skin;Fingernail dysplasia;Nasolacrimal duct obstruction;Alopecia;Breast hypoplasia;Toe syndactyly;Ventricular septal defect;Lacrimal duct atresia;Palmoplantar keratoderma;Anonychia;Wide nasal bridge;Selective tooth agenesis;Vaginal dryness;Cleft upper lip;2-3 toe syndactyly;Hypoplasia of the maxilla;Blepharitis;Autosomal dominant inheritance;Hyperpigmentation of the skin;Hyperconvex nail;Hypospadias;Cleft palate;Absent eyelashes;Oval face;Patent ductus arteriosus;Nail dystrophy;Conical tooth;Sparse body hair;Widely spaced teeth;Hypodontia;Atresia of the external auditory canal;Supernumerary nipple;Abnormality of the nervous system;Anhidrosis;Conjunctivitis;Sparse eyelashes;Conductive hearing impairment;Patchy alopecia;Micropenis;Ankyloblepharon;Triphalangeal thumb;Aplasia/Hypoplasia of metatarsal bones;Aplasia/Hypoplasia of the phalanges of the hand;Aplasia/Hypoplasia of the phalanges of the toes;Split hand;Aplasia/Hypoplasia involving the metacarpal bones;Autosomal dominant inheritance;Syndactyly;Ectrodactyly;Split foot;Sparse axillary hair;Ureterocele;Cleft upper lip;Ectodermal dysplasia;Hypogonadotropic hypogonadism;Blepharophimosis;Intellectual disability;Sparse scalp hair;Megacystis;Abnormality of the nasopharynx;Blepharitis;Hydronephrosis;Malar flattening;Split foot;Split hand;Transverse vaginal septum;Sparse eyelashes;Xerostomia;Hydroureter;Depressed nasal tip;Absence of Stensen duct;Bladder diverticulum;Microtia;Ectrodactyly;Hyperkeratosis;Hearing impairment;Dacryocystitis;Duplicated collecting system;Hypoplasia of the maxilla;Selective tooth agenesis;Sparse and thin eyebrow;Nail pits;Hypoplastic nipples;Cryptorchidism;Generalized hypopigmentation;Carious teeth;Choanal atresia;Fair hair;Cleft palate;Renal dysplasia;Blue irides;Nail dystrophy;Vesicoureteral reflux;Photophobia;Microdontia;Renal agenesis;Toe syndactyly;Micropenis;Autosomal dominant inheritance;Central diabetes insipidus;Urethral stenosis;Growth hormone deficiency;Sparse pubic hair;Conductive hearing impairment;Polyhydramnios;Umbilical hernia;Abnormality of the Eustachian tube;Situs inversus totalis;Speech articulation difficulties;Velopharyngeal insufficiency;Supernumerary maxillary incisor;Bilateral cleft lip;Chronic otitis media;Small for gestational age;Talipes equinovarus;Maternal teratogenic exposure;Low self esteem;Hypodontia;Specific learning disability;Macrodontia;Hypodontia;Hallux valgus;Bifid uvula;Syndactyly;Nail dysplasia;Hypohidrosis;Split hand;Joint contracture of the hand;Camptodactyly;Autosomal dominant inheritance;Split foot;Lacrimal duct atresia;Hypoplastic nipples		0.003036	462.0	152174.0	2.0	33	0.97	PASS	amr	0.00719707	110.0	0.00402716	274.0	0.00305965	769.0	251336.0	4.0	90	1.0	PASS	amr	0.00474153	164.0	0.00419747	477.0	0.0027716	431	0.016	54.0	0.01229	140		23.8	3.09871	0.323	14	7	21	PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred	TP63	0.03	0.0	0.0	0.0	-23.0	-1.0	38.0	-23.0						0.00668	0.98	0.000000000	1.0	1.026	immune system phenotype; renal/urinary system phenotype; skeleton phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; vision/eye phenotype; cardiovascular system phenotype ; reproductive system phenotype; normal phenotype; mortality/aging ; neoplasm; embryo phenotype; respiratory system phenotype; behavior/neurological phenotype ; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype ; taste/olfaction phenotype; endocrine/exocrine gland phenotype; 			ciliary ganglion;trachea;appendix;tongue;dorsal root ganglion;skin;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;	.	negative regulation of transcription by RNA polymerase II;replicative cell aging;skeletal system development;establishment of planar polarity;epithelial cell development;chromatin remodeling;apoptotic process;Notch signaling pathway;spermatogenesis;ectoderm and mesoderm interaction;cell population proliferation;proximal/distal pattern formation;multicellular organism aging;epidermal cell division;regulation of epidermal cell division;positive regulation of keratinocyte proliferation;keratinocyte differentiation;polarized epithelial cell differentiation;hair follicle morphogenesis;negative regulation of intracellular estrogen receptor signaling pathway;embryonic forelimb morphogenesis;embryonic hindlimb morphogenesis;post-anal tail morphogenesis;odontogenesis of dentin-containing tooth;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;regulation of apoptotic process;regulation of cysteine-type endopeptidase activity involved in apoptotic process;skin morphogenesis;negative regulation of keratinocyte differentiation;positive regulation of osteoblast differentiation;positive regulation of Notch signaling pathway;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;sympathetic nervous system development;female genitalia morphogenesis;protein homotetramerization;neuron apoptotic process;cloacal septation;prostatic bud formation;squamous basal epithelial stem cell differentiation involved in prostate gland acinus development;establishment of skin barrier;positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;regulation of signal transduction by p53 class mediator;positive regulation of somatic stem cell population maintenance;cranial skeletal system development;positive regulation of fibroblast apoptotic process;negative regulation of mesoderm development	nuclear chromatin;nucleus;nucleoplasm;cytoplasm;mitochondrion;rough endoplasmic reticulum;Golgi apparatus;cytosol;dendrite;protein-containing complex	DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;p53 binding;DNA binding;chromatin binding;damaged DNA binding;double-stranded DNA binding;DNA-binding transcription factor activity;protein binding;identical protein binding;sequence-specific DNA binding;transcription regulatory region DNA binding;metal ion binding;WW domain binding;MDM2/MDM4 family protein binding	HNRNPCL1[20085233];ORM1[21988832];PPP1R13B[14729977];HSP90AB1[20085233];RPL3[20085233];RPLP0[20085233];PINX1[21988832];HP[21988832];HNRNPR[20085233];CCNC[21988832];TUBA1C[20085233];SYNCRIP[20085233];GOLGA4[20085233];PPP1R13L[18275817];PSMD2[20085233];HIST1H1D[20085233];SACS[20085233];PLS3[20085233];UBASH3A[unassigned1304];KRT6C[20085233];TP63[20085233;21335238;19815500;21464285];UPF2[20085233];CAD[20085233];PRKCD[26112605];RPL13A[20085233];RPSA[20085233];KRT5[20085233];SAFB[20085233];EEF1A1[20085233];MAP1A[20085233];PELI1[unassigned1304];RPL24[20085233];ZNF676[20085233];TP53[19345189;21741598];SNRPA[20085233];YAP1[11278685];ITIH4[21988832];BECN1[19050071];VCP[20085233];DHX9[20085233];RPL12[20085233];SATB2[20829881];PELI2[unassigned1304];UACA[20085233];ZBTB4[20085233];MYL12A[20085233];BAG6[21988832];HPX[21988832];ATP5F1A[20085233];TP53BP2[18275817];CCT8[20085233];FLNC[20085233];S1PR5[20085233];A2M[20085233];SMAD2[19345189;21741598];HNRNPA3[20085233];CPSF6[20085233];SLC35A3[21988832];NIPSNAP3A[21988832];HSPA5[20085233];FUS[20085233];NONO[20085233];GCGR[21988832];MCRS1[unassigned1304];CABLES1[20559324];HNRNPAB[20085233];HIPK2[21602882];HNRNPL[20085233];CENPE[20085233];COPS6[21988832];ITCH[16908849];HNRNPK[20085233];CARM1[20085233];FASN[20085233];PIN1[21741598;unassigned1304];CEP83[26638075];SEC24C[20085233];TP73[19815500];	189607152
4493	chr4	5620310	G	A	chr4:5620310	EVC2	EvC ciliary complex subunit 2	SNV	0/1	0.36	43_24	67	99	rs116514447	EXONIC	YES	NM_147127.5	Transcript	protein_coding	synonymous_variant		15/22	NM_147127.5:c.2601C>T	NP_667338.3:p.Ala867%3D		-1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Curry-Hall_syndrome|Ellis-van_Creveld_syndrome|not_specified|not_provided	Ellis-van Creveld syndrome, 225500 (3), Autosomal recessive; Weyers acrofacial dysostosis, 193530 (3), Autosomal dominant	Ellis Van Creveld syndrome;Acrofacial dysostosis, Weyers type	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Neonatal short-limb short stature;Capitate-hamate fusion;Delayed skeletal maturation;Hypoplastic toenails;Abnormal morphology of female internal genitalia;Hand polydactyly;Aplasia/Hypoplasia of the lungs;Cubitus valgus;Hypospadias;Atrioventricular canal defect;Hydroureter;Strabismus;Emphysema;Abnormal oral frenulum morphology;Situs inversus totalis;Failure to thrive;Hypodontia;Atrial septal defect;Abnormal heart valve morphology;Delayed eruption of teeth;Acute leukemia;Intellectual disability;Synostosis of carpal bones;Abnormal hair quantity;Abnormal oral mucosa morphology;Abnormality of pelvic girdle bone morphology;Foot polydactyly;Cryptorchidism;Genu valgum;Thin vermilion border;Abnormality of bone marrow cell morphology;Short distal phalanx of finger;Narrow chest;Ventricular septal defect;Epispadias;Conical incisor;Intrauterine growth retardation;Microdontia;Micromelia;Abnormal fingernail morphology;Renal hypoplasia/aplasia;Short thorax;Nail dysplasia;Abnormal oral frenulum morphology;Small hand;Hypodontia;Abnormal fingernail morphology;Facial cleft;Abnormality of the antihelix;Overlapping fingers;Single median maxillary incisor;Clinodactyly of the 5th finger;Toenail dysplasia;Nail dystrophy;Advanced eruption of teeth;Mild short stature;Conical tooth;Hypoplastic toenails;Postaxial hand polydactyly;Atrial septal defect;Narrow chest;Genu valgum;Nail dysplasia;Epispadias;Postaxial hand polydactyly;Cleft upper lip;Hypodontia;Dandy-Walker malformation;Postaxial foot polydactyly;Abnormality of the alveolar ridges;Short long bone;Neonatal short-limb short stature;Cryptorchidism;Autosomal recessive inheritance;Ectodermal dysplasia;Hypoplastic iliac wing;Acetabular spurs;Horizontal ribs;Natal tooth;Pectus carinatum;Short ribs;Capitate-hamate fusion;Intellectual disability;Hypospadias;Common atrium;Talipes equinovarus;Cone-shaped epiphyses of phalanges 2 to 5;Delayed eruption of teeth;Autosomal dominant inheritance;Mild short stature;Postaxial hand polydactyly;Short palm;Single median maxillary incisor;Small nail;Conical tooth;Nail dysplasia;Brachydactyly;Postaxial foot polydactyly;Prominent antihelix;Clinodactyly of the 5th finger;Hypotelorism		0.00354228	539.0	152162.0	3.0	33	0.97	PASS	nfe	0.00618936	421.0	0.00618936	421.0	0.00387974	974.0	251048.0	4.0	100	0.97	PASS	nfe	0.00644752	732.0	0.00644752	732.0	0.0039227	610	0.009	29.0	0.00587	67		7.845	0.350848		0	0	0			EVC2	0.0	0.0	0.0	0.0	-10.0	-34.0	-10.0	39.0						0.947	0.0	5.505832032			cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; skeleton phenotype; limbs/digits/tail phenotype; mortality/aging ; normal phenotype; 			superior cervical ganglion;trigeminal ganglion;	.	smoothened signaling pathway	nucleus;cytoplasm;cytoskeleton;cilium;integral component of membrane;ciliary membrane;plasma membrane protein complex	.	LMBR1L[26638075];VEZT[26638075];ANKLE2[26638075];CCDC47[26638075];MAGT1[26638075];JPH1[26638075];GYS1[26638075];NUDCD3[26638075];NSDHL[26638075];GRM5[26638075];NUDCD2[26638075];SMPD4[26638075];CLCC1[26638075];UBXN4[26638075];EMD[26638075];LBR[26638075];SEC63[26638075];YWHAH[26638075];UNC45A[26638075];NDC1[26638075];ACTR2[26638075];NUDC[26638075];ATP6AP1[26638075];CAMLG[26638075];ATP6AP2[26638075];MOGS[26638075];CDKAL1[26638075];VRK2[26638075];ACSL3[26638075];FNDC3A[26638075];CKAP4[26638075];ALDH3A2[26638075];POR[26638075];SOAT1[26638075];STIM1[26638075];DNAJC7[26638075];TMX1[26638075];CDC37[26638075];RABL3[26638075];TRIM13[26638075];FKBP8[26638075];PREB[26638075];AHCY[26638075];RPN1[26638075];HSPBP1[26638075];PLD3[26638075];TOR1AIP1[26638075];UBE2J1[26638075];STIP1[26638075];SCFD1[26638075];PGRMC2[26638075];BAG2[26638075];DDRGK1[26638075];EMC2[26638075];ISOC1[26638075];STX5[26638075];THEM6[26638075];SEC11A[26638075];HMOX2[26638075];BCAP31[26638075];PTPN1[26638075];SEC24B[26638075];NUP155[26638075];SLC33A1[26638075];GLMN[26638075];CYP51A1[26638075];SMAD9[15231748];TTC1[26638075];MACO1[26638075];TMEM199[26638075];VANGL1[26638075];SPCS3[26638075];MLXIPL[26638075];SPCS2[26638075];DHRS7[26638075];VMA21[26638075];ST7[26638075];SRPRA[26638075];SRPRB[26638075];STUB1[26638075];ESYT1[26638075];STT3B[26638075];SUGT1[26638075];ACBD3[26638075];	5620310
4494	chr4	5627493	G	T	chr4:5627493	EVC2	EvC ciliary complex subunit 2	SNV	0/1	0.33	10_5	15	99	rs73198165,CM098965,COSV100186358,COSV60392438	EXONIC	YES	NM_147127.5	Transcript	protein_coding	synonymous_variant		13/22	NM_147127.5:c.2029C>A	NP_667338.3:p.Arg677%3D		-1.0		Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Curry-Hall_syndrome|Ellis-van_Creveld_syndrome|not_specified|not_provided	Ellis-van Creveld syndrome, 225500 (3), Autosomal recessive; Weyers acrofacial dysostosis, 193530 (3), Autosomal dominant	Ellis Van Creveld syndrome;Acrofacial dysostosis, Weyers type	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Neonatal short-limb short stature;Capitate-hamate fusion;Delayed skeletal maturation;Hypoplastic toenails;Abnormal morphology of female internal genitalia;Hand polydactyly;Aplasia/Hypoplasia of the lungs;Cubitus valgus;Hypospadias;Atrioventricular canal defect;Hydroureter;Strabismus;Emphysema;Abnormal oral frenulum morphology;Situs inversus totalis;Failure to thrive;Hypodontia;Atrial septal defect;Abnormal heart valve morphology;Delayed eruption of teeth;Acute leukemia;Intellectual disability;Synostosis of carpal bones;Abnormal hair quantity;Abnormal oral mucosa morphology;Abnormality of pelvic girdle bone morphology;Foot polydactyly;Cryptorchidism;Genu valgum;Thin vermilion border;Abnormality of bone marrow cell morphology;Short distal phalanx of finger;Narrow chest;Ventricular septal defect;Epispadias;Conical incisor;Intrauterine growth retardation;Microdontia;Micromelia;Abnormal fingernail morphology;Renal hypoplasia/aplasia;Short thorax;Nail dysplasia;Abnormal oral frenulum morphology;Small hand;Hypodontia;Abnormal fingernail morphology;Facial cleft;Abnormality of the antihelix;Overlapping fingers;Single median maxillary incisor;Clinodactyly of the 5th finger;Toenail dysplasia;Nail dystrophy;Advanced eruption of teeth;Mild short stature;Conical tooth;Hypoplastic toenails;Postaxial hand polydactyly;Atrial septal defect;Narrow chest;Genu valgum;Nail dysplasia;Epispadias;Postaxial hand polydactyly;Cleft upper lip;Hypodontia;Dandy-Walker malformation;Postaxial foot polydactyly;Abnormality of the alveolar ridges;Short long bone;Neonatal short-limb short stature;Cryptorchidism;Autosomal recessive inheritance;Ectodermal dysplasia;Hypoplastic iliac wing;Acetabular spurs;Horizontal ribs;Natal tooth;Pectus carinatum;Short ribs;Capitate-hamate fusion;Intellectual disability;Hypospadias;Common atrium;Talipes equinovarus;Cone-shaped epiphyses of phalanges 2 to 5;Delayed eruption of teeth;Autosomal dominant inheritance;Mild short stature;Postaxial hand polydactyly;Short palm;Single median maxillary incisor;Small nail;Conical tooth;Nail dysplasia;Brachydactyly;Postaxial foot polydactyly;Prominent antihelix;Clinodactyly of the 5th finger;Hypotelorism	25741868	0.00363581	553.0	152098.0	3.0	32	0.97	PASS	nfe	0.00636521	433.0	0.00636521	433.0	0.00393823	990.0	251382.0	4.0	89	1.0	PASS	nfe	0.0066058	751.0	0.0066058	751.0	0.0039613	616	0.009	30.0	0.00597	68		10.58	0.631966		0	0	0			EVC2	0.0	0.0	0.0	0.0	-26.0	1.0	-26.0	-17.0						0.947	0.0	0.000000000			cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; skeleton phenotype; limbs/digits/tail phenotype; mortality/aging ; normal phenotype; 			superior cervical ganglion;trigeminal ganglion;	.	smoothened signaling pathway	nucleus;cytoplasm;cytoskeleton;cilium;integral component of membrane;ciliary membrane;plasma membrane protein complex	.	LMBR1L[26638075];VEZT[26638075];ANKLE2[26638075];CCDC47[26638075];MAGT1[26638075];JPH1[26638075];GYS1[26638075];NUDCD3[26638075];NSDHL[26638075];GRM5[26638075];NUDCD2[26638075];SMPD4[26638075];CLCC1[26638075];UBXN4[26638075];EMD[26638075];LBR[26638075];SEC63[26638075];YWHAH[26638075];UNC45A[26638075];NDC1[26638075];ACTR2[26638075];NUDC[26638075];ATP6AP1[26638075];CAMLG[26638075];ATP6AP2[26638075];MOGS[26638075];CDKAL1[26638075];VRK2[26638075];ACSL3[26638075];FNDC3A[26638075];CKAP4[26638075];ALDH3A2[26638075];POR[26638075];SOAT1[26638075];STIM1[26638075];DNAJC7[26638075];TMX1[26638075];CDC37[26638075];RABL3[26638075];TRIM13[26638075];FKBP8[26638075];PREB[26638075];AHCY[26638075];RPN1[26638075];HSPBP1[26638075];PLD3[26638075];TOR1AIP1[26638075];UBE2J1[26638075];STIP1[26638075];SCFD1[26638075];PGRMC2[26638075];BAG2[26638075];DDRGK1[26638075];EMC2[26638075];ISOC1[26638075];STX5[26638075];THEM6[26638075];SEC11A[26638075];HMOX2[26638075];BCAP31[26638075];PTPN1[26638075];SEC24B[26638075];NUP155[26638075];SLC33A1[26638075];GLMN[26638075];CYP51A1[26638075];SMAD9[15231748];TTC1[26638075];MACO1[26638075];TMEM199[26638075];VANGL1[26638075];SPCS3[26638075];MLXIPL[26638075];SPCS2[26638075];DHRS7[26638075];VMA21[26638075];ST7[26638075];SRPRA[26638075];SRPRB[26638075];STUB1[26638075];ESYT1[26638075];STT3B[26638075];SUGT1[26638075];ACBD3[26638075];	5627493
4499	chr4	6302689	T	G	chr4:6302689	WFS1	wolframin ER transmembrane glycoprotein	SNV	0/1	0.47	31_28	59	99	rs201282601	EXONIC	YES	NM_006005.3	Transcript	protein_coding	missense_variant		8/8	NM_006005.3:c.1167T>G	NP_005996.2:p.Asp389Glu		1.0	.,.	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Type_II_diabetes_mellitus|Cataract_41|Wolfram_syndrome_1|Autosomal_dominant_nonsyndromic_hearing_loss_6|Wolfram-like_syndrome,_autosomal_dominant|not_provided	Deafness, autosomal dominant 6/14/38, 600965 (3), Autosomal dominant; ?Cataract 41, 116400 (3), Autosomal dominant; Wolfram-like syndrome, autosomal dominant, 614296 (3), Autosomal dominant; {Diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), Autosomal dominant; Wolfram syndrome 1, 222300 (3), Autosomal recessive	Wolfram syndrome;Wolfram-like syndrome;Autosomal dominant non-syndromic sensorineural deafness type DFNA;Early-onset nuclear cataract	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Optic atrophy;Depressivity;Autistic behavior;Progressive cerebellar ataxia;Abnormality of the upper urinary tract;Male hypogonadism;Abnormality of the pinna;Dementia;Central diabetes insipidus;Gastrointestinal dysmotility;Psychosis;Glaucoma;Diabetes mellitus;Peripheral axonal neuropathy;Hypothyroidism;Congenital sensorineural hearing impairment;Severe postnatal growth retardation;Delayed puberty;Primary gonadal insufficiency;Anxiety;Respiratory insufficiency;Developmental cataract;Nuclear cataract;Autosomal dominant inheritance;Glaucoma;Diabetes mellitus;Depressivity;Optic atrophy;Impaired glucose tolerance;Autosomal dominant inheritance;Schizophrenia;Psychosis;Autism;Hearing impairment;Hallucinations;Anxiety;Joint stiffness;Cerebral cortical atrophy;Gastric ulcer;Central apnea;Seizure;Feeding difficulties in infancy;Glaucoma;Dysarthria;Constipation;Hallucinations;Peripheral neuropathy;Dementia;Dysuria;Nystagmus;Respiratory insufficiency;Abnormality of mesentery morphology;Intellectual disability;Anemia;Abnormal autonomic nervous system physiology;Cardiomyopathy;Polydipsia;Diabetes mellitus;Nephropathy;Sensorineural hearing impairment;Malabsorption;Sleep disturbance;Ataxia;Delayed puberty;Myopathy;Male hypogonadism;Recurrent urinary tract infections;Ophthalmoplegia;Diabetes insipidus;Developmental regression;Gastrointestinal hemorrhage;Optic atrophy;Nystagmus;Tremor;Hydronephrosis;Diabetes insipidus;Growth delay;Hypothyroidism;Behavioral abnormality;Sensorineural hearing impairment;Pigmentary retinopathy;Testicular atrophy;Thrombocytopenia;Intellectual disability;Dysphagia;Hydroureter;Ptosis;Diabetes mellitus;Megaloblastic anemia;Sideroblastic anemia;Neurogenic bladder;Cerebral atrophy;Autosomal recessive inheritance;Optic atrophy;Dysarthria;Seizure;Stroke-like episode;Limited mobility of proximal interphalangeal joint;Ataxia;Cardiomyopathy;Type II diabetes mellitus;Increased waist to hip ratio;Insulin resistance;Autosomal dominant inheritance;Late onset;Autosomal dominant inheritance;Low-frequency sensorineural hearing impairment;Progressive sensorineural hearing impairment		6.57333e-05	10.0	152130.0	0.0	33	0.94	PASS	amr	0.000458415	7.0	2.9404e-05	2.0	0.000107364	27.0	251482.0	0.0	100	1.0	PASS	amr	0.000491557	17.0	5.27408e-05	6.0	0.0001029	16	0.0	1.0	0.00053	6		22.3	2.382126	0.322	14	7	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,FATHMM_pred,MetaRNN_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred	Polyphen2_HVAR_pred,PROVEAN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred,fathmm-XF_coding_pred	WFS1	0.0	0.0	0.0	0.0	1.0	10.0	0.0	15.0						0.00682		0.000000000	0.998	-0.256	behavior/neurological phenotype ; mortality/aging ; digestive/alimentary phenotype; integument phenotype ; growth/size/body region phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; 			dorsal root ganglion;trigeminal ganglion;superior cervical ganglion;atrioventricular node;testis;	.	negative regulation of transcription by RNA polymerase II;kidney development;renal water homeostasis;ER overload response;visual perception;sensory perception of sound;protein maturation by protein folding;ubiquitin-dependent ERAD pathway;pancreas development;positive regulation of protein ubiquitination;endoplasmic reticulum calcium ion homeostasis;response to endoplasmic reticulum stress;IRE1-mediated unfolded protein response;olfactory behavior;glucose homeostasis;negative regulation of programmed cell death;negative regulation of DNA-binding transcription factor activity;negative regulation of neuron apoptotic process;post-translational protein modification;cellular protein metabolic process;positive regulation of growth;protein stabilization;nervous system process;positive regulation of protein metabolic process;positive regulation of calcium ion transport;calcium ion homeostasis;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;negative regulation of ATF6-mediated unfolded protein response;negative regulation of type B pancreatic cell apoptotic process	proteasome complex;endoplasmic reticulum;endoplasmic reticulum lumen;endoplasmic reticulum membrane;integral component of endoplasmic reticulum membrane;integral component of synaptic vesicle membrane;dendrite	protein binding;calmodulin binding;ubiquitin protein ligase binding;activating transcription factor binding;calcium-dependent protein binding;ATPase binding	CD79A[unassigned1304];TUSC5[unassigned1304];LTB4R2[28298427];TCTN3[26638075];AQP6[unassigned1304];F2RL1[28298427];FAM209A[unassigned1304];MAPK6[21900206];TERF1[21044950];DRD2[28298427];ITGB3BP[16169070];CFTR[17110338];	6302689
4515	chr4	71347407	A	G	chr4:71347407	MUC7	mucin 7, secreted	SNV	0/1	0.42	18_13	31	99	rs147182531	EXONIC	YES	NM_001145006.2	Transcript	protein_coding	missense_variant		4/4	NM_001145006.2:c.946A>G	NP_001138478.1:p.Thr316Ala		1.0	.,.,.				{Asthma, protection against}, 600807 (3), Autosomal dominant	.	.	Autosomal dominant inheritance;Multifactorial inheritance;Asthma		0.00126872	193.0	152122.0	0.0	32	0.96	PASS	afr	0.00391153	162.0	0.000132302	9.0	0.000457865	115.0	251166.0	1.0	100	1.0	PASS	afr	0.00399951	65.0	0.00022007	25.0	0.0005530	86	0.001	3.0	0.00123	14		0.001	-1.296844	0.035	0	18	18		SIFT,PolyPhen,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MUC7	0.01	0.0	0.0	0.0	1.0	34.0	1.0	-34.0						0.927	0.0	0.000000000	0.0	-0.299	.			salivary gland;trachea;thyroid;liver;superior cervical ganglion;prostate;	.	stimulatory C-type lectin receptor signaling pathway;O-glycan processing;killing of cells of other organism;antimicrobial humoral immune response mediated by antimicrobial peptide	Golgi lumen;plasma membrane;other organism cell membrane;extracellular exosome;other organism cytoplasm	protein binding	PRDX3[16203048];HTN3[16203048];PRR4[16203048];LAMA5[16203048];SMR3B[16203048];AMY1A[16203048];PCGF1[27107012];STATH[16203048];PRH1[16203048];HTN1[16203048];PFN2[16203048];	71347407
4594	chr4	153268228	AA		chr4:153268228-153268229	FBXW7	F-box and WD repeat domain containing 7	deletion	0/1	0.6	2_3	5	31	rs745908066	SPLICING	YES	NM_001349798.2	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	5/13		NM_001349798.2:c.585-6_585-5del			-1.0						.	.	.		0.000406785	20.0	49166.0	0.0	32	0.9	PASS	afr	0.000555467	7.0	0.00013272	3.0	0.0264913	2630.0	99278.0	0.0	27	0.69	InbreedingCoeff	amr	0.0343187	404.0	0.0253127	1202.0	0.0171764,0.0000064	2671,1			0.04453	496		1.533	-0.086908		0	0	0			FBXW7	0.0	0.0	0.0	0.0	-4.0	-30.0	-12.0	4.0						0.0563	1.0				cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; integument phenotype ; growth/size/body region phenotype; embryo phenotype; immune system phenotype; vision/eye phenotype; nervous system phenotype ; digestive/alimentary phenotype; neoplasm; mortality/aging ; normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; respiratory system phenotype; liver/biliary system phenotype; 			pons;temporal lobe;amygdala;occipital lobe;prefrontal cortex;subthalamic nucleus;cingulate cortex;trigeminal ganglion;parietal lobe;globus pallidus;medulla oblongata;	Neurodegenerative Diseases;Ubiquitin mediated proteolysis	protein polyubiquitination;vasculogenesis;vasculature development;sister chromatid cohesion;Notch signaling pathway;negative regulation of gene expression;negative regulation of triglyceride biosynthetic process;regulation of lipid storage;ubiquitin recycling;viral process;protein ubiquitination;lung development;SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;positive regulation of protein ubiquitination;protein destabilization;negative regulation of DNA endoreduplication;regulation of protein localization;proteasome-mediated ubiquitin-dependent protein catabolic process;post-translational protein modification;positive regulation of epidermal growth factor-activated receptor activity;negative regulation of Notch signaling pathway;protein stabilization;positive regulation of ubiquitin-protein transferase activity;lipid homeostasis;positive regulation of ERK1 and ERK2 cascade;regulation of cell migration involved in sprouting angiogenesis;positive regulation of proteasomal protein catabolic process;regulation of cell cycle G1/S phase transition;negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding;regulation of autophagy of mitochondrion;positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway;positive regulation of protein targeting to mitochondrion;positive regulation of ubiquitin-dependent protein catabolic process;negative regulation of hepatocyte proliferation;negative regulation of SREBP signaling pathway;negative regulation of osteoclast development	nucleus;nucleoplasm;nucleolus;cytoplasm;mitochondrion;endoplasmic reticulum;Golgi apparatus;cytosol;SCF ubiquitin ligase complex;perinuclear region of cytoplasm;Parkin-FBXW7-Cul1 ubiquitin ligase complex	ubiquitin-protein transferase activity;protein binding;cyclin binding;protein binding, bridging;ubiquitin protein ligase binding;identical protein binding;ubiquitin binding;phosphothreonine residue binding;ubiquitin-protein transferase activator activity	HEMGN[24412244];GALNT12[24412244];HSP90AB1[22939624];STOML1[23082202];BEX1[25640309];NOTCH1[23022380;17909182;20823234;25344755];ARL6IP1[16169070];SHC1[24412244];IL24[25640309];CUL1[14603323;23108047];XPA[24412244];PPP3R2[24412244];NUDCD2[25036637];MYC[17157259;17314511;23791182];DVL1[24412244];AKT1[24412244];TRIM25[25640309];SEC61B[24412244];NANS[24412244];HRAS[24412244];SKP1[15070733;21620836;22632967;23791182;19412162;20596027];TMOD1[24412244];LINGO1[16169070];SMAD1[24412244];BCAS3[25640309];SHPRH[16169070];MAP2K1[24412244];TGFB1[24412244];FBXW7[21620836;23791182];IGFBP3[24412244];WDR97[16169070];FANCC[24412244];SUMF2[16169070];NFKB2[14743216];MMS22L[16169070];MYCN[19111882];MAPKAPK3[24412244];CCNE1[11533444];CDK2[23082202];MDM2[20708156];CCDC6[23108047];SCGB3A1[25640309];EIF3E[20890303];ANP32B[24412244];ANGPTL4[25640309];FBP1[24412244];ZNF510[24412244];FBP2[24412244];	153268227
4636	chr5	10973700	G	A	chr5:10973700	CTNND2	catenin delta 2	SNV	0/1	0.33	44_22	66	99	rs549060878	EXONIC	YES	NM_001332.4	Transcript	protein_coding	synonymous_variant		22/22	NM_001332.4:c.3543C>T	NP_001323.1:p.Pro1181%3D		-1.0						Monosomy 5p;Benign adult familial myoclonic epilepsy	Role in the phenotype of;Disease-causing germline mutation(s) in	Intellectual disability, severe;Microcephaly;Hypertelorism;Muscular hypotonia;Epicanthus;Severe global developmental delay;Finger syndactyly;Preauricular skin tag;Scoliosis;Cat cry;Low-set, posteriorly rotated ears;Short stature;High palate;High pitched voice;Abnormality of bone mineral density;Microretrognathia;Round face;Wide nasal bridge;Inguinal hernia;Joint hyperflexibility;Short neck;Downslanted palpebral fissures;Intrauterine growth retardation;Small hand;Recurrent fractures;Abnormality of cardiovascular system morphology;EEG abnormality;Amaurosis fugax;Hand tremor;Focal-onset seizure;Intellectual disability;Headache;Generalized-onset seizure;Myoclonus		7.22838e-05	11.0	152178.0	0.0	33	0.97	PASS	amr	0.000261849	4.0	5.87976e-05	4.0	6.77917e-05	17.0	250768.0	0.0	52	0.99	PASS	amr	0.000231307	8.0	5.30607e-05	6.0	0.0000322	5	0.001	2.0	0.00073	7		8.878	0.446006		0	0	0			CTNND2	0.0	0.0	0.0	0.0	17.0	-6.0	-4.0	18.0						0.00475	1.0	33.326885890			behavior/neurological phenotype ; nervous system phenotype ; 			caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;cerebellum peduncles;cerebellum;pons;occipital lobe;fetal brain;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;hypothalamus;medulla oblongata;thalamus;	.	cell-cell junction assembly;cell adhesion;signal transduction;Wnt signaling pathway;synapse organization;regulation of canonical Wnt signaling pathway;dendritic spine morphogenesis;cell-cell adhesion	nucleus;cytoplasm;plasma membrane;cell-cell junction;cell-cell adherens junction;postsynaptic density;dendrite;perikaryon	protein binding;beta-catenin binding;cadherin binding	PTGER4[28298427];NUDT21[21900206];DLG1[24550280;30126976];TTR[21900206];LRRC7[24550280];DLG4[30126976];ERBIN[24550280];SCRIB[24550280;30126976];	10973700
4646	chr5	35641648	G	A	chr5:35641648	SPEF2	sperm flagellar 2	SNV	0/1	0.52	16_17	33	99	rs149043842	EXONIC	YES	NM_024867.4	Transcript	protein_coding	missense_variant		3/37	NM_024867.4:c.277G>A	NP_079143.3:p.Ala93Thr		1.0	.,CH-like domain in sperm protein&Calponin homology domain,CH-like domain in sperm protein&Calponin homology domain,CH-like domain in sperm protein&Calponin homology domain,CH-like domain in sperm protein&Calponin homology domain,.				Spermatogenic failure 43, 618751 (3), Autosomal recessive	.	.	Hydrocephalus;Pectus excavatum;Chronic otitis media;Tachypnea;Impaired nasal mucociliary clearance;Delayed speech and language development;Asthma;Atelectasis;Headache;Ectopic pregnancy;Nasal polyposis;Clubbing of fingers;Pulmonary obstruction;Asplenia;Scoliosis;Reduced sperm motility;Respiratory distress;Immotile cilia;Chronic sinusitis;Infertility;Chronic bronchitis;Corneal dystrophy;Glue ear;Pneumonia;Spontaneous abortion;Conductive hearing impairment;Recurrent respiratory infections;Situs inversus totalis;Cough;Bronchiectasis;Ventriculomegaly;Rhinitis;Halitosis		0.00063128	96.0	152072.0	0.0	32	0.95	PASS	eas	0.00212355	11.0	0.000441138	30.0	0.000768416	193.0	251166.0	0.0	72	1.0	PASS	eas	0.00103306	19.0	0.000501911	57.0	0.0007460	116			0.00031	3		26.9	3.89265	0.53	13	8	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	MetaLR_pred,MetaSVM_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred	SPEF2	0.01	0.03	0.0	0.0	-48.0	39.0	-4.0	39.0						0.972	0.0	0.000000000	0.998	1.155	reproductive system phenotype; mortality/aging ; respiratory system phenotype; immune system phenotype; skeleton phenotype; nervous system phenotype ; craniofacial phenotype; cellular phenotype; 			ciliary ganglion;dorsal root ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;parietal lobe;globus pallidus;	.	spermatogenesis;cell differentiation	Golgi apparatus	.	HIST1H2BM[30021884];KATNAL1[26929214];APOA1[15174051];MYH9[30021884];VIM[30021884];IGHA1[15174051];	35641648
4648	chr5	41149448	C	T	chr5:41149448	C6	complement C6	SNV	0/1	0.24	28_9	37	99	rs142836385,COSV54711940	EXONIC	YES	NM_001115131.4	Transcript	protein_coding	missense_variant		17/18	NM_001115131.4:c.2518G>A	NP_001108603.2:p.Gly840Ser		-1.0	.,.	Benign	criteria_provided,_single_submitter	not_provided	C6 deficiency, 612446 (3); Combined C6/C7 deficiency (3)	Immunodeficiency due to a late component of complement deficiency	Disease-causing germline mutation(s) in	Complement deficiency;Autosomal recessive inheritance;Recurrent meningococcal disease		0.00274801	418.0	152110.0	2.0	32	0.97	PASS	nfe	0.00307145	209.0	0.00307145	209.0	0.00277242	696.0	251044.0	4.0	100	1.0	PASS	nfe	0.00268068	304.0	0.00268068	304.0	0.0024565	382	0.005	17.0	0.0057	65		18.13	1.790668	0.046	2	16	18	MutationAssessor_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred	C6	0.19	0.07	0.0	0.0	-2.0	2.0	-2.0	2.0						0.273	0.0	0.000000000	0.279	1.026	homeostasis/metabolism phenotype; cardiovascular system phenotype ; 			liver;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;fetal liver;	Complement and coagulation cascades;Systemic lupus erythematosus	in utero embryonic development;positive regulation of activation of membrane attack complex;complement activation;complement activation, classical pathway;cytolysis;regulation of complement activation;innate immune response;positive regulation of angiogenesis	extracellular region;membrane attack complex;extracellular exosome	protein binding	SART3[21988832];ABL1[17474147];FYN[17474147];GRB2[17474147];NCK1[17474147];	41149448
4704	chr5	112174071	C	G	chr5:112174071	APC	APC, WNT signaling pathway regulator	SNV	0/1	0.27	32_12	44	99	rs587781500,COSV57400150	EXONIC	YES	NM_001354896.2	Transcript	protein_coding	missense_variant		17/17	NM_001354896.2:c.2834C>G	NP_001341825.1:p.Ala945Gly		1.0	.,.,.,.	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_specified|not_provided	Colorectal cancer, somatic, 114500 (3); Brain tumor-polyposis syndrome 2, 175100 (3), Autosomal dominant; Desmoid disease, hereditary, 135290 (3), Autosomal dominant; Adenoma, periampullary, somatic, 175100 (3); Hepatoblastoma, somatic, 114550 (3); Gastric cancer, somatic, 613659 (3); Gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), Autosomal dominant; Gardner syndrome, 175100 (3), Autosomal dominant; Adenomatous polyposis coli, 175100 (3), Autosomal dominant	APC-related attenuated familial adenomatous polyposis;Familial adenomatous polyposis due to 5q22.2 microdeletion;Cenani-Lenz syndrome;Gastric adenocarcinoma and proximal polyposis of the stomach;Desmoid tumor;Gardner syndrome;Turcot syndrome with polyposis	Disease-causing germline mutation(s) in;Role in the phenotype of;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Nausea;Hepatoblastoma;Headache;Hematochezia;Increased intracranial pressure;Lymphoma;Cafe-au-lait spot;Glioblastoma multiforme;Desmoid tumors;Alternating esotropia;Melena;Leukemia;Spinal cord compression;Abdominal pain;Cerebellar medulloblastoma;Basal cell carcinoma;Hyperpigmentation of the fundus;Constipation;Ependymoma;Hearing impairment;Epidermoid cyst;Visual acuity no light perception;Papilledema;Brain neoplasm;Colon cancer;Vomiting;Ataxia;Epiretinal membrane;Pituitary adenoma;Papillary thyroid carcinoma;Adenomatous colonic polyposis;Soft tissue neoplasm;Pilomatrixoma;Astrocytoma;Small intestine carcinoid;Desmoid tumors;Increased number of teeth;Epidermoid cyst;Variable expressivity;Keloids;Hepatoblastoma;Adrenocortical adenoma;Congenital hypertrophy of retinal pigment epithelium;Multiple lipomas;Papillary thyroid carcinoma;Duodenal adenocarcinoma;Odontoma;Unerupted tooth;Autosomal dominant inheritance;Colon cancer;Duodenal polyposis;Carcinoma;Hyperpigmentation of the skin;Astrocytoma;Osteoma;Carious teeth;Adenomatous colonic polyposis;Adrenocortical carcinoma;Fibroadenoma of the breast;Multiple gastric polyps;Medulloblastoma;Small intestine carcinoid;Desmoid tumors;Increased number of teeth;Epidermoid cyst;Variable expressivity;Keloids;Hepatoblastoma;Adrenocortical adenoma;Congenital hypertrophy of retinal pigment epithelium;Multiple lipomas;Papillary thyroid carcinoma;Duodenal adenocarcinoma;Odontoma;Unerupted tooth;Autosomal dominant inheritance;Colon cancer;Duodenal polyposis;Carcinoma;Hyperpigmentation of the skin;Astrocytoma;Osteoma;Carious teeth;Adenomatous colonic polyposis;Adrenocortical carcinoma;Fibroadenoma of the breast;Multiple gastric polyps;Medulloblastoma;Gastrointestinal carcinoma;Neoplasm of the pancreas;Thyroid nodule;Ampulla of Vater carcinoma;Osteoma;Epidermoid cyst;Increased number of teeth;Prostate cancer;Abnormality of skin pigmentation;Multiple unerupted teeth;Medulloblastoma;Duodenal polyposis;Multiple gastric polyps;Odontoma;Hepatoblastoma;Astrocytoma;Pilomatrixoma;Adenomatous colonic polyposis;Papillary thyroid carcinoma;Small intestine carcinoid;Lipoma;Adrenocortical carcinoma;Adrenocortical adenoma;Keloids;Esophageal carcinoma;Congenital hypertrophy of retinal pigment epithelium;Breast carcinoma;Brain neoplasm;Desmoid tumors;Colon cancer;Intellectual disability, moderate;Hepatocellular carcinoma;Micronodular cirrhosis;Somatic mutation;Autosomal dominant inheritance;Subacute progressive viral hepatitis;Heterogeneous;Stomach cancer;Somatic mutation;Increased level of L-fucose in urine;Autosomal dominant inheritance;Colon cancer;Desmoid tumors;Epidermoid cyst;Proptosis;Absent fingernail;High, narrow palate;Scoliosis;Ptosis;Micromelia;Synostosis of carpal bones;Nystagmus;Toe syndactyly;Short philtrum;Finger syndactyly;Hypothyroidism;Malar flattening;Protruding ear;Convex nasal ridge;Renal hypoplasia/aplasia;Laryngomalacia;Abnormal form of the vertebral bodies;Radioulnar synostosis;Short thumb;Foot oligodactyly;Hypoplasia of the radius;Crossed fused renal ectopia;Abnormal dermatoglyphics;Downslanted palpebral fissures;Ectropion;Hypodontia;Abnormality of the metacarpal bones;Hypertelorism;Elbow dislocation;Frontal bossing;Hypoplasia of the ulna;Absent toenail;Cataract;Hip dislocation;Abnormality of dental enamel;Short nose;Abnormality of the ribs;Hearing impairment;Duodenal adenocarcinoma;Medulloblastoma;Lipoma;Esophageal carcinoma;Osteoma;Papillary thyroid carcinoma;Multiple gastric polyps;Neoplasm of the pancreas;Fibroadenoma of the breast;Breast carcinoma;Astrocytoma;Thyroid nodule;Pilomatrixoma;Desmoid tumors;Congenital hypertrophy of retinal pigment epithelium;Epidermoid cyst;Colon cancer;Adrenocortical adenoma;Duodenal polyposis;Adenomatous colonic polyposis;Adrenocortical carcinoma;Odontoma;Increased number of teeth;Subcutaneous nodule;Myalgia;Chest pain;Sepsis;Neoplasm of the skin;Arthralgia;Desmoid tumors;Osteolysis;Intestinal obstruction;Hydronephrosis;Malabsorption;Abnormality of the abdominal wall;Abdominal pain;Abnormality of retinal pigmentation;Intestinal polyposis;Limitation of joint mobility;Abnormality of the musculature;Gastrointestinal hemorrhage;Spastic gait;Relative macrocephaly;Mandibular prognathia;Abnormality of canine;Micrognathia;Duodenal polyposis;Low posterior hairline;Hepatoblastoma;Abnormality of the kidney;Congenital hypertrophy of retinal pigment epithelium;Desmoid tumors;Pulmonary obstruction;Epidermoid cyst;Broad nasal tip;Intellectual disability, mild;Thick upper lip vermilion;Hypertelorism;Single transverse palmar crease;Short neck;Long philtrum;Long face;Adenomatous colonic polyposis;Colon cancer;High forehead;Iron deficiency anemia;High palate;Optic disc hypoplasia;Narrow mouth;Downslanted palpebral fissures;Generalized hypotonia;Posterior polar cataract;Early balding;Intestinal bleeding;Dyslexia;Osteoma						32	0.98							1.99291e-05	5.0	250890.0	0.0	95	0.99	PASS	sas	6.53381e-05	2.0	1.76429e-05	2.0	0.0000257	4			9e-05	1		21.2	2.174288	0.056	6	11	17	M-CAP_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,DEOGEN2_pred,fathmm-MKL_coding_pred	LRT_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-XF_coding_pred	APC	0.0	0.0	0.0	0.0	-1.0	-30.0	-1.0	36.0						0.00386	1.0	0.000000000	0.934	1.026	homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype ; endocrine/exocrine gland phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; immune system phenotype; renal/urinary system phenotype; skeleton phenotype; digestive/alimentary phenotype; nervous system phenotype ; hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; vision/eye phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; mortality/aging ; normal phenotype; reproductive system phenotype; pigmentation phenotype; neoplasm; embryo phenotype; 			ciliary ganglion;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;trigeminal ganglion;fetal brain;occipital lobe;subthalamic nucleus;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;thalamus;	Wnt signaling pathway;Regulation of actin cytoskeleton;Colorectal cancer;Endometrial cancer;Basal cell carcinoma	mitotic cytokinesis;cell fate specification;cellular response to DNA damage stimulus;negative regulation of microtubule depolymerization;cell cycle arrest;mitotic spindle assembly checkpoint;cell adhesion;pattern specification process;negative regulation of cell population proliferation;insulin receptor signaling pathway;positive regulation of cell death;Wnt signaling pathway;cell migration;protein deubiquitination;positive regulation of cell migration;positive regulation of pseudopodium assembly;regulation of microtubule-based process;positive regulation of apoptotic process;regulation of cell differentiation;positive regulation of protein catabolic process;negative regulation of cyclin-dependent protein serine/threonine kinase activity;protein homooligomerization;regulation of attachment of spindle microtubules to kinetochore;protein-containing complex assembly;bicellular tight junction assembly;negative regulation of canonical Wnt signaling pathway;positive regulation of cold-induced thermogenesis;positive regulation of protein localization to centrosome;beta-catenin destruction complex assembly;beta-catenin destruction complex disassembly	kinetochore;nucleus;nucleoplasm;cytoplasm;centrosome;cytosol;microtubule;cytoplasmic microtubule;plasma membrane;cell-cell adherens junction;bicellular tight junction;lateral plasma membrane;catenin complex;lamellipodium;beta-catenin destruction complex;ruffle membrane;perinuclear region of cytoplasm;Wnt signalosome	protein binding;beta-catenin binding;microtubule binding;protein kinase regulator activity;protein kinase binding;ubiquitin protein ligase binding;identical protein binding;gamma-catenin binding;cadherin binding;microtubule plus-end binding;dynein complex binding	FHOD1[20936779];CASC3[25640309];SMC3[20936779];TOMM20[29568061];CEP128[26638075];GOLGA2[20936779];C4A[20936779];HNRPM[20936779];TRIM28[16212417];KIF5B[20936779];PSMD1[20936779];TRIM25[25640309];BBX[26496610];BTRC[19615732];SYNPO[26496610];NCKAP5[20936779];TRIM21[20936779];AGFG1[20936779];NUP214[20936779];TMOD1[24412244];PNISR[20936779];MAP2K1[24412244];RBFOX2[26496610];CSNK2A1[25241761];COG5[20936779];TSTD2[24412244];ACTN1[20936779];COG4[20936779];KRT1[16212417];CTNNBIP1[15327768];SCRIB[16611247;30126976];CSNK1E[17218255;25241761;11425858];KRT5[20936779];RPGRIP1L[26638075];KRT9[16212417];DKK3[25640309];PROCR[19116273];HGS[20936779];SPECC1L[20936779];SPATA13[17599059;17145773];PKP2[26496610];NUP98[20936779];TELO2[26496610];MAD1L1[26496610];ND4[20936779];ANKRD17[20936779];MACF1[20936779];KHDRBS1[22000517];POM121[20936779];EPAS1[20936779];CTBP1[26496610];MRPL18[26496610];PXN[20224554];NOLC1[30021884];GIGYF2[20936779];SAV1[26496610];ARHGAP21[26496610];PPP3R2[24412244];POM121C[20936779];DVL1[20224554;11425858];MYO6[20936779];TPR[20936779];DVL2[20224554;26496610];SFN[15778465];MYH11[20936779];IGHA1[16212417];MYH10[20936779];SPTBN1[20936779];MARK2[26496610];FAM83B[26496610];SEC31A[20936779];SPTBN2[20936779];EXPH5[20936779];HOXC6[25640309];ASCC3L1[20936779];ANKRD28[24255178];SMAD1[24412244];CREBBP[20936779];ST14[25640309];TGFB1[24412244];HSPA5[20936779];JUP[20936779;25241761;26496610];SETDB1[20936779];SIAH1[25241761];NUP153[20936779];NEB[20936779];FANCC[24412244];FBXO30[20936779];PTK2[25241761];DVL1P1[20224554];DLG1[30126976];RPS27[20936779];NAT2[25640309];NOSTRIN[20936779];SASS6[26638075];ANP32B[24412244];DIRAS3[25640309];GSK3B[23602568;21118991;8638126;29568061];PPP1R13B[20936779];IL24[25640309];KRT23[20936779];CTSV[24412244];SYNE1[20936779];ING5[20936779];AKAP13[26496610];ANXA7[20936779];RAC1[21311754];NANS[24412244];CGNL1[20936779];DST[20936779];AXIN1[19131971;22682247;26496610;17510365];NAV1[20936779];NAV2[20936779];BAAT[24412244];KIF7[26496610];YWHAZ[15161933];PTBP3[22575643];SENP1[26496610];DDB1[16212417];TMEFF1[24412244];NAV3[20936779];EEF1D[26496610];RASA1[24412244];FAM20C[22582013];ARHGEF4[17145773;10947987;22000517];MCM5[16212417];NUP54[20936779];TFF1[25640309];MAPRE1[11943150;19632184;26496610];FBP1[24412244];ZNF510[24412244];NUP58[20936779];AMER1[24251807;26496610;17510365];AMER2[24251807];SEC23A[16212417];AMER3[24251807];LAMA4[20936779];LAMA3[20936779];RBM4B[20936779];WIZ[26496610];ASAP1[20509626];FAM214A[20936779];LRP8[19116273];STRN3[24255178];CYP17A1[25640309];CDC42[17145773;21311754];CYTH2[20936779];KIAA1328[20936779];PDLIM2[25640309];CCL5[25640309];CTNNA1[20936779;25241761;26496610];FLNA[20936779];AGR3[25640309];ZNF106[20936779];BUB1[25241761];RANBP2[20936779];MBD4[26496610];MBD5[20936779];EGLN3[26972000];NCKAP5L[20936779];ERBIN[20936779];KRT13[20936779];RANBP9[20936779];AP2B1[20936779];PTPN13[17240990];KRT19[20936779];MCM3AP[20936779];KRT17[20936779;26496610];KRT15[20936779];CAPZA2[16212417];KRT14[20936779];CTNNB1[16212417;15327768;15327769;17318191;22682247;25241761;9707618;8638126;26496610;17510365;22056988];ADGRL1[20936779];NUPL2[20936779];TAF1[20936779];	112174071
4755	chr5	137013351	A		chr5:137013351	KLHL3	kelch like family member 3	deletion	0/1	0.4	3_2	5	38	rs112292887	SPLICING	YES	NM_017415.3	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	5/14		NM_017415.3:c.527-8del			-1.0					Pseudohypoaldosteronism, type IID, 614495 (3), Autosomal recessive, Autosomal dominant	Pseudohypoaldosteronism type 2D	Disease-causing germline mutation(s) in	Autosomal recessive inheritance;Hyperchloremia;Autosomal dominant inheritance;Hyperchloremic metabolic acidosis;Pseudohypoaldosteronism;Hypertension;Hyperkalemia		0.00416267	547.0	131406.0	0.0	31	0.9	AS_VQSR	nfe	0.00400501	243.0	0.00400501	243.0	0.425796	43059.0	101126.0	0.0	15	0.44	InbreedingCoeff	nfe	0.435343	22300.0	0.435343	22300.0	0.0000579,0.0016334	9,254			0.30779	3502		1.401	-0.100559		0	0	0			KLHL3	0.02	0.0	0.0	0.0	-12.0	-7.0	-23.0	-33.0						0.199	0.92				hematopoietic system phenotype; cardiovascular system phenotype ; renal/urinary system phenotype; homeostasis/metabolism phenotype; 			cerebellum peduncles;cerebellum;	.	ubiquitin-dependent protein catabolic process;protein ubiquitination;post-translational protein modification;ion homeostasis;selective autophagy;renal sodium ion absorption;protein K48-linked ubiquitination;distal tubule morphogenesis	cytosol;cytoskeleton;Cul3-RING ubiquitin ligase complex	actin binding;structural molecule activity;protein binding	CUL3[23665031;25416956;unassigned1304];MORF4L2[25416956];WNK4[23665031];KEAP1[25416956;unassigned1304];KLHL2[unassigned1304];KLHL12[25416956;unassigned1304];KLHL3[25416956];CFAP206[25416956];TNPO2[unassigned1304];	137013350
4781	chr5	149514461	G	A	chr5:149514461	PDGFRB	platelet derived growth factor receptor beta	SNV	0/1	0.38	35_21	56	99	rs780974007	EXONIC	YES	NM_002609.4	Transcript	protein_coding	synonymous_variant		4/23	NM_002609.4:c.483C>T	NP_002600.1:p.His161%3D		-1.0					Premature aging syndrome, Penttinen type, 601812 (3), Autosomal dominant; Kosaki overgrowth syndrome, 616592 (3), Autosomal dominant; Myofibromatosis, infantile, 1, 228550 (3), Autosomal dominant; Basal ganglia calcification, idiopathic, 4, 615007 (3), Autosomal dominant; Myeloproliferative disorder with eosinophilia, 131440 (4), Autosomal dominant	Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement;Bilateral striopallidodentate calcinosis;Infantile myofibromatosis;Primary hypereosinophilic syndrome;Acroosteolysis-keloid-like lesions-premature aging syndrome;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;Chronic myeloproliferative disease, unclassifiable;Chronic myelomonocytic leukemia	Part of a fusion gene in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Part of a fusion gene in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in;Part of a fusion gene in;Part of a fusion gene in	Scoliosis;Increased thyroid-stimulating hormone level;Delayed skeletal maturation;Midface retrusion;Prominent nasal bridge;Hypermetropia;Thin calvarium;Sparse hair;Autosomal dominant inheritance;Delayed cranial suture closure;Abnormality of the skin;Lipoatrophy;Osteolytic defects of the phalanges of the hand;Brachydactyly;Micrognathia;Hyperkeratosis;Hypoplasia of the maxilla;Proptosis;Slender long bone;Delayed eruption of teeth;Osteopenia;Growth abnormality;Thin vermilion border;Sensorineural hearing impairment;Wormian bones;Narrow nose;Intrauterine growth retardation;Subcutaneous hemorrhage;Seizure;Hepatomegaly;Corneal opacity;Microcephaly;Abnormality of neuronal migration;Thrombocytopenia;Ventriculomegaly;Cerebral calcification;Autosomal dominant inheritance;Migraine;Parkinsonism;Depressivity;Nystagmus;Dementia;Basal ganglia calcification;Fragile skin;Hyperextensible skin;Autosomal dominant inheritance;Pointed chin;Long foot;Thin upper lip vermilion;Prominent supraorbital ridges;Wide nasal bridge;Downslanted palpebral fissures;Ptosis;Proptosis;Thin skin;Progressive neurologic deterioration;Thoracolumbar scoliosis;Prominent forehead;Depressivity;Anxiety;Overgrowth;Fibroma;Myofibromatosis;Abnormality of connective tissue;Autosomal dominant inheritance;Myofibromatosis;Abnormality of the thorax;Abnormal skull morphology;Abnormality of the metaphysis;Abnormality of the musculature;Osteolysis;Tracheoesophageal fistula;Neoplasm of the pancreas;Intestinal obstruction;Limitation of joint mobility;Neoplasm of the lung;Hemiplegia/hemiparesis;Abnormal sacrum morphology;Skin ulcer;Neoplasm of the skin;Benign neoplasm of the central nervous system;Abnormality of the eye;Subcutaneous nodule;Gingival fibromatosis;Chondrocalcinosis;Bone cyst;Abnormality of the kidney;Hypercalcemia;Abnormal hair morphology;Irregular hyperpigmentation;Psychosis;Mental deterioration;Depressivity;Rigidity;Tremor;Mask-like facies;Micrographia;Calcification of the small brain vessels;Gait disturbance;Autosomal dominant inheritance;Dysarthria;Progressive;Dysdiadochokinesis;Hyperreflexia;Basal ganglia calcification;Abnormal pyramidal sign;Postural instability;Limb dysmetria;Urinary incontinence;Dystonia;Athetosis;Adult onset;Chorea;Bradykinesia;Dense calcifications in the cerebellar dentate nucleus;Memory impairment;Parkinsonism;Myeloproliferative disorder;Autosomal dominant inheritance;Eosinophilia;Malignant eosinophil proliferation		3.94197e-05	6.0	152208.0	0.0	33	0.98	PASS	nfe	5.87907e-05	4.0	5.87907e-05	4.0	1.59058e-05	4.0	251480.0	0.0	65	1.0	PASS	nfe	2.63718e-05	3.0	2.63718e-05	3.0	0.0000193	3			0.0001	1		8.967	0.454936		0	0	0			PDGFRB	0.0	0.02	0.0	0.0	-7.0	25.0	33.0	15.0						0.123	1.0	56.764961468			endocrine/exocrine gland phenotype; adipose tissue phenotype ; integument phenotype ; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype ; limbs/digits/tail phenotype; digestive/alimentary phenotype; muscle phenotype; reproductive system phenotype; mortality/aging ; normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; behavior/neurological phenotype ; embryo phenotype; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; 			atrioventricular node;adipose tissue;trigeminal ganglion;	MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	MAPK cascade;hematopoietic progenitor cell differentiation;glycosaminoglycan biosynthetic process;signal transduction;transmembrane receptor protein tyrosine kinase signaling pathway;G protein-coupled receptor signaling pathway;aging;positive regulation of cell population proliferation;male gonad development;positive regulation of phospholipase C activity;positive regulation of phosphatidylinositol 3-kinase signaling;positive regulation of smooth muscle cell migration;cell migration;peptidyl-tyrosine phosphorylation;positive regulation of cell migration;response to estradiol;positive regulation of phosphoprotein phosphatase activity;response to retinoic acid;regulation of actin cytoskeleton organization;positive regulation of collagen biosynthetic process;response to fluid shear stress;positive regulation of Rho protein signal transduction;cell migration involved in vasculogenesis;metanephric mesenchymal cell migration;platelet-derived growth factor receptor-beta signaling pathway;positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway;aorta morphogenesis;cellular response to platelet-derived growth factor stimulus;positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway;wound healing;response to hydrogen peroxide;positive regulation of apoptotic process;positive regulation of MAP kinase activity;positive regulation of MAPK cascade;positive regulation of phosphatidylinositol 3-kinase activity;response to estrogen;positive regulation of mitotic nuclear division;phosphatidylinositol metabolic process;protein autophosphorylation;phosphatidylinositol phosphorylation;platelet-derived growth factor receptor signaling pathway;phosphatidylinositol-mediated signaling;positive regulation of fibroblast proliferation;positive regulation of smooth muscle cell proliferation;inner ear development;positive regulation of chemotaxis;positive regulation of protein kinase B signaling;cardiac myofibril assembly;response to hyperoxia;cell chemotaxis;lung growth;cell migration involved in coronary angiogenesis;retina vasculature development in camera-type eye;positive regulation of ERK1 and ERK2 cascade;smooth muscle cell chemotaxis;metanephric mesenchyme development;metanephric glomerular mesangial cell proliferation involved in metanephros development;metanephric glomerular capillary formation;metanephric comma-shaped body morphogenesis;metanephric S-shaped body morphogenesis;positive regulation of calcium ion import;positive regulation of reactive oxygen species metabolic process;positive regulation of hepatic stellate cell activation;positive regulation of DNA biosynthetic process	nucleus;cytoplasm;Golgi apparatus;plasma membrane;integral component of plasma membrane;focal adhesion;cell surface;membrane;apical plasma membrane;intrinsic component of plasma membrane;cytoplasmic vesicle;lysosomal lumen;intracellular membrane-bounded organelle;receptor complex	protein tyrosine kinase activity;transmembrane receptor protein tyrosine kinase activity;platelet activating factor receptor activity;platelet-derived growth factor-activated receptor activity;platelet-derived growth factor beta-receptor activity;Ras guanyl-nucleotide exchange factor activity;signaling receptor binding;platelet-derived growth factor receptor binding;protein binding;ATP binding;enzyme binding;protein kinase binding;vascular endothelial growth factor binding;phosphatidylinositol 3-kinase binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity;platelet-derived growth factor binding	PTPRR[19167335];HSP90AB1[22939624];PTPRO[19167335];PTEN[16456542;25241761;24012959];SLA[9742401];PTPRJ[19167335;10821867];PTPN22[19167335];PTPRK[19167335];PIK3C2B[10805725];PTPRG[19167335];CRKL[23397142];LAPTM4B[25594178];GRB10[10454568];NCK2[11027258];KDR[18997771];NCK1[7692233];PDGFRB[18505839];PDGFRA[11331882];IL1R1[16477012];KRT34[unassigned1304];KRT31[unassigned1304];KRTAP4-12[16189514];RASA1[1314164;1375321;8382774];RAF1[23397142];ATP6V0C[1334459];CRK[10733900];KPRP[unassigned1304];GRB7[8940081];SRC[7685273];PDGFB[17981115;7679113;10806482;11297552;20534510];PIK3R3[25241761];PDGFA[7679113];PIK3R2[1330535];KLHL12[25416956;unassigned1304];FOXK1[26496610];PIK3R1[1314164;1330535;10752619;11710529;11896612;7536927;7680644;7692233;9153411;8382612;8564419;8670861;19864249];CBL[17620338];LRP6[21245321];SLC9A3R2[16456542];SLC9A3R1[16456542;23397142;24012959];BCLAF1[26496610];FGD6[26496610];PDGFC[11297552];FYN[1661130;7685273;7687537];PLCG1[1396585;15641795;11896612;23397142;23063561];CEP76[unassigned1304];SH2B2[9989826];STAT5A[25241761];PTPN1[9355745;19167335;12614164];KRTAP12-3[unassigned1304];YES1[7685273];STAT1[23397142];KRTAP10-9[unassigned1304];STAT3[25241761];PTPN11[7530043;7688466;8119896;8183548;8538796;12614164;23397142];PTPN12[19167335;21376233;12614164];ZZEF1[26496610];VEGFA[17470632];PTPRE[19167335];MYO1E[26496610];PTPRB[19167335];PTPRC[19167335];TRIP6[25416956];PTPN6[19167335];GRB2[7935391];	149514461
4939	chr6	65016978	GAGA		chr6:65016978-65016981	EYS	eyes shut homolog	sequence_alteration	1/2	0.25	0_2_6	8	50	rs35395170	SPLICING	YES	NM_001292009.2	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	29/43		NM_001292009.2:c.6079-6_6079-3del			-1.0		Benign	criteria_provided,_single_submitter	Retinitis_pigmentosa_25|not_provided	Retinitis pigmentosa 25, 602772 (3), Autosomal recessive	Retinitis pigmentosa	Disease-causing germline mutation(s) in	Undetectable electroretinogram;Nyctalopia;Optic disc pallor;Attenuation of retinal blood vessels;Rod-cone dystrophy;Autosomal recessive inheritance;Chorioretinal atrophy;Photophobia;Constriction of peripheral visual field;Bone spicule pigmentation of the retina;Posterior subcapsular cataract;Hyperinsulinemia;Optic atrophy;Nystagmus;Abnormal retinal vascular morphology;Obesity;Hypoplasia of penis;Cataract;Abnormality of retinal pigmentation;Keratoconus;Progressive night blindness;Ophthalmoplegia;Abnormal testis morphology;Atypical scarring of skin;Hyperreflexia;Sensorineural hearing impairment;Blindness;Type II diabetes mellitus;Conductive hearing impairment;Photophobia;Intellectual disability;Anteverted nares;Abnormal electroretinogram;Wide nasal bridge;Hypogonadism;Glaucoma	22363543	0.000542256	81.0	149376.0	0.0	8	0.3	PASS	amr	0.00147	22.0	0.000462783	31.0	0.103296	9665.0	93566.0	0.0	9	0.26	RF	sas	0.130149	1605.0	0.109415	4049.0	0.0000643,0.0026302,0.0233177	10,409,3626			0.18543	2108		2.865	0.015702		0	0	0			EYS	0.03	0.0	0.0	0.0	-2.0	-15.0	-6.0	-13.0						0.0537	0.0				.			ciliary ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;skin;	.	skeletal muscle tissue regeneration;detection of light stimulus involved in visual perception	extracellular exosome	molecular_function;calcium ion binding	.	65016977
4941	chr6	65301445	T	G	chr6:65301445	EYS	eyes shut homolog	SNV	0/1	0.3	7_3	10	38		EXONIC	YES	NM_001292009.2	Transcript	protein_coding	missense_variant		26/44	NM_001292009.2:c.4315A>C	NP_001278938.1:p.Asn1439His		-1.0	.,.				Retinitis pigmentosa 25, 602772 (3), Autosomal recessive	Retinitis pigmentosa	Disease-causing germline mutation(s) in	Undetectable electroretinogram;Nyctalopia;Optic disc pallor;Attenuation of retinal blood vessels;Rod-cone dystrophy;Autosomal recessive inheritance;Chorioretinal atrophy;Photophobia;Constriction of peripheral visual field;Bone spicule pigmentation of the retina;Posterior subcapsular cataract;Hyperinsulinemia;Optic atrophy;Nystagmus;Abnormal retinal vascular morphology;Obesity;Hypoplasia of penis;Cataract;Abnormality of retinal pigmentation;Keratoconus;Progressive night blindness;Ophthalmoplegia;Abnormal testis morphology;Atypical scarring of skin;Hyperreflexia;Sensorineural hearing impairment;Blindness;Type II diabetes mellitus;Conductive hearing impairment;Photophobia;Intellectual disability;Anteverted nares;Abnormal electroretinogram;Wide nasal bridge;Hypogonadism;Glaucoma						32	0.95											82	0.58											9e-05	1		16.34	1.513405	0.048	5	14	19	SIFT,M-CAP_pred,FATHMM_pred,ClinPred_pred,fathmm-MKL_coding_pred	PolyPhen,Polyphen2_HDIV_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-XF_coding_pred	EYS	0.0	0.0	0.0	0.0	35.0	-40.0	-47.0	37.0						0.0537	0.0	27.682289627	0.922	1.137	.			ciliary ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;skin;	.	skeletal muscle tissue regeneration;detection of light stimulus involved in visual perception	extracellular exosome	molecular_function;calcium ion binding	.	65301445
5006	chr6	144875865	G	A	chr6:144875865	UTRN	utrophin	SNV	0/1	0.3	16_7	23	99	rs757500422	EXONIC	YES	NM_007124.2	Transcript	protein_coding	missense_variant		48/74	NM_007124.2:c.6970G>A	NP_009055.2:p.Val2324Ile		1.0						.	.	.		6.57843e-06	1.0	152012.0	0.0	32	0.95	PASS	nfe	1.47042e-05	1.0	1.47042e-05	1.0	7.95931e-06	2.0	251278.0	0.0	88	1.0	PASS	sas	3.26648e-05	1.0	8.80359e-06	1.0	0.0000064	1	0.001	2.0	0.00035	4		23.3	2.878982	0.147	8	13	21	PolyPhen,LRT_pred,MutationAssessor_pred,MutationTaster_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	UTRN	0.0	0.0	0.0	0.0	44.0	-41.0	-34.0	29.0						0.595	0.0	0.000000000	0.008	1.176	growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; respiratory system phenotype; behavior/neurological phenotype ; mortality/aging ; cardiovascular system phenotype ; limbs/digits/tail phenotype; nervous system phenotype ; skeleton phenotype; 			.	.	positive regulation of cell-matrix adhesion;muscle contraction;muscle organ development;neuromuscular junction development;response to denervation involved in regulation of muscle adaptation;regulation of sodium ion transmembrane transporter activity	nucleoplasm;cytoplasm;cytoskeleton;plasma membrane;dystrophin-associated glycoprotein complex;membrane;cell junction;filopodium;growth cone;cortical actin cytoskeleton;filopodium membrane;neuromuscular junction;protein-containing complex;sarcolemma;postsynaptic membrane;extracellular exosome;contractile ring	actin binding;integrin binding;protein binding;zinc ion binding;vinculin binding;protein kinase binding;actin filament binding	RBM8A[26496610];TTK[26496610];C1QTNF9[23414517];MKI67[26949251];PIK3CG[20562859];SAV1[24255178];HSPD1[30021884];PPP3CA[18838687];NUDCD1[29021621];DAG1[10767429;unassigned1793];PDK3[26496610];DISC1[17043677];HMGN2[30021884];MARK2[19615732];TNS2[28330616];HIST1H1C[30021884];ABCA1[16192269;25170080];EGLN3[26972000];DTNA[10767429];DTNB[10545507];MME[17342744];USP21[19615732];PTPN12[15231748];LRFN4[22677168];TMEM17[26638075];ITGB1BP1[23414517];PI4KB[26496610];EZR[29568061];PPIA[18838687];SNTB1[8576247];SNTB2[8576247];	144875865
5099	chr7	35288459	AG		chr7:35288459-35288460	TBX20	T-box 20	deletion	0/1	0.29	5_2	7	54	rs147314121	SPLICING	YES	NM_001077653.2	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	2/7		NM_001077653.2:c.381-7_381-6del			-1.0					Atrial septal defect 4, 611363 (3)	Atrial septal defect, ostium secundum type;Atrial septal defect, ostium secundum type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (gain of function) in	Autosomal dominant inheritance;Coarctation of aorta;Patent foramen ovale		0.000167864	25.0	148930.0	0.0	31	0.94	PASS	nfe	0.000194279	13.0	0.000194279	13.0	0.0100084	1072.0	107110.0	0.0	100	1.0	InbreedingCoeff	nfe	0.0125175	661.0	0.0125175	661.0	0.0000643,0.0001929,0.0891810	10,30,13868	0.198	651.0	0.12143	1385		12.28	0.841714		0	0	0			TBX20	0.03	0.0	0.0	0.0	-8.0	-5.0	-8.0	-26.0						0.13	0.34				cardiovascular system phenotype ; normal phenotype; mortality/aging ; embryo phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; growth/size/body region phenotype; 			.	.	negative regulation of transcription by RNA polymerase II;branching involved in blood vessel morphogenesis;endoderm formation;neuron migration;heart looping;embryonic heart tube morphogenesis;outflow tract septum morphogenesis;tricuspid valve development;aortic valve morphogenesis;pulmonary valve formation;endocardial cushion morphogenesis;cardiac chamber formation;cardiac right ventricle morphogenesis;endocardial cushion formation;cardiac septum development;pericardium morphogenesis;muscle contraction;blood circulation;cell population proliferation;dorsal/ventral pattern formation;negative regulation of SMAD protein complex assembly;visceral motor neuron differentiation;foramen ovale closure;embryonic heart tube elongation;negative regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;lateral mesoderm formation;cardiac muscle tissue morphogenesis;positive regulation of cardiac muscle cell proliferation;atrial septum morphogenesis;pulmonary vein morphogenesis	nucleus;cytoplasm	RNA polymerase II regulatory region sequence-specific DNA binding;RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;RNA polymerase II transcription factor binding;RNA polymerase II activating transcription factor binding;DNA-binding transcription activator activity, RNA polymerase II-specific	.	35288458
5180	chr7	92733358	G	A	chr7:92733358	SAMD9	sterile alpha motif domain containing 9	SNV	0/1	0.62	5_8	13	99	rs763070754,COSV66077326	EXONIC	YES	NM_017654.4	Transcript	protein_coding	stop_gained		3/3	NM_017654.4:c.2053C>T	NP_060124.2:p.Arg685Ter		-1.0	.,.,.	Uncertain_significance	criteria_provided,_single_submitter	not_provided	Tumoral calcinosis, familial, normophosphatemic, 610455 (3), Autosomal recessive; Monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 (3), Autosomal dominant; MIRAGE syndrome, 617053 (3), Autosomal dominant	Familial normophosphatemic tumoral calcinosis;MIRAGE syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Esophageal stricture;Anemia;Hypergonadotropic hypogonadism;Petechiae;Hyperkalemia;Recurrent urinary tract infections;Decreased testicular size;Recurrent bacterial infections;Cryptorchidism;Patent ductus arteriosus;Gastroesophageal reflux;Overlapping fingers;Thrombocytopenia;Motor delay;Achalasia;Talipes equinovarus;Seizure;Radial club hand;Autosomal dominant inheritance;Leukopenia;Lymphopenia;Myelodysplasia;Hypospadias;Hydrocephalus;Adrenal insufficiency;Intrauterine growth retardation;Hypoplastic spleen;Aspiration pneumonia;Shawl scrotum;Global developmental delay;Hypoglycemia;Paraplegia;Decreased body weight;Rocker bottom foot;Microphallus;Sepsis;Hyponatremia;Intracranial hemorrhage;Short stature;Chronic diarrhea;Scoliosis;Calcinosis;Gingivitis;Conjunctivitis;Abnormality of the skin;Autosomal recessive inheritance		5.26004e-05	8.0	152090.0	0.0	32	0.98	PASS	amr	0.000458355	7.0	0.0	0.0	5.57405e-05	14.0	251164.0	0.0	100	1.0	PASS	amr	0.000260206	9.0	4.40544e-05	5.0	0.0000643	10	0.0	1.0	0.00026	3		35.0	6.158663		4	2	6	MutationTaster_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred	LRT_pred,fathmm-XF_coding_pred	SAMD9	0.0	0.0	0.0	0.0	-47.0	24.0	-45.0	-3.0						0.991	0.0	0.000000000	0.992	0.11	.			.	.	endosomal vesicle fusion	cytoplasm;cytosol;intracellular membrane-bounded organelle	protein binding	EEA1[24029230];WTAP[29507755];EOGT[26496610];RSRP1[26496610];TRAPPC13[26496610];	92733358
5187	chr7	98592335	G	A	chr7:98592335	TRRAP	transformation/transcription domain associated protein	SNV	0/1	0.45	35_29	64	99	rs56282945,COSV62838115	EXONIC	YES	NM_001375524.1	Transcript	protein_coding	synonymous_variant		67/73	NM_001375524.1:c.10173G>A	NP_001362453.1:p.Thr3391%3D		1.0					?Deafness, autosomal dominant 75, 618778 (3), Autosomal dominant; Developmental delay with or without dysmorphic facies and autism, 618454 (3), Autosomal dominant	.	.	Atrophy/Degeneration affecting the brainstem;Global developmental delay;Cerebellar vermis hypoplasia;Poor speech;Microphallus;Feeding difficulties;Patent ductus arteriosus;Supernumerary nipple;Clinodactyly of the 5th finger;Wide nasal bridge;Cleft lip;Generalized hypotonia;Hearing impairment;Small nail;Hypertelorism;Hydronephrosis;Depressed nasal bridge;Bulbous nose;Microcephaly;Smooth philtrum;Delayed ability to walk;Umbilical hernia;Renal cyst;Short foot;Inguinal hernia;Scrotal hypoplasia;Deeply set eye;Cerebral cortical atrophy;Nail dysplasia;Short philtrum;Upslanted palpebral fissure;Vesicoureteral reflux;Autistic behavior;Wide mouth;Visual impairment;Highly arched eyebrow;Prominent nasal bridge;Coarctation of aorta;Cleft palate;Autosomal dominant inheritance;Hypoplasia of the corpus callosum;Anteverted nares;Posteriorly rotated ears;Obsessive-compulsive behavior;Polymicrogyria;Prominent forehead;Cryptorchidism;Short stature;Low-set ears;Seizure;Congenital diaphragmatic hernia;Delayed myelination;Laryngotracheomalacia;Epicanthus;Thin upper lip vermilion;Micrognathia;Patent foramen ovale;Absent speech;Hypotelorism;Renal hypoplasia;Scoliosis;Narrow nose;Short nose		0.000203655	31.0	152218.0	0.0	32	0.97	PASS	nfe	0.000308642	21.0	0.000308642	21.0	0.000155072	39.0	251496.0	0.0	100	1.0	PASS	nfe	0.000246111	28.0	0.000246111	28.0	0.0001286	20	0.0	1.0	0.00018	2		1.463	-0.094046		0	0	0			TRRAP	0.0	0.0	0.02	0.0	-9.0	-11.0	-9.0	-5.0						0.0406	1.0	97.224060386			vision/eye phenotype; embryo phenotype; mortality/aging ; hematopoietic system phenotype; homeostasis/metabolism phenotype; 			superior cervical ganglion;testis;	.	DNA repair;regulation of transcription, DNA-templated;histone acetylation;histone deubiquitination;protein deubiquitination;histone H4 acetylation;histone H2A acetylation;beta-catenin-TCF complex assembly	SAGA complex;PCAF complex;Swr1 complex;nucleus;nucleoplasm;Golgi apparatus;STAGA complex;transcription factor TFTC complex;NuA4 histone acetyltransferase complex	transcription coregulator activity;protein binding;thiol-dependent ubiquitinyl hydrolase activity	MRFAP1[17353931];YEATS4[26496610];SGF29[26496610];MKI67[26949251];MED15[18418385];ING3[26496610];KAT5[10966108];VPS72[15647280;26496610];MYC[9708738;17353931;17314511;21150319];RUVBL2[26496610];RUVBL1[20371770;26496610];EPC1[26496610];EPC2[26496610];SUPT20H[26496610];NCK1[26496610];MED1[18418385];NCBP1[26496610];ACTL6A[12963728;15647280];SUPT3H[26496610];TTI2[26496610];SUPT7L[26496610];TTI1[20371770;26496610];KRT72[26496610];KAT2A[15115762;10373431;18418385];TELO2[18160036];DOT1L[20203130];MLLT3[20203130];FOXO3[25609649];BRINP1[26496610];HIST1H3A[29568061];ATXN7[15115762];E2F1[11418595];EP400[26496610];E2F3[22157815];BRD8[12963728;26496610];E2F4[11418595];DMAP1[26496610];SMNDC1[17353931];JAZF1[26496610];KDM4A[23871696];TAF10[15115762];USP22[19615732];CDC5L[20467437];FOXR2[25609649];TADA2B[26496610];CDK8[18418385];FOXR1[25609649];MRGBP[12963728;15647280];TADA3[26496610];TADA1[26496610];TAF4[18418385];MPHOSPH8[26496610];	98592335
5189	chr7	99022873	C	T	chr7:99022873	ATP5J2-PTCD1		SNV	0/1	0.37	46_27	73	99	rs147045279	EXONIC	YES	NM_001198879.2	Transcript	protein_coding	missense_variant		7/9	NM_001198879.2:c.1429G>A	NP_001185808.1:p.Ala477Thr		-1.0	.,.									0.00142568	217.0	152208.0	2.0	32	0.98	PASS	sas	0.00745959	36.0	0.00174918	119.0	0.00231642	580.0	250386.0	6.0	100	0.98	PASS	sas	0.00891979	272.0	0.00196951	223.0	0.0020321	316	0.003	8.0	0.00228	26		7.634	0.333219	0.007	0	18	18		SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	ATP5J2-PTCD1	0.0	0.0	0.0	0.0	-4.0	26.0	43.0	25.0							0.0	0.000000000,0.000000000	0.001	-0.131										99022873
5190	chr7	99022873	C	T	chr7:99022873	PTCD1	pentatricopeptide repeat domain 1	SNV	0/1	0.37	46_27	73	99	rs147045279	EXONIC	YES	NM_015545.4	Transcript	protein_coding	missense_variant		6/8	NM_015545.4:c.1282G>A	NP_056360.2:p.Ala428Thr		-1.0	.,.					.	.	.		0.00142568	217.0	152208.0	2.0	32	0.98	PASS	sas	0.00745959	36.0	0.00174918	119.0	0.00231642	580.0	250386.0	6.0	100	0.98	PASS	sas	0.00891979	272.0	0.00196951	223.0	0.0020321	316	0.003	8.0	0.00228	26		7.634	0.333219	0.007	0	18	18		SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PTCD1	0.0	0.0	0.0	0.0	-4.0	26.0	43.0	25.0							0.0	0.000000000,0.000000000	0.001	-0.131	muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; mortality/aging ; growth/size/body region phenotype; cardiovascular system phenotype ; liver/biliary system phenotype; 			superior cervical ganglion;	.	tRNA 3'-end processing	mitochondrion;mitochondrial matrix	tRNA binding;RNA binding	CARD10[unassigned1304];FASTKD3[20869947];MGST3[29568061];MTUS2[unassigned1304];MRPL58[20186120];TFIP11[unassigned1304];YBX1[25497084];SYP[unassigned1304];HSPD1[29568061];GEMIN4[unassigned1304];FKBP7[unassigned1304];AURKAIP1[29568061];NFKBID[unassigned1304];TRMT61B[29568061];PDK1[29568061];	99022873
5206	chr7	103138572	G	T	chr7:103138572	RELN	reelin	SNV	0/1	0.4	15_10	25	99	rs139225791,COSV104640289	EXONIC	YES	NM_005045.4	Transcript	protein_coding	missense_variant		54/65	NM_005045.4:c.8795C>A	NP_005036.2:p.Ser2932Tyr		-1.0	.,.,.	Uncertain_significance	criteria_provided,_multiple_submitters,_no_conflicts	Norman-Roberts_syndrome|Epilepsy,_familial_temporal_lobe,_7|not_provided	{Epilepsy, familial temporal lobe, 7}, 616436 (3), Autosomal dominant; Lissencephaly 2 (Norman-Roberts type), 257320 (3), Autosomal recessive	Lissencephaly syndrome, Norman-Roberts type;Autosomal dominant epilepsy with auditory features	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Bilateral tonic-clonic seizure with focal onset;Autosomal dominant inheritance;Focal impaired awareness seizure;Focal sensory seizure with auditory features;Incomplete penetrance;Focal aware seizure;Autosomal dominant inheritance;Incomplete penetrance;Focal sensory seizure with auditory features;Lymphedema;4-layered lissencephaly;Generalized-onset seizure;Hypoplasia of the pons;Sloping forehead;Thick cerebral cortex;Cerebellar hypoplasia;Microcephaly;Prominent nasal bridge;Global developmental delay;Muscular hypotonia;Autosomal recessive inheritance		0.000131555	20.0	152028.0	0.0	33	0.96	PASS	nfe	0.000294092	20.0	0.000294092	20.0	9.1578e-05	23.0	251152.0	0.0	91	1.0	PASS	nfe	0.000149772	17.0	0.000149772	17.0	0.0000900	14	0.0	1.0	9e-05	1		23.3	2.877585	0.175	5	16	21	LRT_pred,MutationTaster_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	RELN	0.0	0.0	0.0	0.0	-27.0	25.0	-4.0	-41.0						0.175	1.0	0.000000000	1.0	1.176	reproductive system phenotype; mortality/aging ; behavior/neurological phenotype ; nervous system phenotype ; digestive/alimentary phenotype; vision/eye phenotype; integument phenotype ; growth/size/body region phenotype; cellular phenotype; muscle phenotype; 			ciliary ganglion;amygdala;olfactory bulb;appendix;superior cervical ganglion;trigeminal ganglion;fetal liver;cerebellum peduncles;cerebellum;pons;dorsal root ganglion;atrioventricular node;skeletal muscle;	Cell Communication;Focal adhesion;ECM-receptor interaction	cell morphogenesis involved in differentiation;neuron migration;proteolysis;cell adhesion;axon guidance;central nervous system development;brain development;long-term memory;associative learning;glial cell differentiation;positive regulation of neuron projection development;positive regulation of phosphatidylinositol 3-kinase signaling;dendrite development;peptidyl-tyrosine phosphorylation;spinal cord patterning;ventral spinal cord development;hippocampus development;cerebral cortex tangential migration;layer formation in cerebral cortex;positive regulation of TOR signaling;positive regulation of CREB transcription factor activity;reelin-mediated signaling pathway;positive regulation of protein kinase activity;response to pain;positive regulation of peptidyl-tyrosine phosphorylation;regulation of behavior;modulation of chemical synaptic transmission;positive regulation of small GTPase mediated signal transduction;positive regulation of synaptic transmission, glutamatergic;long-term synaptic potentiation;positive regulation of dendritic spine morphogenesis;positive regulation of protein tyrosine kinase activity;positive regulation of synapse maturation;NMDA glutamate receptor clustering;postsynaptic density protein 95 clustering;receptor localization to synapse;lateral motor column neuron migration;positive regulation of long-term synaptic potentiation;positive regulation of lateral motor column neuron migration;regulation of NMDA receptor activity;positive regulation of excitatory postsynaptic potential;positive regulation of AMPA receptor activity	extracellular region;extracellular space;cytoplasm;plasma membrane;dendrite;extracellular matrix	serine-type peptidase activity;metal ion binding;lipoprotein particle receptor binding;very-low-density lipoprotein particle receptor binding	.	103138572
5362	chr7	114271580	CAG		chr7:114271580-114271582	FOXP2	forkhead box P2	deletion	0/1	0.17	34_7	41	93		SPLICING	YES	NM_148898.4	Transcript	protein_coding	splice_acceptor_variant,splice_polypyrimidine_tract_variant,intron_variant	6/17		NM_148898.4:c.693_695del			1.0		Likely_benign	criteria_provided,_single_submitter	History_of_neurodevelopmental_disorder	Speech-language disorder-1, 602081 (3), Autosomal dominant	7q31 microdeletion syndrome;Childhood apraxia of speech	Role in the phenotype of;Disease-causing germline mutation(s) in	Abnormality of the face;Abnormality of the basal ganglia;Oromotor apraxia;Delayed speech and language development;Autosomal dominant inheritance;Incomprehensible speech;Abnormal speech prosody;Submucous cleft hard palate;Grammar-specific speech disorder;Autistic behavior;Poor speech;Poor fine motor coordination;Poor gross motor coordination;Specific learning disability;Caudate atrophy;Expressive language delay;Receptive language delay;Delayed social development;Overfolded helix;Drooling;Incomprehensible speech;Feeding difficulties;High, narrow palate;Horizontal eyebrow;Dysarthria;Speech apraxia		0.000435649	66.0	151498.0	0.0	32	0.96	PASS	sas	0.000414938	2.0	0.00028012	19.0	0.00317231	461.0	145320.0	1.0	100	0.59	PASS	nfe	0.0035128	205.0	0.0035128	205.0	0.0000193,0.0000322,0.0061863	3,5,962			0.01455	166	1.0	22.7	2.587428		0	0	0			FOXP2	0.75	0.98	0.0	0.0	10.0	4.0	13.0	10.0						0.117	1.0				muscle phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype ; nervous system phenotype ; hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; embryo phenotype; behavior/neurological phenotype ; respiratory system phenotype; mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; 			ciliary ganglion;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	.	negative regulation of transcription by RNA polymerase II;positive regulation of mesenchymal cell proliferation;skeletal muscle tissue development;post-embryonic development;cerebellum development;caudate nucleus development;putamen development;cerebral cortex development;response to testosterone;vocal learning;camera-type eye development;negative regulation of transcription, DNA-templated;lung alveolus development;smooth muscle tissue development;righting reflex;positive regulation of epithelial cell proliferation involved in lung morphogenesis;innate vocalization behavior	nucleus	RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;protein binding;identical protein binding;protein homodimerization activity;sequence-specific DNA binding;metal ion binding;protein heterodimerization activity;androgen receptor binding	HSP90AB1[22939624];CTBP2[25416956;unassigned1304];TSACC[25416956;unassigned1304];NEK4[25798074];CTBP1[25416956;27107012];CCNC[25416956];TBR1[25232744];FOXP4[25609649;19907493];FOXP3[25609649];FOXP2[25609649;16407075;24893771];AES[25416956;unassigned1304];FOXP1[25609649;19907493;26647308;24893771];RPIA[25416956];SDCBP[25416956];FAM124A[25416956];SP4[25416956];CDK3[unassigned1304];LNX1[unassigned1304];PIN1[25416956;unassigned1304];	114271579
5383	chr7	116339642	G	T	chr7:116339642	MET	MET proto-oncogene, receptor tyrosine kinase	SNV	0/1	0.59	16_23	39	99	rs55985569,COSV59258005	EXONIC	YES	NM_001127500.3	Transcript	protein_coding	missense_variant		2/21	NM_001127500.3:c.504G>T	NP_001120972.1:p.Glu168Asp		1.0	Sema domain,Sema domain&Sema domain&Sema domain,Sema domain&Sema domain&Sema domain,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Hepatocellular_carcinoma|Renal_cell_carcinoma|Renal_cell_carcinoma,_papillary,_1|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); Hepatocellular carcinoma, childhood type, somatic, 114550 (3); {Osteofibrous dysplasia, susceptibility to}, 607278 (3), Autosomal dominant; ?Deafness, autosomal recessive 97, 616705 (3), Autosomal recessive	Papillary renal cell carcinoma;Osteofibrous dysplasia;Pediatric hepatocellular carcinoma;Hereditary papillary renal cell carcinoma;Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Pectus excavatum;Fibular hypoplasia;Autosomal dominant inheritance;Pseudoarthrosis;Hepatocellular carcinoma;Micronodular cirrhosis;Somatic mutation;Autosomal dominant inheritance;Subacute progressive viral hepatitis;Heterogeneous;Vomiting;Hepatic necrosis;Portal vein thrombosis;Hepatic fibrosis;Fatigue;Hepatomegaly;Abdominal pain;Elevated alpha-fetoprotein;Epigastric pain;Autosomal recessive inheritance;Sensorineural hearing impairment;Papillary renal cell carcinoma;Autosomal dominant inheritance;Incomplete penetrance	25741868,22703879,23757202,24728327,21970370,15735036,19318576	0.00407466	620.0	152160.0	4.0	32	0.97	PASS	nfe	0.00637991	434.0	0.00637991	434.0	0.00372365	921.0	247338.0	3.0	100	1.0	PASS	nfe	0.00665877	742.0	0.00665877	742.0	0.0039870	620	0.009	28.0	0.00833	95		16.05	1.460691	0.05	3	18	21	LRT_pred,MutationTaster_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-XF_coding_pred	MET	0.01	0.0	0.0	0.0	-8.0	-38.0	-9.0	24.0						0.442	1.0	0.000000000	0.643	1.176	endocrine/exocrine gland phenotype; growth/size/body region phenotype; craniofacial phenotype; muscle phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype ; liver/biliary system phenotype; respiratory system phenotype; embryo phenotype; neoplasm; normal phenotype; mortality/aging ; cardiovascular system phenotype ; limbs/digits/tail phenotype; nervous system phenotype ; digestive/alimentary phenotype; renal/urinary system phenotype; 			ciliary ganglion;appendix;thyroid;dorsal root ganglion;trigeminal ganglion;atrioventricular node;superior cervical ganglion;placenta;fetal lung;fetal liver;skeletal muscle;globus pallidus;	Cytokine-cytokine receptor interaction;Axon guidance;Focal adhesion;Adherens junction;Epithelial cell signaling in Helicobacter pylori infection;Colorectal cancer;Renal cell carcinoma;Melanoma	MAPK cascade;endothelial cell morphogenesis;liver development;phagocytosis;signal transduction;cell surface receptor signaling pathway;transmembrane receptor protein tyrosine kinase signaling pathway;nervous system development;cell population proliferation;negative regulation of autophagy;Wnt signaling pathway;cell migration;peptidyl-tyrosine phosphorylation;neuron differentiation;pancreas development;positive regulation of microtubule polymerization;negative regulation of Rho protein signal transduction;entry of bacterium into host cell;positive regulation of transcription by RNA polymerase II;phosphatidylinositol phosphorylation;hepatocyte growth factor receptor signaling pathway;branching morphogenesis of an epithelial tube;positive chemotaxis;negative regulation of stress fiber assembly;positive regulation of protein kinase B signaling;establishment of skin barrier;negative regulation of thrombin-activated receptor signaling pathway;semaphorin-plexin signaling pathway;negative regulation of hydrogen peroxide-mediated programmed cell death;negative regulation of guanyl-nucleotide exchange factor activity;positive regulation of endothelial cell chemotaxis	extracellular region;plasma membrane;integral component of plasma membrane;basal plasma membrane;cell surface;integral component of membrane;receptor complex	protein tyrosine kinase activity;transmembrane receptor protein tyrosine kinase activity;hepatocyte growth factor-activated receptor activity;Ras guanyl-nucleotide exchange factor activity;protein binding;ATP binding;Wnt-protein binding;protein phosphatase binding;identical protein binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity	BCAR3[24728074];ITK[24728074];PTPRO[19167335;28330616];INPPL1[24728074];PTPRJ[19167335;12475979];PTPRK[19167335];SHB[24728074];SLA2[24728074];SHD[24728074];PTPRG[19167335];LAPTM4B[25594178];GRB14[24728074];LAMP1[29568061];CASP3[25241761];KDR[22789536];NCK2[24728074];TNS4[24728074];TNS3[24728074];TNS2[24728074];NCK1[24728074];TNS1[24728074];VAV3[24728074];SYK[24728074];HGF[15167892;17981115;22897854;1846706;16537482;17804794;20624990];SH2D3C[24728074];GAB1[10913131];MATK[24728074];SCRIB[24550280];PASK[21418524];YWHAZ[17353931];VAV2[24728074];FGR[24728074];ZAP70[24728074];HCK[24728074];HSH2D[24728074];PKM[24606918];LCK[24728074];RASA1[24728074];BTK[24728074];CRK[24728074];MET[16537482;20624990];CD44[22897854];SHC4[24728074];BLK[24728074];GRB7[24728074];SHC2[24728074];SHC3[24728074];SRC[20624308;24034250;24728074];SHC1[24728074];SH2D2A[24728074];TXK[24728074];PIK3R3[24728074];PIK3R2[24728074];PIK3R1[24728074];CBL[11894096;18273061;21163258;25241761];EGFR[20624308;24189400;23866081;26551075];SOCS2[24728074];SOCS3[24728074];MUC1[22962849];SOCS1[24728074];ERBB3[25326665];SH3BP2[24728074];PLCG2[24728074];STAP1[24728074];ABL2[24728074];PLCG1[24728074];SOCS6[24728074];SH2B3[24728074];SH2B2[24728074];SOCS5[24728074];SH2B1[24728074];LYN[24728074];PTPN1[16537444;18579758;22789536];YES1[24728074];SH2D1A[24728074];SH2D1B[24728074];RANBP9[12147692];PTPN11[18579758;24728074];PTK6[24728074];PTPN12[19167335];PTPRB[16101282];PTPRC[19167335];TEC[24728074];FES[24728074];DNAJA3[21242965];PLXNB3[15184888];PLXNB2[15184888];PLXNB1[12198496;15184888;22404908];PTPN3[19167335];	116339642
5389	chr7	127251733	A		chr7:127251733	PAX4	paired box 4	deletion	0/1	0.35	11_6	17	99	rs35434068	SPLICING	YES	NM_001366110.1	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	10/11		NM_001366110.1:c.772-3del			-1.0		Uncertain_significance	criteria_provided,_single_submitter	Maturity_onset_diabetes_mellitus_in_young	{Diabetes mellitus, ketosis-prone, susceptibility to}, 612227 (3), Autosomal recessive, Autosomal dominant; Maturity-onset diabetes of the young, type IX, 612225 (3); Diabetes mellitus, type 2, 125853 (3), Autosomal dominant	MODY	Disease-causing germline mutation(s) in	Diabetes mellitus;Multifactorial inheritance;Beta-cell dysfunction;Ketoacidosis;Autosomal dominant inheritance;Autoimmunity;Autosomal recessive inheritance;Insulin resistance;Obesity;Overweight;Glycosuria;Renal cyst;Hyperinsulinemic hypoglycemia;Retinopathy;Intrauterine growth retardation;Neonatal hypoglycemia;Pancreatic hypoplasia;Hepatocellular adenoma;Elevated hemoglobin A1c;Nephropathy;Large for gestational age;Exocrine pancreatic insufficiency;Transient neonatal diabetes mellitus;Abnormal oral glucose tolerance;Abnormal C-peptide level;Hypoinsulinemia;Hyperglycemia;Maturity-onset diabetes of the young;Autosomal dominant inheritance;Type II diabetes mellitus;Increased waist to hip ratio;Insulin resistance;Autosomal dominant inheritance;Late onset		0.00283052	404.0	142730.0	0.0	31	0.87	PASS	afr	0.00672841	263.0	0.0011911	77.0	0.126231	10437.0	82682.0	0.0	68	0.98	InbreedingCoeff_RF	amr	0.159552	1480.0	0.119572	4725.0	0.0000193,0.0003601	3,56			0.17064	1946		4.253	0.099449		0	0	0			PAX4	0.0	0.04	0.0	0.01	24.0	-2.0	-2.0	25.0						0.174	0.0				homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; normal phenotype; mortality/aging ; growth/size/body region phenotype; 			.	Maturity onset diabetes of the young	negative regulation of transcription by RNA polymerase II;circadian rhythm;animal organ morphogenesis;cell differentiation;endocrine pancreas development;response to drug;negative regulation of apoptotic process;positive regulation of cell differentiation;response to cAMP;retina development in camera-type eye	nucleoplasm	RNA polymerase II distal enhancer sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA binding	NECAB1[unassigned1304];NFYC[unassigned1304];NTM[unassigned1304];FBXO2[unassigned1304];CABP5[unassigned1304];EIF4A3[unassigned1304];NAIF1[unassigned1304];NRXN3[unassigned1304];HNRNPU[30021884];NUTF2[unassigned1304];GMCL1[unassigned1304;25910212];FLJ13057[25416956];UBL5[unassigned1304];NME7[unassigned1304];PSMC1[unassigned1304];	127251732
5474	chr7	153750065	C	G	chr7:153750065	DPP6	dipeptidyl peptidase like 6	SNV	0/1	0.51	19_20	39	99	rs949589423,COSV66748904	EXONIC	YES	NM_130797.4	Transcript	protein_coding	missense_variant		1/26	NM_130797.4:c.160C>G	NP_570629.2:p.Arg54Gly		1.0	.,.				Mental retardation, autosomal dominant 33, 616311 (3); {Ventricular fibrillation, paroxysmal familial, 2}, 612956 (3), Autosomal dominant	Autosomal dominant primary microcephaly;Idiopathic ventricular fibrillation, non Brugada type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Short stature;Alternating esotropia;Reduced number of teeth;Protruding ear;Microcephaly;Horizontal nystagmus;Ventricular fibrillation;Autosomal dominant inheritance;Sudden cardiac death;Autosomal dominant inheritance;Short stature;Microcephaly;Delayed skeletal maturation;Attention deficit hyperactivity disorder;Decreased body weight;Amblyopia;Intellectual disability;Scoliosis;Chorioretinal degeneration		0.000897984	132.0	146996.0	0.0	31	0.89	PASS	nfe	0.00154102	102.0	0.00154102	102.0	0.0022409	8.0	3570.0	0.0	0	0.0	PASS	nfe	0.00266565	7.0	0.00266565	7.0	0.0000193	3			0.00168	16		14.97	1.259432	0.09	3	14	17	SIFT,PrimateAI_pred,fathmm-MKL_coding_pred	PolyPhen,Polyphen2_HDIV_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-XF_coding_pred	DPP6	0.0	0.0	0.0	0.0	-12.0	3.0	0.0	30.0							0.97		0.683	-0.026	nervous system phenotype ; 			caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;cerebellum peduncles;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;parietal lobe;globus pallidus;medulla oblongata;thalamus;	.	proteolysis;protein localization to plasma membrane;regulation of potassium ion transmembrane transport	plasma membrane;voltage-gated potassium channel complex;integral component of membrane	serine-type peptidase activity;dipeptidyl-peptidase activity;potassium channel regulator activity	PHB[20195357];	153750065
5626	chr8	30998961	G	A	chr8:30998961	WRN	Werner syndrome RecQ like helicase	SNV	0/1	0.33	10_5	15	78	rs140768346,COSV104591538	EXONIC	YES	NM_000553.6	Transcript	protein_coding	missense_variant		25/35	NM_000553.6:c.2983G>A	NP_000544.2:p.Ala995Thr		1.0	RQC domain&RQC domain	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Werner_syndrome|not_specified|not_provided	Werner syndrome, 277700 (3), Autosomal recessive	Werner syndrome	Disease-causing germline mutation(s) in	Meningioma;Progeroid facial appearance;Scleroderma;Convex nasal ridge;Osteoporosis;Short stature;Abnormal hair morphology;Diabetes mellitus;Osteosarcoma;Retinal degeneration;Premature arteriosclerosis;Hypogonadism;Cataract;Subcutaneous calcification;Autosomal recessive inheritance;Slender build;Neoplasm of the small intestine;Chondrocalcinosis;Congestive heart failure;Hyperkeratosis;Squamous cell carcinoma;Gastrointestinal carcinoma;Telangiectasia of the skin;Sparse scalp hair;Spontaneous abortion;Pulmonary artery stenosis;Type II diabetes mellitus;Osteoporosis;Convex nasal ridge;Atherosclerosis;Decreased fertility;Small hand;Neoplasm of the lung;Aplasia/Hypoplasia of the testes;Laryngomalacia;White forelock;Skeletal muscle atrophy;Pili torti;Short stature;Renal neoplasm;Rocker bottom foot;Increased bone mineral density;Cataract;Lack of skin elasticity;Breast carcinoma;Abnormality of the cerebral vasculature;Meningioma;Abnormal hair whorl;Hypertension;Aplasia/Hypoplasia of the skin;Acral lentiginous melanoma;Hypogonadism;Thyroid carcinoma;Abnormality of retinal pigmentation;Secondary amenorrhea;Premature graying of hair;Subcutaneous calcification;Insulin resistance;Myocardial infarction;Sarcoma;Joint stiffness;Lipoatrophy;Ovarian neoplasm;Skin ulcer;Abnormality of the voice;Abnormality of the thorax;Neoplasm of the oral cavity;Narrow face	24728327	0.00194627	296.0	152086.0	0.0	32	0.96	PASS	nfe	0.00248449	169.0	0.00248449	169.0	0.00239061	601.0	251400.0	8.0	78	1.0	PASS	nfe	0.00280523	319.0	0.00280523	319.0	0.0020578	320	0.004	14.0	0.00265	30		18.05	1.780279	0.031	2	17	19	SIFT,LIST-S2_pred	PolyPhen,LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	WRN	0.07	0.0	0.0	0.0	17.0	-6.0	-3.0	7.0						0.988	0.0	0.000000000	0.652	-0.7	neoplasm; hematopoietic system phenotype; cardiovascular system phenotype ; reproductive system phenotype; mortality/aging ; vision/eye phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; skeleton phenotype; immune system phenotype; homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype ; growth/size/body region phenotype; integument phenotype ; craniofacial phenotype; 			skeletal muscle;	.	telomere maintenance;double-strand break repair via homologous recombination;DNA synthesis involved in DNA repair;replicative cell aging;DNA metabolic process;DNA replication;DNA repair;base-excision repair;double-strand break repair;DNA recombination;cellular response to DNA damage stimulus;response to oxidative stress;brain development;aging;cell aging;determination of adult lifespan;cellular response to starvation;response to UV-C;multicellular organism aging;replication fork processing;DNA duplex unwinding;regulation of growth rate;regulation of apoptotic process;G-quadruplex DNA unwinding;positive regulation of hydrolase activity;telomeric D-loop disassembly;cellular response to gamma radiation;nucleic acid phosphodiester bond hydrolysis;t-circle formation;positive regulation of strand invasion;protein localization to nucleolus	chromosome, telomeric region;nucleus;nucleoplasm;replication fork;DNA replication factor A complex;chromosome;nucleolus;cytoplasm;centrosome;nuclear speck;site of double-strand break;neuron projection	magnesium ion binding;four-way junction DNA binding;Y-form DNA binding;bubble DNA binding;DNA binding;DNA helicase activity;chromatin binding;ATP-dependent DNA helicase activity;helicase activity;exonuclease activity;protein binding;ATP binding;3'-5' exonuclease activity;four-way junction helicase activity;ATPase activity;manganese ion binding;MutLalpha complex binding;protein homodimerization activity;3'-5' DNA helicase activity;ATP-dependent 3'-5' DNA helicase activity;protein-containing complex binding;G-quadruplex DNA binding;forked DNA-dependent helicase activity;telomeric D-loop binding;telomeric G-quadruplex DNA binding;3'-flap-structured DNA binding;8-hydroxy-2'-deoxyguanosine DNA binding	VCP[15037256];BLM[11919194];FEN1[11598021;14688284;14657243];WDR48[19615732];ARL3[27173435;unassigned1312];SUV39H1[25931448];BRCA1[29656893];WRN[10783163];UBC[18588880];NLRP2[15733840];E2F3[22157815];POLL[27173435;unassigned1312];CTNNBL1[30021884];TMPO[25931448];XRCC6[10783163;14734561;11328876;26496610];CREBBP[18203716];SUPT16H[unassigned1312];CBX5[25931448];PARP1[14734561;14596914];XRCC5[10783163;14734561;11328876;21679440;26496610];H2AFX[15733840;20802463];TINF2[26496610];RPA1[10373438;15965237;15735006;24126761];RPA2[20802463;24126761];TERF2[12181313];SIRT1[19343720;18203716];RAD52[12750383];RAD51[18562274];RPA3[24126761;unassigned1312];TP53[11427532;15735006];	30998961
5641	chr8	32505910	AG		chr8:32505910-32505911	NRG1	neuregulin 1	deletion	0/1	0.33	4_2	6	57	rs146965117	SPLICING	YES	NM_001322205.2	Transcript	protein_coding	splice_region_variant,intron_variant	1/8		NM_001322205.2:c.667+22_667+23del			1.0					{?Schizophrenia, susceptibility to}, 603013 (1)	Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency	Disease-causing germline mutation(s) in	Autosomal dominant inheritance;Recurrent thromboembolism;Hypercoagulability		0.000342158	51.0	149054.0	0.0	31	0.94	PASS	nfe	0.000328525	22.0	0.000328525	22.0	0.177657	21306.0	119928.0	0.0	36	0.86	InbreedingCoeff_RF	sas	0.240749	3396.0	0.170444	9506.0	0.0001929,0.0007460,0.1270321	30,116,19754			0.26604	2952		17.05	1.632465		0	0	0																	0.325	0.95				homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; growth/size/body region phenotype; integument phenotype ; endocrine/exocrine gland phenotype; respiratory system phenotype; behavior/neurological phenotype ; nervous system phenotype ; vision/eye phenotype; cardiovascular system phenotype ; reproductive system phenotype; mortality/aging ; embryo phenotype; 			ciliary ganglion;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;testis;skeletal muscle;	ErbB signaling pathway	MAPK cascade;activation of MAPK activity;cell morphogenesis;cardiac conduction system development;ventricular trabecula myocardium morphogenesis;cell communication;activation of transmembrane receptor protein tyrosine kinase activity;nervous system development;synapse assembly;locomotory behavior;positive regulation of cell population proliferation;regulation of signaling receptor activity;positive regulation of gene expression;neural crest cell development;peptidyl-tyrosine phosphorylation;glial cell fate commitment;chemorepulsion involved in interneuron migration from the subpallium to the cortex;myelination in peripheral nervous system;mammary gland development;activation of protein kinase B activity;intracellular signal transduction;ERBB signaling pathway;ERBB2 signaling pathway;ERBB3 signaling pathway;wound healing;negative regulation of protein catabolic process;regulation of protein homodimerization activity;regulation of protein heterodimerization activity;neurotransmitter receptor metabolic process;negative regulation of transcription, DNA-templated;positive regulation of Ras protein signal transduction;phosphatidylinositol phosphorylation;neuron fate commitment;oligodendrocyte differentiation;negative regulation of secretion;positive regulation of striated muscle cell differentiation;positive regulation of protein kinase B signaling;cardiac muscle cell differentiation;cardiac muscle cell myoblast differentiation;endocardial cell differentiation;positive regulation of protein tyrosine kinase activity;positive regulation of calcineurin-NFAT signaling cascade;postsynapse to nucleus signaling pathway;regulation of cell motility;positive regulation of cardiac muscle cell differentiation;negative regulation of neuron migration	extracellular region;extracellular space;nucleoplasm;cytoplasm;integral component of plasma membrane;membrane;axon;neuromuscular junction;glutamatergic synapse;GABA-ergic synapse	transcription coregulator activity;protein tyrosine kinase activity;Ras guanyl-nucleotide exchange factor activity;signaling receptor binding;cytokine activity;ErbB-2 class receptor binding;integrin binding;growth factor activity;protein tyrosine kinase activator activity;transmembrane receptor protein tyrosine kinase activator activity;receptor tyrosine kinase binding;ErbB-3 class receptor binding;chemorepellent activity;phosphatidylinositol-4,5-bisphosphate 3-kinase activity	LAPTM4B[unassigned1304];JAGN1[unassigned1304];CD72[unassigned1304];ERBB3[7592681;17697999];TMEM54[unassigned1304];ERBB2[7592681];PLP1[unassigned1304];CDC5L[20467437];HIST1H2BH[30021884];EGFR[24658140];ASGR2[unassigned1304];MS4A4A[unassigned1304];	32505909
5658	chr8	41529890	G	A	chr8:41529890	ANK1	ankyrin 1	SNV	0/1	0.2	16_4	20	70	rs567116417,COSV55892252	EXONIC	YES	NM_001142446.2	Transcript	protein_coding	missense_variant		39/43	NM_001142446.2:c.5201C>T	NP_001135918.1:p.Thr1734Met		-1.0	.,.,.				Spherocytosis, type 1, 182900 (3), Autosomal recessive, Autosomal dominant	8p11.2 deletion syndrome;Hereditary spherocytosis	Role in the phenotype of;Disease-causing germline mutation(s) in	Patent ductus arteriosus;Seizure;Iris coloboma;Nystagmus;Atrial septal defect;Short stature;Micrognathia;Epicanthus;Mitral valve prolapse;Microcephaly;Abnormality of the hypothalamus-pituitary axis;Retinal dystrophy;Preauricular pit;Splenomegaly;Hypogonadotropic hypogonadism;Anosmia;Global developmental delay;Cryptorchidism;Blepharophimosis;Intellectual disability;Feeding difficulties;Hypertelorism;High palate;Sacral dimple;Azoospermia;Spherocytosis;Talipes equinovarus;Microcornea;Supernumerary ribs;Hypoplasia of penis;External ear malformation;Depressed nasal bridge;Upslanted palpebral fissure;Hemolytic anemia;Restrictive cardiomyopathy;Pallor;Abdominal pain;Fever;Hypercoagulability;Growth delay;Reticulocytosis;Extramedullary hematopoiesis;Spherocytosis;Chills;Jaundice;Hepatomegaly;Abdominal distention;Ataxia;Myalgia;Gout;Splenomegaly;Hypofibrinogenemia;Muscle weakness;Maculopapular exanthema;Cholelithiasis;Spontaneous hemolytic crises;Increased red cell osmotic fragility;Increased mean corpuscular hemoglobin concentration;Skin ulcer;Hyperbilirubinemia;Autosomal dominant inheritance;Cholelithiasis;Hemolytic anemia;Splenomegaly;Reticulocytosis;Hyperbilirubinemia;Autosomal recessive inheritance;Spherocytosis;Jaundice		4.59982e-05	7.0	152180.0	0.0	33	0.97	PASS	nfe	7.3497e-05	5.0	7.3497e-05	5.0	2.79196e-05	7.0	250720.0	0.0	85	1.0	PASS	afr	0.000123031	2.0	1.76944e-05	2.0	0.0000322	5			9e-05	1		16.61	1.55914	0.018	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	ANK1	0.0	0.0	0.0	0.06	-18.0	46.0	5.0	-18.0						0.109	1.0	0.000000000	0.001	-2.122	liver/biliary system phenotype; behavior/neurological phenotype ; reproductive system phenotype; mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; pigmentation phenotype; nervous system phenotype ; immune system phenotype; skeleton phenotype; renal/urinary system phenotype; integument phenotype ; growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; homeostasis/metabolism phenotype; 			ciliary ganglion;pons;tongue;superior cervical ganglion;trigeminal ganglion;fetal liver;skeletal muscle;cerebellum peduncles;cerebellum;bone marrow;medulla oblongata;	.	exocytosis;endoplasmic reticulum to Golgi vesicle-mediated transport;cytoskeleton organization;signal transduction;positive regulation of organelle organization;maintenance of epithelial cell apical/basal polarity;protein localization to plasma membrane	nucleus;cytosol;cytoskeleton;plasma membrane;cytoplasmic side of plasma membrane;spectrin-associated cytoskeleton;membrane;basolateral plasma membrane;sarcoplasmic reticulum;Z disc;axolemma;M band;sarcolemma;axon initial segment;postsynaptic membrane	structural molecule activity;structural constituent of cytoskeleton;protein binding;cytoskeletal adaptor activity;enzyme binding;protein phosphatase binding;spectrin binding;ion channel binding;ATPase binding	OBSCN[12527750;16962094;25416956];SLC30A8[unassigned1304];TMEM203[unassigned1304];FXYD3[unassigned1304];DWORF[unassigned1304];NRM[unassigned1304];HSPB1[25277244];EMP1[unassigned1304];RBFA[unassigned1304];EMD[unassigned1304];	41529890
5676	chr8	41554268	G	A	chr8:41554268	ANK1	ankyrin 1	SNV	0/1	0.25	24_8	32	99	rs1464161575	EXONIC	YES	NM_001142446.2	Transcript	protein_coding	synonymous_variant		26/43	NM_001142446.2:c.2784C>T	NP_001135918.1:p.Asp928%3D		-1.0					Spherocytosis, type 1, 182900 (3), Autosomal recessive, Autosomal dominant	8p11.2 deletion syndrome;Hereditary spherocytosis	Role in the phenotype of;Disease-causing germline mutation(s) in	Patent ductus arteriosus;Seizure;Iris coloboma;Nystagmus;Atrial septal defect;Short stature;Micrognathia;Epicanthus;Mitral valve prolapse;Microcephaly;Abnormality of the hypothalamus-pituitary axis;Retinal dystrophy;Preauricular pit;Splenomegaly;Hypogonadotropic hypogonadism;Anosmia;Global developmental delay;Cryptorchidism;Blepharophimosis;Intellectual disability;Feeding difficulties;Hypertelorism;High palate;Sacral dimple;Azoospermia;Spherocytosis;Talipes equinovarus;Microcornea;Supernumerary ribs;Hypoplasia of penis;External ear malformation;Depressed nasal bridge;Upslanted palpebral fissure;Hemolytic anemia;Restrictive cardiomyopathy;Pallor;Abdominal pain;Fever;Hypercoagulability;Growth delay;Reticulocytosis;Extramedullary hematopoiesis;Spherocytosis;Chills;Jaundice;Hepatomegaly;Abdominal distention;Ataxia;Myalgia;Gout;Splenomegaly;Hypofibrinogenemia;Muscle weakness;Maculopapular exanthema;Cholelithiasis;Spontaneous hemolytic crises;Increased red cell osmotic fragility;Increased mean corpuscular hemoglobin concentration;Skin ulcer;Hyperbilirubinemia;Autosomal dominant inheritance;Cholelithiasis;Hemolytic anemia;Splenomegaly;Reticulocytosis;Hyperbilirubinemia;Autosomal recessive inheritance;Spherocytosis;Jaundice						32	0.96											100	0.97									0.0	1.0	0.00018	2		3.256	0.039831		0	0	0			ANK1	0.07	0.0	0.0	0.0	-15.0	13.0	13.0	-42.0						0.109	1.0	91.223814321			liver/biliary system phenotype; behavior/neurological phenotype ; reproductive system phenotype; mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; pigmentation phenotype; nervous system phenotype ; immune system phenotype; skeleton phenotype; renal/urinary system phenotype; integument phenotype ; growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; homeostasis/metabolism phenotype; 			ciliary ganglion;pons;tongue;superior cervical ganglion;trigeminal ganglion;fetal liver;skeletal muscle;cerebellum peduncles;cerebellum;bone marrow;medulla oblongata;	.	exocytosis;endoplasmic reticulum to Golgi vesicle-mediated transport;cytoskeleton organization;signal transduction;positive regulation of organelle organization;maintenance of epithelial cell apical/basal polarity;protein localization to plasma membrane	nucleus;cytosol;cytoskeleton;plasma membrane;cytoplasmic side of plasma membrane;spectrin-associated cytoskeleton;membrane;basolateral plasma membrane;sarcoplasmic reticulum;Z disc;axolemma;M band;sarcolemma;axon initial segment;postsynaptic membrane	structural molecule activity;structural constituent of cytoskeleton;protein binding;cytoskeletal adaptor activity;enzyme binding;protein phosphatase binding;spectrin binding;ion channel binding;ATPase binding	OBSCN[12527750;16962094;25416956];SLC30A8[unassigned1304];TMEM203[unassigned1304];FXYD3[unassigned1304];DWORF[unassigned1304];NRM[unassigned1304];HSPB1[25277244];EMP1[unassigned1304];RBFA[unassigned1304];EMD[unassigned1304];	41554268
5686	chr8	53580701	A	G	chr8:53580701	RB1CC1	RB1 inducible coiled-coil 1	SNV	0/1	0.35	30_16	46	99	rs35009616	EXONIC	YES	NM_014781.5	Transcript	protein_coding	synonymous_variant		8/24	NM_014781.5:c.1053T>C	NP_055596.3:p.Ile351%3D		-1.0		Benign	criteria_provided,_single_submitter	not_provided	Breast cancer, somatic, 114480 (3)	.	.	Somatic mutation;Autosomal dominant inheritance;Heterogeneous;Breast carcinoma		0.00388901	592.0	152224.0	0.0	33	0.98	PASS	nfe	0.00618845	421.0	0.00618845	421.0	0.00360517	906.0	251306.0	1.0	58	1.0	PASS	nfe	0.00589457	670.0	0.00589457	670.0	0.0033375	519	0.007	22.0	0.00754	86		11.94	0.798362		0	0	0			RB1CC1	0.01	0.0	0.0	0.0	19.0	39.0	19.0	39.0						0.345	1.0	27.450840706			immune system phenotype; digestive/alimentary phenotype; mortality/aging ; normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; liver/biliary system phenotype; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; integument phenotype ; 			amygdala;temporal lobe;occipital lobe;testis - interstitial;prefrontal cortex;subthalamic nucleus;superior cervical ganglion;cingulate cortex;trigeminal ganglion;parietal lobe;globus pallidus;medulla oblongata;	.	autophagosome assembly;autophagy of mitochondrion;liver development;positive regulation of protein phosphorylation;autophagy;cell cycle;heart development;macroautophagy;regulation of macroautophagy;autophagy of peroxisome;piecemeal microautophagy of the nucleus;positive regulation of cell size;positive regulation of JNK cascade;reticulophagy;glycophagy;negative regulation of extrinsic apoptotic signaling pathway	phagophore assembly site;lysosome;endoplasmic reticulum membrane;cytosol;extrinsic component of membrane;nuclear membrane;phagophore assembly site membrane;Atg1/ULK1 kinase complex	protein binding;protein kinase binding;protein-containing complex scaffold activity	ERRFI1[25640309];ERCC6L[17353931];DYRK2[23602568];CALCOCO2[21988832];IL24[25640309];WDR41[20562859];MRC2[25640309];MAP1LC3B[24290141];TBK1[20562859];MAP1LC3A[24290141];TBC1D32[20562859];MAP1LC3C[20562859;24290141];RB1CC1[20562859];SESN2[25040165];EPSTI1[25640309];LONP2[20562859];IL13RA2[25640309];SH3GL1[20562859];WASHC3[20562859];PRKAB2[20562859];DBNL[17353931];TSC22D1[17353931];HSBP1[20562859];GLCE[25640309];WIPI2[20562859];SAFB[20562859];ATG13[20562859;23392225;19597335];ATG12[17353931];SYN1[25640309];PTBP3[22575643];SGO1[26496610];MADD[25640309];POLR1E[17353931];ULK2[20562859];ULK1[20562859;23392225;23524951;25686248];SMCR8[20562859];UMPS[25640309];TP53[21775823];C9orf72[20562859;27334615;29950492];ITIH5[25640309];PRKAA2[20562859];LYPD3[25640309];GABARAP[20562859];HSP90B1[30021884];PSMC3IP[25640309];NSD3[25640309];NFS1[20562859];TCEAL4[26496610];ATG101[20562859;23392225;19597335];WIF1[25640309];SAFB2[20562859];VHL[17986458];MAP4[20562859];ATG5[23392225;23262492];RNF20[25640309];CDK19[17353931];SGTB[26496610];PLK1[20562859];GREB1[25640309];RPA1[20562859];HUWE1[26496610];RPA2[20562859];MOB4[17353931];DLG3[26496610];ATG16L1[20562859;23392225;23262492];HNRNPA2B1[20562859];TBKBP1[21903422];HBP1[25640309];BLID[25640309];THRSP[25640309];TACC1[26496610];VPS45[25640309];RBMX[20562859];TRIM33[20562859];BAP1[25640309];	53580701
5718	chr8	99162828	C	T	chr8:99162828	POP1	POP1 homolog, ribonuclease P/MRP subunit	SNV	0/1	0.33	18_9	27	99	rs146207855,COSV62892874	EXONIC	YES	NM_001145860.2	Transcript	protein_coding	missense_variant		14/16	NM_001145860.2:c.2018C>T	NP_001139332.1:p.Ala673Val		1.0	POPLD domain,POPLD domain				Anauxetic dysplasia 2, 617396 (3), Autosomal recessive	Anauxetic dysplasia	Disease-causing germline mutation(s) (loss of function) in	Shield chest;Thoracolumbar kyphoscoliosis;Short femoral neck;Short stature;Brachydactyly;Sparse hair;Hypoplastic iliac body;Small nail;Cubitus valgus;Midface retrusion;Short neck;Ovoid vertebral bodies;Autosomal recessive inheritance;Flexion contracture;Coxa valga;Metaphyseal dysplasia;Relative macrocephaly;Nail dysplasia;Hypoplasia of the femoral head;Delayed skeletal maturation;Hyperlordosis;Coxa vara;Macroglossia;Cervical spine instability;Hypodontia		7.88478e-05	12.0	152192.0	0.0	33	0.96	PASS	amr	0.000196335	3.0	5.87907e-05	4.0	6.76294e-05	17.0	251370.0	0.0	64	1.0	PASS	amr	0.000231321	8.0	7.91515e-05	9.0	0.0000643	10	0.0	1.0	0.00026	3		27.1	3.922958	0.346	13	8	21	SIFT,PolyPhen,Polyphen2_HDIV_pred,LRT_pred,M-CAP_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	Polyphen2_HVAR_pred,MetaLR_pred,MetaSVM_pred,FATHMM_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred	POP1	0.0	0.0	0.0	0.0	-36.0	-24.0	-6.0	30.0						0.969	0.0	0.000000000	0.899	1.026	.			.	.	tRNA 5'-leader removal;tRNA processing;tRNA catabolic process;RNA phosphodiester bond hydrolysis, endonucleolytic	ribonuclease MRP complex;extracellular space;nucleoplasm;nucleolar ribonuclease P complex;nucleolus;multimeric ribonuclease P complex	ribonuclease MRP activity;RNA binding;ribonuclease P activity;protein binding	ANKRD17[30021884];POP5[15096576];RPL10[26496610];POP1[15096576];POP4[15096576];PINX1[17353931];HNRNPU[26496610];YBX1[25497084];RBPJ[25609649];MKI67[26949251];FOXQ1[25609649];HIST1H3A[29568061];IFI16[25665578];RPP38[15096576];NOP56[26496610];EGR1[26496610];JUN[25609649];RPP40[15096576];RPS6[29568061];FOXL2[25609649];ESR1[21182205];NIPSNAP1[26496610];MNDA[25665578];KIF2C[26496610];RPP25[15096576];	99162828
5721	chr8	100133450	A	G	chr8:100133450	VPS13B	vacuolar protein sorting 13 homolog B	SNV	0/1	0.41	16_11	27	99	rs181625846	EXONIC	YES	NM_017890.5	Transcript	protein_coding	missense_variant		8/62	NM_017890.5:c.983A>G	NP_060360.3:p.His328Arg		1.0	.,.,.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Cohen_syndrome|History_of_neurodevelopmental_disorder|not_specified|not_provided	Cohen syndrome, 216550 (3), Autosomal recessive	Cohen syndrome	Disease-causing germline mutation(s) in	Myopia;Intrauterine growth retardation;Kyphosis;Prominent nasal bridge;Iris coloboma;Sandal gap;Gingival overgrowth;Microcephaly;Aplasia/Hypoplasia of the earlobes;Clinodactyly of the 5th finger;Narrow palm;Micrognathia;Nystagmus;Joint hyperflexibility;Cat cry;Chorioretinal dystrophy;Tapered finger;Abnormality of retinal pigmentation;Muscular hypotonia;Neutropenia;Abnormality of skin pigmentation;Hypoplasia of the zygomatic bone;Pectus excavatum;Reduced number of teeth;Neurological speech impairment;Cryptorchidism;Arachnodactyly;Finger syndactyly;Failure to thrive in infancy;High, narrow palate;Macrodontia;Scoliosis;Thick eyebrow;Preauricular skin tag;Hypoplasia of the maxilla;Obesity;Short philtrum;Mitral valve prolapse;Short stature;Open mouth;Feeding difficulties in infancy;Optic atrophy;Weak cry;Aplasia/Hypoplasia of the tongue;Genu valgum;Downslanted palpebral fissures;Intellectual disability;Slender toe;Long eyelashes;Cubitus valgus;Delayed puberty;Ventricular septal defect;Abnormality of the hip bone;Seizure;Low anterior hairline;Microphthalmia;Sensorineural hearing impairment;Strabismus;Global developmental delay;Thick hair;Decreased fetal movement;Joint hypermobility;Pes planus;Convex nasal ridge;Mitral valve prolapse;Microcephaly;Short metatarsal;Bone spicule pigmentation of the retina;Single transverse palmar crease;Visual impairment;Short metacarpal;Neutropenia;Lumbar hyperlordosis;Downslanted palpebral fissures;Narrow palm;Thick corpus callosum;Hypoplasia of the maxilla;Feeding difficulties in infancy;Seizure;Growth hormone deficiency;Neonatal hypotonia;Childhood-onset truncal obesity;Open mouth;Optic atrophy;Chorioretinal dystrophy;Autosomal recessive inheritance;Prominent nasal bridge;Thoracic scoliosis;Micrognathia;Cubitus valgus;Short stature;Reduced visual acuity;Cerebellar hypoplasia;Intellectual disability;Bull's eye maculopathy;Myopia;High, narrow palate;Nyctalopia;Motor delay;Tapered finger;Laryngomalacia;Delayed puberty;Facial hypotonia;Generalized hypotonia;Short philtrum;Macrodontia of permanent maxillary central incisor;Narrow palm;Thick eyebrow;Genu valgum;Small for gestational age;Leukopenia		0.000545349	83.0	152196.0	0.0	32	0.97	PASS	nfe	0.000940706	64.0	0.000940706	64.0	0.000545752	137.0	251030.0	0.0	42	0.98	PASS	amr	0.00110094	38.0	0.000775358	88.0	0.0005530	86	0.001	4.0	0.00194	22		15.8	1.415669	0.025	3	16	19	M-CAP_pred,FATHMM_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-XF_coding_pred	VPS13B	0.01	0.0	0.0	0.0	-45.0	26.0	-1.0	5.0						0.933	0.0	0.000000000	0.972	0.307	.			pons;ciliary ganglion;appendix;subthalamic nucleus;dorsal root ganglion;cingulate cortex;trigeminal ganglion;atrioventricular node;superior cervical ganglion;skeletal muscle;	.	protein transport	.	.	TGOLN2[29568061];HSPA8[30021884];DNAJC7[26496610];HIST3H3[30021884];CSNK1E[23455922];HIST1H1A[30021884];BET1[29568061];	100133450
5731	chr8	113317147	A	G	chr8:113317147	CSMD3	CUB and Sushi multiple domains 3	SNV	0/1	0.21	22_6	28	90	rs369450370	SPLICING	YES	NM_198123.2	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	51/70		NM_198123.2:c.8072-3T>C			-1.0						.	.	.		7.22838e-05	11.0	152178.0	0.0	32	0.97	PASS	amr	0.000196412	3.0	8.82249e-05	6.0	0.000137071	34.0	248046.0	0.0	79	0.86	PASS	nfe	0.000205449	23.0	0.000205449	23.0	0.0001158	18			0.00026	3		11.2	0.705617		0	0	0			CSMD3	0.0	0.02	0.0	0.0	-3.0	-49.0	-3.0	-49.0	3.56735433584142e-05	0.0	7.013	-1.061	5.952	0.585	1.0				.			ciliary ganglion;temporal lobe;prefrontal cortex;trigeminal ganglion;cingulate cortex;superior cervical ganglion;cerebellum peduncles;subthalamic nucleus;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;	.	regulation of dendrite development	plasma membrane;integral component of membrane	.	NEK4[25798074];	113317147
5761	chr8	144994028	C	T	chr8:144994028	PLEC	plectin	SNV	0/1	0.49	98_95	193	99	rs34132016	EXONIC	YES	NM_201380.4	Transcript	protein_coding	missense_variant		32/32	NM_201380.4:c.10372G>A	NP_958782.1:p.Gly3458Arg		-1.0	.,.,.,.,.,.,.,.,.,.	Conflicting_interpretations_of_pathogenicity	criteria_provided,_conflicting_interpretations	Epidermolysis_bullosa_simplex,_Ogna_type|Epidermolysis_bullosa_simplex_with_muscular_dystrophy|Epidermolysis_bullosa_simplex_with_pyloric_atresia|Limb-girdle_muscular_dystrophy,_type_2Q|Epidermolysis_bullosa_simplex_with_nail_dystrophy|not_specified|not_provided	?Epidermolysis bullosa simplex 5D, generalized intermediate, autosomal recessive, 616487 (3), Autosomal recessive; Epidermolysis bullosa simplex 5B, with muscular dystrophy, 226670 (3), Autosomal recessive; Epidermolysis bullosa simplex 5C, with pyloric atresia, 612138 (3), Autosomal recessive; Epidermolysis bullosa simplex 5A, Ogna type, 131950 (3), Autosomal dominant; Muscular dystrophy, limb-girdle, autosomal recessive 17, 613723 (3), Autosomal recessive	Epidermolysis bullosa simplex with pyloric atresia;Autosomal recessive limb-girdle muscular dystrophy type 2Q;Epidermolysis bullosa simplex with muscular dystrophy;Epidermolysis bullosa simplex, Ogna type	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Bruising susceptibility;Abnormal blistering of the skin;Onychogryposis;Skin erosion;Lumbar hyperlordosis;Muscular dystrophy;Motor delay;Difficulty climbing stairs;Skeletal muscle atrophy;Flexion contracture;Generalized muscle weakness;Autosomal recessive inheritance;Elevated serum creatine kinase;Rapidly progressive;Gowers sign;Fatigable weakness;Papule;Ptosis;Hypoplastic fingernail;Skin vesicle;Fatigue;Dermal atrophy;Abnormality of dental enamel;Mutism;Ophthalmoplegia;Aphasia;Myopathy;Oculomotor nerve palsy;Muscle flaccidity;Alopecia;Echolalia;Dysphasia;Hyperconvex fingernails;Urethral stricture;Carious teeth;Milia;Punctate keratitis;Scarring alopecia of scalp;Hypoplasia of dental enamel;Keratitis;Neonatal respiratory distress;Short stature;Abnormal blistering of the skin;Nail dystrophy;Increased connective tissue;Nail dysplasia;Muscular dystrophy;Autosomal recessive inheritance;Anemia;Palmoplantar hyperkeratosis;Skin fragility with non-scarring blistering;Hypoplastic dermoepidermal hemidesmosomes;Autosomal dominant inheritance;Bruising susceptibility;Onychogryposis of toenails;Abnormal blistering of the skin;Fragile skin;Polyhydramnios;Underdeveloped nasal alae;Flexion contracture;Congenital onset;Microtia;Autosomal recessive inheritance;Deeply set eye;Plantar hyperkeratosis;Autosomal recessive inheritance;Nail dystrophy;Dysphagia;Limitation of joint mobility;Aplasia cutis congenita;Anemia;Glomerulosclerosis;Renal dysplasia;Ureterocele;Aplasia of the bladder;Dehydration;Hydronephrosis;Sepsis;Polyhydramnios;Premature birth;Abnormality of the stomach;Failure to thrive;Skin erosion;Oral mucosal blisters;Difficulty climbing stairs;Calf muscle hypertrophy;Skeletal muscle atrophy;Achilles tendon contracture;Bilateral facial palsy;Bilateral ptosis;Gowers sign;Frequent falls;Generalized muscle weakness;Elevated serum creatine kinase;Dysphagia;Increased lactate dehydrogenase level;Global developmental delay;Areflexia;Exertional dyspnea;Atelectasis;Loss of ability to walk;Nasal speech;Bronchiolitis;Progressive proximal muscle weakness;Proximal upper limb muscle hypertrophy;Distal lower limb muscle weakness;Decreased cervical spine flexion due to contractures of posterior cervical muscles;Delayed gross motor development;Pelvic girdle muscle weakness;Right bundle branch block;Axial muscle atrophy;EMG: myopathic abnormalities;Pulmonary fibrosis;Autosomal recessive inheritance;Esophageal atresia;Nail dysplasia;Nail dystrophy;Congenital onset;Abnormality of the genitourinary system;Ectropion;Arthrogryposis multiplex congenita;Congenital pyloric atresia;Death in infancy;Elevated maternal serum alpha-fetoprotein;Axillary pterygium;Fragile skin;Intractable diarrhea;Polyhydramnios;Aplasia cutis congenita;Junctional split;Anonychia;Atrophic scars;Hypoplasia of dental enamel;Milia;Facial palsy;Skin ulcer;Toe syndactyly;Congenital localized absence of skin;Spinal dysraphism;Aplasia cutis congenita over the scalp vertex;Prolonged bleeding time;Finger syndactyly;Calvarial skull defect;Abnormality of bone mineral density	25741868	0.00551775	840.0	152236.0	5.0	33	0.98	PASS	nfe	0.00878843	598.0	0.00878843	598.0	0.00572259	1418.0	247790.0	7.0	100	0.99	PASS	nfe	0.00908718	1018.0	0.00908718	1018.0	0.0056783	883	0.01	29.0	0.01026	117		0.44	-0.272919	0.044	0	18	18		SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PLEC	0.0	0.0	0.0	0.0	-2.0	20.0	-2.0	20.0						0.00999	0.02	0.000000000	0.001	-2.021	integument phenotype ; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; normal phenotype; mortality/aging ; cardiovascular system phenotype ; hematopoietic system phenotype; behavior/neurological phenotype ; immune system phenotype; nervous system phenotype ; 			lung;ciliary ganglion;prefrontal cortex;atrioventricular node;placenta;skeletal muscle;	.	hemidesmosome assembly;wound healing;intermediate filament cytoskeleton organization	cytoplasm;cytosol;intermediate filament;plasma membrane;brush border;focal adhesion;membrane;sarcoplasm;hemidesmosome;sarcolemma;costamere;intermediate filament cytoskeleton;perinuclear region of cytoplasm;extracellular exosome	RNA binding;actin binding;structural molecule activity;structural constituent of cytoskeleton;protein binding;structural constituent of muscle;ankyrin binding;cadherin binding	ZNF451[30021884];GALNT14[30021884];UBE2D2[unassigned1312];OR4K17[30021884];PPP1CB[26496610];TUBB3[27291054];PPIP5K2[unassigned1312];PSMD3[30021884];SSX6[30021884];ZNF721[30021884];SYNPO[26496610];KRT6C[30021884];GBP6[30021884];GABARAPL1[20562859];PRKCH[30021884];KRT8[30021884];KAZN[30021884];OCRL[25107275];ANK3[21223964];CNPY3[30021884];GPR37L1[30021884];PPP1R3B[23414517];EWSR1[22240165];GPR161[30021884];PAPPA[30021884];MAP1A[30021884];KCTD13[19615732];SBDS[30021884];ROR1[30021884];DNA2[30021884];SQSTM1[20562859];SCG2[30021884];MXRA5[30021884];MAGEB4[30021884];CCDC27[30021884];KHDRBS1[30021884];CTTNBP2[30021884];ITPR1[30021884];IQGAP1[26496610];ADH6[30021884];MBTD1[30021884];PGBD4[30021884];TP53BP2[30021884];DVL3[unassigned1312];NUP88[unassigned1312];KIF3C[30021884];TAC1[30021884];N4BP2[30021884];QSER1[unassigned1312];MOAP1[30021884];SNAPIN[23414517];VCAM1[22623428];PDHA1[29128334];FANCM[30021884];FUS[22240165];TRAPPC5[30021884];SMAD9[15231748];ESR1[21182205];ESR2[25604459;21951318];SNUPN[30021884];PAN2[19615732];CS[30021884];ANLN[26496610];CCDC88A[unassigned1312];SNW1[20467437];WNK1[unassigned1312;30021884];AAK1[unassigned1312];GRB2[12577067];CDK12[30021884];ATR[30021884];AHCTF1[30021884];HIP1[30021884];MCM7[23764002];C2CD3[30021884];ITGB4[19242489];CTSZ[30021884];IFNA2[30021884];KIF14[30021884];MTR[30021884];PHF8[26496610];MAP1LC3B[20562859];METTL14[29507755];ACTR1A[30021884];TUBA1A[27291054];EXO1[30021884];TRPS1[30021884];MYO18B[30021884];MYO18A[26496610];ACP2[30021884];RBM6[30021884];PRMT5[30021884];TSC22D1[17353931];UTP11[30021884];DIS3[30021884];TRAF2[unassigned1774];URB2[30021884];ASH1L[30021884];ARFGAP3[unassigned1312];NIPSNAP1[26496610];PTBP3[22575643];TMIGD1[30021884];KIFC1[30021884];THRAP3[30021884];PEX5[30021884];CASQ2[30021884];MYH9[26496610];MAPRE1[26496610];INA[30021884];DNAH3[30021884];PPP1R15A[30021884];BECN1[22081109];LAMA5[30021884];AHNAK[unassigned1312];LUZP1[unassigned1312];DNAH5[30021884];DLST[29128334];RRBP1[30021884];TANK[unassigned1774];AXDND1[30021884];RECQL4[30021884];LIMA1[26496610];FGD5[30021884];FLNA[26496610];STAT6[30021884];FILIP1L[30021884];BUB1[26496610];PDLIM7[26496610];SLC25A25[30021884];R3HDML[30021884];SEC24B[unassigned1312];TAF15[22240165];URGCP[unassigned1312];USP20[19615732];STAT1[26966684];EYA4[unassigned1312];PLEKHA5[20936779];CDC5L[20467437];RSRC2[30021884];MYO19[26496610];TJP1[16944923];MCM3AP[30021884];KRT18[30021884];ACTC1[30021884];MYBBP1A[30021884];KANSL3[30021884];CAPZA2[26496610];HIST3H3[30021884];KRT14[30021884];ANKS4B[30021884];NCAPD3[30021884];PLCD1[30021884];CCDC62[30021884];	144994028
5783	chr8	144997856	C	T	chr8:144997856	PLEC	plectin	SNV	0/1	0.43	78_59	137	99	rs782450868	EXONIC	YES	NM_201380.4	Transcript	protein_coding	missense_variant		31/32	NM_201380.4:c.6652G>A	NP_958782.1:p.Gly2218Ser		-1.0	.,.,.,.,.,.,.,.,.	Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Epidermolysis_bullosa_simplex,_Ogna_type|Epidermolysis_bullosa_simplex_with_muscular_dystrophy|Epidermolysis_bullosa_simplex_with_pyloric_atresia|Limb-girdle_muscular_dystrophy,_type_2Q|Epidermolysis_bullosa_simplex_with_nail_dystrophy|not_specified	?Epidermolysis bullosa simplex 5D, generalized intermediate, autosomal recessive, 616487 (3), Autosomal recessive; Epidermolysis bullosa simplex 5B, with muscular dystrophy, 226670 (3), Autosomal recessive; Epidermolysis bullosa simplex 5C, with pyloric atresia, 612138 (3), Autosomal recessive; Epidermolysis bullosa simplex 5A, Ogna type, 131950 (3), Autosomal dominant; Muscular dystrophy, limb-girdle, autosomal recessive 17, 613723 (3), Autosomal recessive	Epidermolysis bullosa simplex with pyloric atresia;Autosomal recessive limb-girdle muscular dystrophy type 2Q;Epidermolysis bullosa simplex with muscular dystrophy;Epidermolysis bullosa simplex, Ogna type	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Bruising susceptibility;Abnormal blistering of the skin;Onychogryposis;Skin erosion;Lumbar hyperlordosis;Muscular dystrophy;Motor delay;Difficulty climbing stairs;Skeletal muscle atrophy;Flexion contracture;Generalized muscle weakness;Autosomal recessive inheritance;Elevated serum creatine kinase;Rapidly progressive;Gowers sign;Fatigable weakness;Papule;Ptosis;Hypoplastic fingernail;Skin vesicle;Fatigue;Dermal atrophy;Abnormality of dental enamel;Mutism;Ophthalmoplegia;Aphasia;Myopathy;Oculomotor nerve palsy;Muscle flaccidity;Alopecia;Echolalia;Dysphasia;Hyperconvex fingernails;Urethral stricture;Carious teeth;Milia;Punctate keratitis;Scarring alopecia of scalp;Hypoplasia of dental enamel;Keratitis;Neonatal respiratory distress;Short stature;Abnormal blistering of the skin;Nail dystrophy;Increased connective tissue;Nail dysplasia;Muscular dystrophy;Autosomal recessive inheritance;Anemia;Palmoplantar hyperkeratosis;Skin fragility with non-scarring blistering;Hypoplastic dermoepidermal hemidesmosomes;Autosomal dominant inheritance;Bruising susceptibility;Onychogryposis of toenails;Abnormal blistering of the skin;Fragile skin;Polyhydramnios;Underdeveloped nasal alae;Flexion contracture;Congenital onset;Microtia;Autosomal recessive inheritance;Deeply set eye;Plantar hyperkeratosis;Autosomal recessive inheritance;Nail dystrophy;Dysphagia;Limitation of joint mobility;Aplasia cutis congenita;Anemia;Glomerulosclerosis;Renal dysplasia;Ureterocele;Aplasia of the bladder;Dehydration;Hydronephrosis;Sepsis;Polyhydramnios;Premature birth;Abnormality of the stomach;Failure to thrive;Skin erosion;Oral mucosal blisters;Difficulty climbing stairs;Calf muscle hypertrophy;Skeletal muscle atrophy;Achilles tendon contracture;Bilateral facial palsy;Bilateral ptosis;Gowers sign;Frequent falls;Generalized muscle weakness;Elevated serum creatine kinase;Dysphagia;Increased lactate dehydrogenase level;Global developmental delay;Areflexia;Exertional dyspnea;Atelectasis;Loss of ability to walk;Nasal speech;Bronchiolitis;Progressive proximal muscle weakness;Proximal upper limb muscle hypertrophy;Distal lower limb muscle weakness;Decreased cervical spine flexion due to contractures of posterior cervical muscles;Delayed gross motor development;Pelvic girdle muscle weakness;Right bundle branch block;Axial muscle atrophy;EMG: myopathic abnormalities;Pulmonary fibrosis;Autosomal recessive inheritance;Esophageal atresia;Nail dysplasia;Nail dystrophy;Congenital onset;Abnormality of the genitourinary system;Ectropion;Arthrogryposis multiplex congenita;Congenital pyloric atresia;Death in infancy;Elevated maternal serum alpha-fetoprotein;Axillary pterygium;Fragile skin;Intractable diarrhea;Polyhydramnios;Aplasia cutis congenita;Junctional split;Anonychia;Atrophic scars;Hypoplasia of dental enamel;Milia;Facial palsy;Skin ulcer;Toe syndactyly;Congenital localized absence of skin;Spinal dysraphism;Aplasia cutis congenita over the scalp vertex;Prolonged bleeding time;Finger syndactyly;Calvarial skull defect;Abnormality of bone mineral density		5.91662e-05	9.0	152114.0	0.0	34	0.98	PASS	sas	0.000620347	3.0	1.47072e-05	1.0	0.000332294	49.0	147460.0	1.0	34	0.55	PASS	sas	0.00129545	31.0	1.69497e-05	1.0	0.0001415	22			0.00026	3		5.031	0.147238	0.003	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	PLEC	0.0	0.0	0.0	0.0	27.0	6.0	-19.0	0.0						0.00999	0.02	0.000000000	0.0	-1.562	integument phenotype ; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; normal phenotype; mortality/aging ; cardiovascular system phenotype ; hematopoietic system phenotype; behavior/neurological phenotype ; immune system phenotype; nervous system phenotype ; 			lung;ciliary ganglion;prefrontal cortex;atrioventricular node;placenta;skeletal muscle;	.	hemidesmosome assembly;wound healing;intermediate filament cytoskeleton organization	cytoplasm;cytosol;intermediate filament;plasma membrane;brush border;focal adhesion;membrane;sarcoplasm;hemidesmosome;sarcolemma;costamere;intermediate filament cytoskeleton;perinuclear region of cytoplasm;extracellular exosome	RNA binding;actin binding;structural molecule activity;structural constituent of cytoskeleton;protein binding;structural constituent of muscle;ankyrin binding;cadherin binding	ZNF451[30021884];GALNT14[30021884];UBE2D2[unassigned1312];OR4K17[30021884];PPP1CB[26496610];TUBB3[27291054];PPIP5K2[unassigned1312];PSMD3[30021884];SSX6[30021884];ZNF721[30021884];SYNPO[26496610];KRT6C[30021884];GBP6[30021884];GABARAPL1[20562859];PRKCH[30021884];KRT8[30021884];KAZN[30021884];OCRL[25107275];ANK3[21223964];CNPY3[30021884];GPR37L1[30021884];PPP1R3B[23414517];EWSR1[22240165];GPR161[30021884];PAPPA[30021884];MAP1A[30021884];KCTD13[19615732];SBDS[30021884];ROR1[30021884];DNA2[30021884];SQSTM1[20562859];SCG2[30021884];MXRA5[30021884];MAGEB4[30021884];CCDC27[30021884];KHDRBS1[30021884];CTTNBP2[30021884];ITPR1[30021884];IQGAP1[26496610];ADH6[30021884];MBTD1[30021884];PGBD4[30021884];TP53BP2[30021884];DVL3[unassigned1312];NUP88[unassigned1312];KIF3C[30021884];TAC1[30021884];N4BP2[30021884];QSER1[unassigned1312];MOAP1[30021884];SNAPIN[23414517];VCAM1[22623428];PDHA1[29128334];FANCM[30021884];FUS[22240165];TRAPPC5[30021884];SMAD9[15231748];ESR1[21182205];ESR2[25604459;21951318];SNUPN[30021884];PAN2[19615732];CS[30021884];ANLN[26496610];CCDC88A[unassigned1312];SNW1[20467437];WNK1[unassigned1312;30021884];AAK1[unassigned1312];GRB2[12577067];CDK12[30021884];ATR[30021884];AHCTF1[30021884];HIP1[30021884];MCM7[23764002];C2CD3[30021884];ITGB4[19242489];CTSZ[30021884];IFNA2[30021884];KIF14[30021884];MTR[30021884];PHF8[26496610];MAP1LC3B[20562859];METTL14[29507755];ACTR1A[30021884];TUBA1A[27291054];EXO1[30021884];TRPS1[30021884];MYO18B[30021884];MYO18A[26496610];ACP2[30021884];RBM6[30021884];PRMT5[30021884];TSC22D1[17353931];UTP11[30021884];DIS3[30021884];TRAF2[unassigned1774];URB2[30021884];ASH1L[30021884];ARFGAP3[unassigned1312];NIPSNAP1[26496610];PTBP3[22575643];TMIGD1[30021884];KIFC1[30021884];THRAP3[30021884];PEX5[30021884];CASQ2[30021884];MYH9[26496610];MAPRE1[26496610];INA[30021884];DNAH3[30021884];PPP1R15A[30021884];BECN1[22081109];LAMA5[30021884];AHNAK[unassigned1312];LUZP1[unassigned1312];DNAH5[30021884];DLST[29128334];RRBP1[30021884];TANK[unassigned1774];AXDND1[30021884];RECQL4[30021884];LIMA1[26496610];FGD5[30021884];FLNA[26496610];STAT6[30021884];FILIP1L[30021884];BUB1[26496610];PDLIM7[26496610];SLC25A25[30021884];R3HDML[30021884];SEC24B[unassigned1312];TAF15[22240165];URGCP[unassigned1312];USP20[19615732];STAT1[26966684];EYA4[unassigned1312];PLEKHA5[20936779];CDC5L[20467437];RSRC2[30021884];MYO19[26496610];TJP1[16944923];MCM3AP[30021884];KRT18[30021884];ACTC1[30021884];MYBBP1A[30021884];KANSL3[30021884];CAPZA2[26496610];HIST3H3[30021884];KRT14[30021884];ANKS4B[30021884];NCAPD3[30021884];PLCD1[30021884];CCDC62[30021884];	144997856
5811	chr8	145641421	G	A	chr8:145641421	SLC39A4	solute carrier family 39 member 4	SNV	0/1	0.59	41_59	100	99	rs1162583725	EXONIC	YES	NM_130849.4	Transcript	protein_coding	missense_variant		2/12	NM_130849.4:c.247C>T	NP_570901.3:p.Pro83Ser		-1.0	.,.				Acrodermatitis enteropathica, 201100 (3), Autosomal recessive	Acrodermatitis enteropathica	Disease-causing germline mutation(s) (loss of function) in	Ridged nail;Furrowed tongue;Abnormal eyebrow morphology;Corneal erosion;Ridged fingernail;Conjunctivitis;Paronychia;Weight loss;Cerebral cortical atrophy;Malabsorption;Anorexia;Short stature;Poor appetite;Blepharitis;Failure to thrive;Dry skin;Cheilitis;Visual impairment;Chronic diarrhea;Pustule;Photophobia;Abnormal blistering of the skin;Erythema;Alopecia;Skin ulcer;Emotional lability;Glossitis;Lethargy;Diarrhea;Infantile onset;Splenomegaly;Alopecia of scalp;Poor appetite;Decreased testicular size;Recurrent candida infections;Irritability;Failure to thrive;Hepatomegaly;Low alkaline phosphatase;Short stature;Ataxia;Decreased serum testosterone level;Tremor;Paronychia;Emotional lability;Impaired T cell function;Decreased taste sensation;Autosomal recessive inheritance;Hypogonadism		2.62895e-05	4.0	152152.0	0.0	34	0.97	PASS	sas	0.000206782	1.0	2.941e-05	2.0	4.9246e-06	1.0	203062.0	0.0	25	0.59	PASS	nfe	1.10344e-05	1.0	1.10344e-05	1.0					9e-05	1		0.665	-0.211594	0.027	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	SLC39A4	0.0	0.0	0.0	0.01	-44.0	-25.0	11.0	-25.0						0.53	0.01	0.000000000	0.0	-0.334	nervous system phenotype ; digestive/alimentary phenotype; vision/eye phenotype; skeleton phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging ; cardiovascular system phenotype ; endocrine/exocrine gland phenotype; muscle phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; 			trigeminal ganglion;	.	cellular zinc ion homeostasis;signal transduction;cellular response to zinc ion starvation;zinc ion import across plasma membrane	plasma membrane;integral component of plasma membrane;apical plasma membrane;cytoplasmic vesicle;recycling endosome membrane	zinc ion transmembrane transporter activity	ADRB2[28298427];	145641421
5925	chr9	73152148	C	T	chr9:73152148	TRPM3	transient receptor potential cation channel subfamily M member 3	SNV	0/1	0.51	37_38	75	99	rs751378692,COSV62596352	EXONIC	YES	NM_001366147.2	Transcript	protein_coding	missense_variant		27/27	NM_001366147.2:c.3956G>A	NP_001353076.1:p.Arg1319His		-1.0	.,.,.,.,.,.,.,.,.,.					.	.	.		0.000164283	25.0	152176.0	0.0	32	0.97	PASS	nfe	0.000293945	20.0	0.000293945	20.0	8.50919e-05	21.0	246792.0	1.0	43	0.78	PASS	nfe	0.000143115	16.0	0.000143115	16.0	0.0000836	13			0.00079	9		22.8	2.638627	0.157	5	11	16	LRT_pred,MutationTaster_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	M-CAP_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred	TRPM3	0.0	0.0	0.0	0.0	-18.0	-50.0	31.0	-40.0						0.767	0.0	0.000000000	0.998	1.026	integument phenotype ; behavior/neurological phenotype ; nervous system phenotype ; 			ciliary ganglion;prefrontal cortex;trigeminal ganglion;cingulate cortex;superior cervical ganglion;cerebellum peduncles;cerebellum;testis - interstitial;subthalamic nucleus;dorsal root ganglion;atrioventricular node;globus pallidus;medulla oblongata;	.	cation transport;detection of temperature stimulus;sensory perception of temperature stimulus;protein tetramerization;calcium ion transmembrane transport	plasma membrane;integral component of membrane	calcium activated cation channel activity;cation channel activity;calcium channel activity	.	73152148
5954	chr9	78943111	C	T	chr9:78943111	PCSK5	proprotein convertase subtilisin/kexin type 5	SNV	0/1	0.48	37_34	71	99	rs550842839,COSV70448053	EXONIC	YES	NM_001372043.1	Transcript	protein_coding	missense_variant		33/38	NM_001372043.1:c.4526C>T	NP_001358972.1:p.Ala1509Val		1.0	EGF-like domain&Tyrosine-protein kinase ephrin type A/B receptor-like,EGF-like domain&Tyrosine-protein kinase ephrin type A/B receptor-like					.	.	.		7.2298e-05	11.0	152148.0	0.0	32	0.96	PASS	sas	0.000414938	2.0	8.81912e-05	6.0	0.000128434	31.0	241370.0	1.0	100	0.98	PASS	sas	0.000757476	23.0	4.67115e-05	5.0	0.0001029	16			0.00031	3		13.34	0.987554	0.058	1	18	19	M-CAP_pred	SIFT,PolyPhen,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred															0.825	0.0	0.000000000	0.002	1.026	mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; respiratory system phenotype; embryo phenotype; skeleton phenotype; renal/urinary system phenotype; immune system phenotype; nervous system phenotype ; limbs/digits/tail phenotype; digestive/alimentary phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; cellular phenotype; craniofacial phenotype; 			.	.	kidney development;renin secretion into blood stream;cardiac septum development;signal peptide processing;cell-cell signaling;determination of left/right symmetry;heart development;embryo implantation;anterior/posterior pattern specification;protein processing;peptide hormone processing;viral life cycle;respiratory tube development;limb morphogenesis;cytokine biosynthetic process;peptide biosynthetic process;embryonic digestive tract development;embryonic skeletal system development;regulation of lipoprotein lipase activity;coronary vasculature development	extracellular region;extracellular space;Golgi apparatus;Golgi lumen;trans-Golgi network;membrane;integral component of membrane;secretory granule;integral component of Golgi membrane	endopeptidase activity;serine-type endopeptidase activity;protein binding;peptidase activity;peptide binding	TRADD[unassigned1774];ATN1[16713569];FAM86C1[unassigned1304];TNFAIP3[unassigned1774];MEOX2[25416956;unassigned1304];FARS2[unassigned1304];DMBX1[unassigned1304];CYSRT1[unassigned1304];ADAMTSL4[unassigned1304];STK16[25416956];C17orf50[unassigned1304];HOXA1[unassigned1304];TEKT4[unassigned1304];KRTAP3-2[unassigned1304];IKBKG[unassigned1774];KRTAP3-1[unassigned1304];KRTAP1-1[unassigned1304];KRTAP11-1[unassigned1304];KRTAP5-9[25416956;unassigned1304];GLRX3[25416956];KRTAP13-3[unassigned1304];C22orf39[unassigned1304];FRS3[unassigned1304];LCE1F[unassigned1304];LCE1D[unassigned1304];AES[unassigned1304];LCE2C[unassigned1304];HOXB9[unassigned1304];TRAF4[unassigned1304];KRTAP4-12[25416956];ZNF837[unassigned1304];PLSCR4[unassigned1304];TRIB3[unassigned1304];DOCK2[unassigned1304];MDFI[unassigned1304];CREB5[unassigned1304];VGLL3[unassigned1304];NUFIP2[25416956;unassigned1304];USP54[unassigned1304];CACNA1A[21078624];DBF4B[unassigned1304];TANK[unassigned1774];LCE3C[25416956;unassigned1304];LCE3D[unassigned1304];GUCD1[unassigned1304];ZNF547[unassigned1304];OTX1[unassigned1304];TRIM42[unassigned1304];TXNDC5[unassigned1304];SMCP[unassigned1304];KRTAP12-2[unassigned1304];KRTAP10-7[25416956];KRTAP10-9[unassigned1304];KRTAP10-8[25416956;unassigned1304];INCA1[unassigned1304];DDIT4L[unassigned1304];NR1D2[unassigned1304];RYDEN[unassigned1304];NOTCH2NLA[25416956;unassigned1304];POU4F2[unassigned1304];NR4A3[unassigned1304];APPBP2[16189514];SPRY1[unassigned1304];TRIP13[unassigned1304];	78943111
5956	chr9	94486847	G	A	chr9:94486847	ROR2	receptor tyrosine kinase like orphan receptor 2	SNV	0/1	0.5	43_43	86	99	rs150089842	EXONIC	YES	NM_004560.4	Transcript	protein_coding	synonymous_variant		9/9	NM_004560.4:c.1929C>T	NP_004551.2:p.Ala643%3D		-1.0					Brachydactyly, type B1, 113000 (3), Autosomal dominant; Robinow syndrome, autosomal recessive, 268310 (3), Autosomal recessive	Autosomal recessive Robinow syndrome;Brachydactyly type B	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (gain of function) in	Intellectual disability;Recurrent respiratory infections;Abnormality of the hip bone;Elbow dislocation;Hypoplastic female external genitalia;Long palpebral fissure;Sandal gap;Strabismus;Exaggerated cupid's bow;Disproportionate short-limb short stature;Wide nasal bridge;Synostosis of carpal bones;Fingernail dysplasia;Rib fusion;Split hand;Anteverted nares;Scoliosis;Short nose;Short neck;Camptodactyly of finger;Atrial septal defect;Short philtrum;Hearing impairment;Abnormal palate morphology;Wide mouth;Abnormal aortic morphology;Increased number of teeth;Toe syndactyly;Downturned corners of mouth;Midface retrusion;Umbilical hernia;Brachydactyly;Tetralogy of Fallot;Multicystic kidney dysplasia;Blue sclerae;Nevus flammeus;Ventricular septal defect;Alopecia;Inguinal hernia;Ankyloglossia;Long philtrum;Ptosis;Micrognathia;Oral cleft;Downslanted palpebral fissures;Finger syndactyly;Death in infancy;Low-set, posteriorly rotated ears;Hypoplasia of penis;Kyphosis;Bilateral single transverse palmar creases;Long eyelashes;Depressed nasal bridge;Cryptorchidism;Abnormal tricuspid valve morphology;Hypertelorism;Frontal bossing;Gingival overgrowth;Mesomelia;Chronic otitis media;Sacral dimple;Abnormal pulmonary valve morphology;Tented upper lip vermilion;Pectus carinatum;Hydronephrosis;Clinodactyly of the 5th finger;Open bite;Ectopic anus;Pectus excavatum;Epicanthus;Macrocephaly;Proptosis;Hypodontia;Vertebral segmentation defect;Short distal phalanx of finger;Bifid tongue;Broad hallux phalanx;Broad thumb;Upslanted palpebral fissure;Absent fingernail;Symphalangism affecting the phalanges of the hand;Short metacarpal;Synostosis of carpal bones;Broad hallux phalanx;Finger syndactyly;Short foot;2nd-5th toe middle phalangeal hypoplasia;Short distal phalanx of finger;Type B brachydactyly;Hypoplastic sacrum;Ventricular septal defect;Delayed cranial suture closure;Broad thumb;Aplasia/Hypoplasia of the distal phalanges of the toes;Camptodactyly;Short long bone;Micropenis;Short middle phalanx of finger;Wide anterior fontanel;Anonychia;Autosomal dominant inheritance;Vertebral fusion;Delayed eruption of permanent teeth;Aplasia/Hypoplasia of the distal phalanges of the hand;Cutaneous finger syndactyly;Hypoplastic fingernail;Syndactyly;Joint contracture of the hand;Hemivertebrae;Thoracolumbar scoliosis;Type B brachydactyly;Micrognathia;Inguinal hernia;Long palpebral fissure;Scoliosis;Anteverted nares;Aplasia/Hypoplasia involving the metacarpal bones;Depressed nasal bridge;Micropenis;Long eyelashes;Umbilical hernia;Autosomal recessive inheritance;Duplication of the distal phalanx of hand;Short nose;Broad thumb;Radial deviation of finger;Intellectual disability;Thoracolumbar scoliosis;Missing ribs;Triangular mouth;Delayed cranial suture closure;Thin upper lip vermilion;Right ventricular outlet tract obstruction;Midface retrusion;Nevus flammeus;Short palm;Global developmental delay;Bifid distal phalanx of toe;Frontal bossing;Small hand;Hypoplastic labia majora;Short stature;Bifid tongue;Hypoplastic sacrum;Macrocephaly;Brachydactyly;Thoracic hemivertebrae;Flat face;Delayed skeletal maturation;Wide anterior fontanel;Macroglossia;Downslanted palpebral fissures;Hydronephrosis;Proptosis;Broad toe;Renal duplication;Long philtrum;Posteriorly rotated ears;Short middle phalanx of the 5th finger;Gingival overgrowth;Cryptorchidism;Thin upper lip vermilion;Low-set ears;Hypertelorism;Wide nasal bridge;Nail dysplasia;Pectus excavatum;Clinodactyly;Absent uvula;Malar flattening;Retrognathia;Delayed eruption of permanent teeth;Vertebral fusion;Dental crowding;Mesomelia;Rib fusion;Clitoral hypoplasia;Short neck		4.59957e-05	7.0	152188.0	0.0	33	0.98	PASS	amr	0.000130856	2.0	5.87959e-05	4.0	3.58032e-05	9.0	251374.0	0.0	100	1.0	PASS	amr	8.67253e-05	3.0	4.39847e-05	5.0	0.0000322	5	0.0	1.0	0.00035	4		1.283	-0.113816		0	0	0			ROR2	0.0	0.0	0.0	0.0	-16.0	-13.0	12.0	-9.0						0.0625	0.46	4.533184568			adipose tissue phenotype ; endocrine/exocrine gland phenotype; growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; respiratory system phenotype; embryo phenotype; mortality/aging ; reproductive system phenotype; cardiovascular system phenotype ; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype ; limbs/digits/tail phenotype; digestive/alimentary phenotype; skeleton phenotype; 			.	.	cartilage condensation;somitogenesis;signal transduction;transmembrane receptor protein tyrosine kinase signaling pathway;Wnt signaling pathway, calcium modulating pathway;smoothened signaling pathway;JNK cascade;multicellular organism development;negative regulation of cell population proliferation;astrocyte development;peptidyl-tyrosine phosphorylation;bone mineralization;positive regulation of cell migration;BMP signaling pathway;embryonic genitalia morphogenesis;male genitalia development;inner ear morphogenesis;embryonic digit morphogenesis;positive regulation of JUN kinase activity;cell fate commitment;positive regulation of macrophage differentiation;positive regulation of transcription, DNA-templated;anatomical structure development;positive regulation of synaptic transmission, glutamatergic;Wnt signaling pathway, planar cell polarity pathway;SMAD protein signal transduction;negative regulation of canonical Wnt signaling pathway;positive regulation of canonical Wnt signaling pathway;positive regulation of protein kinase C activity;macrophage migration	microtubule;plasma membrane;integral component of plasma membrane;cell surface;axon;dendrite;clathrin-coated endocytic vesicle membrane;neuronal cell body;receptor complex	transmembrane receptor protein tyrosine kinase activity;frizzled binding;protein binding;ATP binding;Wnt-protein binding;mitogen-activated protein kinase kinase kinase binding;metal ion binding;coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway	"C1orf94[25416956;unassigned1304];DAZAP2[25416956;unassigned1304];RHOXF2[unassigned1304];HSP90AB1[22939624];CRX[25416956;unassigned1304];CREM[unassigned1304];FAM168B[unassigned1304];ZMYM4[25416956];PRR20C[25416956];KRTAP7-1[unassigned1304];KRTAP6-2[unassigned1304];PRR20D[unassigned1304];C10orf55[unassigned1304];PITX1[unassigned1304];LINC00311[unassigned1304];STOX1[unassigned1304];PRKAB2[unassigned1304];C19orf54[unassigned1304];RBPMS[25416956];MSX2[unassigned1304];KU-MEL-3[unassigned1304];DSCR10[unassigned1304];ARID5A[unassigned1304];ALG13[unassigned1304];SOX14[unassigned1304];DDIT4L[unassigned1304];""Em[unassigned1304];C3orf56[unassigned1304];DAB1[25416956];TMEM17[26638075];KIAA1218[unassigned1304];TLX3[unassigned1304];TMEM216[26638075];POU2AF1[unassigned1304];BHLHE40[unassigned1304];PLA2G10[unassigned1304];LHX6[unassigned1304];FOSB[unassigned1304];ROR2[25416956];"	94486847
5971	chr9	107546669	TT		chr9:107546669-107546670	ABCA1	ATP binding cassette subfamily A member 1	deletion	0/1	0.12	14_2	16	44		EXONIC	YES	NM_005502.4	Transcript	protein_coding	frameshift_variant		50/50	NM_005502.4:c.6712_6713del	NP_005493.2:p.Asn2238ProfsTer16		-1.0					Tangier disease, 205400 (3), Autosomal recessive; HDL deficiency, familial, 1, 604091 (3), Autosomal dominant	Apolipoprotein A-I deficiency;Tangier disease	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Hyporeflexia;Facial diplegia;Dry skin;Coronary artery atherosclerosis;Nail dysplasia;Autosomal recessive inheritance;Nail dystrophy;Cicatricial ectropion;Peripheral demyelination;Visual impairment;Myocardial infarction;Decreased HDL cholesterol concentration;Impaired temperature sensation;Distal amyotrophy;Opacification of the corneal stroma;Impaired pain sensation;Left ventricular hypertrophy;Splenomegaly;Peripheral axonal neuropathy;Hepatomegaly;Ectropion;Autosomal dominant inheritance;Myocardial infarction;Premature coronary artery atherosclerosis;Decreased HDL cholesterol concentration;Anemia;EMG abnormality;Splenomegaly;Hemiplegia/hemiparesis;Lymphadenopathy;Blurred vision;Xanthomatosis;Corneal opacity;Decreased HDL cholesterol concentration;Abnormality of the liver;Coronary artery stenosis;Thrombocytopenia;Chronic noninfectious lymphadenopathy;Left ventricular hypertrophy;Impaired thermal sensitivity;Anemia;Accelerated atherosclerosis;Progressive peripheral neuropathy;Corneal opacity;Hypocholesterolemia;Orange discolored tonsils;Carotid artery stenosis;Facial diplegia;Nail dystrophy;Hepatosplenomegaly;Hypertriglyceridemia;Peripheral axonal neuropathy;Distal muscle weakness;Syringomyelia;Dry skin;Ectropion;Abdominal pain						32	0.97											94	1.0											9e-05	1					0	0	0			ABCA1	0.03	0.02	0.0	0.0	47.0	-43.0	41.0	39.0						0.0388	0.0	57.919392056			digestive/alimentary phenotype; nervous system phenotype ; vision/eye phenotype; immune system phenotype; skeleton phenotype; renal/urinary system phenotype; embryo phenotype; liver/biliary system phenotype; respiratory system phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; reproductive system phenotype; mortality/aging ; pigmentation phenotype; endocrine/exocrine gland phenotype; muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; 			.	ABC transporters	protein lipidation;lipid transport;phagocytosis, engulfment;lysosome organization;G protein-coupled receptor signaling pathway;adenylate cyclase-activating G protein-coupled receptor signaling pathway;response to nutrient;cholesterol metabolic process;negative regulation of macrophage derived foam cell differentiation;positive regulation of cholesterol efflux;negative regulation of cholesterol storage;endosomal transport;regulation of lipid metabolic process;intracellular cholesterol transport;regulation of Cdc42 protein signal transduction;cholesterol efflux;phospholipid efflux;high-density lipoprotein particle assembly;response to laminar fluid shear stress;apolipoprotein A-I-mediated signaling pathway;response to drug;cholesterol homeostasis;reverse cholesterol transport;phospholipid translocation;interleukin-1 beta secretion;phospholipid homeostasis;platelet dense granule organization;cellular response to lipopolysaccharide;cellular response to retinoic acid;cellular response to cholesterol;cellular response to low-density lipoprotein particle stimulus;regulation of high-density lipoprotein particle assembly;anion transmembrane transport	endoplasmic reticulum membrane;Golgi apparatus;plasma membrane;integral component of plasma membrane;external side of plasma membrane;endocytic vesicle;intracellular membrane-bounded organelle;membrane raft;phagocytic vesicle;perinuclear region of cytoplasm	signaling receptor binding;lipid transporter activity;protein binding;ATP binding;phospholipid binding;phospholipid transporter activity;high-density lipoprotein particle binding;anion transmembrane transporter activity;cholesterol binding;ATPase activity;cholesterol transporter activity;syntaxin binding;small GTPase binding;apolipoprotein binding;apolipoprotein A-I binding;apolipoprotein A-I receptor activity;ATPase activity, coupled to transmembrane movement of substances;ATPase binding;phosphatidylcholine-translocating ATPase activity;phosphatidylserine-translocating ATPase activity	STX12[15469992];KIF11[25170080];ABCA12[23931754];LIN7B[16192269];CDC42[16443932];SPTLC1[25170080];MYC[21150319];FLOT1[15469992];FLNA[25170080];DMD[25170080];IKBKG[21988832];MPDZ[16192269];SNTA1[16192269];TGM2[21988832];ARHGEF11[16192269];ARHGEF12[16192269];DTNB[16192269];NR1H2[23931754];APOA1[12084722];DLG2[16192269];DLG3[16192269];CANX[25170080];UTRN[16192269;25170080];SNTB1[16192269];SNTB2[12054535;16192269];	107546668
6022	chr9	133333859	G	A	chr9:133333859	ASS1	argininosuccinate synthase 1	SNV	0/1	0.47	30_27	57	99	rs757342268	EXONIC	YES	NM_000050.4	Transcript	protein_coding	synonymous_variant		5/16	NM_000050.4:c.246G>A	NP_000041.2:p.Leu82%3D		1.0		Likely_benign	criteria_provided,_single_submitter	Citrullinemia	Citrullinemia, 215700 (3), Autosomal recessive	Acute neonatal citrullinemia type I;Adult-onset citrullinemia type I	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in	Protein avoidance;Neonatal onset;Intellectual disability;Seizure;Hyperammonemia;Hepatomegaly;Ataxia;Autosomal recessive inheritance;Global developmental delay;Hypoargininemia;Coma;Oroticaciduria;Failure to thrive;Cerebral edema;Respiratory alkalosis;Vomiting;Hyperglutaminemia;Irritability;Lethargy;Cirrhosis;Stroke;Episodic ammonia intoxication		1.31387e-05	2.0	152222.0	0.0	33	0.98	PASS	nfe	1.46955e-05	1.0	1.46955e-05	1.0	1.1953e-05	3.0	250982.0	0.0	100	1.0	PASS	sas	3.26627e-05	1.0	8.82597e-06	1.0	0.0000064	1			9e-05	1		7.094	0.290943		0	0	0			ASS1	0.0	0.0	0.0	0.0	39.0	-48.0	39.0	-1.0						0.0989	0.0	1.044461522			mortality/aging ; normal phenotype; behavior/neurological phenotype ; nervous system phenotype ; digestive/alimentary phenotype; integument phenotype ; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; 			kidney;liver;adipose tissue;fetal lung;fetal liver;	Urea cycle and metabolism of amino groups;Alanine and aspartate metabolism;Arginine and proline metabolism	urea cycle;citrulline metabolic process;argininosuccinate metabolic process;kidney development;liver development;arginine biosynthetic process;aspartate metabolic process;acute-phase response;midgut development;aging;response to nutrient;circadian rhythm;response to zinc ion;response to mycotoxin;response to estradiol;positive regulation of nitric oxide biosynthetic process;response to growth hormone;diaphragm development;cellular response to lipopolysaccharide;cellular response to amino acid stimulus;cellular response to ammonium ion;cellular response to cAMP;cellular response to interferon-gamma;cellular response to tumor necrosis factor;cellular response to glucagon stimulus;cellular response to oleic acid;cellular response to amine stimulus;cellular response to laminar fluid shear stress;cellular response to dexamethasone stimulus;negative regulation of leukocyte cell-cell adhesion	nucleus;cytoplasm;mitochondrial outer membrane;lysosome;endoplasmic reticulum;cytosol;perikaryon;myelin sheath;extracellular exosome;cell body fiber	RNA binding;argininosuccinate synthase activity;protein binding;ATP binding;toxic substance binding;amino acid binding;identical protein binding	RAB2A[26496610];PTPN1[21988832];SGTB[26496610];SORT1[26496610];AKTIP[16169070];MBD2[27593931];ARAF[12620389];SCLT1[26638075];RPGRIP1L[26638075];MLH1[20706999];TERF1[21044950];YWHAZ[15161933];TERF2[21044950];ASS1[16189514;21988832;25416956];USF1[26496610];NMRAL1[17496144];LATS1[24255178];MT2A[21988832];MYC[17314511];ASCC2[16169070];JAK2[21988832];CDR2[11988016];	133333859
6157	chr9	138670668	G	A	chr9:138670668	KCNT1	potassium sodium-activated channel subfamily T member 1	SNV	0/1	0.48	33_30	63	99	rs151272083,CM159563	SPLICING	YES	NM_020822.3	Transcript	protein_coding	missense_variant,splice_region_variant		23/31	NM_020822.3:c.2729G>A	NP_065873.2:p.Arg910Gln		1.0	.,.,.,.,.,.,.,.,.,.	Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Seizure|Early_infantile_epileptic_encephalopathy_14|Epilepsy,_nocturnal_frontal_lobe,_5|not_specified|not_provided	Developmental and epileptic encephalopathy 14, 614959 (3), Autosomal dominant; Epilepsy nocturnal frontal lobe, 5, 615005 (3), Autosomal dominant	Malignant migrating partial seizures of infancy;Autosomal dominant nocturnal frontal lobe epilepsy	Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in	Gliosis;Progressive;Cerebral cortical atrophy;Autosomal dominant inheritance;Developmental regression;Epileptic encephalopathy;Clonus;Poor eye contact;Status epilepticus;Spasticity;Microcephaly;Hypoplasia of the corpus callosum;Neuronal loss in central nervous system;Tetraplegia;Generalized hypotonia;Delayed myelination;Status epilepticus;Autosomal dominant inheritance;Cognitive impairment;Psychosis;Depressivity;Focal-onset seizure;Aggressive behavior;Behavioral abnormality;Intellectual disability;Personality disorder	26105150	0.00153854	234.0	152092.0	1.0	33	0.97	PASS	nfe	0.00252919	172.0	0.00252919	172.0	0.000456321	114.0	249824.0	0.0	52	0.99	PASS	nfe	0.000835496	94.0	0.000835496	94.0	0.0013376	208	0.002	6.0	0.00252	24		35.0	6.076848	0.946	14	6	20	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred,fathmm-XF_coding_pred	FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred	KCNT1	0.0	0.0	0.0	0.48	2.0	11.0	-17.0	0.0	0.999984816029826	1.0	5.645	4.095	9.74	0.577	0.01	0.000000000	0.985	1.083	nervous system phenotype ; behavior/neurological phenotype ; integument phenotype ; normal phenotype; 			.	.	regulation of membrane potential;potassium ion transmembrane transport	plasma membrane;integral component of membrane	intracellular sodium activated potassium channel activity;outward rectifier potassium channel activity	.	138670668
6185	chr9	140109647	C	T	chr9:140109647	NDOR1	NADPH dependent diflavin oxidoreductase 1	SNV	0/1	0.29	61_25	86	99	rs150718423,COSV104657580	EXONIC	YES	NM_001144026.3	Transcript	protein_coding	missense_variant		9/14	NM_001144026.3:c.1166C>T	NP_001137498.1:p.Ser389Leu		1.0	.,.,.,Sulfite reductase [NADPH] flavoprotein alpha-component-like, FAD-binding&Flavoprotein pyridine nucleotide cytochrome reductase&FAD-binding domain, ferredoxin reductase-type					.	.	.		0.00338335	515.0	152216.0	3.0	33	0.98	PASS	nfe	0.00398307	271.0	0.00398307	271.0	0.00388181	953.0	245504.0	14.0	49	0.86	PASS	sas	0.00450093	136.0	0.00370797	412.0	0.0036012	560	0.003	9.0	0.00359	41		25.0	3.500274	0.727	13	7	20	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,MetaLR_pred,MetaSVM_pred,MutationAssessor_pred,MutationTaster_pred,PROVEAN_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred	FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,ClinPred_pred,fathmm-XF_coding_pred	NDOR1	0.0	0.0	0.0	0.0	-20.0	1.0	3.0	19.0						0.0805	0.0	0.000000000	0.159	1.022	integument phenotype ; growth/size/body region phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype ; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; reproductive system phenotype; mortality/aging ; hematopoietic system phenotype; cardiovascular system phenotype ; neoplasm; pigmentation phenotype; embryo phenotype; respiratory system phenotype; liver/biliary system phenotype; behavior/neurological phenotype ; immune system phenotype; renal/urinary system phenotype; skeleton phenotype; nervous system phenotype ; limbs/digits/tail phenotype; digestive/alimentary phenotype; 			testis - seminiferous tubule;cingulate cortex;skeletal muscle;	.	cell death;iron-sulfur cluster assembly;cellular response to menadione;oxidation-reduction process	nucleus;cytoplasm;cytosol;intermediate filament cytoskeleton;perinuclear region of cytoplasm	NADPH-hemoprotein reductase activity;protein binding;FMN binding;oxidoreductase activity;flavin adenine dinucleotide binding;NADP binding	NAB2[unassigned1304];GPS2[unassigned1304];ZBTB42[unassigned1304];NLK[unassigned1304];MEOX1[unassigned1304];TCHP[25416956;unassigned1304];TEPSIN[unassigned1304];PSMB6[unassigned1304];UBQLN1[unassigned1304];ZNF620[unassigned1304];UBQLN2[unassigned1304];LMO2[unassigned1304];MTUS2[25416956;unassigned1304];REXO1L1P[unassigned1304];AES[unassigned1304];ZC2HC1C[unassigned1304];LNX1[unassigned1304];TCF4[25416956;unassigned1304];HOXB2[unassigned1304];CIAPIN1[25416956;unassigned1304];EFHC2[25416956];ZNF774[unassigned1304];GAS8[unassigned1304];KIAA0408[unassigned1304];GLYR1[unassigned1304];CCDC84[unassigned1304];	140109647
6207	chrX	19389185	A		chrX:19389185	MAP3K15	mitogen-activated protein kinase kinase kinase 15	deletion	0/1	0.21	15_4	19	51	rs372545551	SPLICING	YES	NM_001001671.4	Transcript	protein_coding	splice_polypyrimidine_tract_variant,splice_region_variant,intron_variant	23/28		NM_001001671.4:c.3295-3del			-1.0						.	.	.		0.00391132	377.0	96387.0	0.0	20	0.52	PASS	nfe	0.00300977	143.0	0.00300977	143.0	0.332209	14672.0	44165.0	0.0	12	0.28	RF	sas	0.380608	1264.0	0.318171	6435.0	0.0005209,0.0000064,0.0992386	81,1,15432			0.21196	2393		3.381	0.047379		0	0	0			MAP3K15	0.0	0.0	0.0	0.0	26.0	-2.0	-1.0	21.0							0.0				cardiovascular system phenotype ; renal/urinary system phenotype; cellular phenotype; 			.	.	MAPK cascade;activation of MAPKK activity	.	protein kinase activity;MAP kinase kinase kinase activity;ATP binding;metal ion binding	PRKAB2[20562859];HSP90AB1[22939624];CDC37[25036637];	19389184
6277	chrX	49104693	G	C	chrX:49104693	CCDC22	coiled-coil domain containing 22	SNV	0/1	0.34	69_35	104	99	rs199995957	EXONIC	YES	NM_014008.5	Transcript	protein_coding	missense_variant		10/17	NM_014008.5:c.1134G>C	NP_054727.1:p.Glu378Asp		1.0					Ritscher-Schinzel syndrome 2, 300963 (3), X-linked recessive	3C syndrome	Disease-causing germline mutation(s) (loss of function) in	Growth delay;Generalized hypotonia;Syndactyly;Macrocephaly;Protruding tongue;Low posterior hairline;Broad forehead;Poor speech;Broad hallux;Camptodactyly;Upslanted palpebral fissure;Short philtrum;Hypertelorism;Ventricular septal defect;Cerebellar hypoplasia;Clinodactyly;Dandy-Walker malformation;Short distal phalanx of finger;Patent ductus arteriosus;Global developmental delay;Scoliosis;Atrial septal defect;Overlapping toe;X-linked recessive inheritance;Cryptorchidism;Broad neck;Glaucoma;Ectopic anus;Abnormality of the fontanelles or cranial sutures;Ventricular septal defect;Abnormality of neuronal migration;High, narrow palate;Feeding difficulties in infancy;Low-set ears;Recurrent respiratory infections;Inguinal hernia;Pulmonic stenosis;Downslanted palpebral fissures;Muscular hypotonia;Micrognathia;Hydrocephalus;Hand polydactyly;Neurological speech impairment;Single umbilical artery;Hydronephrosis;Dandy-Walker malformation;Finger syndactyly;Aplasia/Hypoplasia of the nipples;Hypertelorism;Prominent occiput;Cleft palate;Short nose;Macrocephaly;Tetralogy of Fallot;Preauricular skin tag;Abnormal mitral valve morphology;Hypoplastic fingernail;Short stature;Short neck;Hypoplasia of penis;Aortic valve stenosis;Wide nasal bridge;Adrenal hypoplasia;Chorioretinal coloboma;Postnatal growth retardation;Global developmental delay;Scoliosis;Abnormality of the hip bone;Hemivertebrae;Hypospadias;Brachydactyly;Intestinal malrotation;Atrioventricular canal defect;Aplasia/Hypoplasia of the cerebellum;Abnormal tricuspid valve morphology;Iris coloboma;Depressed nasal bridge;Missing ribs;Hypoplastic left heart;Frontal bossing;Anal atresia;Atrial septal defect;Gastroesophageal reflux;Optic atrophy;Death in infancy;Facial hemangioma;Intellectual disability;Kyphosis		0.000171364	19.0	110875.0	0.0	22	0.57	PASS	nfe	0.000303139	16.0	0.000303139	16.0	0.000144074	25.0	173522.0	0.0	51	0.89	PASS	nfe	0.000271356	21.0	0.000271356	21.0	0.0000900	14			0.00018	2		22.0	2.288539	0.094	6	13	19	SIFT,PolyPhen,LRT_pred,MutationAssessor_pred,MutationTaster_pred,fathmm-MKL_coding_pred	Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,ClinPred_pred,LIST-S2_pred	CCDC22	0.02	0.0	0.0	0.0	10.0	-48.0	33.0	1.0							1.0	0.000000000	0.619	1.16	.			.	.	cellular copper ion homeostasis;Golgi to plasma membrane transport;cytoplasmic sequestering of NF-kappaB;protein transport;positive regulation of I-kappaB kinase/NF-kappaB signaling;negative regulation of I-kappaB kinase/NF-kappaB signaling;post-translational protein modification;positive regulation of ubiquitin-dependent protein catabolic process	cellular_component;nucleoplasm;endosome;cytosol	protein binding;cullin family protein binding	VPS29[26496610];FAM45A[26496610];ARAF[26496610];ACTG1[25416956];CEP128[26638075];PCM1[26638075];KRT27[unassigned1304];OIP5[unassigned1304];CCDC93[26496610];NINL[26638075];FADS1[26496610];SKP1[23563313];OFD1[26638075];ARSA[unassigned1304];COMMD10[23563313;26496610];COMMD2[23563313;26496610];COMMD3[23563313;26496610];COMMD1[23563313;26496610];BAZ1A[26496610];COMMD6[23563313;26496610];COMMD7[23563313;26496610];HSPG2[26496610];COMMD4[23563313;26496610];COMMD5[23563313;26496610];OAS3[26496610];FAM32A[26496610];CEP63[26638075];C16orf62[26496610];CUL5[23563313];USHBP1[25416956];CUL3[23563313];CUL2[23563313];CUL1[23563313];VPS26C[26496610];BLOC1S6[21988832];COMMD8[23563313;26496610];COMMD9[23563313;26496610];GMDS[26496610];SAP18[26496610];PLXNA3[26496610];DECR1[26496610];TOE1[26496610];ARHGEF33[26496610];SCLT1[26638075];HPS5[26496610];SORBS3[26496610];RPGRIP1[26638075];MFHAS1[26496610];UBE2M[26496610];	49104693
6296	chrX	69479172	C	T	chrX:69479172	P2RY4	pyrimidinergic receptor P2Y4	SNV	0/1	0.48	33_31	64	99	rs148362984	EXONIC	YES	NM_002565.4	Transcript	protein_coding	stop_gained		1/1	NM_002565.4:c.303G>A	NP_002556.1:p.Trp101Ter		-1.0	GPCR, rhodopsin-like, 7TM					.	.	.		0.00085916	97.0	112901.0	0.0	24	0.65	PASS	sas	0.00144875	4.0	0.0013496	72.0	0.000970629	177.0	182356.0	0.0	60	0.88	PASS	sas	0.00195778	37.0	0.0014876	121.0	0.0011768	183	0.002	6.0	0.00096	11		37.0	7.022102		4	0	4	MutationTaster_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,fathmm-MKL_coding_pred		P2RY4	0.0	0.0	0.0	0.0	13.0	-23.0	-19.0	-23.0						0.445	0.34	0.000000000	1.0	1.026	digestive/alimentary phenotype; mortality/aging ; 			.	Neuroactive ligand-receptor interaction	G protein-coupled receptor signaling pathway;phospholipase C-activating G protein-coupled receptor signaling pathway;positive regulation of cytosolic calcium ion concentration;transepithelial chloride transport;G protein-coupled purinergic nucleotide receptor signaling pathway;cellular response to ATP;cellular response to prostaglandin E stimulus;regulation of presynaptic cytosolic calcium ion concentration;regulation of synaptic vesicle exocytosis	plasma membrane;integral component of plasma membrane;basolateral plasma membrane;apical plasma membrane;glutamatergic synapse;integral component of presynaptic active zone membrane	ATP binding;uridine nucleotide receptor activity;G protein-coupled purinergic nucleotide receptor activity;UTP-activated nucleotide receptor activity	TMED2[21219331];	69479172
6317	chrX	73961499	G	C	chrX:73961499	KIAA2022		SNV	0/1	0.65	7_13	20	99	COSV99280172	EXONIC	YES	NM_001008537.3	Transcript	protein_coding	missense_variant		3/4	NM_001008537.3:c.2893C>G	NP_001008537.1:p.Gln965Glu		-1.0	.,.,.													22	0.61											100	1.0											9e-05	1		24.9	3.489215	0.246	9	10	19	SIFT,PolyPhen,Polyphen2_HDIV_pred,Polyphen2_HVAR_pred,LRT_pred,M-CAP_pred,MutationTaster_pred,ClinPred_pred,fathmm-MKL_coding_pred	MetaLR_pred,MetaSVM_pred,PROVEAN_pred,FATHMM_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,LIST-S2_pred	KIAA2022	0.0	0.0	0.0	0.0	-48.0	-18.0	47.0	-45.0						0.196	0.95	73.761016956	0.998	1.176										73961499
6320	chrX	107863540	A	G	chrX:107863540	COL4A5	collagen type IV alpha 5 chain	SNV	0/1	0.45	6_5	11	96	rs763428268	EXONIC	YES	NM_033380.3	Transcript	protein_coding	missense_variant		31/53	NM_033380.3:c.2561A>G	NP_203699.1:p.Asp854Gly		1.0	.,.,.	Likely_benign	criteria_provided,_single_submitter	not_provided	Alport syndrome 1, X-linked, 301050 (3), X-linked dominant	X-linked Alport syndrome-diffuse leiomyomatosis;X-linked Alport syndrome	Role in the phenotype of;Disease-causing germline mutation(s) in	Microscopic hematuria;Proteinuria;Corneal erosion;Developmental cataract;Thrombocytopenia;Renal insufficiency;Heterogeneous;X-linked dominant inheritance;Progressive;Nephrotic syndrome;Hypoparathyroidism;Nephritis;Lenticonus;Stage 5 chronic kidney disease;Diffuse glomerular basement membrane lamellation;Ichthyosis;Thickening of the glomerular basement membrane;Diffuse leiomyomatosis;Sensorineural hearing impairment;X-linked inheritance;Hypertension;Anterior lenticonus;Myopia						22	0.59							1.64805e-05	3.0	182033.0	0.0	55	0.99	PASS	nfe	3.72389e-05	3.0	3.72389e-05	3.0	0.0000064	1			9e-05	1		23.0	2.731087	0.901	10	9	19	LRT_pred,M-CAP_pred,MetaLR_pred,MetaSVM_pred,MutationTaster_pred,FATHMM_pred,BayesDel_addAF_pred,BayesDel_noAF_pred,LIST-S2_pred,fathmm-MKL_coding_pred	SIFT,PolyPhen,Polyphen2_HDIV_pred,MutationAssessor_pred,PROVEAN_pred,MetaRNN_pred,PrimateAI_pred,DEOGEN2_pred,ClinPred_pred	COL4A5	0.0	0.0	0.0	0.0	-45.0	-33.0	-1.0	17.0						0.00255	1.0	0.000000000	1.0	1.312	renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; cardiovascular system phenotype ; hematopoietic system phenotype; mortality/aging ; homeostasis/metabolism phenotype; adipose tissue phenotype ; 			uterus;uterus corpus;superior cervical ganglion;spinal cord;parietal lobe;	.	neuromuscular junction development;extracellular matrix organization;collagen-activated tyrosine kinase receptor signaling pathway	extracellular region;collagen type IV trimer;extracellular space;endoplasmic reticulum lumen;extracellular matrix;neuromuscular junction;collagen-containing extracellular matrix	extracellular matrix structural constituent;extracellular matrix structural constituent conferring tensile strength	RNF10[16169070];DAZAP2[21900206];CDKN1A[21900206];SAR1A[unassigned1304];ABHD4[unassigned1304];VPS26B[26496610];MFF[unassigned1304];KLK6[12878203];STRN3[24366813];NCR3LG1[unassigned1304];BSND[unassigned1304];ANXA7[21900206];FFAR2[unassigned1304];SMN1[21900206];TK1[21900206];KIF21B[26496610];SLC39A2[unassigned1304];SLC18A1[unassigned1304];PDK1[26496610];CD53[unassigned1304];CERS4[unassigned1304];ATP6V0B[unassigned1304];SLC10A6[unassigned1304];KCNJ6[unassigned1304];ELOVL4[unassigned1304];NR1H2[21900206];SLC35C2[unassigned1304];GPX8[unassigned1304];KNL1[26496610];FAM209A[unassigned1304];TMEM80[unassigned1304];THAP4[unassigned1304];CEP170P1[26496610];TSPO2[unassigned1304];CLDN7[unassigned1304];RELL2[unassigned1304];ERGIC3[unassigned1304];DAP3[26496610];	107863540
6322	chrX	108708473	T	C	chrX:108708473	GUCY2F	guanylate cyclase 2F, retinal	SNV	0/1	0.43	12_9	21	99	rs139194214	EXONIC	YES	NM_001522.3	Transcript	protein_coding	synonymous_variant		3/20	NM_001522.3:c.930A>G	NP_001513.2:p.Ala310%3D		-1.0		Benign	criteria_provided,_single_submitter	not_provided		.	.	.		0.00429714	481.0	111935.0	4.0	23	0.6	PASS	amr	0.00945805	100.0	0.00609011	324.0	0.00412016	756.0	183488.0	0.0	82	1.0	PASS	nfe	0.00627372	514.0	0.00627372	514.0	0.0037234	579	0.01	33.0	0.00714	68		11.28	0.716346		0	0	0			GUCY2F	0.0	0.0	0.0	0.0	-17.0	-2.0	-17.0	-2.0						0.291	0.0	7.538973576			nervous system phenotype ; vision/eye phenotype; 			superior cervical ganglion;trigeminal ganglion;fetal liver;skeletal muscle;	Purine metabolism;Gap junction;Long-term depression	cGMP biosynthetic process;protein phosphorylation;signal transduction;receptor guanylyl cyclase signaling pathway;visual perception;cGMP-mediated signaling;regulation of rhodopsin mediated signaling pathway;detection of light stimulus involved in visual perception	nuclear outer membrane;plasma membrane;integral component of plasma membrane;photoreceptor disc membrane	peptide receptor activity;guanylate cyclase activity;protein kinase activity;ATP binding;GTP binding;signaling receptor activity;protein homodimerization activity;protein heterodimerization activity	GABARAPL2[20562859];	108708473
6323	chrX	115582750	C	T	chrX:115582750	SLC6A14	solute carrier family 6 member 14	SNV	0/1	0.27	19_7	26	99	rs12720085	EXONIC	YES	NM_007231.5	Transcript	protein_coding	synonymous_variant		8/14	NM_007231.5:c.1074C>T	NP_009162.1:p.Ser358%3D		1.0		Benign	criteria_provided,_single_submitter	not_provided		.	.	.		0.00419463	465.0	110856.0	4.0	23	0.6	PASS	nfe	0.00530589	281.0	0.00530589	281.0	0.00464079	849.0	182943.0	1.0	68	0.98	PASS	nfe	0.00543632	443.0	0.00543632	443.0	0.0042121	655	0.006	19.0	0.01219	139		9.734	0.535814		0	0	0			SLC6A14	0.0	0.0	0.01	0.0	49.0	0.0	-27.0	2.0						0.327	0.99				neoplasm; hematopoietic system phenotype; reproductive system phenotype; immune system phenotype; endocrine/exocrine gland phenotype; integument phenotype ; homeostasis/metabolism phenotype; 			.	.	amino acid transmembrane transport;cellular amino acid metabolic process;neurotransmitter transport;amino acid transport;response to toxic substance	plasma membrane;integral component of membrane;vesicle;extracellular exosome	neurotransmitter:sodium symporter activity;amino acid transmembrane transporter activity	.	115582750
6346	chrX	153581728	A	G	chrX:153581728	FLNA	filamin A	SNV	0/1	0.39	83_54	137	99	rs782787843	EXONIC	YES	NM_001110556.2	Transcript	protein_coding	synonymous_variant		37/48	NM_001110556.2:c.5958T>C	NP_001104026.1:p.Thr1986%3D		-1.0		Benign/Likely_benign	criteria_provided,_multiple_submitters,_no_conflicts	Periventricular_nodular_heterotopia_1|Oto-palato-digital_syndrome,_type_II|Melnick-Needles_syndrome|Frontometaphyseal_dysplasia|History_of_neurodevelopmental_disorder|not_provided	Otopalatodigital syndrome, type II, 304120 (3), X-linked dominant; Intestinal pseudoobstruction, neuronal, 300048 (3), X-linked recessive; Cardiac valvular dysplasia, X-linked, 314400 (3), X-linked; ?FG syndrome 2, 300321 (3), X-linked; Melnick-Needles syndrome, 309350 (3), X-linked dominant; Terminal osseous dysplasia, 300244 (3), X-linked dominant; Congenital short bowel syndrome, 300048 (3), X-linked recessive; Otopalatodigital syndrome, type I, 311300 (3), X-linked dominant; Heterotopia, periventricular, 1, 300049 (3), X-linked dominant; Frontometaphyseal dysplasia 1, 305620 (3), X-linked recessive	Congenital short bowel syndrome;Frontometaphyseal dysplasia;Melnick-Needles syndrome;Congenital valvular dysplasia;Ehlers-Danlos syndrome, cardiac valvular type;X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome;Terminal osseous dysplasia-pigmentary defects syndrome;Otopalatodigital syndrome type 2;Otopalatodigital syndrome type 1;Ehlers-Danlos syndrome with periventricular heterotopia;Periventricular nodular heterotopia;Neuronal intestinal pseudoobstruction	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) (gain of function) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Toe syndactyly;Rocker bottom foot;Hypospadias;Depressed nasal bridge;Hypertelorism;Narrow chest;Posteriorly rotated ears;Stillbirth;Omphalocele;Respiratory insufficiency;Radial deviation of the 2nd finger;Overlapping fingers;Platyspondyly;Intellectual disability;Femoral bowing;Short thumb;Prominent forehead;Delayed closure of the anterior fontanelle;Midface retrusion;Conductive hearing impairment;Wormian bones;Pectus excavatum;Cryptorchidism;Frontal bossing;Short metatarsal;Tibial bowing;Short metacarpal;Nonossified fifth metatarsal;Micrognathia;Irregular metacarpals;Spondylolysis;Wide anterior fontanel;X-linked dominant inheritance;Hypoplastic ilia;Bulbous tips of toes;Broad face;Undulate clavicles;Radial bowing;Cleft palate;Vertical clivus;Rudimentary fibula;Short ribs;Broad hallux;Broad thumb;Hydrocephalus;Downslanted palpebral fissures;Short stature;Malar flattening;Postaxial hand polydactyly;Low-set ears;Postnatal growth retardation;Narrow mouth;Sclerosis of skull base;Hydronephrosis;Congenital hip dislocation;Respiratory failure;Ulnar bowing;Short hallux;Natal tooth;Decreased circulating antibody level;Congenital diaphragmatic hernia;Malabsorption;Abnormal cardiac septum morphology;Patent ductus arteriosus;Recurrent infections;Focal-onset seizure;Joint hypermobility;Thin skin;Periventricular heterotopia;Abnormal heart valve morphology;Pyloric stenosis;Aortic aneurysm;Abnormal bleeding;Scoliosis;Shoulder dislocation;Aortic regurgitation;Patellar dislocation;Gastroesophageal reflux;Hernia;Patent ductus arteriosus;Large fontanelles;Narrow chest;Broad forehead;Anodontia;Glossoptosis;Pulmonary hypoplasia;Omphalocele;Skeletal dysplasia;Hydronephrosis;Hearing impairment;Intellectual disability;Malar flattening;Hypoplastic frontal sinuses;Cerebellar hypoplasia;Elbow dislocation;Thickened calvaria;Pierre-Robin sequence;Abnormality of the ribs;Camptodactyly of finger;Hypospadias;Abnormal cardiac septum morphology;Tarsal synostosis;Cleft palate;Hydrocephalus;Fibular aplasia;Downslanted palpebral fissures;Micrognathia;Cataract;Short nose;Ureteral obstruction;Myelomeningocele;Short hallux;Abnormal heart valve morphology;Oligodontia;Short palm;Low-set ears;Increased bone mineral density;Flared iliac wings;Hypertelorism;Short thumb;Abnormal vertebral segmentation and fusion;Abnormality of the pinna;Preaxial polydactyly;Abnormality of the metacarpal bones;Synostosis of carpal bones;Scoliosis;Developmental glaucoma;Encephalocele;Narrow mouth;Prominent supraorbital ridges;Global developmental delay;Failure to thrive;Bowing of the long bones;Depressed nasal bridge;Cutis laxa;Short chordae tendineae of the mitral valve;Mitral valve prolapse;Short chordae tendineae of the tricuspid valve;Mitral regurgitation;Abnormality of metabolism/homeostasis;Ptosis;Prominent supraorbital ridges;Joint laxity;X-linked recessive inheritance;Bicuspid aortic valve;Congestive heart failure;Aortic regurgitation;Joint stiffness;Thick vermilion border;Hypertelorism;Tricuspid regurgitation;Bicuspid aortic valve;Gray matter heterotopia;Seizure;Stroke;X-linked dominant inheritance;Intellectual disability, mild;Patent ductus arteriosus;Abnormality of the coagulation cascade;Abnormality of neuronal migration;Proptosis;Abnormality of the pubic bone;Facial asymmetry;Osteolytic defects of the phalanges of the hand;Recurrent respiratory infections;Short stature;Hydronephrosis;Joint hyperflexibility;Abnormal cortical bone morphology;Vesicoureteral reflux;Coxa valga;Bowing of the long bones;Short clavicles;Scoliosis;Short thorax;Craniofacial hyperostosis;Abnormal cardiac septum morphology;Full cheeks;Prominent supraorbital ridges;Misalignment of teeth;Delayed cranial suture closure;Abnormality of the ribs;Micrognathia;Anisospondyly;Cone-shaped epiphyses of the phalanges of the hand;Hypertelorism;Respiratory insufficiency;Frontal bossing;Short distal phalanx of finger;Narrow chest;Abnormality of the metaphysis;Hip dislocation;Delayed eruption of teeth;Omphalocele;Hearing impairment;Short distal phalanx of the thumb;Absent/hypoplastic paranasal sinuses;Abnormality of the metaphysis;Scoliosis;Ulnar deviation of finger;Ureteral stenosis;Abnormal form of the vertebral bodies;Posterior vertebral hypoplasia;Long fingers;Conductive hearing impairment;Tracheal stenosis;Atrioventricular canal defect;Reduced number of teeth;Sensorineural hearing impairment;Downslanted palpebral fissures;Urethral stenosis;Hypoplasia of the musculature;Hypertelorism;Long metacarpals;Joint stiffness;Synostosis of carpal bones;Micrognathia;Bowing of the long bones;Hydronephrosis;Camptodactyly of finger;Short distal phalanx of hallux;Accelerated skeletal maturation;Elbow dislocation;High palate;Craniosynostosis;Irregular metacarpals;Prominent supraorbital ridges;Fused cervical vertebrae;Craniofacial hyperostosis;Subglottic stenosis;Abnormality of dental morphology;Delayed eruption of teeth;X-linked recessive inheritance;Selective tooth agenesis;Coxa valga;Coarse facial features;Large foramen magnum;Skeletal muscle atrophy;Scoliosis;Short chin;Antegonial notching of mandible;Camptodactyly of finger;Wrist flexion contracture;Sensorineural hearing impairment;Partial fusion of tarsals;Ankle flexion contracture;Prominent supraorbital ridges;Hydronephrosis;Hypertelorism;Fused cervical vertebrae;Anteriorly placed odontoid process;Knee flexion contracture;Scapular winging;Partial fusion of carpals;Increased density of long bone diaphyses;Stridor;Genu valgum;Intellectual disability;Long phalanx of finger;Coat hanger sign of ribs;Dental malocclusion;Pointed chin;Downslanted palpebral fissures;Long foot;Persistence of primary teeth;Elbow flexion contracture;Hydroureter;Cor pulmonale;High palate;Wide nasal bridge;Hirsutism;Arachnodactyly;Mitral valve prolapse;Broad phalanges of the hand;Tricuspid valve prolapse;Pulmonary arterial hypertension;Short clavicles;Frontal hirsutism;Ureteral stenosis;Small face;Recurrent respiratory infections;Tibial bowing;Misalignment of teeth;Short humerus;Narrow chest;Coxa valga;Motor delay;Hoarse voice;Short distal phalanx of finger;Delayed cranial suture closure;Omphalocele;Long neck;Kyphoscoliosis;Cone-shaped epiphyses of the phalanges of the hand;Gait disturbance;Mitral valve prolapse;Osteolytic defects of the phalanges of the hand;Cleft palate;Strabismus;Stillbirth;Flared metaphysis;Recurrent otitis media;Limited elbow extension;Micrognathia;Hip dislocation;Genu valgum;Hydronephrosis;X-linked dominant inheritance;Delayed eruption of teeth;Anterior concavity of thoracic vertebrae;Macrotia;Pes planus;Failure to thrive;Hypertelorism;Talipes equinovarus;Hypoplastic scapulae;Pectus excavatum;Obtuse angle of mandible;Prominent supraorbital ridges;Coarse hair;Proptosis;Hypertelorism;Fibroma;Ptosis;Mesomelic arm shortening;Depressed nasal tip;Abnormal oral frenulum morphology;Toe clinodactyly;Camptodactyly of finger;Brachydactyly;Camptodactyly of toe;Iris coloboma;Low-set ears;Epicanthus;Cleft palate;Syndactyly;Abnormal foot bone ossification;Short toe;Localized skin lesion;Malar flattening;X-linked dominant inheritance;Telecanthus;Abnormality of skin pigmentation;Abnormal hand bone ossification;Mesomelic leg shortening;Multiple joint contractures;Broad hallux;Underdeveloped superior crus of antihelix;Decreased body weight;Protruding ear;X-linked inheritance;Large forehead;Frontal upsweep of hair;Prominent forehead;Neonatal hypotonia;Constipation;Delayed speech and language development;Intestinal malrotation;Patent ductus arteriosus;Congenital shortened small intestine;Hypertelorism;Smooth philtrum;Low-set ears;Increased size of the mandible;Hydronephrosis;Abnormal facial shape;Vomiting;Abdominal distention;Intestinal pseudo-obstruction;Seizure;Spastic diplegia;Feeding difficulties in infancy;Infantile onset;Pyloric stenosis;Increased mean platelet volume;X-linked recessive inheritance;Thrombocytopenia;Downslanted palpebral fissures;Narrow mouth;Short nose;Bipartite calcaneus;Wide nasal bridge;Conductive hearing impairment;Bulbous tips of toes;Prominent occiput;Cleft palate;Capitate-hamate fusion;Broad hallux;Prominent supraorbital ridges;Downslanted palpebral fissures;Limited knee flexion;Omphalocele;Dislocated radial head;Coxa valga;Short stature;Toe syndactyly;Accessory carpal bones;Short distal phalanx of finger;Delayed closure of the anterior fontanelle;Hypertelorism;Short hallux;Selective tooth agenesis;Broad distal phalanx of the thumb;Short 4th metacarpal;Thick skull base;X-linked dominant inheritance;Nail dysplasia;Sandal gap;Short 3rd metacarpal;Pectus excavatum;Limited elbow extension;Abnormality of the fifth metatarsal bone;Frontal bossing;Absent frontal sinuses;Synostosis of carpal bones;Malar flattening;Nail dystrophy;Lateral femoral bowing;Multiple impacted teeth;Flat face;Hip dislocation;Scoliosis;Intellectual disability, mild;Short 5th metacarpal;Short palm;Sandal gap;Anodontia;Bowing of the long bones;Limitation of joint mobility;Abnormal vertebral segmentation and fusion;Increased bone mineral density;Wide nasal bridge;Short thumb;Prominent supraorbital ridges;Hypoplastic frontal sinuses;Oligodontia;Intellectual disability, mild;Proximal placement of thumb;Skeletal dysplasia;Abnormality of the metacarpal bones;Cleft palate;Hearing impairment;Abnormality of the tarsal bones;Short hallux;Depressed nasal bridge;Hypertelorism;Thickened calvaria;Short distal phalanx of finger;Downslanted palpebral fissures;Elbow dislocation;Synostosis of carpal bones;Inguinal hernia;Thin skin;Gastroesophageal reflux;Joint hyperflexibility;Hyperextensible skin;Bruising susceptibility;Short stature;Umbilical hernia;Abnormality of cardiovascular system morphology;Intestinal malrotation;Short stature;Sparse hair;Displacement of the urethral meatus;Cognitive impairment;Lipoatrophy;Intestinal hypoplasia		2.65877e-05	3.0	112834.0	0.0	25	0.64	PASS	amr	0.000185322	2.0	0.0	0.0	4.9607e-05	9.0	181426.0	0.0	100	1.0	PASS	afr	0.000161878	2.0	6.15551e-05	5.0	0.0000322	5	0.0	1.0	0.00105	12		0.318	-0.320131		0	0	0			FLNA	0.0	0.0	0.0	0.0	15.0	28.0	-49.0	-31.0						0.000896	1.0	15.601985831			growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; skeleton phenotype; liver/biliary system phenotype; respiratory system phenotype; hematopoietic system phenotype; cardiovascular system phenotype ; reproductive system phenotype; normal phenotype; mortality/aging ; digestive/alimentary phenotype; nervous system phenotype ; vision/eye phenotype; immune system phenotype; 			lung;uterus;white blood cells;appendix;adipose tissue;whole blood;prostate;heart;	MAPK signaling pathway;Focal adhesion	platelet degranulation;adenylate cyclase-inhibiting dopamine receptor signaling pathway;negative regulation of transcription by RNA polymerase I;formation of radial glial scaffolds;cerebral cortex development;platelet activation;regulation of cell migration;actin cytoskeleton reorganization;positive regulation of actin filament bundle assembly;cell junction assembly;protein localization to cell surface;negative regulation of protein catabolic process;positive regulation of protein import into nucleus;mRNA transcription by RNA polymerase II;negative regulation of apoptotic process;receptor clustering;positive regulation of I-kappaB kinase/NF-kappaB signaling;negative regulation of DNA-binding transcription factor activity;wound healing, spreading of cells;establishment of protein localization;protein stabilization;cytoplasmic sequestering of protein;defense response to virus;actin crosslink formation;cilium assembly;platelet aggregation;semaphorin-plexin signaling pathway;protein localization to plasma membrane;mitotic spindle assembly;establishment of Sertoli cell barrier;positive regulation of substrate adhesion-dependent cell spreading;positive regulation of potassium ion transmembrane transport;protein localization to bicellular tight junction;regulation of membrane repolarization during atrial cardiac muscle cell action potential;regulation of membrane repolarization during cardiac muscle cell action potential;positive regulation of neural precursor cell proliferation;positive regulation of integrin-mediated signaling pathway;positive regulation of neuron migration	extracellular region;nucleus;nucleolus;cytoplasm;cytosol;plasma membrane;cell-cell junction;focal adhesion;actin cytoskeleton;membrane;Z disc;cortical cytoskeleton;Myb complex;filamentous actin;neuronal cell body;dendritic shaft;perinuclear region of cytoplasm;extracellular exosome;apical dendrite;postsynapse;glutamatergic synapse	G protein-coupled receptor binding;RNA binding;protein binding;transcription factor binding;potassium channel regulator activity;Rho GTPase binding;Ral GTPase binding;kinase binding;small GTPase binding;mu-type opioid receptor binding;Fc-gamma receptor I complex binding;protein homodimerization activity;ion channel binding;cadherin binding;SMAD binding;Rac GTPase binding;actin filament binding;GTPase binding	TES[26496610];EHMT2[26028330];DIXDC1[26496610];ARPC5L[26496610];ANTXR1[26496610];ACTB[26496610];ALKBH8[30021884];HERC2[29426014];MPRIP[26496610];MYC[21150319];MYB[18548008];TRIM24[22307607];SYNPO[26496610];MYOZ1[unassigned1304];PRKACB[15225631];PELO[unassigned1304];GABARAPL1[20562859];DAPK3[26496610];LGALS14[25416956;27107012;unassigned1304];AFAP1[26496610];ACTN4[26496610];KCTD10[26496610];BTK[21080425];ULK2[20562859];DHX8[30021884];FLII[26496610];HHLA3[unassigned1304];TWF1[26496610];PIK3R1[17474147];IQGAP1[26496610];MYO6[26496610];DND1[30021884];PLCG1[17474147];SPTBN1[26496610];SPTBN2[26496610];S100A10[26496610];ABCA1[25170080];JUN[25609649];JUP[26496610];FN1[19738201];MYO5A[26496610];DDIT4L[unassigned1304];GNG12[26496610];ANLN[26496610];AGO3[19167051];MYO5C[26496610];ATG2A[20562859];REL[25416956];GRB2[12577067;17474147;21706016];CALM1[26496610];NRP1[24021649];ARPC1B[26496610];CLTC[26496610];CLTB[26496610];CLTA[26496610];AP2A1[26496610];STON2[26496610];PRPF19[30021884];PPP1R18[26496610];CLINT1[26496610];IKBKB[14743216];TUBA1A[27291054];ADAMTSL4[25416956];IKBKG[14743216];SPTAN1[26496610];SEC13[26496610];RIPK3[14743216];ANXA2[26496610];MAMDC2[30021884];GP1BA[25241761];INF2[26496610];CTTN[26496610];MAPRE1[26496610];CD44[26496610];DBN1[26496610];FOXC1[15684392];NEXN[26496610];CENPA[20080577];GNAI1[26496610];AKAP2[26496610];CAMKK2[20562859];LIMA1[26496610];PAK1[17389360];SLX4[19596235];FLNA[2391361];FLNB[12393796;26496610];CD59[26496610];MISP[26496610];EPS15[26496610];MAP3K2[30021884];MAP3K3[14743216;25241761];SVIL[26496610];MAP3K1[14743216];GSN[26496610];SORBS2[26496610];AP2B1[26496610];PLEKHA7[28877994];RFLNA[25416956;unassigned1304];PPP1CA[26496610];TJP1[16944923];FABP1[25416956;25910212];CAPZA1[26496610];CAPZA2[26496610];OTUD5[19615732];ITGA2B[25849143];ZBTB20[26496610];DUX4[26816005];ACTG1[26496610];PPP1CB[26496610];PPP1CC[26496610];CYSRT1[unassigned1304];BASP1[26496610];TUBB3[27291054];CFL2[26496610];PALM[26496610];CFL1[26496610];MAP3K7[14743216];AP2M1[26496610];TMOD1[26496610];RPS9[17461779];TPM4[26496610];ZGRF1[30021884];TMOD3[26496610];TPM2[26496610];TPM1[26496610];MTNR1A[17215244;26514267];PHOSPHO2[unassigned1304];MTNR1B[17215244;26514267];DMWD[19615732];FSCN1[26496610];CHMP4B[26496610];RPP25[unassigned1304];PHLDB2[20236936;26496610];RAI14[26496610];GLYR1[unassigned1304];PSEN2[9437013];KLHL12[25416956;unassigned1304];UAP1[26496610];ITPR3[26496610];PSEN1[9437013];CORO1B[26496610];CORO1C[26496610];CCNB2[17408621];ARHGAP21[26496610];G3BP1[19615732];ABL1[17474147];MYH11[26496610];SPECC1[26496610];ITPRID2[26496610];SMAD3[15231748];VCAM1[22623428];HSPA6[unassigned1304];CYBRD1[26496610];ARPC4[26496610];CORO2A[26496610];SSH2[26496610];ESR1[21182205;25604459];ARHGAP24[16862148;21926999];ESR2[25604459];DAB2[26496610];ARPC3[26496610];GNB2[26496610];GNAS[26496610];TAB2[14743216];TCF4[25416956];ITGB1[15225631;17690686;9722563;10604475;18177638];PRR5[17461779];ARHGAP11A[26496610];PLEKHF2[unassigned1304];CPM[26496610];HSP90AB1[16263121;25241761;26496610];WDR1[26496610];ITGB4[15225631];ITGB3[25849143];HSPB7[25416956;unassigned1304];HMGB2[26496610];ARRB1[17620599];ARRB2[17620599];PIK3C2A[26496610];CHD2[30021884];PPP1R9B[26496610];METTL14[29507755];CAPZB[26496610];MYO18A[26496610];FLOT1[26496610];FLOT2[26496610];ITGB7[15225631;17690686;21926999];SPANXD[unassigned1304];TPRN[26496610];IQCB1[21565611];ACTR3[26496610];PLEKHG3[26496610];ACTR2[26496610];PPP1R12A[26496610];ITGA4[10604475];USP45[19615732];COBL[26496610];TRAF2[25241761];OPRM1[14573758];TNFRSF1B[14743216];YWHAZ[15161933];PALLD[26496610];POLR1C[22307607];BMP2K[26496610];MYH9[26496610];DSG2[26496610];CRK[17474147;25241761];PLEC[26496610];NLGN3[25464930];LUZP1[26496610];SRC[20936779];KIAA1211[26496610];TTN[16902413];ABLIM1[26496610];FYN[17474147];CAMK2G[25241761];KCNJ2[12923176];PDLIM7[26496610];WTAP[29507755];MAPK14[20936779];MYO19[26496610];MYO1E[26496610];MYO1B[26496610];MYO1C[26496610];APC[20936779];CEP162[26496610];OTUD1[19615732];	153581728
